[
    {
        "id": "86b7cb3d-6186-4a04-9aa6-b174ab764eed",
        "primaryId": "NCT00662129",
        "statement_text": "Patients with Platelet count over 100,000/mm¬¨‚â•, ANC smaller than 1,700/mm¬¨‚â• and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial ",
        "statement_nums": [
            "100,000/mm¬¨‚â•, ANC",
            "1,700/mm¬¨‚â• and",
            "4 to 5"
        ],
        "label": "Contradiction",
        "premise_text": "PATIENT CHARACTERISTICS: ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL ",
        "premise_nums": [
            "100,000/mm³ Hemoglobin",
            "Hemoglobin 9.0 g/dL",
            "1,500/mm³ Platelet"
        ]
    },
    {
        "id": "8765009d-ffc4-4395-ab7a-11ecdfd43a40",
        "primaryId": "NCT00201773",
        "statement_text": "Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial",
        "statement_nums": [
            "85 year old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Must be female with histologically confirmed breast cancer Stage II-IV disease ER and/or PR positive ECOG Performance Status 0-1 Postmenopausal ",
        "premise_nums": [
            "0-1 Postmenopausal"
        ]
    },
    {
        "id": "0ad7293d-df35-42e8-881d-f2afc3f7d3fd",
        "primaryId": "NCT02606708",
        "secondaryId": "NCT02504424",
        "label": "Contradiction",
        "statement_text": "Only patients in the primary trial receive 40.5 Gy of brachytherapy  patients in the secondary trial receive no radiotherapy whatsoever ",
        "statement_nums": [
            "receive 40.5 Gy of"
        ],
        "premise_text": "INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  ",
        "premise_nums": [
            "of 40.5 Gy to",
            "3 weeks delivered",
            "in 2.7 Gy/fraction",
            "of 0.50 Gy will"
        ]
    },
    {
        "id": "d76d6c7f-ba39-483c-a89e-152af5ae2878",
        "primaryId": "NCT02525718",
        "secondaryId": "NCT02606708",
        "label": "Entailment",
        "statement_text": "Patients in group 1 of the secondary trial and the primary trial do not receive the same dosage of AIMRT ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) ",
        "premise_nums": [
            "of 40.5 Gy to",
            "3 weeks delivered",
            "in 2.7 Gy/fraction",
            "of 0.50 Gy will",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "65f3e755-3e23-4e84-a218-87922759094d",
        "primaryId": "NCT01669343",
        "secondaryId": "NCT00146172",
        "label": "Contradiction",
        "statement_text": "the primary trial administers letrozole for 28 days  whereas the secondary trial administers is intervention over 4 cycles of 21 days ",
        "statement_nums": [
            "4 cycles of"
        ],
        "premise_text": "INTERVENTION 1: Post-menopausal Women Using Adjuvant Letrozole Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants Letrozole: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  Part B In overweight/obese participants who completed Part A  provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd ",
        "premise_nums": [
            "80 mg Neratinib",
            "80 mg qd",
            "40 mg Neratinb",
            "40 mg qd"
        ]
    },
    {
        "id": "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Entailment",
        "statement_text": "There were no completed suicides in either the primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) ",
        "premise_nums": [
            "1/116 (0.86%)",
            "31/116 (26.72%)",
            "3/116 (2.59%)",
            "0/116 (0.00%)"
        ]
    },
    {
        "id": "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Entailment",
        "statement_text": "There were no completed suicides in either the primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Nausea 2/116 (1.72%)Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115 (0.87%) Abdominal pain 0/115 (0.00%) Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) ",
        "premise_nums": [
            "24/115 (20.87%)",
            "1/115 (0.87%)",
            "2/116 (1.72%)Adverse",
            "4/115 (3.48%)",
            "0/115 (0.00%)"
        ]
    },
    {
        "id": "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Entailment",
        "statement_text": "There were no completed suicides in either the primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Intestinal haemorrhage 0/115 (0.00%)Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) ",
        "premise_nums": [
            "3/115 (2.61%)",
            "8/54 (14.81%)",
            "1/54 (1.85%)",
            "0/115 (0.00%)Nausea"
        ]
    },
    {
        "id": "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Entailment",
        "statement_text": "There were no completed suicides in either the primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Dyspnoea 1/54 (1.85%)",
        "premise_nums": [
            "1/54 (1.85%)"
        ]
    },
    {
        "id": "589e2f5b-9286-465b-8162-bb1549cd5ece",
        "primaryId": "NCT00305448",
        "statement_text": "At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "4 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 17.6 ",
        "premise_nums": [
            "45 Measure Type:",
            "1 Results 2:",
            "250 mg Overall",
            "participants 11.1 Results 2",
            "51 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "8275f846-59b6-404d-a6d8-e01335279f1a",
        "primaryId": "NCT03066947",
        "statement_text": "Less than 1/4 patients in the primary trial experienced adverse events ",
        "statement_nums": [
            "4 patients in",
            "1/4 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 8/24 (33.33%) ",
        "premise_nums": [
            "8/24 (33.33%)"
        ]
    },
    {
        "id": "6fb9056d-277c-4dc2-9b45-d7661bb41831",
        "primaryId": "NCT01925170",
        "secondaryId": "NCT00324259",
        "label": "Contradiction",
        "statement_text": "Participant in cohort 1 of the primary trial undergo a Mammography  whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography ",
        "statement_nums": [
            "6 mg Estradiol",
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 1: Arm 1 (6 mg Estradiol) 6 mg of estradiol daily (2 mg tid)  ",
        "premise_nums": [
            "2 mg tid)",
            "6 mg Estradiol)",
            "6 mg of"
        ]
    },
    {
        "id": "95e05332-4926-4381-90a4-87941269e7bf",
        "primaryId": "NCT00431067",
        "statement_text": "More than 5% of the primary trial participants achieved partial response (PR) ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Objective Response (OR) Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria   Time frame: From first dose of study medication to response measurement  up to 34 month Results 1: Arm/Group Title: Afatinib 50 mg Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: Participants 4 ",
        "premise_nums": [
            "50 mg therapy",
            "41 Measure Type:",
            "34 month Results",
            "50 mg Arm",
            "28-day treatment"
        ]
    },
    {
        "id": "15c83d26-f9ba-44cc-a920-6941781cdd8b",
        "primaryId": "NCT01427933",
        "statement_text": "Neutropenia affected the majority of patients in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Neutropenia 4/69 (5.80%) ",
        "premise_nums": [
            "4/69 (5.80%)"
        ]
    },
    {
        "id": "56d2a387-49dd-49b9-93bb-bcb092bf2714",
        "primaryId": "NCT02286843",
        "statement_text": "the primary trial is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions ",
        "statement_nums": [
            "89Zr-trastuzumab to"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: HER2-targeted PET/CT Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT  89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions  89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions  PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions  rather than evaluation of only single lesions by biopsy  ",
        "premise_nums": [
            "89Zr-pertuzumab is",
            "2-targeted PET/CT",
            "89Zr-trastuzumab is"
        ]
    },
    {
        "id": "16dc5a77-5758-4d19-9801-6e9932d9fbc9",
        "primaryId": "NCT01401166",
        "statement_text": "several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants by Preferred Method of Drug Administration The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant  Participants were asked  \"All things considered  which method of administration did you prefer?\" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported  Time frame: Week 24 Results 1: Arm/Group Title: Cohort 1: SC (SID) Then IV Herceptin ",
        "premise_nums": [
            "24 Results 1:"
        ]
    },
    {
        "id": "16dc5a77-5758-4d19-9801-6e9932d9fbc9",
        "primaryId": "NCT01401166",
        "statement_text": "several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles  During Cycles 1 to 4 of the crossover period  SC Herceptin was administered via SID  and during Cycles 5 to 8, IV Herceptin was given  In the continuation period  participants received IV Herceptin for up to 10 remaining cycles  Administration was performed by HCP  Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP  The SC dose was 600 mg for all cycles where SC Herceptin was given  and the IV dose was 6 mg/kg for all cycles where IV Herceptin was given Overall Number of Participants Analyzed: 117 ",
        "premise_nums": [
            "5 to 8,",
            "1 of each",
            "1 to 4",
            "10 remaining cycles",
            "3-week cycle",
            "600 mg for",
            "2 treatment cycles",
            "6 mg/kg for",
            "18-cycle treatment"
        ]
    },
    {
        "id": "16dc5a77-5758-4d19-9801-6e9932d9fbc9",
        "primaryId": "NCT01401166",
        "statement_text": "several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Measure Type: NumberUnit of Measure: percentage of participants SC Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0 ",
        "premise_nums": [
            "7 IV Herceptin:",
            "3 No Preference:"
        ]
    },
    {
        "id": "2ed770a0-fe98-4029-9511-ad04a94a1a69",
        "primaryId": "NCT00190671",
        "secondaryId": "NCT00455533",
        "label": "Contradiction",
        "statement_text": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia ",
        "statement_nums": [
            "1 had more",
            "2 had more",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144 (0.00%) ",
        "premise_nums": [
            "2/61 (3.28%)",
            "0/42 (0.00%)",
            "2/145 (1.38%)",
            "0/144 (0.00%)"
        ]
    },
    {
        "id": "b4c97206-66fd-468b-8388-fac076222c10",
        "primaryId": "NCT00863655",
        "statement_text": "There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "statement_nums": [
            "7 more cases",
            "1 of the",
            "1 more case"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238 (0.84%) Disseminated intravascular coagulation 0/238 (0.00%) ",
        "premise_nums": [
            "37/238 (15.55%)",
            "1/482 (0.21%)",
            "2/238 (0.84%)",
            "158/482 (32.78%)",
            "0/238 (0.00%)",
            "7/482 (1.45%)"
        ]
    },
    {
        "id": "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 had Pyrexia ",
        "statement_nums": [
            "2 had Pyrexia",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Febrile neutropenia 4/52 (7.69%) Pancytopenia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain 1/52 (1.92%) Constipation 1/52 (1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%) Sepsis 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "4/52 (7.69%)",
            "17 Anaemia 2",
            "1/52 (1.92%)",
            "2/52 (3.85%)"
        ]
    },
    {
        "id": "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 had Pyrexia ",
        "statement_nums": [
            "2 had Pyrexia",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2:Total: 7 Anaemia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%) Pyrexia 1/21 (4.76%) Hepatic failure 0/21 (0.00%) Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%) Sepsis 0/21 (0.00%) ",
        "premise_nums": [
            "7 Anaemia 0",
            "2:Total: 7",
            "0/21 (0.00%)",
            "1/21 (4.76%)"
        ]
    },
    {
        "id": "d417aa7b-6d2c-46f8-812c-426ea60e0328",
        "primaryId": "NCT00894504",
        "statement_text": "There were only 3 adverse events in the primary trial which occurred more than twice ",
        "statement_nums": [
            "3 adverse events"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 10/71 (14.08%) ATRIAL FIBRILLATION 1/71 (1.41%) CARDIAC TAMPONADE 1/71 (1.41%) PERICARDIAL EFFUSION 1/71 (1.41%) SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%) DIARRHOEA 1/71 (1.41%) NAUSEA 1/71 (1.41%) VOMITING 1/71 (1.41%) CHEST PAIN 1/71 (1.41%) PNEUMONIA 1/71 (1.41%) MALIGNANT PLEURAL EFFUSION 1/71 (1.41%) HEPATIC ENCEPHALOPATHY 1/71 (1.41%) ",
        "premise_nums": [
            "1/71 (1.41%)",
            "10/71 (14.08%)"
        ]
    },
    {
        "id": "2e4717fd-b349-48a3-b751-88674dfaaa18",
        "primaryId": "NCT02392611",
        "statement_text": "In the primary trial cohort 1 patients must have failed or be intolerant to standard therapy  or have no standard therapy available  and cohort 2 patients must respond well to standard therapy ",
        "statement_nums": [
            "1 patients must",
            "2 patients must"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Monotherapy: Alobresib 0.6 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  ",
        "premise_nums": [
            "of 0.6 mg orally",
            "Alobresib 0.6 mg Participants",
            "Alobresib 1.4 mg Participants",
            "28 days cycle",
            "D28 of",
            "of 1.4 mg orally",
            "1 through C1D28"
        ]
    },
    {
        "id": "28e20650-e100-4e30-a319-5eceb69a979d",
        "primaryId": "NCT00509769",
        "statement_text": "1 patient in the primary trial had toxic hepatitis ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hepatotoxicity 1/112 (0.89%) ",
        "premise_nums": [
            "1/112 (0.89%)"
        ]
    },
    {
        "id": "34a75478-e7cc-495e-86c3-d0accdaf1ddd",
        "primaryId": "NCT00317603",
        "statement_text": "Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer  ECOGsmaller than 2 and a life expectancy exceeding 6 months ",
        "statement_nums": [
            "2 and a",
            "4 breast cancer"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Histologically confirmed Stage IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy of greater than or equal to 6 months 18 years of age or older ",
        "premise_nums": [
            "6 months 18",
            "0 or 1"
        ]
    },
    {
        "id": "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c",
        "primaryId": "NCT00179309",
        "statement_text": "There were 2 cases of severe back pain observed in the primary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/25 (12.00%) Anemia 0/25 (0.00%) Sinus tachycardia 0/25 (0.00%) Pericardial effusion 1/25 (4.00%) Gastrointestinal disorders - Other  specify -stomatitis) 0/25 (0.00%) Vomiting 1/25 (4.00%) Fever 0/25 (0.00%) Injection site reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23 (4.35%) ",
        "premise_nums": [
            "1/25 (4.00%)",
            "0/25 (0.00%)",
            "3/25 (12.00%)",
            "1/23 (4.35%)",
            "2/23 (8.70%)"
        ]
    },
    {
        "id": "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c",
        "primaryId": "NCT00179309",
        "statement_text": "There were 2 cases of severe back pain observed in the primary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Sinus tachycardia 1/23 (4.35%)Pericardial effusion 0/23 (0.00%) Gastrointestinal disorders - Other  specify -stomatitis) 1/23 (4.35%) Vomiting 0/23 (0.00%) Fever 1/23 (4.35%) Injection site reaction 1/23 (4.35%) Catheter related infection 1/23 (4.35%) Activated partial thromboplastin time prolonged 1/23 (4.35%) ",
        "premise_nums": [
            "0/23 (0.00%)",
            "1/23 (4.35%)Pericardial"
        ]
    },
    {
        "id": "c4dd814d-f525-465f-abe1-a7975771d57e",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered Methylprednisolone 3 times per week for 6 doses ",
        "statement_nums": [
            "3 times per",
            "45 kg receive",
            "5 million units",
            "1 of the",
            "2 less of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm 1: CsA Fludarabine: Administered intravenously  25 mg/m^2, days -6 through -2 (5 days)  Cyclophosphamide: Administered intravenously  60 mg/kg  days -5 and -4. Cyclosporine (CsA): Administered intravenously  1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14 Natural Killer cells: Administered by infusion over less than 1 hour; no more than 8.0 x 10^7 cells/kg will be given  ",
        "premise_nums": [
            "10^7 cells",
            "60 mg/kg",
            "25 mg/m^2,",
            "14 Natural Killer",
            "1.5 mg/kg",
            "150-250 ng/mL",
            "than 8.0 x 10",
            "3 through day"
        ]
    },
    {
        "id": "c4dd814d-f525-465f-abe1-a7975771d57e",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered Methylprednisolone 3 times per week for 6 doses ",
        "statement_nums": [
            "3 times per",
            "45 kg receive",
            "5 million units",
            "1 of the",
            "2 less of"
        ],
        "label": "Contradiction",
        "premise_text": "Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of 6 doses  beginning 4 hours after NK cell infusion  (For patients weighing less than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses) ",
        "premise_nums": [
            "3 times per",
            "2 will be",
            "3 times a",
            "9 million units",
            "5 million units",
            "4 hours after"
        ]
    },
    {
        "id": "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Entailment",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had High blood sugar  0% of the secondary trial patients were recorded as having High blood sugar ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "Adverse Events 1: Total: 6/22 (27.27%) Thrombocytopenia 1/22 (4.55%) leucocytopenia 1/22 (4.55%) neutropenia 1/22 (4.55%) papilledema 1/22 (4.55%) Nausea 1/22 (4.55%) hyperglycemia 1/22 (4.55%) Adverse Events 1: Total: 24/101 (23.76%) LYMPHADENOPATHY 0/101 (0.00%) FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ",
        "premise_nums": [
            "24/101 (23.76%)",
            "6/22 (27.27%)",
            "1/101 (0.99%)",
            "20/101 (0.00%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Entailment",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had High blood sugar  0% of the secondary trial patients were recorded as having High blood sugar ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "ARRHYTHMIA 20/101 (0.00%)CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%) Adverse Events 2: Total: 22/103 (21.36%) LYMPHADENOPATHY 1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ",
        "premise_nums": [
            "21/103 (0.97%)",
            "22/103 (21.36%)",
            "21/101 (0.99%)",
            "20/101 (0.00%)CARDIAC",
            "22/101 (1.98%)"
        ]
    },
    {
        "id": "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Entailment",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had High blood sugar  0% of the secondary trial patients were recorded as having High blood sugar ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "ARRHYTHMIA 21/103 (0.97%)CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) CORONARY OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%) ",
        "premise_nums": [
            "20/103 (0.00%)",
            "21/103 (0.97%)CARDIAC"
        ]
    },
    {
        "id": "19921113-538e-4fd2-81a6-6053f2dd6459",
        "primaryId": "NCT02622074",
        "statement_text": "There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "38% more"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) The following events  if considered to be study-treatment-related by the Investigator  were considered a DLT: Hematologic: Grade 4 neutropenia lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48 hours  or Grade 3 asymptomatic hepatic toxicities lasting 7 days; or ",
        "premise_nums": [
            "3 thrombocytopenia with",
            "4 neutropenia lasting",
            "4 thrombocytopenia requiring",
            "3 asymptomatic hepatic",
            "3 symptomatic hepatic",
            "3 or Grade"
        ]
    },
    {
        "id": "19921113-538e-4fd2-81a6-6053f2dd6459",
        "primaryId": "NCT02622074",
        "statement_text": "There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "38% more"
        ],
        "label": "Contradiction",
        "premise_text": "Grade 3 non-hematologic  non-hepatic organ toxicity  with exceptionsOther: Any treatment delays for 14 days due to unresolved toxicity; Grade 5 treatment-related adverse event (AE); A dose reduction of study treatment during the DLT evaluation period  Time frame: Cycle 1 Day 1 through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 7 (Up to ~150 days from first dose of first combination regimen); Each cycle was 21 days  Results 1: Arm/Group Title: Cohort A: KNp / KAC ",
        "premise_nums": [
            "3 non-hematologic",
            "150 days from",
            "1 Day 1",
            "14 days due",
            "6 Day 1",
            "5 treatment-related adverse",
            "3 and Cycle"
        ]
    },
    {
        "id": "6a013bb4-0688-4f02-96c5-062f3ca67ae1",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were 5x more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%) Acute renal failure * 21/26 (3.85%) Adverse Events 2: Total: 1/28 (3.57%) Febrile neutropenia * 0/28 (0.00%) Gastric volvulus * 21/28 (3.57%) General Malaise * 20/28 (0.00%) ",
        "premise_nums": [
            "20/26 (0.00%)",
            "20/28 (0.00%)",
            "21/26 (3.85%)",
            "4/26 (15.38%)",
            "21/28 (3.57%)"
        ]
    },
    {
        "id": "6a013bb4-0688-4f02-96c5-062f3ca67ae1",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were 5x more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)Acute renal failure * 20/28 (0.00%) ",
        "premise_nums": [
            "20/28 (0.00%)Acute"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "Evidence of metastatic involvement (stage IV disease) DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally recurrent or metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past Measurable disease  defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than 20 mm by conventional techniques or as greater than 10 mm by spiral CT scan  No known CNS disease Hormone receptor status not specified PATIENT CHARACTERISTICS: Inclusion criteria: Postmenopausal status not specified ",
        "premise_nums": [
            "10 mm by",
            "2-positive, must",
            "20 mm by",
            "2-negative breast"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%Life expectancy greater than 12 weeks WBC 3,000/mcL Absolute neutrophil count 1,500/mcL Platelet count 100,000/mcL Total bilirubin normal AST and ALT 2.5 times upper limit of normal (ULN) Alkaline phosphatase 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis) Creatinine 1.5 mg/dL Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other concurrent malignancies within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix Exclusion criteria: ",
        "premise_nums": [
            "1,500/mcL Platelet",
            "70-100%Life expectancy",
            "3,000/mcL Absolute",
            "Creatinine 1.5 mg/dL",
            "5 years except",
            "1 OR Karnofsky",
            "phosphatase 2.5 times ULN",
            "0-1 OR",
            "100,000/mcL Total",
            "12 weeks WBC",
            "ALT 2.5 times upper"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "Pre-existing neuropathy grade 1Uncontrolled intercurrent illness including  but not limited to  any of the following: Ongoing or active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Serious  non-healing wound  ulcer  or bone fracture Psychiatric illness/social situations that would limit compliance with study requirements Inadequately controlled hypertension (defined as systolic blood pressure greater than 150 mm Hg and/or diastolic blood pressure greater than 100 mm Hg on antihypertensive medications) History of hypertensive crisis or hypertensive encephalopathy New York Heart Association class II-IV congestive heart failure History of myocardial infarction or unstable angina within the past 6 months ",
        "premise_nums": [
            "150 mm Hg",
            "100 mm Hg"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "History of stroke or transient ischemic attack within the past 6 monthsSignificant vascular disease (e.g.  aortic aneurysm  aortic dissection) Symptomatic peripheral vascular disease Evidence of bleeding diathesis or coagulopathy Significant traumatic injury within the past 28 days History of abdominal fistula  gastrointestinal perforation  or intra-abdominal abscess within the past 6 months Proteinuria  as demonstrated by either urine protein:creatinine ratio 1.0 OR urine dipstick for proteinuria 2+ Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline must demonstrate 24-hour urine protein 1g ",
        "premise_nums": [
            "ratio 1.0 OR urine",
            "6 months Proteinuria",
            "28 days History",
            "24-hour urine",
            "6 monthsSignificant vascular"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "History of allergy or hypersensitivity to paclitaxel albumin-stabilized nanoparticle formulation  paclitaxel  bevacizumab  carboplatin  albumin  drug product excipients  or chemically similar agentsPRIOR CONCURRENT THERAPY: See Disease Characteristics Recovered from all prior therapy No prior chemotherapy for locally recurrent or metastatic disease Prior neoadjuvant or adjuvant chemotherapy allowed More than 1 week since prior core biopsy or other minor surgical procedure  excluding placement of a vascular access device More than 4 weeks since prior and no concurrent major surgical procedure or open biopsy More than 4 weeks since prior radiotherapy More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) At least 1 year since prior taxane regimen ",
        "premise_nums": [
            "1 year since",
            "4 weeks since",
            "6 weeks for",
            "1 week since"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "label": "Contradiction",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "3 cancer are"
        ],
        "premise_text": "No other concurrent investigational agentsConcurrent anticoagulation allowed  provided the following criteria are met: Stable dose of warfarin or low molecular weight heparin INR within desired range (2-3) No evidence of active bleeding or coagulopathy No concurrent combination antiretroviral therapy for HIV-positive patients No other concurrent radiotherapy  chemotherapy  immunotherapy  or antitumor hormonal therapy ",
        "premise_nums": [
            "(2-3) No"
        ]
    },
    {
        "id": "682f5e80-75c4-4a36-9bc1-b389a98ad160",
        "primaryId": "NCT00193037",
        "statement_text": "None of the patients in Cohort 1 of the primary trial suffered from Hypotension ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hypotension 0/50 (0.00%) ",
        "premise_nums": [
            "0/50 (0.00%)"
        ]
    },
    {
        "id": "348c9273-6aa1-43a8-840d-3cf080874669",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there were at least 2 patients with a fever ",
        "statement_nums": [
            "2 patients with"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 0/6 (0.00%) Thrombocytopenia * 1/6 (16.67%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 1/6 (16.67%) Cholecystitis * 1/6 (16.67%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "1/6 (16.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "348c9273-6aa1-43a8-840d-3cf080874669",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there were at least 2 patients with a fever ",
        "statement_nums": [
            "2 patients with"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 1/6 (16.67%) Thrombocytopenia * 0/6 (0.00%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 0/6 (0.00%) Cholecystitis * 0/6 (0.00%) ",
        "premise_nums": [
            "0/6 (0.00%)",
            "2/6 (33.33%)",
            "1/6 (16.67%)",
            "2:Total: 2/6"
        ]
    },
    {
        "id": "c1f8c7fb-22de-4501-af86-d9eb59542ae3",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (CR Plus PR Plus SD) Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0 CR = disappearance of all target lesions PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease SD is defined as lack of disease progression by 24 weeks  Time frame: 24 weeks after start of treatment Results 1: Arm/Group Title: Arm 1 (6 mg Estradiol) Arm/Group Description: 6 mg of estradiol daily (2 mg tid)  Overall Number of Participants Analyzed: 34 Measure Type: Number ",
        "premise_nums": [
            "30% decrease",
            "0 CR =",
            "24 weeks after",
            "2 mg tid)",
            "34 Measure Type:",
            "6 mg of",
            "6 mg Estradiol)"
        ]
    },
    {
        "id": "c1f8c7fb-22de-4501-af86-d9eb59542ae3",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: participants Complete response (CR): 0Partial response (PR): 3 Stable disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 32 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 1 Stable disease (SD): 8 CR+PR+SD: 9 ",
        "premise_nums": [
            "30 mg Estradiol)",
            "1 Stable disease",
            "3 Stable disease",
            "0 Partial response",
            "32 Measure Type:",
            "30 mg of",
            "10 Results 2:",
            "10 mg tid)"
        ]
    },
    {
        "id": "6630047b-7ebc-4435-8203-cf6bbe6b6ee7",
        "primaryId": "NCT00331630",
        "statement_text": "Left ventricular ejection fraction greater than 50% is required for participation in the primary trial ",
        "statement_nums": [
            "50% is"
        ],
        "label": "Entailment",
        "premise_text": "LVEF 50% as measured by echocardiogram or MUGA scan ",
        "premise_nums": [
            "50% as"
        ]
    },
    {
        "id": "f8028143-35d1-4cc3-895a-acb577db4715",
        "primaryId": "NCT00537771",
        "secondaryId": "NCT00354640",
        "label": "Contradiction",
        "statement_text": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD ",
        "statement_nums": [
            "1 milligram of",
            "1 in the",
            "40 milligrams of"
        ],
        "premise_text": "INTERVENTION 1: Arimidex Group Anastrozole(ARIMIDEX): 1 mg once daily oral dose INTERVENTION 1: anastrozole : 1 milligram tablet PO QD for 14 days ",
        "premise_nums": [
            "1 mg once",
            "1 milligram tablet"
        ]
    },
    {
        "id": "907f7e56-b6ec-4a43-bf3a-14f93c644bc1",
        "primaryId": "NCT00193180",
        "statement_text": "A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for the primary trial ",
        "statement_nums": [
            "18 suffering from"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Age 18 years or older Exclusion Criteria: Known chronic liver disease ",
        "premise_nums": [
            "18 years or"
        ]
    },
    {
        "id": "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b",
        "primaryId": "NCT00853996",
        "statement_text": "Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial ",
        "statement_nums": [
            "5 years and"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Gail risk greater than or equal 1.7% and/or relative risk greater than or equal 3 times that for 5-year age group ",
        "premise_nums": [
            "5-year age",
            "3 times that",
            "equal 1.7% and/or"
        ]
    },
    {
        "id": "a41bf7b0-9a09-4ce0-8832-f13758581f20",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more optical adversse events than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202 (0.00%) CONSTIPATION 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: ",
        "premise_nums": [
            "2/202 (0.99%)",
            "61/202 (30.20%)",
            "5/202 (2.48%)",
            "1/202 (0.50%)",
            "0/202 (0.00%)"
        ]
    },
    {
        "id": "a41bf7b0-9a09-4ce0-8832-f13758581f20",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more optical adversse events than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 42/201 (20.90%)FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%) CATARACT 1/201 (0.50%) OPTIC NEUROPATHY 1/201 (0.50%) ABDOMINAL PAIN 1/201 (0.50%) CONSTIPATION 1/201 (0.50%) DIARRHOEA 3/201 (1.49%) ",
        "premise_nums": [
            "0/201 (0.00%)",
            "42/201 (20.90%)FEBRILE",
            "3/201 (1.49%)",
            "1/201 (0.50%)"
        ]
    },
    {
        "id": "5f2d2015-eaf9-45a8-9583-fddbc9807287",
        "primaryId": "NCT00130533",
        "statement_text": "Less than 0.25% of patients in cohort 1 of the primary trial suffered from Hyperbilirrubinemia ",
        "statement_nums": [
            "than 0.25% of patients",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hyperbilirrubinemia [1]1/436 (0.23%) ",
        "premise_nums": [
            "1/436 (0.23%)"
        ]
    },
    {
        "id": "43ff9425-5e6e-4a85-a8ca-0c0c67a96623",
        "primaryId": "NCT00431067",
        "statement_text": "More than 5% of the primary trial participants achieved Objective Response (OR) ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response (OR) Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria   Time frame: From first dose of study medication to response measurement  up to 34 month Results 1: Arm/Group Title: Afatinib 50 mg Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: Participants 4 ",
        "premise_nums": [
            "50 mg therapy",
            "41 Measure Type:",
            "34 month Results",
            "50 mg Arm",
            "28-day treatment"
        ]
    },
    {
        "id": "ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a",
        "primaryId": "NCT01575522",
        "secondaryId": "NCT00181363",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial are testing completely different modalities of interventions  but utilising the same 21 day cycle ",
        "statement_nums": [
            "21 day cycle"
        ],
        "premise_text": "INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Patients undergo blood sample collection at baseline and periodically during study for c-Met expression  relevant markers (HGF and VEGF)  PTEN loss  and PI3K mutation analysis by FISH and IHC  Archived tumor tissue samples are also analyzed  Laboratory Biomarker Analysis: Correlative studies Tivantinib: Given PO INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position ",
        "premise_nums": [
            "1-21. Courses",
            "21 days in"
        ]
    },
    {
        "id": "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6",
        "primaryId": "NCT00741260",
        "statement_text": "Patients with ERBB2 positive tumors are eligible for the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "label": "Entailment",
        "premise_text": "INCLUSION CRITERIA erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)  based on local testing  or based on centralized FISH testing prior to day 1. ",
        "premise_nums": [
            "2 gene amplified",
            "3+, or",
            "2 overexpression (IHC"
        ]
    },
    {
        "id": "5bdd61d9-aadf-4944-afe3-a04242d9c2b2",
        "primaryId": "NCT02321527",
        "statement_text": "Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial ",
        "statement_nums": [
            "4 cm are"
        ],
        "label": "Entailment",
        "premise_text": "Ipsilateral biopsy-proven invasive breast cancer smaller than 5 cm in maximal dimension by Ultrasound or Mammography  ",
        "premise_nums": [
            "5 cm in"
        ]
    },
    {
        "id": "b8ce7d6a-d707-48e0-816c-de7ac3a63823",
        "primaryId": "NCT01252277",
        "statement_text": "Fiona's sister  who is 34 years old was diagnosed with a ductal carcinoma  therefore fiona may be eligible for the primary trial ",
        "statement_nums": [
            "34 years old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria A first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer  ",
        "premise_nums": [
            "60 or multiple"
        ]
    },
    {
        "id": "8257bf5c-fae6-44c0-a86d-293746fdc468",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/26 (19.23%) Febrile neutropenia 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Nausea 1/26 (3.85%) Pancreatitis 1/26 (3.85%) Vomiting 2/26 (7.69%) Pain 0/26 (0.00%) Pneumonia 0/26 (0.00%) Urinary tract infection 1/26 (3.85%) Lumbar vertebral fracture 1/26 (3.85%) Ammonia increased 1/26 (3.85%) ",
        "premise_nums": [
            "5/26 (19.23%)",
            "2/26 (7.69%)",
            "0/26 (0.00%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "8257bf5c-fae6-44c0-a86d-293746fdc468",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Hepatic encephalopathy 1/26 (3.85%)Adverse Events 2: Total: 4/13 (30.77%) Febrile neutropenia 1/13 (7.69%) Abdominal pain 1/13 (7.69%) Constipation 1/13 (7.69%) Nausea 0/13 (0.00%) Pancreatitis 0/13 (0.00%) Vomiting 0/13 (0.00%) Pain 1/13 (7.69%) Pneumonia 1/13 (7.69%) Urinary tract infection 0/13 (0.00%) Lumbar vertebral fracture 0/13 (0.00%) ",
        "premise_nums": [
            "1/13 (7.69%)",
            "0/13 (0.00%)",
            "4/13 (30.77%)",
            "1/26 (3.85%)Adverse"
        ]
    },
    {
        "id": "8257bf5c-fae6-44c0-a86d-293746fdc468",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Ammonia increased 0/13 (0.00%)Hepatic encephalopathy 0/13 (0.00%) ",
        "premise_nums": [
            "0/13 (0.00%)Hepatic"
        ]
    },
    {
        "id": "7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2",
        "primaryId": "NCT00372424",
        "secondaryId": "NCT00041067",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 positive breast tumors are eligible for the primary trial  but excluded from the secondary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "premise_text": "Inclusion Criteria: Breast cancer with evidence of unresectable  locally recurrent  or metastatic disease  Tumors over-expressing Her-2 Candidate for treatment with docetaxel/trastuzumab HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting ",
        "premise_nums": [
            "2-positive by",
            "2 Candidate for"
        ]
    },
    {
        "id": "34ee4f66-e6f7-458c-964c-12fa730a9d56",
        "primaryId": "NCT02556632",
        "statement_text": "Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study ",
        "statement_nums": [
            "4-6 hours",
            "6 hours every"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies ",
        "premise_nums": [
            "1 week after",
            "6 hours beginning",
            "4-6 hours"
        ]
    },
    {
        "id": "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.",
        "statement_nums": [
            "1 in the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  INTERVENTION 2: ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "2 Cohort 1:",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "28-day cycle",
            "100mg/Trastuzumab",
            "80mg/m2 Cohort"
        ]
    },
    {
        "id": "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.",
        "statement_nums": [
            "1 in the"
        ],
        "label": "Contradiction",
        "premise_text": "Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2Cohort 2: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 140mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "80mg/m2Cohort",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "140mg/Trastuzumab",
            "28-day cycle"
        ]
    },
    {
        "id": "27acc6d7-c12d-4a38-9133-a5c8429dd264",
        "primaryId": "NCT00656669",
        "statement_text": "the primary trial recorded 23 adverse events ",
        "statement_nums": [
            "23 adverse events"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/23 (0.00%) ",
        "premise_nums": [
            "0/23 (0.00%)"
        ]
    },
    {
        "id": "5919a080-2f0d-4c3b-9b03-10df80b2e680",
        "primaryId": "NCT01007942",
        "statement_text": "There were no adverse event in the primary trial which affected more than 10% of a particular patient cohort ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile neutropenia 30/280 (10.71%) ",
        "premise_nums": [
            "30/280 (10.71%)"
        ]
    },
    {
        "id": "b351a091-d5fb-49f9-a864-5c89c6316b1b",
        "primaryId": "NCT01688609",
        "statement_text": "Patients must have histologically or cytologically confirmed PR+ invasive breast cancer  with Primary tumor greater than 2 cm in diameter TO PARTICIPATE in the primary trial ",
        "statement_nums": [
            "2 cm in"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients must have histologically or cytologically confirmed primary invasive breast cancer Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) + when IHC 2+ ",
        "premise_nums": [
            "2 is confirmed",
            "2 cm in",
            "(T2) as"
        ]
    },
    {
        "id": "d5ca2086-8404-42d1-bf45-5370f3d4e8e8",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "label": "Contradiction",
        "statement_text": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial ",
        "statement_nums": [
            "was 16.67% more cases"
        ],
        "premise_text": "Adverse Events 1: Total: 7/15 (46.67%) Cardiac arrest * 1/15 (6.67%) Chest pain - cardiac * 1/15 (6.67%) Diarrhea * 1/15 (6.67%) Duodenal hemorrhage * 1/15 (6.67%) Fatigue * 1/15 (6.67%) Fever * 1/15 (6.67%) Sudden death NOS * 1/15 (6.67%) Sepsis * 1/15 (6.67%) Skin infection * 1/15 (6.67%) Neutrophil count decreased * 1/15 (6.67%) Platelet count decreased * 1/15 (6.67%) Adverse Events 1: ",
        "premise_nums": [
            "7/15 (46.67%)",
            "1/15 (6.67%)"
        ]
    },
    {
        "id": "d5ca2086-8404-42d1-bf45-5370f3d4e8e8",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "label": "Contradiction",
        "statement_text": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial ",
        "statement_nums": [
            "was 16.67% more cases"
        ],
        "premise_text": "Total: 69/258 (26.74%)Anaemia 3/258 (1.16%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 1/258 (0.39%) Pericardial effusion 0/258 (0.00%) Sinus tachycardia 0/258 (0.00%) Abdominal pain 3/258 (1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 2: ",
        "premise_nums": [
            "1/258 (0.39%)",
            "13/258 (5.04%)",
            "3/258 (1.16%)",
            "0/258 (0.00%)",
            "5/258 (1.94%)",
            "69/258 (26.74%)Anaemia"
        ]
    },
    {
        "id": "d5ca2086-8404-42d1-bf45-5370f3d4e8e8",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "label": "Contradiction",
        "statement_text": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial ",
        "statement_nums": [
            "was 16.67% more cases"
        ],
        "premise_text": "Total: 64/224 (28.57%)Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224 (0.89%) Sinus tachycardia 1/224 (0.45%) Abdominal pain 3/224 (1.34%) Abdominal pain upper 0/224 (0.00%) Colitis 0/224 (0.00%) ",
        "premise_nums": [
            "2/224 (0.89%)",
            "1/224 (0.45%)",
            "4/224 (1.79%)",
            "64/224 (28.57%)Anaemia",
            "3/224 (1.34%)",
            "0/224 (0.00%)"
        ]
    },
    {
        "id": "286e74e5-74ed-4d42-b32d-f1398c514d37",
        "primaryId": "NCT01125566",
        "statement_text": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "25 mg/meter^2",
            "40 milligram (mg)",
            "10 minutes intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as time from randomisation to disease progression or death whichever occurs first  Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). RECIST is a set of published rules that define when tumors in cancer patients improve (\"respond\")  stay the same (\"stabilize\") or worsen (\"progress\") during treatment  Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered  ",
        "premise_nums": [
            "(08Jun2013) were",
            "RECIST 1.1 based endpoints"
        ]
    },
    {
        "id": "286e74e5-74ed-4d42-b32d-f1398c514d37",
        "primaryId": "NCT01125566",
        "statement_text": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "25 mg/meter^2",
            "40 milligram (mg)",
            "10 minutes intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Progression of disease was determined if at least 1 of the following criteria applied:At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started  together with an absolute increase in the SoD of at least 5 mm Appearance of 1 or more new lesions Unequivocal progression of existing non-target lesions Time frame: From randomization (07Sep2010) until disease progression  death or data cut-off (08Jun2013); Up to 34 months Results 1: ",
        "premise_nums": [
            "(07Sep2010) until",
            "5 mm Appearance",
            "34 months Results",
            "1 or more",
            "1 of the",
            "20% increase"
        ]
    },
    {
        "id": "a529e364-2da7-4067-acb6-9fb2f0adf08b",
        "primaryId": "NCT01401062",
        "statement_text": "A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial ",
        "statement_nums": [
            "2 weeks would"
        ],
        "label": "Entailment",
        "premise_text": "Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia): immunotherapy; ",
        "premise_nums": [
            "4 weeks since"
        ]
    },
    {
        "id": "de955acc-ce0e-4416-9884-644a06971603",
        "primaryId": "NCT00195013",
        "secondaryId": "NCT00620373",
        "label": "Contradiction",
        "statement_text": "Cohort 2 of the primary trial and the secondary trial are test groups ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Glutamine 10 grams three times a day (orally) for four days and then stop glutamine: 10 grams three times a day (orally) for four days and then stop INTERVENTION 2: Placebo 10 grams three times a day (orally) for four days and then stop Placebo: 10 grams three times a day (orally) for four days and then stop INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 2: Gamma Imaging For this reporting arm  the interpretation and analysis was done with gamma imaging only  ",
        "premise_nums": [
            "10 grams three"
        ]
    },
    {
        "id": "70dd1a42-6e40-4880-80a8-45dfd4941ce4",
        "primaryId": "NCT00089973",
        "statement_text": "the primary trial uses a 3 week cycle for SB-715992 administration ",
        "statement_nums": [
            "3 week cycle"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: SB-715992 The eligible participants were administered Ispinesib  intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle  at a dose of 18 mg/m^2. The dosing was repeated for up to multiple cycles  until disease progression or removal from treatment due to an unacceptable toxicity or withdrawal of consent  ",
        "premise_nums": [
            "21-day treatment",
            "715992 The eligible",
            "1 of every",
            "18 mg/m^2."
        ]
    },
    {
        "id": "85f43677-b680-4127-b1da-7e1cc966e4b2",
        "primaryId": "NCT01943916",
        "secondaryId": "NCT01653964",
        "label": "Entailment",
        "statement_text": "Not all subjects in the primary trial and the secondary trial will be adminstered 4-8 mCi Tc-99m sestamibi ",
        "statement_nums": [
            "4-8 mCi"
        ],
        "premise_text": "INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  ",
        "premise_nums": [
            "4 mCi Tc",
            "8 mCi Tc"
        ]
    },
    {
        "id": "8574ecd7-4da7-49b0-a273-de495bc1fee7",
        "primaryId": "NCT00951665",
        "statement_text": "Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%) ",
        "premise_nums": [
            "0/26 (0.00%)",
            "1/26 (3.85%)",
            "7/26 (26.92%)"
        ]
    },
    {
        "id": "93149dfc-667b-48d3-a46d-ad48b15e701f",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 17/94 (18.09%) Anaemia 2/94 (2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Ileus 1/94 (1.06%) Nausea 1/94 (1.06%) Vomiting 1/94 (1.06%) Asthenia 1/94 (1.06%) Disease progression 0/94 (0.00%) Oedema peripheral 1/94 (1.06%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "17/94 (18.09%)",
            "0/94 (0.00%)",
            "2/94 (2.13%)"
        ]
    },
    {
        "id": "93149dfc-667b-48d3-a46d-ad48b15e701f",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/39 (0.00%) Ischaemic cardiomyopathy 0/39 (0.00%) Myocardial infarction 1/39 (2.56%) Haemorrhoids 1/39 (2.56%) Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Vomiting 1/39 (2.56%) Asthenia 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%) ",
        "premise_nums": [
            "2/39 (5.13%)",
            "1/39 (2.56%)",
            "0/39 (0.00%)",
            "9/39 (23.08%)",
            "2:Total: 9/39"
        ]
    },
    {
        "id": "d080eec7-412f-4a44-8c56-91e0ec459acc",
        "primaryId": "NCT01422408",
        "statement_text": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks ",
        "statement_nums": [
            "fluocinonide 0.05% cream to"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Supportive Care (Fluocinonide Cream) This is a single-arm  single-stage  open-label phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms  All subjects will receive topical fluocinonide 0.05% cream to apply twice daily for two weeks and then once daily for two weeks to the vagina  The duration of treatment will be 4 weeks  ",
        "premise_nums": [
            "fluocinonide 0.05% cream to"
        ]
    },
    {
        "id": "fd18a599-f94a-478a-975f-854a4210ccad",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "label": "Contradiction",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is only a single day after removal of the drains ",
        "statement_nums": [
            "5 year long"
        ],
        "premise_text": "INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS  INTERVENTION 1: Single Drain ",
        "premise_nums": [
            "5 years INTERVENTION",
            "q28 days",
            "75 mg by",
            "5 years plus",
            "28 days for"
        ]
    },
    {
        "id": "5152d810-7669-4fb2-a66b-a0a1d6026af5",
        "primaryId": "NCT00577122",
        "secondaryId": "NCT01923168",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure  and use a 6 month time frame ",
        "statement_nums": [
            "6 month time"
        ],
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (CR + PR + SD greater than 6 Months)  To determine the clinical benefit rate (Complete Response + Partial Response + Stable Disease greater than 6 months) per Response Evaluation Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer  This will show the percent of patients who had Clinical Benefit and the Exact 95% Confidence Interval  Time frame: baseline through end of study  up to 3 years Outcome Measurement: Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs  Placebo for PIK3CA Mutant Cohort ",
        "premise_nums": [
            "3 years Outcome",
            "95% Confidence"
        ]
    },
    {
        "id": "5152d810-7669-4fb2-a66b-a0a1d6026af5",
        "primaryId": "NCT00577122",
        "secondaryId": "NCT01923168",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure  and use a 6 month time frame ",
        "statement_nums": [
            "6 month time"
        ],
        "premise_text": "Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy  or who did not receive surgery for any reason  or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate Time frame: After 24 weeks of treatment ",
        "premise_nums": [
            "0/Tis ypN0",
            "24 weeks of"
        ]
    },
    {
        "id": "3fa8b747-b48d-4fb4-995d-38a23c64ccb3",
        "primaryId": "NCT02069093",
        "statement_text": "2 of the patients in the primary trial were either symptomatic  but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Stomatitis Grade 2 The incidence of grade 2 stomatitis was reported  Grade 1 = minimal symptoms  normal diet; grade 2 = symptomatic  but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences  Time frame: 56 days Results 1: Arm/Group Title: Dexamethasone Based Mouthwash ",
        "premise_nums": [
            "2 The incidence",
            "2 stomatitis was",
            "56 days Results"
        ]
    },
    {
        "id": "3fa8b747-b48d-4fb4-995d-38a23c64ccb3",
        "primaryId": "NCT02069093",
        "statement_text": "2 of the patients in the primary trial were either symptomatic  but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks  Participants remained without food or drink (NPO) for one hour after administration of the mouthwash  Also  participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations Overall Number of Participants Analyzed: 86 Measure Type: Number Unit of Measure: Participants Stomatitis grade greater than or equal 2: Yes: 2 Stomatitis grade greater than or equal 2: No: 83 ",
        "premise_nums": [
            "2 Stomatitis grade",
            "10 mg and",
            "4 times daily",
            "of 0.5mg/5mL",
            "2 minutes each",
            "86 Measure Type:",
            "25 mg (study"
        ]
    },
    {
        "id": "b9c294c3-93b7-4681-be02-285f9e5cd867",
        "primaryId": "NCT03167359",
        "secondaryId": "NCT01385137",
        "label": "Entailment",
        "statement_text": "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort ",
        "statement_nums": [
            "3-fatty Acids"
        ],
        "premise_text": "INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast conserving surgery or mastectomy and clear margins  will receive 15 doses of radiation over three weeks  Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment  The boost treatment will be given on the same days as the whole breast treatment  The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions  INTERVENTION 1: Arm I (Omega-3-fatty Acid) ",
        "premise_nums": [
            "of 2.66 Gy per",
            "0-III Breast",
            "15 doses of",
            "receive 0.54 Gy per",
            "3-fatty Acid",
            "15 fractions simultaneously",
            "0-III breast"
        ]
    },
    {
        "id": "b9c294c3-93b7-4681-be02-285f9e5cd867",
        "primaryId": "NCT03167359",
        "secondaryId": "NCT01385137",
        "label": "Entailment",
        "statement_text": "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort ",
        "statement_nums": [
            "3-fatty Acids"
        ],
        "premise_text": "Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicityINTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "3-fatty acid",
            "24 weeks in"
        ]
    },
    {
        "id": "9df90d78-d857-4e1d-a650-e47f7b6b68d6",
        "primaryId": "NCT00322374",
        "statement_text": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone  at a higher frequency  than cohort 1,",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  ",
        "premise_nums": [
            "30 mg/m^2",
            "2 Ixabepilone as",
            "25 mg/m^2",
            "75 mg^m2 Participants",
            "30 mg^m2",
            "2 Participants received",
            "25 mg^m2",
            "2 epirubicin every",
            "3-hour IV",
            "5-minute IV",
            "75 mg/m^2"
        ]
    },
    {
        "id": "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe",
        "primaryId": "NCT03098550",
        "statement_text": "There results section indicates there were no patients in the primary trial with 0 adverse events ",
        "statement_nums": [
            "0 adverse events"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Adverse Events (AEs) Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab Time frame: From first dose to 30 days post last dose (up to 34 months) Results 1: Arm/Group Title: Nivolumab + Daratumumab (TNBC) ",
        "premise_nums": [
            "30 days post"
        ]
    },
    {
        "id": "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe",
        "primaryId": "NCT03098550",
        "statement_text": "There results section indicates there were no patients in the primary trial with 0 adverse events ",
        "statement_nums": [
            "0 adverse events"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of Measure: Participants 41 100.0% Results 2: Arm/Group Title: Nivolumab + Daratumumab (NSCLC) ",
        "premise_nums": [
            "1 to 8),",
            "41 100.0% Results 2",
            "16 mg/kg Q",
            "41 Measure Type:",
            "3 to 24)",
            "240 mg Q2W",
            "9-24)Overall Number"
        ]
    },
    {
        "id": "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe",
        "primaryId": "NCT03098550",
        "statement_text": "There results section indicates there were no patients in the primary trial with 0 adverse events ",
        "statement_nums": [
            "0 adverse events"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of Measure: Participants 21 100.0% ",
        "premise_nums": [
            "1 to 8),",
            "16 mg/kg Q",
            "3 to 24)",
            "240 mg Q2W",
            "21 Measure Type:",
            "9-24)Overall Number"
        ]
    },
    {
        "id": "f0aff1fc-4a67-4b28-a974-a4a67a5c930f",
        "primaryId": "NCT00733408",
        "statement_text": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "14 weeks difference"
        ],
        "label": "Entailment",
        "premise_text": "Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Kaplan-Meier survival curves will be used  A 95% confidence interval for the median PFS will be calculated  A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab  However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results ",
        "premise_nums": [
            "95% confidence",
            "8 months would",
            "13 months or",
            "20% increase"
        ]
    },
    {
        "id": "f0aff1fc-4a67-4b28-a974-a4a67a5c930f",
        "primaryId": "NCT00733408",
        "statement_text": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "14 weeks difference"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause  assessed up to 8 yearsResults 1: Arm/Group Title: Tx (Chemo  MoAb  and Enzyme Inhibitor) Arm/Group Description: INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "8 yearsResults 1:",
            "6 courses in",
            "30-90 minutes",
            "15 and bevacizumab",
            "90 minutes on",
            "28 days for",
            "1 and 15."
        ]
    },
    {
        "id": "f0aff1fc-4a67-4b28-a974-a4a67a5c930f",
        "primaryId": "NCT00733408",
        "statement_text": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "14 weeks difference"
        ],
        "label": "Entailment",
        "premise_text": "MAINTENANCE THERAPY: Patients achieving complete response  partial response  or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity paclitaxel albumin-stabilized nanoparticle formulation: Given IV bevacizumab: Given IV erlotinib hydrochloride: Given PO Overall Number of Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: Months 9.1 (7.2 to 11.1) ",
        "premise_nums": [
            "14 or 21",
            "30-90 minutes",
            "90 minutes once",
            "95% Confidence",
            "2 to 11.1)"
        ]
    },
    {
        "id": "95154c62-9f79-4d80-90fd-2f61612285b0",
        "primaryId": "NCT01095003",
        "secondaryId": "NCT01702571",
        "label": "Contradiction",
        "statement_text": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "premise_text": "Adverse Events 1: Total: 107/383 (27.94%) Anaemia 4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383 (0.26%) Abdominal pain 6/383 (1.57%) ",
        "premise_nums": [
            "6/383 (1.57%)",
            "0/383 (0.00%)",
            "107/383 (27.94%)",
            "1/383 (0.26%)",
            "7/383 (1.83%)",
            "2/383 (0.52%)",
            "4/383 (1.04%)"
        ]
    },
    {
        "id": "95154c62-9f79-4d80-90fd-2f61612285b0",
        "primaryId": "NCT01095003",
        "secondaryId": "NCT01702571",
        "label": "Contradiction",
        "statement_text": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "premise_text": "Adverse Events 2:Total: 85/383 (22.19%) Anaemia 3/383 (0.78%) Febrile neutropenia 2/383 (0.52%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 0/383 (0.00%) Neutropenia 1/383 (0.26%) Thrombocytopenia 1/383 (0.26%) Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383 (0.00%) Abdominal pain 3/383 (0.78%) ",
        "premise_nums": [
            "0/383 (0.00%)",
            "1/383 (0.26%)",
            "2/383 (0.52%)",
            "3/383 (0.78%)",
            "2:Total: 85/383",
            "85/383 (22.19%)"
        ]
    },
    {
        "id": "95154c62-9f79-4d80-90fd-2f61612285b0",
        "primaryId": "NCT01095003",
        "secondaryId": "NCT01702571",
        "label": "Contradiction",
        "statement_text": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "premise_text": "Adverse Events 1:Total: 427/2002 (21.33%) ANAEMIA 13/2002 (0.65%) BONE MARROW FAILURE 1/2002 (0.05%) DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%) FEBRILE NEUTROPENIA 1/2002 (0.05%) THROMBOCYTOPENIA 11/2002 (0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC ARREST 1/2002 (0.05%) CARDIAC FAILURE 1/2002 (0.05%) CARDIAC TAMPONADE 1/2002 (0.05%) Adverse Events 2: Total: 36/181 (19.89%) ",
        "premise_nums": [
            "13/2002 (0.65%)",
            "11/2002 (0.55%)",
            "1/2002 (0.05%)",
            "36/181 (19.89%)",
            "1:Total: 427/2002",
            "3/2002 (0.15%)",
            "427/2002 (21.33%)"
        ]
    },
    {
        "id": "95154c62-9f79-4d80-90fd-2f61612285b0",
        "primaryId": "NCT01095003",
        "secondaryId": "NCT01702571",
        "label": "Contradiction",
        "statement_text": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "premise_text": "ANAEMIA 0/181 (0.00%)BONE MARROW FAILURE 0/181 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/181 (0.00%) FEBRILE NEUTROPENIA 0/181 (0.00%) THROMBOCYTOPENIA 10/181 (5.52%) ACUTE CORONARY SYNDROME 1/181 (0.55%) ANGINA PECTORIS 0/181 (0.00%) CARDIAC ARREST 0/181 (0.00%) CARDIAC FAILURE 0/181 (0.00%) CARDIAC TAMPONADE 0/181 (0.00%) ",
        "premise_nums": [
            "10/181 (5.52%)",
            "0/181 (0.00%)BONE",
            "1/181 (0.55%)"
        ]
    },
    {
        "id": "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d",
        "primaryId": "NCT02630693",
        "statement_text": "A 30% of patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "30% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Vomiting 0/90 (0.00%) Death NOS 1/90 (1.11%) Fever 0/90 (0.00%) Other general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) ",
        "premise_nums": [
            "2/90 (2.22%)",
            "1/90 (1.11%)",
            "0/90 (0.00%)",
            "9/90 (10.00%)",
            "12/89 (13.48%)"
        ]
    },
    {
        "id": "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d",
        "primaryId": "NCT02630693",
        "statement_text": "A 30% of patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "30% of"
        ],
        "label": "Contradiction",
        "premise_text": "Febrile neutropenia 0/89 (0.00%)Ascites 1/89 (1.12%) Nausea 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders 0/89 (0.00%) Lung infection 0/89 (0.00%) Sepsis 1/89 (1.12%) Spinal fracture 1/89 (1.12%) ",
        "premise_nums": [
            "1/89 (1.12%)",
            "2/89 (2.25%)",
            "0/89 (0.00%)Ascites"
        ]
    },
    {
        "id": "80245791-4a95-4682-bd5f-856694c9f52f",
        "primaryId": "NCT00721409",
        "secondaryId": "NCT02413320",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial",
        "statement_nums": [
            "2 negative tumours"
        ],
        "premise_text": "Inclusion Criteria: Inoperable estrogen receptor positive and HER2 negative breast cancer  Inclusion Criteria: Patients with newly diagnosed stage I (Tgreater than 1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy ",
        "premise_nums": [
            "2 negative breast"
        ]
    },
    {
        "id": "f0da58e6-e937-41ac-b53a-d46ec8a28d11",
        "primaryId": "NCT01923168",
        "statement_text": "Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily ",
        "statement_nums": [
            "300 mg alpelisib",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Alpelisib + Letrozole Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily  ",
        "premise_nums": [
            "300 mg once",
            "letrozole 2.5 mg once"
        ]
    },
    {
        "id": "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d",
        "primaryId": "NCT01125566",
        "statement_text": "At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "10 minutes intravenous",
            "25 mg/meter^2",
            "40 milligram (mg)",
            "400 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as time from randomisation to disease progression or death whichever occurs first  Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). RECIST is a set of published rules that define when tumors in cancer patients improve (\"respond\")  stay the same (\"stabilize\") or worsen (\"progress\") during treatment  Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered  ",
        "premise_nums": [
            "(08Jun2013) were",
            "RECIST 1.1 based endpoints"
        ]
    },
    {
        "id": "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d",
        "primaryId": "NCT01125566",
        "statement_text": "At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "10 minutes intravenous",
            "25 mg/meter^2",
            "40 milligram (mg)",
            "400 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Progression of disease was determined if at least 1 of the following criteria applied:At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started  together with an absolute increase in the SoD of at least 5 mm Appearance of 1 or more new lesions Unequivocal progression of existing non-target lesions Time frame: From randomization (07Sep2010) until disease progression  death or data cut-off (08Jun2013); Up to 34 months Results 1: ",
        "premise_nums": [
            "(07Sep2010) until",
            "5 mm Appearance",
            "34 months Results",
            "1 or more",
            "1 of the",
            "20% increase"
        ]
    },
    {
        "id": "d905f4cb-32aa-41b8-8f61-40578d8ea9ae",
        "primaryId": "NCT00274469",
        "statement_text": "No less than 2 patients from either cohorts of the primary trial felt nauseous ",
        "statement_nums": [
            "2 patients from"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: NAUSEA 1/101 (0.99%) Adverse Events 2: NAUSEA 0/103 (0.00%) ",
        "premise_nums": [
            "0/103 (0.00%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "45510043-7931-493b-8251-41b0be9aabbd",
        "primaryId": "NCT00232505",
        "statement_text": "There were 2 instances of patients with Atrial tachycardia in the primary trial ",
        "statement_nums": [
            "2 instances of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/31 (9.68%) Edema: limb * 2/31 (6.45%) Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%) Cardiac General - Other (Specify  __) * [1]0/31 (0.00%) Cardiac General - Other (Specify  __) * [2]0/31 (0.00%) Left ventricular diastolic dysfunction * 0/31 (0.00%) Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/31 (0.00%) Adverse Events 2: Total: 8/25 (32.00%) ",
        "premise_nums": [
            "2/31 (6.45%)",
            "3/31 (9.68%)",
            "8/25 (32.00%)",
            "0/31 (0.00%)"
        ]
    },
    {
        "id": "45510043-7931-493b-8251-41b0be9aabbd",
        "primaryId": "NCT00232505",
        "statement_text": "There were 2 instances of patients with Atrial tachycardia in the primary trial ",
        "statement_nums": [
            "2 instances of"
        ],
        "label": "Contradiction",
        "premise_text": "Edema: limb * 1/25 (4.00%)Neutrophils/granulocytes (ANC/AGC) * 0/25 (0.00%) Cardiac General - Other (Specify  __) * [1]1/25 (4.00%) Cardiac General - Other (Specify  __) * [2]0/25 (0.00%) Left ventricular diastolic dysfunction * 1/25 (4.00%) Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/25 (0.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "1/25 (4.00%)Neutrophils/granulocytes"
        ]
    },
    {
        "id": "e7037f34-bd2e-402e-a19c-48073781885a",
        "primaryId": "NCT00193037",
        "statement_text": "10 of the patients in Cohort 1 of the primary trial suffered from Hypotension ",
        "statement_nums": [
            "10 of the",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Hypotension 0/50 (0.00%) ",
        "premise_nums": [
            "0/50 (0.00%)"
        ]
    },
    {
        "id": "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4",
        "primaryId": "NCT01566721",
        "statement_text": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.",
        "statement_nums": [
            "1 Adverse Event"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period Participants were planned to receive a total of 18 cycles of SC Herceptin  An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin  Examples included unfavorable/unintended signs and symptoms  new or exacerbated disease  recurrence of intermittent condition  deterioration in laboratory value or other clinical test  or adverse procedure-related events  The percentage of participants with at least 1 AE during the treatment period (regardless of severity or seriousness) was reported  Time frame: From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year) Results 1: ",
        "premise_nums": [
            "19 cycles (cycle",
            "1 AE during",
            "18 cycles of",
            "1 up to",
            "1 Adverse Event"
        ]
    },
    {
        "id": "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4",
        "primaryId": "NCT01566721",
        "statement_text": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.",
        "statement_nums": [
            "1 Adverse Event"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Cohort A: SC Herceptin by Needle/SyringeArm/Group Description: Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe  Overall Number of Participants Analyzed: 1864 Measure Type: Number Unit of Measure: percentage of participants 88.6 Results 2: Arm/Group Title: Cohort B: SC Herceptin by SID ",
        "premise_nums": [
            "1864 Measure Type:",
            "18 doses/cycles",
            "3 weeks for",
            "6 Results 2:",
            "600 mg every",
            "participants 88.6 Results 2"
        ]
    },
    {
        "id": "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4",
        "primaryId": "NCT01566721",
        "statement_text": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.",
        "statement_nums": [
            "1 Adverse Event"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was administered from a pre-filled SID  The first administration was performed by an HCP  Subsequent doses were self-administered by participants who were willing and judged competent by the HCP Overall Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants 89.0 ",
        "premise_nums": [
            "18 doses/cycles",
            "3 weeks for",
            "600 mg every",
            "709 Measure Type:"
        ]
    },
    {
        "id": "a1c99d5b-d53a-4195-ad5f-5e1b48c22078",
        "primaryId": "NCT03176238",
        "secondaryId": "NCT01498458",
        "label": "Entailment",
        "statement_text": "Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial  no robust comparisons can be made due to the significant differences in cohort sizes ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 59/199 (29.65%) Anaemia 7/199 (3.52%) Thrombocytopenia 2/199 (1.01%) Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) ",
        "premise_nums": [
            "2/199 (1.01%)",
            "6/8 (75.00%)",
            "7/199 (3.52%)",
            "1/8 (12.50%)",
            "59/199 (29.65%)"
        ]
    },
    {
        "id": "0203435e-03a0-4c41-afdf-6c497d8908c1",
        "primaryId": "NCT00331630",
        "statement_text": "Men with Left ventricular ejection fraction greater than 50% are excluded from participating in the primary trial ",
        "statement_nums": [
            "50% are"
        ],
        "label": "Contradiction",
        "premise_text": "LVEF 50% as measured by echocardiogram or MUGA scan Male or female ",
        "premise_nums": [
            "50% as"
        ]
    },
    {
        "id": "879f2f14-38a8-419a-bae0-e62ed81eb9dd",
        "primaryId": "NCT00146172",
        "statement_text": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of LA-EP2006.",
        "statement_nums": [
            "60% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd ",
        "premise_nums": [
            "80 mg Neratinib",
            "80 mg qd",
            "40 mg Neratinb",
            "40 mg qd"
        ]
    },
    {
        "id": "2ec46285-dd0c-4420-b9f6-e44a1ac74f20",
        "primaryId": "NCT01752907",
        "secondaryId": "NCT01940497",
        "label": "Contradiction",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "premise_text": "Adverse Events 1: Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Diarrhoea 2/149 (1.34%) Dyspepsia 0/149 (0.00%) Gastritis haemorrhagic 0/149 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: ",
        "premise_nums": [
            "16/149 (10.74%)",
            "7/149 (4.70%)",
            "0/149 (0.00%)",
            "1/149 (0.67%)",
            "2/149 (1.34%)"
        ]
    },
    {
        "id": "2ec46285-dd0c-4420-b9f6-e44a1ac74f20",
        "primaryId": "NCT01752907",
        "secondaryId": "NCT01940497",
        "label": "Contradiction",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "premise_text": "Total: 20/151 (13.25%)Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation 0/151 (0.00%) Cardiac failure congestive 1/151 (0.66%) Abdominal pain 1/151 (0.66%) Diarrhoea 3/151 (1.99%) Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%) Adverse Events 1: ",
        "premise_nums": [
            "1/151 (0.66%)",
            "2/151 (1.32%)",
            "4/151 (2.65%)",
            "3/151 (1.99%)",
            "20/151 (13.25%)Anaemia",
            "0/151 (0.00%)"
        ]
    },
    {
        "id": "2ec46285-dd0c-4420-b9f6-e44a1ac74f20",
        "primaryId": "NCT01752907",
        "secondaryId": "NCT01940497",
        "label": "Contradiction",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "premise_text": "Total: 5/95 (5.26%)Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Vomiting 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "5/95 (5.26%)Febrile",
            "1/95 (1.05%)",
            "0/95 (0.00%)"
        ]
    },
    {
        "id": "2ec46285-dd0c-4420-b9f6-e44a1ac74f20",
        "primaryId": "NCT01752907",
        "secondaryId": "NCT01940497",
        "label": "Contradiction",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "premise_text": "Total: 3/20 (15.00%)Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) Intervertebral disc protrusion 1/20 (5.00%) ",
        "premise_nums": [
            "3/20 (15.00%)Febrile",
            "0/20 (0.00%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "f8afffdc-649b-4921-942a-66b804a3717f",
        "primaryId": "NCT00121992",
        "statement_text": "In order to be eligible for the primary trial  patients must not have prior radiation  anthracycline or systemic anticancer therapy   and must have T1-4, N1 and M1 bilateral breast cancer ",
        "statement_nums": [
            "1 and M1",
            "1-4, N1"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Prior systemic anticancer therapy for breast cancer (immunotherapy  hormonotherapy  chemotherapy)  Prior anthracycline therapy or taxoids (paclitaxel  docetaxel) for any malignancy  Prior radiation therapy for breast cancer  Any T4 or N1-3 or M1 breast cancer  ",
        "premise_nums": [
            "N1-3 or",
            "3 or M1"
        ]
    },
    {
        "id": "65f22210-47dd-4865-99e2-ddd414dddb08",
        "primaryId": "NCT01806259",
        "statement_text": "In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years ",
        "statement_nums": [
            "82% patient"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg Arm/Group Description: Active drug to be compared with placebo Ketorolac 30 mg IV Overall Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of Measure: Participants 80 83.3% Results 2: Arm/Group Title: NaCl 0.9% 3mL Arm/Group Description: Ketorolac 30 mg IV Overall Number of Participants Analyzed: 107 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7% ",
        "premise_nums": [
            "96 Measure Type:",
            "30 mg Arm",
            "80 83.3% Results 2",
            "3 additional years",
            "2 years for",
            "30 mg IV",
            "107 Measure Type:",
            "5 years Results"
        ]
    },
    {
        "id": "ff8a1e0d-d2ee-4687-b429-5b3b6081edc6",
        "primaryId": "NCT00915603",
        "secondaryId": "NCT02511730",
        "label": "Contradiction",
        "statement_text": "INR of 1.35 is enough for participation in the primary trial and the secondary trial ",
        "statement_nums": [
            "of 1.35 is enough"
        ],
        "premise_text": "Inclusion Criteria: International normalized ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  ",
        "premise_nums": [
            "5 or prothrombin"
        ]
    },
    {
        "id": "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b",
        "primaryId": "NCT00917735",
        "statement_text": "One patient in cohort 2 of the primary trial crashed their motorbike ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) ",
        "premise_nums": [
            "8/537 (1.49%)",
            "1/537 (0.19%)",
            "2/537 (0.37%)",
            "0/537 (0.00%)"
        ]
    },
    {
        "id": "0aa3c085-b9c6-4918-a5d0-eabc55bdd177",
        "primaryId": "NCT01560416",
        "statement_text": "There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial ",
        "statement_nums": [
            "10 more cases",
            "2 than in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/15 (13.33%) Adverse Events 2: Total: 11/35 (31.43%) ",
        "premise_nums": [
            "11/35 (31.43%)",
            "2/15 (13.33%)"
        ]
    },
    {
        "id": "333c2723-e2e8-4c68-9591-36b7f169ff26",
        "primaryId": "NCT00828074",
        "statement_text": "A higher percentage of cohort 1 of the primary trial showed signs of fever  compared to cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Fever * 2/41 (4.88%) Adverse Events 2: Fever * 0/5 (0.00%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "0/5 (0.00%)"
        ]
    },
    {
        "id": "1fa01b9a-1288-404c-ad58-8dcf3db3264c",
        "primaryId": "NCT00477464",
        "statement_text": "59% of Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "59% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Clinical Benefit Response (Independent Reviewer-assessed) CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months (24 weeks)  A \"complete response\" is defined as the disappearance of all target or non-target lesions  \"partial response\" and \"disease progression\" as at least a 30% decrease and at least a 20% increase  respectively  in the sum of the longest diameter of target lesions  and \"stable disease\" as neither \"partial response\" nor \"disease progression.\" Time frame: Baseline  every 6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119) Results 1: ",
        "premise_nums": [
            "30% decrease",
            "6 weeks until",
            "6 months (24",
            "12 weeks until",
            "24 and then",
            "20% increase"
        ]
    },
    {
        "id": "1fa01b9a-1288-404c-ad58-8dcf3db3264c",
        "primaryId": "NCT00477464",
        "statement_text": "59% of Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "59% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Lapatinib 1250 mg and Capecitabine 2000 mg/m^2Arm/Group Description: Participants took lapatinib and capecitabine  Lapatinib was orally administered at 1250 milligrams (mg) once daily  Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle  Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 59 ",
        "premise_nums": [
            "1250 milligrams (mg)",
            "1250 mg and",
            "1000 mg per",
            "2000 mg/m^2Arm/Group",
            "51 Measure Type:",
            "21-day cycle"
        ]
    },
    {
        "id": "b1497cf4-6b06-4227-b679-19e2ac5fb5c3",
        "primaryId": "NCT01421017",
        "statement_text": "the primary trial studies the effects of CTX/IMQ/RT and Epothilone on Central Nervous System (CNS) Progression-free Survival(PFS)  9 weeks after the start of treatment ",
        "statement_nums": [
            "9 weeks after"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Systemic Tumor Response Rates (Complete Response+Partial Response) The systemic tumor response refers to the response at the time of best overall response  The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok  et al.  2009). Time frame: 9 weeks from the start of the treatment of RT ",
        "premise_nums": [
            "9 weeks from"
        ]
    },
    {
        "id": "0e8e4a92-b104-4192-ad36-33b683f94216",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate  in Centrally Confirmed Androgen Receptor (AR)+ Subjects To estimate the clinical benefit rate (defined as complete response  partial response  or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD  Time frame: 24 weeks ",
        "premise_nums": [
            "30% decrease"
        ]
    },
    {
        "id": "0e8e4a92-b104-4192-ad36-33b683f94216",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Entailment",
        "premise_text": "Results 1:Arm/Group Title: GTx-024 9 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: participants 16 Results 2: Arm/Group Title: GTx-024 18 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 52 Measure Type: Number ",
        "premise_nums": [
            "50 Measure Type:",
            "16 Results 2:",
            "18 mg GTx",
            "1:Arm/Group Title:",
            "18 mg Arm",
            "52 Measure Type:",
            "9 mg Arm",
            "9 mg GTx",
            "024 softgel capsules"
        ]
    },
    {
        "id": "7d7a9a69-533a-4480-b2e7-aa59eb8a738b",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial  than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: CNS Objective Response Rate (ORR) The central nervous system (CNS) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on treatment: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  ",
        "premise_nums": [
            "30% decrease",
            "RECIST 1.1 criteria in"
        ]
    },
    {
        "id": "7d7a9a69-533a-4480-b2e7-aa59eb8a738b",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial  than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: Disease assessments occurred every 6 cycles  Patients with stable or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles  Response was evaluated up to 25 months Results 1: Arm/Group Title: Cohort 1 - Cabozantinib  Trastuzumab for HER2+ Arm/Group Description: HER2-positive Cabozantinib- orally administered daily per treatment cycle Trastuzumab- IV administered once per cycle MRI- Baseline  Cycle 2 Day 1, and every 2 cycles Magnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, ",
        "premise_nums": [
            "6 cycles could",
            "2 Day 1,",
            "2 cycles Magnetic",
            "2-positive Cabozantinib-",
            "25 months Results"
        ]
    },
    {
        "id": "7d7a9a69-533a-4480-b2e7-aa59eb8a738b",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial  than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Contradiction",
        "premise_text": "Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops Trastuzumab: For HER2-Positive participants only  Administered by IV on day 1 of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort 2 - Cabozantinib for ER+ and/or PR+ Arm/Group Description: Hormone receptor-positive (ER+ and/or PR+) Cabozantinib- orally administered daily per treatment cycle ",
        "premise_nums": [
            "60 mg tablet",
            "1 of each",
            "2-Positive participants",
            "2 to 24)",
            "21 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "7d7a9a69-533a-4480-b2e7-aa59eb8a738b",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial  than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Contradiction",
        "premise_text": "MRI- Baseline  Cycle 2 Day 1, and every 2 cyclesMagnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage of participants 14 (.4 to 58) ",
        "premise_nums": [
            "2 Day 1,",
            "4 to 58)",
            "60 mg tablet",
            "2 cyclesMagnetic Resonance",
            "7 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "c6fc8336-7c74-443e-9548-3bbafe21fc37",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years Number of events (disease relapse or death) to time of observation for DFS  DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal  receptor positive  node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years  Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC)  Intercurrent death: death without disease relapse  Time frame: Baseline (Month 0) up to 2.75 years Results 1: ",
        "premise_nums": [
            "to 2.75 years Results",
            "to 2.75 Years Number"
        ]
    },
    {
        "id": "c6fc8336-7c74-443e-9548-3bbafe21fc37",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: ExemestaneArm/Group Description: Exemestane (Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4898 Measure Type: Number Unit of Measure: Events (disease relapse or death) 352 Results 2: Arm/Group Title: Tamoxifen Followed by Exemestane Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen  participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy  Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events (disease relapse or death) 388 ",
        "premise_nums": [
            "4868 Measure Type:",
            "completing 2.5 years to",
            "5 years endocrine",
            "20 mg QD;",
            "25 mg QD",
            "352 Results 2:",
            "4898 Measure Type:",
            "3 years of"
        ]
    },
    {
        "id": "46d65581-7a0a-423b-907e-662c1f5843cc",
        "primaryId": "NCT01127763",
        "statement_text": "There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial ",
        "statement_nums": [
            "1 more case)",
            "4% more"
        ],
        "label": "Entailment",
        "premise_text": "Dehydration 1/25 (4.00%) Dyspnea (Shortness Of Breath) 2/25 (8.00%) ",
        "premise_nums": [
            "1/25 (4.00%)",
            "2/25 (8.00%)"
        ]
    },
    {
        "id": "932728c5-2e7f-401f-be64-e90597ff2ce2",
        "primaryId": "NCT00129935",
        "statement_text": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin * [2]0/669 (0.00%) CNS cerebrovascular ischemia * [1]0/669 (0.00%) CNS cerebrovascular ischemia * [3]0/669 (0.00%) Heart Failure * [1]3/669 (0.45%) Thrombosis/embolism * [1]1/669 (0.15%) ",
        "premise_nums": [
            "0/669 (0.00%)",
            "3/669 (0.45%)",
            "111/669 (16.59%)",
            "1/669 (0.15%)"
        ]
    },
    {
        "id": "932728c5-2e7f-401f-be64-e90597ff2ce2",
        "primaryId": "NCT00129935",
        "statement_text": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Thrombosis/embolism * [3]0/669 (0.00%)Adverse Events 2: Total: 138/715 (19.30%) Leukocytes * [1]0/715 (0.00%) Hemoglobin * [1]0/715 (0.00%) Hemoglobin * [2]1/715 (0.14%) CNS cerebrovascular ischemia * [1]1/715 (0.14%) CNS cerebrovascular ischemia * [3]1/715 (0.14%) Heart Failure * [1]1/715 (0.14%) ",
        "premise_nums": [
            "0/669 (0.00%)Adverse",
            "0/715 (0.00%)",
            "138/715 (19.30%)",
            "1/715 (0.14%)"
        ]
    },
    {
        "id": "932728c5-2e7f-401f-be64-e90597ff2ce2",
        "primaryId": "NCT00129935",
        "statement_text": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Thrombosis/embolism * [1]3/715 (0.42%)Thrombosis/embolism * [3]2/715 (0.28%) ",
        "premise_nums": [
            "3/715 (0.42%)Thrombosis/embolism",
            "2/715 (0.28%)"
        ]
    },
    {
        "id": "54ad9406-852c-40fc-bd0e-8e7e81eacc71",
        "primaryId": "NCT00291577",
        "statement_text": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours",
        "statement_nums": [
            "17 or 20"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation  Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose ",
        "premise_nums": [
            "011248 and SU012662",
            "SU011248 and",
            "24 hours postdose"
        ]
    },
    {
        "id": "a87e6e20-c7d0-4941-9933-204fab99b299",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment ",
        "statement_nums": [
            "6 months of",
            "1/3 participants",
            "3 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment The PFS rate is defined as the percentage of subjects who have shown no evidence of disease progression or death from any cause following 12 weeks of treatment  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Since there is no independent reviewer  only the investigator response was reported  Time frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab ",
        "premise_nums": [
            "12 Weeks of",
            "12 Results 1:",
            "12 weeks of",
            "20% increase"
        ]
    },
    {
        "id": "a87e6e20-c7d0-4941-9933-204fab99b299",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment ",
        "statement_nums": [
            "6 months of",
            "1/3 participants",
            "3 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks)Overall Number of Participants Analyzed: 52 Measure Type: Count of Participants Unit of Measure: Participants No disease progression by Week 12: 36 69.2% Disease progression or death by Week 12: 16 30.8% ",
        "premise_nums": [
            "36 69.2% Disease progression",
            "1500 mg once",
            "52 Measure Type:"
        ]
    },
    {
        "id": "6c3427a8-27a1-459c-9fbc-175649210868",
        "primaryId": "NCT01940497",
        "statement_text": "There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Vomiting 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/95 (0.00%)",
            "5/95 (5.26%)",
            "1/95 (1.05%)"
        ]
    },
    {
        "id": "6c3427a8-27a1-459c-9fbc-175649210868",
        "primaryId": "NCT01940497",
        "statement_text": "There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 3/20 (15.00%)Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) ",
        "premise_nums": [
            "3/20 (15.00%)Febrile",
            "0/20 (0.00%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "883bec6a-bce2-4e60-9304-49a056e66df7",
        "primaryId": "NCT00101400",
        "statement_text": "A female with Hemoglobin greater than 10.0 g/dl  Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin smaller than 1.2 x ULN are eligilbe for the primary trial ",
        "statement_nums": [
            "than 10.0 g/dl",
            "than 1.2 x ULN",
            "1,733/mm3, platelet",
            "100,000/¬¨¬µl and"
        ],
        "label": "Contradiction",
        "premise_text": "Hemoglobin greater than 9.0 g/dl Absolute neutrophil count (ANC) greater than 1,500/mm3 Platelet count = 100,000/µl Total bilirubin =1.5 x the upper limit of normal  ",
        "premise_nums": [
            "3 Platelet count",
            "than 9.0 g/dl",
            "1,500/mm3 Platelet",
            "100,000/µl Total",
            "5 x the"
        ]
    },
    {
        "id": "0fdda7a2-4119-40a7-84f3-6c5c6077df49",
        "primaryId": "NCT02186015",
        "statement_text": "Women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol ",
        "statement_nums": [
            "30 ng/ml did"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Cholecalciferol Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks  INTERVENTION 2: No Cholecalciferol Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention  ",
        "premise_nums": [
            "received 50,000 IUs weekly",
            "30 ng/ml received"
        ]
    },
    {
        "id": "e7eae332-6b6a-41e0-aa31-86a781fd373f",
        "primaryId": "NCT01273896",
        "statement_text": "There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Cardiac General  other1/22 (4.55%) Dyspnea (shortness of breath)2/22 (9.09%) ",
        "premise_nums": [
            "2/22 (9.09%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591",
        "primaryId": "NCT01439945",
        "statement_text": "In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide ",
        "statement_nums": [
            "400 mg/day less"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Low Dose Magnesium Oxide (800 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: ",
        "premise_nums": [
            "400 mg tablet",
            "4-9: Patients"
        ]
    },
    {
        "id": "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591",
        "primaryId": "NCT01439945",
        "statement_text": "In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide ",
        "statement_nums": [
            "400 mg/day less"
        ],
        "label": "Entailment",
        "premise_text": "Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD) ",
        "premise_nums": [
            "400 mg tablet"
        ]
    },
    {
        "id": "6f143256-52e4-40b7-950c-5c892f8632b9",
        "primaryId": "NCT00003199",
        "statement_text": "The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients  and the worst was Stage IV Disease patients ",
        "statement_nums": [
            "5 months in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Event-free Survival Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF  Time frame: 11 years Results 1: Arm/Group Title: TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer Arm/Group Description: See Detailed Description  tamoxifen citrate: Given orally busulfan: Given orally thiotepa: Given IV melphalan: Given IV aldesleukin: Given SC sargramostim: Given SC peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion ",
        "premise_nums": [
            "11 years Results"
        ]
    },
    {
        "id": "6f143256-52e4-40b7-950c-5c892f8632b9",
        "primaryId": "NCT00003199",
        "statement_text": "The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients  and the worst was Stage IV Disease patients ",
        "statement_nums": [
            "5 months in"
        ],
        "label": "Contradiction",
        "premise_text": "radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSFOverall Number of Participants Analyzed: 50 Measure Type: Count of Participants Unit of Measure: Participants Stage IIIB Disease: 18 participants 11 61.1% Stage IV Disease: 32 participants 9 28.1% ",
        "premise_nums": [
            "32 participants 9",
            "50 Measure Type:",
            "18 participants 11",
            "11 61.1% Stage IV",
            "2/GM-CSFOverall Number"
        ]
    },
    {
        "id": "d2718f05-1d35-4c84-a054-06a3fe4a0a9c",
        "primaryId": "NCT00217399",
        "statement_text": "To be included in the primary trial  patients must have at least 1 unidimensionally measurable lesion  and must meet some specific size conditions ",
        "statement_nums": [
            "1 unidimensionally measurable"
        ],
        "label": "Entailment",
        "premise_text": "Measurable disease  defined as greater than or equal 1 unidimensionally measurable lesion  including greater than or equal 1 of the following: Lesion greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or MRI (10 mm sections) Lesion greater than or equal 10 mm on physical exam ",
        "premise_nums": [
            "1 unidimensionally measurable",
            "10 mm on",
            "10 mm sections)",
            "20 mm on",
            "5 mm sections)",
            "1 of the"
        ]
    },
    {
        "id": "7f49cafd-3a27-4fc8-872d-914b9176442e",
        "primaryId": "NCT01427933",
        "statement_text": "Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 26/69 (37.68%) Anaemia 2/69 (2.90%) Febrile neutropenia 3/69 (4.35%) Neutropenia 4/69 (5.80%) Cardiac arrest 1/69 (1.45%) Cardiac failure congestive 1/69 (1.45%) Cardiac tamponade 1/69 (1.45%) Pericardial effusion 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Ascites 2/69 (2.90%) Colitis 1/69 (1.45%) Gastritis 1/69 (1.45%) Gastritis erosive 1/69 (1.45%) ",
        "premise_nums": [
            "2/69 (2.90%)",
            "3/69 (4.35%)",
            "1/69 (1.45%)",
            "26/69 (37.68%)",
            "4/69 (5.80%)"
        ]
    },
    {
        "id": "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25",
        "primaryId": "NCT01998906",
        "statement_text": "The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Neutropenia * 1/115 (0.87%) Pancytopenia * 1/115 (0.87%) ",
        "premise_nums": [
            "1/115 (0.87%)"
        ]
    },
    {
        "id": "3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8",
        "primaryId": "NCT00428922",
        "secondaryId": "NCT00499083",
        "label": "Contradiction",
        "statement_text": "Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago  are not eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "4 cancer over",
            "5 years ago"
        ],
        "premise_text": "Inclusion Criteria: Histologically confirmed breast cancer with evidence of metastatic disease HER2 3+ or FISH (fluorescent in situ hybridization)+ Age 18 years No prior trastuzumab  except as given in the adjuvant or neoadjuvant setting  No prior chemotherapy in the metastatic setting  Exclusion Criteria: CNS (central nervous system) metastases Prior radiation therapy within the last 4 weeks Pregnant (positive pregnancy test) or lactating women Major surgical procedure  open biopsy  non-healing wounds  or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study  No prior chemotherapy or radiotherapy ",
        "premise_nums": [
            "4 weeks Pregnant",
            "18 years No",
            "7 days prior",
            "28 days prior"
        ]
    },
    {
        "id": "59fd53e4-b38c-4018-bafc-6fd7f7becebe",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their blood vessels ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Anorexia 1/31 (3.23%) ",
        "premise_nums": [
            "2/31 (6.45%)",
            "10/31 (32.26%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "59fd53e4-b38c-4018-bafc-6fd7f7becebe",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their blood vessels ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Dyspnea 2/31 (6.45%)",
        "premise_nums": [
            "2/31 (6.45%)"
        ]
    },
    {
        "id": "021e79d2-ce70-43cf-aac9-fa8d4c8d3770",
        "primaryId": "NCT00193063",
        "statement_text": "In the primary trial patient cohort  3 different types of infections are observed  these are pneumonia  urinary tract and Athlete's foot ",
        "statement_nums": [
            "3 different types"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 14/41 (34.15%) Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41 (2.44%) Infection - pneumonia 2/41 (4.88%) Infection - port site 2/41 (4.88%) Infection - urinary tract 1/41 (2.44%) Disease progression 3/41 (7.32%) Confusion 1/41 (2.44%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "14/41 (34.15%)",
            "1/41 (2.44%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "06aa0fbc-fe49-4715-88cc-507646f6323f",
        "primaryId": "NCT00486525",
        "statement_text": "The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga  whereas cohort 2 abstained from yoga ",
        "statement_nums": [
            "1 participated in",
            "2 abstained from"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I: Yoga Therapy Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs  INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  ",
        "premise_nums": [
            "90 minutes twice"
        ]
    },
    {
        "id": "4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37",
        "primaryId": "NCT00203502",
        "statement_text": "Every single patient in the primary trial experienced at least 1 adverse event ",
        "statement_nums": [
            "1 adverse event"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 39/39 (100.00%) ",
        "premise_nums": [
            "39/39 (100.00%)"
        ]
    },
    {
        "id": "507a4189-4905-4752-8348-d715a5ce3962",
        "primaryId": "NCT01940497",
        "statement_text": "There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "3 more allergic",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Vomiting 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/95 (0.00%)",
            "5/95 (5.26%)",
            "1/95 (1.05%)"
        ]
    },
    {
        "id": "507a4189-4905-4752-8348-d715a5ce3962",
        "primaryId": "NCT01940497",
        "statement_text": "There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "3 more allergic",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 3/20 (15.00%)Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) ",
        "premise_nums": [
            "3/20 (15.00%)Febrile",
            "0/20 (0.00%)",
            "1/20 (5.00%)"
        ]
    },
    {
        "id": "24001e83-6a8c-4f67-9c24-55dc285c4cc2",
        "primaryId": "NCT00096356",
        "statement_text": "the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo ",
        "statement_nums": [
            "10 reduces the",
            "CoQ10 reduces"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization POMS-F is the Profile of Mood States - fatigue scale  It ranges from 0 to 28; higher values indicate greater fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1 - CoQ10 & Vitamin E Arm/Group Description: CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day  Overall Number of Participants Analyzed: 122 Least Squares Mean (Standard Error) Unit of Measure: units on a scale 6.96 (0.71) Results 2: Arm/Group Title: Arm 2 - Placebo & Vitamin E Arm/Group Description: Placebo-Vitamin E 100 mg/day in 3 doses Overall Number of Participants Analyzed: 114 ",
        "premise_nums": [
            "24 Weeks Following",
            "10 on Fatigue",
            "3 doses Overall",
            "100 IU taken",
            "Q10 on",
            "100 mg/day in",
            "122 Least Squares",
            "24 weeks Results",
            "0 to 28;"
        ]
    },
    {
        "id": "44cd16f5-6638-4d82-9121-1941eb8ce4b5",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%) Acute renal failure * 21/26 (3.85%) Adverse Events 2: Total: 1/28 (3.57%) Febrile neutropenia * 0/28 (0.00%) Gastric volvulus * 21/28 (3.57%) General Malaise * 20/28 (0.00%) ",
        "premise_nums": [
            "20/26 (0.00%)",
            "20/28 (0.00%)",
            "21/26 (3.85%)",
            "4/26 (15.38%)",
            "21/28 (3.57%)"
        ]
    },
    {
        "id": "44cd16f5-6638-4d82-9121-1941eb8ce4b5",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)Acute renal failure * 20/28 (0.00%) ",
        "premise_nums": [
            "20/28 (0.00%)Acute"
        ]
    },
    {
        "id": "d2961e96-bd3b-4994-aa7e-2b310eb6204e",
        "primaryId": "NCT01300351",
        "statement_text": "At least 1 participant in the primary trial showed signs of poor liver function ",
        "statement_nums": [
            "1 participant in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hepatic function abnormal * 1/109 (0.92%) ",
        "premise_nums": [
            "1/109 (0.92%)"
        ]
    },
    {
        "id": "8a5d7285-f4be-4e50-9057-19f74bcc410b",
        "primaryId": "NCT03106077",
        "statement_text": "Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks ",
        "statement_nums": [
            "IMGN853 by",
            "853 by IV"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W ",
        "premise_nums": [
            "6 mg/kg IMGN",
            "853 IV Q3W",
            "IMGN853 IV"
        ]
    },
    {
        "id": "512990dd-45d2-4b31-b571-66735ff02308",
        "primaryId": "NCT00394251",
        "statement_text": "There were 4 different adverse events  for which 0 cases were recorded in cohort 1.",
        "statement_nums": [
            "0 cases were",
            "4 different adverse"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 30/98 (30.61%) Coagulopathy 1/98 (1.02%) Febrile neutropenia 7/98 (7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure 0/98 (0.00%) Cardiac failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98 (1.02%) Colitis 1/98 (1.02%) Ileus 1/98 (1.02%) Abdominal pain upper 1/98 (1.02%) Gastrointestinal haemorrhage 0/98 (0.00%) ",
        "premise_nums": [
            "1/98 (1.02%)",
            "7/98 (7.14%)",
            "0/98 (0.00%)",
            "30/98 (30.61%)",
            "2/98 (2.04%)"
        ]
    },
    {
        "id": "383db144-4bcd-4ebc-989c-b6ae7d282026",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Contradiction",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial  than cohort 1 of the primary trial  ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Nausea 2/83 (2.41%) Vomiting 2/83 (2.41%) Diarrhea 1/83 (1.20%) Gastrointestinal Haemorrhage 1/83 (1.20%) Asthenia 1/83 (1.20%) Hyperbilirubinaemia 1/83 (1.20%) Anal abscess 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) ",
        "premise_nums": [
            "2/83 (2.41%)",
            "13/83 (15.66%)",
            "3/83 (3.61%)",
            "1/83 (1.20%)"
        ]
    },
    {
        "id": "383db144-4bcd-4ebc-989c-b6ae7d282026",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Contradiction",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial  than cohort 1 of the primary trial  ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 2:Total: 5/10 (50.00%) Febrile neutropenia 0/10 (0.00%) Neutropenia 0/10 (0.00%) Thrombocytopenia 1/10 (10.00%) Cardiac failure congestive 0/10 (0.00%) Extrasystoles 0/10 (0.00%) Nausea 0/10 (0.00%) Abdominal pain 0/10 (0.00%) Constipation 0/10 (0.00%) Gastrointestinal haemorrhage 0/10 (0.00%) Death - unknown cause 0/10 (0.00%) ",
        "premise_nums": [
            "5/10 (50.00%)",
            "2:Total: 5/10",
            "1/10 (10.00%)",
            "0/10 (0.00%)"
        ]
    },
    {
        "id": "383db144-4bcd-4ebc-989c-b6ae7d282026",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Contradiction",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial  than cohort 1 of the primary trial  ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Thrombosis in device 0/10 (0.00%)",
        "premise_nums": [
            "0/10 (0.00%)"
        ]
    },
    {
        "id": "bfa07fb7-f8cb-4215-9bca-ddee8b3bea73",
        "primaryId": "NCT00951665",
        "statement_text": "Most patients in cohort 1 of the primary trial died of unknown causes ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%) ",
        "premise_nums": [
            "0/26 (0.00%)",
            "1/26 (3.85%)",
            "7/26 (26.92%)"
        ]
    },
    {
        "id": "73c37b9c-e7ba-4c90-b26e-23b7a65509c4",
        "primaryId": "NCT00005957",
        "statement_text": "T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial ",
        "statement_nums": [
            "0 adenocarcinoma of"
        ],
        "label": "Entailment",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically proven invasive carcinoma of the breast No evidence of T4, N2-3, or M1 disease prior to surgery Node positive or high-risk node negative ",
        "premise_nums": [
            "2-3, or",
            "1 disease prior"
        ]
    },
    {
        "id": "cdba382e-894b-4f79-a8e2-ff818746adc5",
        "primaryId": "NCT01202591",
        "statement_text": "100% of patients in the primary trial suffered adverse events ",
        "statement_nums": [
            "100% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious) [Not Specified] Time frame: 3 years  10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: AZD4547 40mg Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 ",
        "premise_nums": [
            "28 days safety",
            "5 Results 2:",
            "5 Measure Type:",
            "AZD4547 BD",
            "80 mg AZD4547",
            "10 months (Adverse",
            "25 mg exemestane",
            "40 mg AZD4547"
        ]
    },
    {
        "id": "0093175a-38cb-4f63-b391-709ac48158b8",
        "primaryId": "NCT00971737",
        "secondaryId": "NCT00392392",
        "label": "Contradiction",
        "statement_text": "Patients with tumors overexpressing HER-2 are eligible for the secondary trial  but not for the primary trial ",
        "statement_nums": [
            "2 are eligible"
        ],
        "premise_text": "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC Stage IV disease Inclusion Criteria: FISH+ HER2 gene amplified breast cancer ",
        "premise_nums": [
            "1+, or",
            "2 gene amplified",
            "2/neu, defined"
        ]
    },
    {
        "id": "b9578bae-6640-4ef1-ba2c-899b45c602ee",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 4 cups of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "4 cups of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I: Alkaline Water Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  alkaline water: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  INTERVENTION 2: Arm II: Distilled Water Patients undergo external beam radiation therapy as in arm I  Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy ",
        "premise_nums": [
            "30 minutes immediately",
            "5 days a",
            "8 ounces of"
        ]
    },
    {
        "id": "b9578bae-6640-4ef1-ba2c-899b45c602ee",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 4 cups of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "4 cups of"
        ],
        "label": "Contradiction",
        "premise_text": "distilled water: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  ",
        "premise_nums": [
            "30 minutes immediately",
            "5 days a",
            "8 ounces of"
        ]
    },
    {
        "id": "405369ef-d216-4d81-a04f-46f36f466a19",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Urinary tract infection 1/26 (3.85%) Lumbar vertebral fracture 1/26 (3.85%) Adverse Events 2: Urinary tract infection 0/13 (0.00%) Lumbar vertebral fracture 0/13 (0.00%) ",
        "premise_nums": [
            "0/13 (0.00%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "e424c65e-7c6f-43a4-95e4-6beb705d9903",
        "primaryId": "NCT00559754",
        "secondaryId": "NCT02924883",
        "label": "Contradiction",
        "statement_text": "A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 13/72 (18.06%) Adverse Events 1: Total: 52/133 (39.10%) ",
        "premise_nums": [
            "13/72 (18.06%)",
            "52/133 (39.10%)"
        ]
    },
    {
        "id": "fadf7710-6e4d-49d6-82fc-4f3137b5e26b",
        "primaryId": "NCT00759785",
        "statement_text": "Only one adverse event is observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 1/25 (4.00%) Diarrhoea 0/25 (0.00%) Breast abscess 0/25 (0.00%) Breast cellulitis 0/25 (0.00%) Syncope 1/25 (4.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "1/25 (4.00%)"
        ]
    },
    {
        "id": "6c0896ac-db42-45b4-a6e2-620a27fd321a",
        "primaryId": "NCT01439945",
        "statement_text": "In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide ",
        "statement_nums": [
            "5% less"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Low Dose Magnesium Oxide (800 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD)  ",
        "premise_nums": [
            "400 mg tablet",
            "4-9: Patients"
        ]
    },
    {
        "id": "5f4880ac-1ce2-4b89-841b-a9918720b6ea",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "label": "Entailment",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "2 x ULN",
            "10 g/dL",
            "5 x ULN"
        ],
        "premise_text": "The following criteria for evidence of adequate hepatic function must be met: alkaline phosphatase must be less than 2.5 x ULN for the lab; and aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab  Platelet count must be greater than/equal to 100,000/mm^3. Hemoglobin must be greater than/equal to 10 g/dL  Platelets greater than 100,000/mm^3 Hemoglobin greater than 10 g/dL ",
        "premise_nums": [
            "100,000/mm^3 Hemoglobin",
            "than 2.5 x ULN",
            "100,000/mm^3. Hemoglobin",
            "10 g/dL",
            "3 Hemoglobin greater",
            "to 1.5 x ULN"
        ]
    },
    {
        "id": "5f4880ac-1ce2-4b89-841b-a9918720b6ea",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "label": "Entailment",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "2 x ULN",
            "10 g/dL",
            "5 x ULN"
        ],
        "premise_text": "AST smaller than 2 times upper limit of normal (ULN)Alkaline phosphatase smaller than 2 times ULN ",
        "premise_nums": [
            "2 times upper",
            "2 times ULN"
        ]
    },
    {
        "id": "b3aabfaa-23cb-4a75-8416-761d8574f0a4",
        "primaryId": "NCT01441596",
        "statement_text": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Afatinib Mono Afatinib monotherapy administered orally: starting dose 40 mg per day  continuous treatment in a 3-weekly course  If well tolerated  the dose may be escalated to 50 mg  ",
        "premise_nums": [
            "40 mg per",
            "3-weekly course"
        ]
    },
    {
        "id": "17b31c1d-db62-4628-b390-02da22512079",
        "primaryId": "NCT01028352",
        "statement_text": "Patients with aromatase inhibitor associated musculoskeletal symptoms  such as Grade 1 or above musculoskeletal pain or sensory neuropathy  are eligible for the primary trial ",
        "statement_nums": [
            "1 or above"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: AI-associated musculoskeletal symptoms  defined as: Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy; ",
        "premise_nums": [
            "6 or 7",
            "7 on CGICS",
            "1 or higher"
        ]
    },
    {
        "id": "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "label": "Contradiction",
        "statement_text": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 MRSA infection",
            "4 in cohort",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 51/486 (10.49%) ANEMIA 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION 1/486 (0.21%) COLITIS 1/486 (0.21%) DEHYDRATION 5/486 (1.03%) DIARRHEA 5/486 (1.03%) GASTRIC INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) ",
        "premise_nums": [
            "51/486 (10.49%)",
            "2/486 (0.41%)",
            "4/486 (0.82%)",
            "1/486 (0.21%)",
            "5/486 (1.03%)",
            "3/486 (0.62%)"
        ]
    },
    {
        "id": "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "label": "Contradiction",
        "statement_text": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 MRSA infection",
            "4 in cohort",
            "1 of the"
        ],
        "premise_text": "NAUSEA AND VOMITING 1/486 (0.21%)Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "3/40 (7.50%)",
            "1/40 (2.50%)",
            "1/486 (0.21%)Adverse",
            "17/40 (42.50%)",
            "5/40 (12.50%)",
            "6/40 (15.00%)"
        ]
    },
    {
        "id": "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "label": "Contradiction",
        "statement_text": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 MRSA infection",
            "4 in cohort",
            "1 of the"
        ],
        "premise_text": "Streptococcal Infection 1/40 (2.50%)",
        "premise_nums": [
            "1/40 (2.50%)"
        ]
    },
    {
        "id": "b3bd3522-8731-448a-bade-a5a350697a98",
        "primaryId": "NCT01421472",
        "statement_text": "Over 9 patients in the primary trial suffered from adverse events associated with a low number of white blood cells present in the bloodstream ",
        "statement_nums": [
            "9 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile Neutropenia * 5/67 (7.46%) ",
        "premise_nums": [
            "5/67 (7.46%)"
        ]
    },
    {
        "id": "8607e8c1-6e99-49be-a63e-e707856c805a",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "label": "Contradiction",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead ",
        "statement_nums": [
            "3 different drugs"
        ],
        "premise_text": "INTERVENTION 1: Pertuzumab + Trastuzumab + Taxane Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end  unacceptable toxicity  withdrawal of consent  disease progression  or death  whichever occurred first  Taxane chemotherapy was docetaxel  paclitaxel  or nab-paclitaxel  per the investigator's choice  INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg ",
        "premise_nums": [
            "50 mg orally",
            "50 mg Patients",
            "21 of each",
            "3 weeks per",
            "2 treatment courses",
            "1 to Day"
        ]
    },
    {
        "id": "8607e8c1-6e99-49be-a63e-e707856c805a",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "label": "Contradiction",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead ",
        "statement_nums": [
            "3 different drugs"
        ],
        "premise_text": "Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial ",
        "premise_nums": [
            "21 of each",
            "1500 mg orally",
            "2 treatment courses",
            "1 to Day"
        ]
    },
    {
        "id": "1c26e1a7-9d77-46ff-b1c6-179ece7c190f",
        "primaryId": "NCT03252431",
        "statement_text": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 ",
        "premise_nums": [
            "4 Neutropenia in"
        ]
    },
    {
        "id": "1c26e1a7-9d77-46ff-b1c6-179ece7c190f",
        "primaryId": "NCT03252431",
        "statement_text": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Entailment",
        "premise_text": "Eligible subjects were randomized in a 1:1 ratio  Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle  Subjects remained in their assigned treatment arm throughout the study  Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles)  Grade 4 (severe) neutropenia was defined as ANC smaller than 0.5 × 109/L within the first 12 days of chemotherapy ",
        "premise_nums": [
            "6 mg/dose as",
            "109/L within",
            "1:1 ratio",
            "12 days of",
            "24 to 28",
            "600 mg/m2 cyclophosphamide",
            "20 mg/dose PFS",
            "2 of each"
        ]
    },
    {
        "id": "1c26e1a7-9d77-46ff-b1c6-179ece7c190f",
        "primaryId": "NCT03252431",
        "statement_text": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks)Results 1: Arm/Group Title: F-627 Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe  administered on Day 2 of each of 4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 197 Mean (Standard Deviation) Unit of Measure: days 0.2 (0.51) Results 2: Arm/Group Title: Neulasta Arm/Group Description: 6 mg fixed dose Neulasta   administered on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe Overall Number of Participants Analyzed: 196 Mean (Standard Deviation) ",
        "premise_nums": [
            "20 mg fixed",
            "197 Mean (Standard",
            "196 Mean (Standard",
            "6 mg fixed",
            "21-day chemotherapy",
            "4 chemotherapy cycles",
            "2 of each"
        ]
    },
    {
        "id": "0a156ee2-eb90-40d2-9802-27b9b4a42ff3",
        "primaryId": "NCT00191789",
        "statement_text": "In cohort 2 and 3 of the primary trial there was only case 1 of jaundice ",
        "statement_nums": [
            "2 and 3",
            "1 of jaundice"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%) Stomatitis 1/65 (1.54%) Vomiting 2/65 (3.08%) Fatigue 1/65 (1.54%) Jaundice 1/65 (1.54%) ",
        "premise_nums": [
            "17/65 (26.15%)",
            "3/65 (4.62%)",
            "5/65 (7.69%)",
            "2/65 (3.08%)",
            "1/65 (1.54%)"
        ]
    },
    {
        "id": "0a156ee2-eb90-40d2-9802-27b9b4a42ff3",
        "primaryId": "NCT00191789",
        "statement_text": "In cohort 2 and 3 of the primary trial there was only case 1 of jaundice ",
        "statement_nums": [
            "2 and 3",
            "1 of jaundice"
        ],
        "label": "Contradiction",
        "premise_text": "Neutropenic infection 2/65 (3.08%)",
        "premise_nums": [
            "2/65 (3.08%)"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Vertigo 0/1408 (0.00%) Diarrhoea 22/1408 (1.56%) Vomiting 12/1408 (0.85%) Nausea 4/1408 (0.28%) Abdominal pain 2/1408 (0.14%) ",
        "premise_nums": [
            "12/1408 (0.85%)",
            "2/1408 (0.14%)",
            "0/1408 (0.00%)",
            "103/1408 (7.32%)",
            "22/1408 (1.56%)",
            "4/1408 (0.28%)",
            "1/1408 (0.07%)"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Pancreatitis 2/1408 (0.14%)Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 1/1408 (0.07%) Sinus tachycardia 1/1408 (0.07%) Tachycardia 1/1408 (0.07%) Vertigo 1/1408 (0.07%) Diarrhoea 1/1408 (0.07%) Vomiting 1/1408 (0.07%) Nausea 1/1408 (0.07%) ",
        "premise_nums": [
            "0/1408 (0.00%)",
            "2/1408 (0.14%)Adverse",
            "1/1408 (0.07%)",
            "85/1408 (6.04%)"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Abdominal pain 0/1408 (0.00%)Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170 (0.59%) Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) ",
        "premise_nums": [
            "0/1408 (0.00%)Pancreatitis",
            "0/170 (0.00%)",
            "46/170 (27.06%)",
            "1/170 (0.59%)",
            "2/170 (1.18%)",
            "1/1408 (0.07%)"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Gastroenteritis eosinophilic 0/170 (0.00%)Intestinal obstruction 0/170 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)",
            "0/170 (0.00%)Intestinal"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Contradiction",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Gastroenteritis eosinophilic 0/1 (0.00%)Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)Intestinal"
        ]
    },
    {
        "id": "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee",
        "primaryId": "NCT03371732",
        "statement_text": "patients with Karnofsky Index = 72 are eligible for the primary trial ",
        "statement_nums": [
            "72 are eligible"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  Individuals able to consent to benefit of intervention focused on substance use  (Karnofsky Index greater than 70). ",
        "premise_nums": [
            "1 or more"
        ]
    },
    {
        "id": "58ccfd13-aa6d-4604-bf3d-c69270fe50d2",
        "primaryId": "NCT01276041",
        "statement_text": "1 patient in the primary trial died in an event not associated with a specifc CTCAE term ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) ",
        "premise_nums": [
            "5/70 (7.14%)",
            "1/70 (1.43%)",
            "2/70 (2.86%)",
            "3/70 (4.29%)",
            "18/70 (25.71%)"
        ]
    },
    {
        "id": "7b48355e-3b9c-4cca-b7fa-1cbd612d1523",
        "primaryId": "NCT00320710",
        "statement_text": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients ",
        "statement_nums": [
            "5% of",
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Anaemia 3/202 (1.49%) Febrile neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202 (0.00%) Pancytopenia 1/202 (0.50%) Atrial fibrillation 1/202 (0.50%) Cardiac failure congestive 1/202 (0.50%) Palpitations 1/202 (0.50%) Pericardial effusion 1/202 (0.50%) Supraventricular tachycardia 1/202 (0.50%) ",
        "premise_nums": [
            "3/202 (1.49%)",
            "2/202 (0.99%)",
            "1/202 (0.50%)",
            "0/202 (0.00%)"
        ]
    },
    {
        "id": "d7e81d80-5cbf-4969-be00-4fdf17aa4eb9",
        "primaryId": "NCT01209195",
        "statement_text": "Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "121 and Paclitaxel",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Part 1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV ",
        "premise_nums": [
            "2 MM-121",
            "80mg/m2 weekly",
            "2 weekly IV",
            "40 mg/kg loading",
            "20 mg/kg weekly",
            "12 mg/kg weekly",
            "1 MM-121",
            "20 mg/kg loading"
        ]
    },
    {
        "id": "2206dc2a-93da-4c11-b110-81f9c39af807",
        "primaryId": "NCT00101400",
        "statement_text": "A female with Hemoglobin greater than 10.0 g/dl  Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin greater than 1.6 x ULN are eligilbe for the primary trial ",
        "statement_nums": [
            "than 10.0 g/dl",
            "1,733/mm3, platelet",
            "100,000/¬¨¬µl and",
            "than 1.6 x ULN"
        ],
        "label": "Entailment",
        "premise_text": "Hemoglobin greater than 9.0 g/dl Absolute neutrophil count (ANC) greater than 1,500/mm3 Platelet count = 100,000/µl Total bilirubin =1.5 x the upper limit of normal  ",
        "premise_nums": [
            "3 Platelet count",
            "than 9.0 g/dl",
            "1,500/mm3 Platelet",
            "100,000/µl Total",
            "5 x the"
        ]
    },
    {
        "id": "87987ebb-6799-4d1d-8529-d33c6b7799f8",
        "primaryId": "NCT00548184",
        "statement_text": "64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response  or better  after 12 weeks ",
        "statement_nums": [
            "2mg/kg every",
            "4mg/kg loading",
            "64 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Pathologic Assessment After Study Treatment Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy  Pathologic complete response: no invasive cancer in the residual breast  Near pathologic complete response: residual disease of less than 1 cm in breast  Time frame: 12 weeks Results 1: Arm/Group Title: Lapatinib + Trastuzumab Arm/Group Description: All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week Overall Number of Participants Analyzed: 64 Measure Type: Number ",
        "premise_nums": [
            "12 weeks Results",
            "12 weeks of",
            "2mg/kg every",
            "4mg/kg loading",
            "64 Measure Type:",
            "1 cm in"
        ]
    },
    {
        "id": "87987ebb-6799-4d1d-8529-d33c6b7799f8",
        "primaryId": "NCT00548184",
        "statement_text": "64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response  or better  after 12 weeks ",
        "statement_nums": [
            "2mg/kg every",
            "4mg/kg loading",
            "64 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: participants Complete Pathologic Response: 18Near Complete Pathologic Response: 16 Not Pathologic response: 30 ",
        "premise_nums": [
            "16 Not Pathologic"
        ]
    },
    {
        "id": "c68f6822-24fa-44b5-bf63-c272a8031fab",
        "primaryId": "NCT02988986",
        "statement_text": "Patients must have either AST or ALT smaller than 1.5 ULN to participate in the primary trial ",
        "statement_nums": [
            "than 1.5 ULN to"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Hepatic status: Serum total bilirubin 1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome  a higher serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5 x ULN; ",
        "premise_nums": [
            "5 x ULN;",
            "than 1.5 x ULN",
            "1 x upper",
            "phosphatase 1.5 x ULN",
            "aminotransferase 1.5 x ULN",
            "5 x ULN]"
        ]
    },
    {
        "id": "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "label": "Entailment",
        "statement_text": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  however cohort 2 of the secondary trial receive all of these ",
        "statement_nums": [
            "2 of the",
            "1 participants in"
        ],
        "premise_text": "INTERVENTION 1: Diagnostic (FLT PET) Patients with early stage  ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment  The surgery follows 1-7 days after the second FLT PET scan  Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine  Positron Emission Tomography: Undergo FLT PET Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen  INTERVENTION 1: Arm A ",
        "premise_nums": [
            "67 staining of",
            "1-6 weeks",
            "1-7 days",
            "6 weeks after",
            "Ki67 staining",
            "[F18] fluorothymidine",
            "7 days after"
        ]
    },
    {
        "id": "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "label": "Entailment",
        "statement_text": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  however cohort 2 of the secondary trial receive all of these ",
        "statement_nums": [
            "2 of the",
            "1 participants in"
        ],
        "premise_text": "Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  lapatinib ditosylate: Given PO and capecitabine: Given POINTERVENTION 2: Arm B ",
        "premise_nums": [
            "1-14 and",
            "14 and oral",
            "1-21. Courses",
            "21 days in"
        ]
    },
    {
        "id": "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "label": "Entailment",
        "statement_text": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  however cohort 2 of the secondary trial receive all of these ",
        "statement_nums": [
            "2 of the",
            "1 participants in"
        ],
        "premise_text": "Patients receive capecitabine and lapatinib ditosylate as in arm I  Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  cixutumumab: Given IV  lapatinib ditosylate: Given PO and capecitabine: Given PO",
        "premise_nums": [
            "1-1½ hours",
            "21 days in"
        ]
    },
    {
        "id": "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b",
        "primaryId": "NCT00325598",
        "statement_text": "There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial  the increase in Gy has a huge effect ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her  Time frame: Within 1 year of protocol registration Results 1: Arm/Group Title: Cohort 1 (36 Gy) Arm/Group Description: 36 Gy in 9 fractions BID x 4 1/2 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 Results 2: ",
        "premise_nums": [
            "9 fractions BID",
            "50 Measure Type:",
            "36 Gy in",
            "1 year of",
            "100 Results 2:",
            "4 patients cannot",
            "4 1/2 treatment",
            "2 treatment days"
        ]
    },
    {
        "id": "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b",
        "primaryId": "NCT00325598",
        "statement_text": "There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial  the increase in Gy has a huge effect ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Cohort 2 (40 Gy)Arm/Group Description: 40 Gy in 10 fractions BID over 5 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 ",
        "premise_nums": [
            "5 treatment days",
            "40 Gy in",
            "50 Measure Type:",
            "10 fractions BID"
        ]
    },
    {
        "id": "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "label": "Contradiction",
        "statement_text": "There were more patients with hypotension in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 6/21 (28.57%) Hypertension 3/21 (14.29%) Edema 3/21 (14.29%) Nausea 2/21 (9.52%) Fracture 1/21 (4.76%) Dizziness 3/21 (14.29%) Syncope 2/21 (9.52%) Headache 2/21 (9.52%) Dyspnea 2/21 (9.52%) Hypoxia 3/21 (14.29%) Adverse Events 1: Total: 1/40 (2.50%) Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) ",
        "premise_nums": [
            "6/21 (28.57%)",
            "1/21 (4.76%)",
            "1/40 (2.50%)",
            "2/21 (9.52%)",
            "3/21 (14.29%)",
            "0/40 (0.00%)"
        ]
    },
    {
        "id": "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "label": "Contradiction",
        "statement_text": "There were more patients with hypotension in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Death 0/40 (0.00%)Headache 0/40 (0.00%) Dyspnea 0/40 (0.00%) Sinusitis 0/40 (0.00%) Wound Dehiscence 0/40 (0.00%) ",
        "premise_nums": [
            "0/40 (0.00%)Headache"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Inclusion Criteria: Female gender; Age 18 years; Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination and mammography or ultrasound  Any N  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization  Known hormone receptor status  Hematopoietic status: CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: ",
        "premise_nums": [
            "75 of institutional",
            "1 cm diameter",
            "count 1,5 x 10",
            "0-1 Histologically",
            "1 Histologically confirmed",
            "2 in the",
            "100 x 10",
            "9/L, Hemoglobin",
            "9/L, Platelet",
            "9 g/dl"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Serum total bilirubin 2 x upper limit of normal (ULN)  In the case of known Gilbert's syndrome  a higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan  ",
        "premise_nums": [
            "50% measured",
            "than 1.5 x ULN",
            "Creatinine 1.5mg/dL",
            "5 x ULN)",
            "phosphatase 2.5 times ULN",
            "2 x upper"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina  clinically significant arrhythmias  congestive heart failure  transmural myocardial infarction  uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at rest  or chronic therapy with oxygen; Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety; Unresolved or unstable  serious adverse events from prior administration of another investigational drug; Dementia  altered mental status  or any psychiatric condition that would prevent the understanding or rendering of ICF; ",
        "premise_nums": [
            "180/110), unstable",
            "2 Known history",
            "5 years prior"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Subjects with ulcerative colitis are also excluded;Concurrent neoadjuvant cancer therapy (chemotherapy  radiation therapy  immunotherapy  biologic therapy other than the trial therapies); Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine  trastuzumab  lapatinib  paclitaxel  abraxane or their components; Pregnant or lactating women; Concomitant use of CYP3A4 inhibitors or inducers ",
        "premise_nums": [
            "4 inhibitors or"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Entailment",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g  active or uncontrolled infection  uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocolPatients have an active infection and require IV or oral antibiotics  Pregnant or breast-feeding women Patients unwilling or unable to comply with the protocol Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  Individuals able to consent to benefit of intervention focused on substance use  (Karnofsky Index greater than 70). Exclusion Criteria : Patients who currently use substances for which a second-line care is already committed  Patients with a Karnofsky index smaller than 70. ",
        "premise_nums": [
            "1 or more"
        ]
    },
    {
        "id": "6cf7d10e-902e-4f78-85f6-e06d63e1cd0e",
        "primaryId": "NCT00347919",
        "statement_text": "less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "statement_nums": [
            "1500 mg had",
            "50% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Progressive Disease at Week 12 in Cohort 1 The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured  Per Response Evaluation Criteria In Solid Tumors (RECIST)  a response of PD is defined as a greater than or equal 20% increase in target lesions  Participants were also classified as having PD if their response at Week 12 was unknown or missing  Response was determined by an independent radiologist and by an investigator  Time frame: Week 12 Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day Overall Number of Participants Analyzed: 72 Measure Type: Number Unit of Measure: percentage of participants Independently Evaluated: 38.9 Investigator Evaluated: 43.1 ",
        "premise_nums": [
            "1500 milligrams (mg)",
            "72 Measure Type:",
            "12 Results 1:",
            "9 Investigator Evaluated:",
            "12 was unknown",
            "12 weeks after",
            "1500 mg Arm",
            "12 in Cohort",
            "1 The percentage",
            "20% increase"
        ]
    },
    {
        "id": "78894316-fc7d-4d61-a2d4-9ea369bfce20",
        "primaryId": "NCT02273973",
        "statement_text": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Erysipelas 2/167 (1.20%) Bacterial diarrhoea 1/167 (0.60%) ",
        "premise_nums": [
            "2/167 (1.20%)",
            "1/167 (0.60%)"
        ]
    },
    {
        "id": "889e6622-1614-4f6c-a47c-e7caad6e154f",
        "primaryId": "NCT00879086",
        "statement_text": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia  but Cohort 1 had 1 more case of Leukopenia than cohort 2.",
        "statement_nums": [
            "1 and 2",
            "1 had 1"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Adverse Events 2: Anaemia 1/50 (2.00%) Leukopenia 0/50 (0.00%) Neutropenia 1/50 (2.00%) ",
        "premise_nums": [
            "0/50 (0.00%)",
            "1/51 (1.96%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "9e046221-7d4b-4681-a374-96793350927d",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Contradiction",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: Up to 2 years  Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) ",
        "premise_nums": [
            "30% decrease",
            "102 given on",
            "q14 day",
            "35 Measure Type:",
            "6 to 46.3)",
            "14 Day Arm",
            "14 day schedule"
        ]
    },
    {
        "id": "9e046221-7d4b-4681-a374-96793350927d",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Contradiction",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Results 2:Arm/Group Title: NKTR-102 21 Days Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 35 (14.6 to 46.3) Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) ",
        "premise_nums": [
            "102 given on",
            "21 Days Arm",
            "2:Arm/Group Title:",
            "q21 day",
            "35 Measure Type:",
            "21 day schedule",
            "6 to 46.3)"
        ]
    },
    {
        "id": "9e046221-7d4b-4681-a374-96793350927d",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Contradiction",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: ",
        "premise_nums": [
            "30% decrease",
            "15 months Results",
            "RECIST 1.0 for target"
        ]
    },
    {
        "id": "9e046221-7d4b-4681-a374-96793350927d",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Contradiction",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Title: Everolimus + LetrozoleArm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol  Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 ",
        "premise_nums": [
            "2 tablets (5",
            "43 Measure Type:",
            "1 tablet of"
        ]
    },
    {
        "id": "a7232387-b266-4bfb-8df8-ca9789188500",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) ",
        "premise_nums": [
            "3/24 (12.50%)",
            "1/24 (4.17%)",
            "13/24 (54.17%)",
            "5/24 (20.83%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "a7232387-b266-4bfb-8df8-ca9789188500",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "PATHOLOGICAL FRACTURE 1/24 (4.17%)Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%) NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) ",
        "premise_nums": [
            "1/24 (4.17%)Adverse",
            "6/24 (25.00%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "a7232387-b266-4bfb-8df8-ca9789188500",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "CHOLECYSTITIS 0/24 (0.00%)PATHOLOGICAL FRACTURE 0/24 (0.00%) ",
        "premise_nums": [
            "0/24 (0.00%)PATHOLOGICAL"
        ]
    },
    {
        "id": "32424458-a3e2-440a-9693-6a2f8d4aaddb",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "61 more patients"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Objective Response Rate Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab ",
        "premise_nums": [
            "30% decrease",
            "6 months Results"
        ]
    },
    {
        "id": "32424458-a3e2-440a-9693-6a2f8d4aaddb",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "61 more patients"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: ",
        "premise_nums": [
            "100 mg/m2 X",
            "9 to 45.0)",
            "2 X 3",
            "15 at 28",
            "1 and 15",
            "39 Measure Type:",
            "5 mg/kg for",
            "10 mg/kg loading",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "32424458-a3e2-440a-9693-6a2f8d4aaddb",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "61 more patients"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Abraxane AloneArm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) ",
        "premise_nums": [
            "2 weekly X",
            "18 to 61.1)",
            "2 cycles (every",
            "21 Measure Type:",
            "15 at 28",
            "100 mg/m2 weekly",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "728721c4-6376-4ab8-9e4a-af8596bd1ab3",
        "primaryId": "NCT00852930",
        "secondaryId": "NCT02308020",
        "label": "Entailment",
        "statement_text": "Laser Therapy is only used in cohort 1 of the primary trial  neither cohort of the secondary trial make use of this ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Laser Therapy Alone therapist administered laser treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual lymphatic drainage manual lymphatic drainage: therapist administered massage therapy INTERVENTION 1: Part A Abemaciclib: HR+  HER2+ Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET)  Participants with hormone receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle  Participants may continue to receive treatment until discontinuation criteria are met  INTERVENTION 2: ",
        "premise_nums": [
            "1-21 of",
            "12 hours on",
            "21 of a",
            "150 mg abemaciclib",
            "200 mg was",
            "21-day cycle"
        ]
    },
    {
        "id": "728721c4-6376-4ab8-9e4a-af8596bd1ab3",
        "primaryId": "NCT00852930",
        "secondaryId": "NCT02308020",
        "label": "Entailment",
        "statement_text": "Laser Therapy is only used in cohort 1 of the primary trial  neither cohort of the secondary trial make use of this ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Part B Abemaciclib: HR+  HER2- Breast CancerAbemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET)  Participants may continue to receive treatment until discontinuation criteria are met  ",
        "premise_nums": [
            "1-21 of",
            "12 hours on",
            "21 of a",
            "200 mg was",
            "21-day cycle"
        ]
    },
    {
        "id": "ef675459-a7d9-4ea1-8963-c95682c38d15",
        "primaryId": "NCT03004534",
        "statement_text": "Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "0 breast carcinoma"
        ],
        "label": "Contradiction",
        "premise_text": "Tumor must be confined to either the breast or to the breast and ipsilateral axilla (Note: patinets with multifocal/multicentric tumors are eligible)  Patient must have (according to TNM 7th edition rules): T1 with T 1.0cm, T2 or T3 by at least one radiographic or clinical measurement Either clinically positive (N1 only) or clinically negative axillary nodes (N0) M0 ",
        "premise_nums": [
            "2 or T3",
            "1 with T",
            "(N0) M"
        ]
    },
    {
        "id": "19c0b2c7-e45c-4740-b25d-f6e738b59893",
        "primaryId": "NCT01764022",
        "statement_text": "Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia ",
        "statement_nums": [
            "2 of the",
            "1 incident of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Anemia with trombocytopenia 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "e3a8be03-20e4-460d-9ebc-f958a515ac45",
        "primaryId": "NCT01095003",
        "statement_text": "Less than 5 patients in the primary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 107/383 (27.94%) Anaemia 4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383 (0.26%) Abdominal pain 6/383 (1.57%) Adverse Events 2: ",
        "premise_nums": [
            "6/383 (1.57%)",
            "0/383 (0.00%)",
            "107/383 (27.94%)",
            "1/383 (0.26%)",
            "7/383 (1.83%)",
            "2/383 (0.52%)",
            "4/383 (1.04%)"
        ]
    },
    {
        "id": "e3a8be03-20e4-460d-9ebc-f958a515ac45",
        "primaryId": "NCT01095003",
        "statement_text": "Less than 5 patients in the primary trial experienced Earache ",
        "statement_nums": [
            "5 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Total: 85/383 (22.19%)Anaemia 3/383 (0.78%) Febrile neutropenia 2/383 (0.52%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 0/383 (0.00%) Neutropenia 1/383 (0.26%) Thrombocytopenia 1/383 (0.26%) Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383 (0.00%) Abdominal pain 3/383 (0.78%) ",
        "premise_nums": [
            "0/383 (0.00%)",
            "85/383 (22.19%)Anaemia",
            "1/383 (0.26%)",
            "2/383 (0.52%)",
            "3/383 (0.78%)"
        ]
    },
    {
        "id": "f1096271-3160-4483-9246-ba0d96735efb",
        "primaryId": "NCT01118624",
        "statement_text": "Less than 5% of the primary trial participants achieved CR or PR ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Tumor response evaluation was performed using RECIST 1.0 using CT/MRI  Proportion of patients achieving a CR or PR is considered in the overall response  Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks)  or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended  Results 1: Arm/Group Title: Pralatrexate Arm/Group Description: Study drug 190 mg/m^2 for 2 to 4 weeks  Overall Number of Participants Analyzed: 22 Measure Type: Number Unit of Measure: participants 1 ",
        "premise_nums": [
            "4 weeks and",
            "2 for 2",
            "22 Measure Type:",
            "RECIST 1.0 using CT",
            "190 mg/m^2",
            "2 to 4"
        ]
    },
    {
        "id": "329b6871-2edc-4142-a4af-e7f8cef118ee",
        "primaryId": "NCT00004888",
        "statement_text": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events ",
        "statement_nums": [
            "1 Cardiotoxicity Events",
            "8 than Grade"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event This table summarizes the cardiotoxicity events of different grades  Grade 1 is a decline of left ventricular ejection fraction(LVEF) greater than or equal 10% but smaller than 20% of baseline value  Grade 2 is LVEF below LLN (50%) or decline of LVEF greater than or equal 20% of baseline value  Grade 3 is congestive heart failure responsive to treatment  Please note that only a subset of patients reported cardiotoxic events so the totals will not add up to the total number of participants  Time frame: Baseline  after cycle 4 (~84 days)  after cycle 8 (~168 days)  and 30 or more days after last cycle of induction therapy ",
        "premise_nums": [
            "10% but",
            "30 or more",
            "2 is LVEF",
            "1 is a",
            "3 is congestive",
            "(50%) or",
            "20% of"
        ]
    },
    {
        "id": "329b6871-2edc-4142-a4af-e7f8cef118ee",
        "primaryId": "NCT00004888",
        "statement_text": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events ",
        "statement_nums": [
            "1 Cardiotoxicity Events",
            "8 than Grade"
        ],
        "label": "Entailment",
        "premise_text": "Results 1:Arm/Group Title: Arm I: Doxorubicin and Taxotere Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour after PLD completion  every 3 weeks for a total of 8 cycles  Dexamthasone 8 mg orally twice a day was administered the day before  the day of  and the day following docetaxel  The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD  Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 ",
        "premise_nums": [
            "200 mg PO",
            "60 mg/m^2",
            "30 mg/m^2",
            "3 weeks for",
            "1:Arm/Group Title:",
            "1 and continued",
            "1 of Cycle",
            "1 After Cycle",
            "16 Measure Type:",
            "240 mg/m^2.",
            "2 IV followed",
            "8 mg orally"
        ]
    },
    {
        "id": "329b6871-2edc-4142-a4af-e7f8cef118ee",
        "primaryId": "NCT00004888",
        "statement_text": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events ",
        "statement_nums": [
            "1 Cardiotoxicity Events",
            "8 than Grade"
        ],
        "label": "Entailment",
        "premise_text": "Grade 1 After Cycle 8 (approx  168 days): 4Grade 1 After 30 days or more after last cycle: 1 Grade 2 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168 days): 4 Grade 2 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84 days): 1 Grade 3 After Cycle 8 (approx 168 days): 0 Grade 3 After 30 days or more after last cycle: 0 ",
        "premise_nums": [
            "4 Grade 2",
            "30 days or",
            "1 Grade 2",
            "1 After 30",
            "1 After Cycle",
            "3 Grade 2",
            "1 Grade 3",
            "0 Grade 3"
        ]
    },
    {
        "id": "67522762-9423-4e3d-bf75-247f84ba7f05",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "label": "Contradiction",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2.5 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "than 2.5 x ULN",
            "10 g/dL"
        ],
        "premise_text": "The following criteria for evidence of adequate hepatic function must be met: alkaline phosphatase must be less than 2.5 x ULN for the lab; and aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab  Platelet count must be greater than/equal to 100,000/mm^3. Hemoglobin must be greater than/equal to 10 g/dL  Platelets greater than 100,000/mm^3 Hemoglobin greater than 10 g/dL ",
        "premise_nums": [
            "100,000/mm^3 Hemoglobin",
            "than 2.5 x ULN",
            "100,000/mm^3. Hemoglobin",
            "10 g/dL",
            "3 Hemoglobin greater",
            "to 1.5 x ULN"
        ]
    },
    {
        "id": "67522762-9423-4e3d-bf75-247f84ba7f05",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "label": "Contradiction",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2.5 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "than 2.5 x ULN",
            "10 g/dL"
        ],
        "premise_text": "AST smaller than 2 times upper limit of normal (ULN)Alkaline phosphatase smaller than 2 times ULN ",
        "premise_nums": [
            "2 times upper",
            "2 times ULN"
        ]
    },
    {
        "id": "efd37946-54f3-4813-b63d-6d7df6123677",
        "primaryId": "NCT02630693",
        "statement_text": "A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Vomiting 0/90 (0.00%) Death NOS 1/90 (1.11%) Fever 0/90 (0.00%) Other general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) ",
        "premise_nums": [
            "2/90 (2.22%)",
            "1/90 (1.11%)",
            "0/90 (0.00%)",
            "9/90 (10.00%)",
            "12/89 (13.48%)"
        ]
    },
    {
        "id": "efd37946-54f3-4813-b63d-6d7df6123677",
        "primaryId": "NCT02630693",
        "statement_text": "A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Febrile neutropenia 0/89 (0.00%)Ascites 1/89 (1.12%) Nausea 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders 0/89 (0.00%) Lung infection 0/89 (0.00%) Sepsis 1/89 (1.12%) Spinal fracture 1/89 (1.12%) ",
        "premise_nums": [
            "1/89 (1.12%)",
            "2/89 (2.25%)",
            "0/89 (0.00%)Ascites"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes  Regardless of Ductal Carcinoma in Situ (DCIS) Subject who went through Neoadjuvant period completely (24 weeks)  will receive surgery within 3-6 weeks after last treatment of neoadjuvant period  The primary endpoint  Pathological complete response  will be assessed using resected bio-specimens collected in breast and axilla during a surgery  Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks) Results 1: Arm/Group Title: CT-P6 ",
        "premise_nums": [
            "3-6 weeks",
            "6 weeks after"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 248 ",
        "premise_nums": [
            "75mg/m^2,",
            "3 to 6",
            "500mg/m^2,",
            "2 through 8",
            "2 during cycles",
            "6 mg/kg on",
            "1 of Cycles",
            "500mg/m^2)",
            "75 mg/m^2",
            "1 through 4",
            "5 through 8.",
            "6 at an",
            "8 treatment cycles",
            "8 mg/kg administered",
            "(3-week cycles"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Measure Type: NumberUnit of Measure: percentage of responders 46.77 (40.43 to 53.19) Results 2: Arm/Group Title: Herceptin ",
        "premise_nums": [
            "43 to 53.19)"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 256 ",
        "premise_nums": [
            "8 treatment cycles",
            "75mg/m^2,",
            "3 to 6",
            "(3-week cycles",
            "1 through 4",
            "5 through 8.",
            "500mg/m^2,",
            "1 of Cycles",
            "2 through 8",
            "8 mg/kg administered",
            "2 during cycles",
            "6 mg/kg on",
            "500mg/m^2)",
            "75 mg/m^2"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "6 and ZA"
        ],
        "label": "Contradiction",
        "premise_text": "Measure Type: NumberUnit of Measure: percentage of responders 50.39 (44.10 to 56.68) ",
        "premise_nums": [
            "10 to 56.68)"
        ]
    },
    {
        "id": "d446920a-2b8e-4452-b9f2-17d2771dbb07",
        "primaryId": "NCT00075764",
        "statement_text": "The most common adverse event in cohort 1 of the primary trial is Neutropenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%) Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%) Cardiac-ischemia/infarction 1/337 (0.30%) Left ventricular diastolic dysfunction 0/337 (0.00%) Left ventricular systolic dysfunction 1/337 (0.30%) Restrictive cardiomyopathy 1/337 (0.30%) ",
        "premise_nums": [
            "0/337 (0.00%)",
            "1/337 (0.30%)",
            "2/337 (0.59%)",
            "21/337 (6.23%)"
        ]
    },
    {
        "id": "aa710138-bf2a-4a7f-8014-4513fa1f448b",
        "primaryId": "NCT01269346",
        "secondaryId": "NCT01597193",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events ",
        "statement_nums": [
            "30% occurrence",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 15/52 (28.85%) Adverse Events 1: Total: 2/7 (28.57%) ",
        "premise_nums": [
            "15/52 (28.85%)",
            "2/7 (28.57%)"
        ]
    },
    {
        "id": "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Entailment",
        "statement_text": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [
            "2 hours of"
        ],
        "premise_text": "Inclusion Criteria: Less than 120 minutes of exercise per week Inclusion Criteria: The patient has provided written informed consent with HIPAA authorization before participating in the study  as has his/her responsible caregiver  if applicable  The patient is a candidate for surgical intervention  with lymph node mapping being a part of the surgical plan  The patient is at least 18 years of age at the time of consent  The patient has an ECOG performance status of Grade 0 - 2 [8]. The patient has a clinical negative node status at the time of study entry  If of child bearing potential  the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek  has been surgically sterilized  or has been postmenopausal for at least 1 year  The patient is currently not participating in another investigational drug study  Melanoma Patients ",
        "premise_nums": [
            "120 minutes of",
            "72 hours prior",
            "18 years of"
        ]
    },
    {
        "id": "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Entailment",
        "statement_text": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [
            "2 hours of"
        ],
        "premise_text": "The patient has a diagnosis of primary melanoma Breast Cancer Patients The patient has a diagnosis of primary breast cancer  Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan  Exclusion Criteria: The patient is pregnant or lactating; The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e.  all patients should be any T,N0,M0); The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V  Melanoma Patients The patient has a tumor with a Breslow depth less than 0.75mm.; ",
        "premise_nums": [
            "0,M0); The"
        ]
    },
    {
        "id": "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "label": "Entailment",
        "statement_text": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [
            "2 hours of"
        ],
        "premise_text": "Patients that have had preoperative chemotherapy  immunotherapy or radiation therapy;Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin; Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma; Patients who have undergone a wide excision for their primary melanoma (greater than 1 cm in dimension) or complex reconstruction (rotation  free flap or skin graft of any type)  Breast Cancer Patients The patient has bilateral primary breast cancers or multiple tumors within their breast; ",
        "premise_nums": [
            "1 cm in"
        ]
    },
    {
        "id": "6a71c114-2e38-4d57-8f8b-8252d9c62cbe",
        "primaryId": "NCT01491737",
        "statement_text": "There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial  and 0 cases of heart failure ",
        "statement_nums": [
            "4 cases of",
            "1 of the",
            "0 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Febrile neutropenia 4/127 (3.15%) Cardiac failure 0/127 (0.00%) ",
        "premise_nums": [
            "0/127 (0.00%)",
            "4/127 (3.15%)"
        ]
    },
    {
        "id": "4333aaa3-dbe4-4275-a982-881fe25c96c0",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "2 of the",
            "3 times in",
            "a21 day",
            "21 day cycle"
        ],
        "label": "Contradiction",
        "premise_text": "Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity  Beginning 1 week later  patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity  Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "1 week later",
            "30 minutes once",
            "30-90 minutes",
            "7 days for",
            "90 minutes once",
            "15 minutes on",
            "12 weeks in",
            "2/neu positive",
            "2-7. Courses",
            "10-15 minutes",
            "1 year in",
            "1-7, and"
        ]
    },
    {
        "id": "d605b820-2915-4b19-b9cd-ca7850645f83",
        "primaryId": "NCT00357110",
        "statement_text": "Only 6 patients in cohort 1 of the primary trial had Varicose Veins ",
        "statement_nums": [
            "6 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Varicose Vein 1/6 (16.67%) ",
        "premise_nums": [
            "1/6 (16.67%)"
        ]
    },
    {
        "id": "d6de70df-d113-4bc8-9d3b-b71f31937ebe",
        "primaryId": "NCT01525589",
        "statement_text": "People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial ",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1) ",
        "premise_nums": [
            "1/2 (Patients"
        ]
    },
    {
        "id": "4606f64f-64cc-4d73-a8be-75701c97008d",
        "primaryId": "NCT00024102",
        "statement_text": "A patient in cohort 2 of the primary trial received a Plasma transfusion ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Total: 17/181 (9.39%) Disseminated intravascular coagulation 0/181 (0.00%) Febrile neutropenia 1/181 (0.55%) Hemoglobin decreased 13/181 (7.18%) Lymphatics 0/181 (0.00%) Transfusion: pRBCs 1/181 (0.55%) Arrhythmia supraventricular 1/181 (0.55%) Cardiac disorder 0/181 (0.00%) Edema 0/181 (0.00%) Left ventricular failure 1/181 (0.55%) Myocardial ischemia 0/181 (0.00%) ",
        "premise_nums": [
            "13/181 (7.18%)",
            "17/181 (9.39%)",
            "0/181 (0.00%)",
            "1/181 (0.55%)"
        ]
    },
    {
        "id": "1a271e29-477b-4819-a472-5c7c7df99e70",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "label": "Contradiction",
        "statement_text": "2 cases of hematolysis were recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Adverse Events 1: Total: 9/157 (5.73%) Blood disorder 1/157 (0.64%) Hemoglobin decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Tinnitus 0/157 (0.00%) Cataract 0/157 (0.00%) Diplopia 0/157 (0.00%) Glaucoma 0/157 (0.00%) Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) ",
        "premise_nums": [
            "14/157 (8.92%)",
            "1/157 (0.64%)",
            "9/157 (5.73%)",
            "0/157 (0.00%)"
        ]
    },
    {
        "id": "1a271e29-477b-4819-a472-5c7c7df99e70",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "label": "Contradiction",
        "statement_text": "2 cases of hematolysis were recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Blood disorder 0/157 (0.00%)Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 0/157 (0.00%) Hearing impaired 2/157 (1.27%) Tinnitus 1/157 (0.64%) Cataract 1/157 (0.64%) Diplopia 0/157 (0.00%) Glaucoma 1/157 (0.64%) Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) ",
        "premise_nums": [
            "6/168 (3.57%)",
            "0/157 (0.00%)Hemoglobin",
            "2/157 (1.27%)",
            "1/157 (0.64%)"
        ]
    },
    {
        "id": "1a271e29-477b-4819-a472-5c7c7df99e70",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "label": "Contradiction",
        "statement_text": "2 cases of hematolysis were recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "FEBRILE NEUTROPENIA 3/168 (1.79%)ENTERITIS 1/168 (0.60%) PERIPHERAL NEUROPATHY 2/168 (1.19%) DEPRESSION 1/168 (0.60%) ",
        "premise_nums": [
            "3/168 (1.79%)ENTERITIS",
            "1/168 (0.60%)",
            "2/168 (1.19%)"
        ]
    },
    {
        "id": "7e89b190-b8f7-4281-b0f1-0e65dcebf402",
        "primaryId": "NCT00941330",
        "statement_text": "Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan ",
        "statement_nums": [
            "2 patients receive",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  ",
        "premise_nums": [
            "6 cycles (6",
            "25 mg daily",
            "3 weeks for",
            "6 to 12"
        ]
    },
    {
        "id": "6036d341-9c6a-49fc-a2f4-19c0e2399f4c",
        "primaryId": "NCT01565083",
        "statement_text": "There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Supraventricular tachycardia * 1/107 (0.93%) Tachycardia * 1/107 (0.93%) ",
        "premise_nums": [
            "1/107 (0.93%)"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Vertigo 0/1408 (0.00%) Diarrhoea 22/1408 (1.56%) Vomiting 12/1408 (0.85%) Nausea 4/1408 (0.28%) Abdominal pain 2/1408 (0.14%) ",
        "premise_nums": [
            "12/1408 (0.85%)",
            "2/1408 (0.14%)",
            "0/1408 (0.00%)",
            "103/1408 (7.32%)",
            "22/1408 (1.56%)",
            "4/1408 (0.28%)",
            "1/1408 (0.07%)"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Pancreatitis 2/1408 (0.14%)Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 1/1408 (0.07%) Sinus tachycardia 1/1408 (0.07%) Tachycardia 1/1408 (0.07%) Vertigo 1/1408 (0.07%) Diarrhoea 1/1408 (0.07%) Vomiting 1/1408 (0.07%) Nausea 1/1408 (0.07%) ",
        "premise_nums": [
            "0/1408 (0.00%)",
            "2/1408 (0.14%)Adverse",
            "1/1408 (0.07%)",
            "85/1408 (6.04%)"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Abdominal pain 0/1408 (0.00%)Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170 (0.59%) Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) ",
        "premise_nums": [
            "0/1408 (0.00%)Pancreatitis",
            "0/170 (0.00%)",
            "46/170 (27.06%)",
            "1/170 (0.59%)",
            "2/170 (1.18%)",
            "1/1408 (0.07%)"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Gastroenteritis eosinophilic 0/170 (0.00%)Intestinal obstruction 0/170 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)",
            "0/170 (0.00%)Intestinal"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "label": "Entailment",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "3 patients experiencing"
        ],
        "premise_text": "Gastroenteritis eosinophilic 0/1 (0.00%)Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)Intestinal"
        ]
    },
    {
        "id": "78c60212-28f7-4306-9f63-549be04687b2",
        "primaryId": "NCT00448591",
        "statement_text": "Only two types of adverse events  Leukopenia and Anaemia  occurred in more than 1% of patient in cohort 1 of the primary trial ",
        "statement_nums": [
            "1% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 672/2264 (29.68%) Febrile neutropenia * 117/2264 (5.17%) Neutropenia * 98/2264 (4.33%) Febrile bone marrow aplasia * 14/2264 (0.62%) Anaemia * 8/2264 (0.35%) Leukopenia * 8/2264 (0.35%) Thrombocytopenia * 6/2264 (0.27%) Disseminated intravascular coagulation * 3/2264 (0.13%) Agranulocytosis * 1/2264 (0.04%) ",
        "premise_nums": [
            "14/2264 (0.62%)",
            "6/2264 (0.27%)",
            "117/2264 (5.17%)",
            "1/2264 (0.04%)",
            "8/2264 (0.35%)",
            "98/2264 (4.33%)",
            "3/2264 (0.13%)",
            "672/2264 (29.68%)"
        ]
    },
    {
        "id": "78c60212-28f7-4306-9f63-549be04687b2",
        "primaryId": "NCT00448591",
        "statement_text": "Only two types of adverse events  Leukopenia and Anaemia  occurred in more than 1% of patient in cohort 1 of the primary trial ",
        "statement_nums": [
            "1% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Bone marrow failure * 1/2264 (0.04%)",
        "premise_nums": [
            "1/2264 (0.04%)"
        ]
    },
    {
        "id": "a72e1259-50be-48e5-bdf8-296040cbf7ce",
        "primaryId": "NCT01593020",
        "secondaryId": "NCT00834678",
        "label": "Contradiction",
        "statement_text": "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both the secondary trial but eligible for the primary trial ",
        "statement_nums": [
            "2 times the"
        ],
        "premise_text": "Exclusion Criteria: AST or ALT greater than 2.5 times the upper limit of normal (ULN) ALT and AST 2.5 times ULN ( 5 times ULN in the presence of documented liver metastases) ",
        "premise_nums": [
            "than 2.5 times the",
            "AST 2.5 times ULN"
        ]
    },
    {
        "id": "19cfd511-8582-4116-8d51-7ec4a6221022",
        "primaryId": "NCT03366428",
        "statement_text": "0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of smaller than 60ms.",
        "statement_nums": [
            "2-expressing Metastatic",
            "49 the primary",
            "0/49 the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported  Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title: DS-8201a Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49 Measure Type: Count of Participants ",
        "premise_nums": [
            "1 of each",
            "3 Day 15",
            "2-expressing Metastatic",
            "received 6.4 mg/kg",
            "7 days before",
            "3 weeks on",
            "49 Measure Type:",
            "21-day cycle"
        ]
    },
    {
        "id": "19cfd511-8582-4116-8d51-7ec4a6221022",
        "primaryId": "NCT03366428",
        "statement_text": "0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of smaller than 60ms.",
        "statement_nums": [
            "2-expressing Metastatic",
            "49 the primary",
            "0/49 the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Participants Maximum change from baseline in QTcF: greater than 30 ms: 3 6.1%Maximum change from baseline in QTcF: greater than 60 ms: 0 0.0% ",
        "premise_nums": [
            "3 6.1%Maximum change"
        ]
    },
    {
        "id": "bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8",
        "primaryId": "NCT00777049",
        "statement_text": "All 4 of the CHF cases in the primary trial  were in cohort 1.",
        "statement_nums": [
            "4 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Cardiac failure congestive 1/32 (3.13%) Adverse Events 2: Cardiac failure congestive 0/20 (0.00%) ",
        "premise_nums": [
            "1/32 (3.13%)",
            "0/20 (0.00%)"
        ]
    },
    {
        "id": "7c5b29bc-ac37-48bb-abb1-a102174f79ef",
        "primaryId": "NCT00826267",
        "statement_text": "Cohort 1 and 2 of the primary trial receive 50mg of different drugs  administered orally from Day 1 to Day 21",
        "statement_nums": [
            "1 and 2",
            "1 to Day"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  ",
        "premise_nums": [
            "50 mg orally",
            "50 mg Patients",
            "21 of each",
            "2 treatment courses",
            "1500 mg Patients",
            "1 to Day",
            "1500 mg orally"
        ]
    },
    {
        "id": "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a",
        "primaryId": "NCT00708214",
        "statement_text": "All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "50 mg With",
            "16 Weeks of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New bone lesion(s) on bone scan or on magnetic resonance imaging; Progression or occurrence of new lesion(s) according to the Response Evaluation Criteria In Solid Tumours version 1.0 (RECIST); an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline  at 2 consecutive examinations; occurrence of disease-related skeletal events  If a patient did not fulfil any criteria and was withdrawn because of clinical deterioration amounting to PD according to the Investigator  they were considered as having PD  Time frame: 16 weeks Results 1: Arm/Group Title: Afatinib 50 mg With Letrozole ",
        "premise_nums": [
            "CA 15.3 of more",
            "16 Weeks of",
            "50 mg With",
            "2 consecutive examinations;",
            "1 of the",
            "16 weeks Results"
        ]
    },
    {
        "id": "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a",
        "primaryId": "NCT00708214",
        "statement_text": "All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "50 mg With",
            "16 Weeks of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 40 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression  Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 0.00 (0.00 to 24.71) ",
        "premise_nums": [
            "50 mg therapy",
            "40 mg With",
            "13 Measure Type:",
            "67 to 70.96)",
            "letrozole 2.5 mg over",
            "00 to 24.71)",
            "40 mg therapy",
            "7 Measure Type:",
            "28-day treatment"
        ]
    },
    {
        "id": "27160f45-e4cb-48be-8cf2-c23ced4578c0",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected more than 10 patients in total ",
        "statement_nums": [
            "10 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 2/2788 (0.07%) Nervous system disorders - Other  specify 0/2788 (0.00%) Respiratory  thoracic and mediastinal disorders - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2800 (0.00%) ",
        "premise_nums": [
            "0/2788 (0.00%)",
            "1/2788 (0.04%)",
            "2/2788 (0.07%)",
            "5/2800 (0.18%)",
            "8/2800 (0.29%)",
            "5/2788 (0.18%)",
            "0/2800 (0.00%)",
            "9/2788 (0.32%)"
        ]
    },
    {
        "id": "27160f45-e4cb-48be-8cf2-c23ced4578c0",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected more than 10 patients in total ",
        "statement_nums": [
            "10 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Nervous system disorders - Other  specify 1/2800 (0.04%)Respiratory  thoracic and mediastinal disorders - Other  specify 1/2800 (0.04%) Thromboembolic event 2/2800 (0.07%) ",
        "premise_nums": [
            "2/2800 (0.07%)",
            "1/2800 (0.04%)Respiratory"
        ]
    },
    {
        "id": "e4b65e9f-10f6-4424-95d2-837e29587a63",
        "primaryId": "NCT00754325",
        "secondaryId": "NCT00399529",
        "label": "Entailment",
        "statement_text": "the secondary trial and the primary trial both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast ",
        "statement_nums": [
            "2/neu-overexpressing adenocarcinoma"
        ],
        "premise_text": "Inclusion Criteria: Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry (IHC) Inclusion Criteria: Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is defined as HER-2+ by immunohistochemistry (IHC) 3+ staining or Fluorescence In-Situ Hybridization (FISH)  Prior adjuvant Trastuzumab therapy is permitted  Patients must not be eligible for therapy of known curative potential for metastatic breast cancer if it is identified during the course of the study  ",
        "premise_nums": [
            "2/neu-overexpressing adenocarcinoma"
        ]
    },
    {
        "id": "68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1",
        "primaryId": "NCT01127373",
        "statement_text": "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for the primary trial ",
        "statement_nums": [
            "1 and TxN1M0"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Pathologic confirmation of metastatic disease in at least one regional lymph node  Regional lymph nodes are defined as the ipsilateral axillary lymph nodes  ipsilateral supraclavicular lymph nodes  and ipsilateral internal mammary lymph nodes  Thus  any T stage is allowed as long as the N stage is 1 and M stage is 0. ",
        "premise_nums": [
            "1 and M"
        ]
    },
    {
        "id": "7796fe1b-1952-4339-90f3-47b051ebe927",
        "primaryId": "NCT01432886",
        "statement_text": "One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Results 1: Arm/Group Title: E7389 With Weekly Trastuzumab Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously weekly  with an initial dose of 4 mg/kg followed by 2 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 Results 2: Arm/Group Title: E7389 With Tri-weekly Trastuzumab ",
        "premise_nums": [
            "1 and Day",
            "2 mg/kg for",
            "3 week cycle",
            "E7389 With",
            "(E7389) was",
            "4 mg/kg followed",
            "7389 With Weekly",
            "6 Measure Type:",
            "0 Results 2:",
            "8 of each"
        ]
    },
    {
        "id": "7796fe1b-1952-4339-90f3-47b051ebe927",
        "primaryId": "NCT01432886",
        "statement_text": "One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously tri-weekly  with an initial dose of 8 mg/kg followed by 6 mg/kg for the remaining doses Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 ",
        "premise_nums": [
            "1 and Day",
            "3 week cycle",
            "(E7389) was",
            "8 mg/kg followed",
            "6 Measure Type:",
            "8 of each",
            "6 mg/kg for"
        ]
    },
    {
        "id": "026e7eb7-37fd-4aae-b74f-dacf905db262",
        "primaryId": "NCT02366130",
        "secondaryId": "NCT01262027",
        "label": "Contradiction",
        "statement_text": "the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial  ",
        "statement_nums": [
            "10 times the"
        ],
        "premise_text": "Adverse Events 1: Total: 28/36 (77.78%) Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36 (30.56%) Fatigue 215/36 (41.67%) Flu-like symptoms 26/36 (16.67%) Hot Flashes 25/36 (13.89%) AST/ALT elevation 211/36 (30.56%) Arthralgia 24/36 (11.11%) Adverse Events 1: ",
        "premise_nums": [
            "26/36 (16.67%)",
            "27/36 (19.44%)",
            "28/36 (77.78%)",
            "29/36 (25.00%)",
            "24/36 (11.11%)",
            "213/36 (36.11%)",
            "25/36 (13.89%)",
            "215/36 (41.67%)",
            "211/36 (30.56%)",
            "210/36 (27.78%)"
        ]
    },
    {
        "id": "026e7eb7-37fd-4aae-b74f-dacf905db262",
        "primaryId": "NCT02366130",
        "secondaryId": "NCT01262027",
        "label": "Contradiction",
        "statement_text": "the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial  ",
        "statement_nums": [
            "10 times the"
        ],
        "premise_text": "Total: 1/22 (4.55%)Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) ",
        "premise_nums": [
            "1/22 (4.55%)Blood"
        ]
    },
    {
        "id": "08b79e0d-5e97-45fb-ac83-0096b56f714b",
        "primaryId": "NCT01492101",
        "statement_text": "less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Pancytopenia *2/425 (0.47%) Coagulopathy *1/425 (0.24%) Adverse Events 2: Pancytopenia *0/406 (0.00%) Coagulopathy *0/406 (0.00%) ",
        "premise_nums": [
            "2/425 (0.47%)",
            "1/425 (0.24%)",
            "0/406 (0.00%)"
        ]
    },
    {
        "id": "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b",
        "primaryId": "NCT01466270",
        "statement_text": "The the primary trial placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group ",
        "statement_nums": [
            "10% higher"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Retention Retention is the percentage of participants who stay in the study for 24 weeks  Time frame: 24 Weeks Results 1: Arm/Group Title: Arm I Arm/Group Description: Patients receive donepezil hydrochloride PO QD  donepezil hydrochloride: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 71.0 (8.3) Results 2: Arm/Group Title: Arm II Arm/Group Description: Patients receive placebo PO QD  Placebo: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 80.7 (7.2) ",
        "premise_nums": [
            "24 Weeks Results",
            "31 Mean (Standard"
        ]
    },
    {
        "id": "d3ca3729-2795-4cd5-9968-666781d17fac",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Congestive Heart Failure Rate Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN)  or symptomatic diastolic dysfunction  223 treated patients were included in the analysis  Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment  then every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry Results 1: Arm/Group Title: Arm A (ddBAC greater than BT greater than B) ",
        "premise_nums": [
            "3 years from",
            "2 years and",
            "17 and 25,",
            "6 months for",
            "3 months for",
            "223 treated patients",
            "2-3 years",
            "1 of cycles"
        ]
    },
    {
        "id": "d3ca3729-2795-4cd5-9968-666781d17fac",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Dose dense bevacizumab  cyclophosphamide and doxorubicin  followed by paclitaxel and bevacizumab  followed by bevacizumabOverall Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.9 (0.6 to 8.3) Results 2: Arm/Group Title: Arm B (ddAC greater than BT greater than B) Arm/Group Description: Dose dense doxorubicin and cyclophosphamide  followed by paclitaxel and bevacizumab  followed by bevacizumab Overall Number of Participants Analyzed: 120 Measure Type: Number ",
        "premise_nums": [
            "120 Measure Type:",
            "6 to 8.3)",
            "103 Measure Type:"
        ]
    },
    {
        "id": "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104",
        "primaryId": "NCT01752907",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Diarrhoea 2/149 (1.34%) Dyspepsia 0/149 (0.00%) Gastritis haemorrhagic 0/149 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: ",
        "premise_nums": [
            "16/149 (10.74%)",
            "7/149 (4.70%)",
            "0/149 (0.00%)",
            "1/149 (0.67%)",
            "2/149 (1.34%)"
        ]
    },
    {
        "id": "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104",
        "primaryId": "NCT01752907",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial ",
        "statement_nums": [
            "0 observed cases"
        ],
        "label": "Entailment",
        "premise_text": "Total: 20/151 (13.25%)Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation 0/151 (0.00%) Cardiac failure congestive 1/151 (0.66%) Abdominal pain 1/151 (0.66%) Diarrhoea 3/151 (1.99%) Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%) ",
        "premise_nums": [
            "1/151 (0.66%)",
            "2/151 (1.32%)",
            "4/151 (2.65%)",
            "3/151 (1.99%)",
            "20/151 (13.25%)Anaemia",
            "0/151 (0.00%)"
        ]
    },
    {
        "id": "b98c7a50-ed79-41ff-9733-fff143f630be",
        "primaryId": "NCT01901146",
        "secondaryId": "NCT00209092",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Febrile neutropenia 3/364 (0.82%) Adverse Events 1: Febrile Neutropenia *0/25 (0.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "3/364 (0.82%)"
        ]
    },
    {
        "id": "1739541a-2d3f-4a13-b956-769a1cbed4d7",
        "primaryId": "NCT00871858",
        "statement_text": "1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma ",
        "statement_nums": [
            "1 patient in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis 0/58 (0.00%) Endometrial atrophy 1/58 (1.72%) ",
        "premise_nums": [
            "2/60 (3.33%)",
            "3/58 (5.17%)",
            "1/60 (1.67%)",
            "0/60 (0.00%)",
            "1/58 (1.72%)",
            "0/58 (0.00%)"
        ]
    },
    {
        "id": "206fc00c-2c34-42bc-8fca-44be696e03c9",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days   the differences between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC and the number of cycles for each cohort  1 for cohort 1 and 4 for cohort 2.",
        "statement_nums": [
            "2 is mBC",
            "1 and 4",
            "1 is NSCLC",
            "145 mg/m¬¨‚â§",
            "1 for cohort"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Cohort A - Pegylated Irinotecan to Treat NSCLC Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "21 days in",
            "90 minutes every"
        ]
    },
    {
        "id": "206fc00c-2c34-42bc-8fca-44be696e03c9",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days   the differences between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC and the number of cycles for each cohort  1 for cohort 1 and 4 for cohort 2.",
        "statement_nums": [
            "2 is mBC",
            "1 and 4",
            "1 is NSCLC",
            "145 mg/m¬¨‚â§",
            "1 for cohort"
        ],
        "label": "Contradiction",
        "premise_text": "Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)INTERVENTION 2: Cohort C - Pegylated Irinotecan to Treat mBC ",
        "premise_nums": [
            "21 days (1",
            "145 mg/m²"
        ]
    },
    {
        "id": "206fc00c-2c34-42bc-8fca-44be696e03c9",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days   the differences between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC and the number of cycles for each cohort  1 for cohort 1 and 4 for cohort 2.",
        "statement_nums": [
            "2 is mBC",
            "1 and 4",
            "1 is NSCLC",
            "145 mg/m¬¨‚â§",
            "1 for cohort"
        ],
        "label": "Contradiction",
        "premise_text": "Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) ",
        "premise_nums": [
            "21 days (1",
            "90 minutes every",
            "21 days in",
            "145 mg/m²"
        ]
    },
    {
        "id": "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Month 33 Results 1: Arm/Group Title: Docetaxel + Sunitinib ",
        "premise_nums": [
            "33 Results 1:"
        ]
    },
    {
        "id": "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib) Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) ",
        "premise_nums": [
            "2 every 3",
            "2 weeks followed",
            "75 milligrams per",
            "100 mg/m^2",
            "95% Confidence",
            "2/1) with",
            "sunitinib 37.5 mg daily",
            "1-week off-treatment",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: months Independent radiology assessment: 8.6 (8.2 to 10.3)Investigator's assessment: 8.2 (7.3 to 8.6) Results 2: Arm/Group Title: Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 297 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 8.3 (7.7 to 9.6) Investigator's assessment: 6.9 (6.5 to 7.3) ",
        "premise_nums": [
            "2 every 3",
            "3 to 8.6)",
            "3 weeks Overall",
            "5 to 7.3)",
            "7 to 9.6)",
            "100 mg/m^2",
            "95% Confidence"
        ]
    },
    {
        "id": "83cef795-d4a8-486c-8ac1-34a9acee9672",
        "primaryId": "NCT00581256",
        "statement_text": "Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial ",
        "statement_nums": [
            "2 are excluded",
            "1-2 are"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: All patients must have left-sided breast cancer  Performance status should be 0-2 by ECOG criteria  Exclusion Criteria: Performance status greater than 2 by ECOG criteria ",
        "premise_nums": [
            "0-2 by",
            "2 by ECOG"
        ]
    },
    {
        "id": "007de11b-4265-4695-b18e-e0d6909a347a",
        "primaryId": "NCT00944047",
        "secondaryId": "NCT00228943",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 positive tumors are excluded from the primary trial  but may be included in the secondary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Inclusion Criteria: HER-2/neu 1+ or 2+ by immunohistochemistry Inclusion Criteria: At least 18 years of age Willing and able to provide informed consent Reporting daily hot flashes Able to read  write  and speak English Postmenopausal to limit sample variability (greater than 12 months amenorrhea) Greater then 1 month but smaller than 5 years post-treatment (surgery  radiation  chemotherapy) for non-metastatic breast cancer  These criteria allow inclusion of women successfully treated for recurrent breast cancer since there is no known reason to exclude them  Menopausal status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users  Exclusion Criteria: ",
        "premise_nums": [
            "1 month but",
            "12 months amenorrhea)",
            "5 years post",
            "2/neu 1+",
            "18 years of"
        ]
    },
    {
        "id": "2570cb04-4edd-48c9-b634-9f2e086469de",
        "primaryId": "NCT00994279",
        "secondaryId": "NCT00545077",
        "label": "Entailment",
        "statement_text": "Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm 1: Yoga Intervention Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Educational Wellness Group Education: Educational Wellness Group INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) ",
        "premise_nums": [
            "3 weeks plus",
            "15mg/kg every"
        ]
    },
    {
        "id": "2570cb04-4edd-48c9-b634-9f2e086469de",
        "primaryId": "NCT00994279",
        "secondaryId": "NCT00545077",
        "label": "Entailment",
        "statement_text": "Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent Letrozole Bevacizumab Fulvestrant ",
        "premise_nums": [
            "15mg/kg i",
            "1 every 3"
        ]
    },
    {
        "id": "f6a7e279-b923-45e3-8ad5-e81e17c0a682",
        "primaryId": "NCT00270894",
        "statement_text": "60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60 patients in",
            "85% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Subjects Able to Complete greater than 85% of the Planned Dose on Schedule Feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with greater than 85% of the protocol-specified dose  Time frame: From the start of treatment through the neoadjuvant treatment period (approximately 20 weeks) Results 1: Arm/Group Title: Neoadjuvant Therapy ",
        "premise_nums": [
            "85% of"
        ]
    },
    {
        "id": "f6a7e279-b923-45e3-8ad5-e81e17c0a682",
        "primaryId": "NCT00270894",
        "statement_text": "60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60 patients in",
            "85% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: percentage of participants 60 ",
        "premise_nums": [
            "4 treatments Overall",
            "4 mg/kg",
            "30 Measure Type:",
            "2 weeks for",
            "3-week break"
        ]
    },
    {
        "id": "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 32 patients in the primary trial had Diarrhoea ",
        "statement_nums": [
            "32 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213 (0.00%) Supraventricular tachycardia 0/213 (0.00%) Diarrhoea 0/213 (0.00%) Colitis 0/213 (0.00%) Vomiting 1/213 (0.47%) Nausea 1/213 (0.47%) Enterocolitis 0/213 (0.00%) Adverse Events 2: Total: 133/416 (31.97%) ",
        "premise_nums": [
            "0/213 (0.00%)",
            "1/213 (0.47%)",
            "19/213 (8.92%)",
            "133/416 (31.97%)"
        ]
    },
    {
        "id": "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 32 patients in the primary trial had Diarrhoea ",
        "statement_nums": [
            "32 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Pancytopenia 1/416 (0.24%)Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416 (0.24%) Supraventricular tachycardia 1/416 (0.24%) Diarrhoea 32/416 (7.69%) Colitis 14/416 (3.37%) Vomiting 4/416 (0.96%) Nausea 3/416 (0.72%) Enterocolitis 2/416 (0.48%) ",
        "premise_nums": [
            "0/416 (0.00%)",
            "4/416 (0.96%)",
            "32/416 (7.69%)",
            "1/416 (0.24%)Anaemia",
            "3/416 (0.72%)",
            "2/416 (0.48%)",
            "14/416 (3.37%)"
        ]
    },
    {
        "id": "91adb350-ab20-41a6-944d-c13b55cf33f2",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded none ",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) ",
        "premise_nums": [
            "49/680 (7.21%)",
            "11/680 (1.62%)",
            "83/680 (12.21%)",
            "0/680 (0.00%)",
            "1/680 (0.15%)"
        ]
    },
    {
        "id": "91adb350-ab20-41a6-944d-c13b55cf33f2",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded none ",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 86/688 (12.50%) Hemoglobin 15/688 (2.18%) Transfusion: Platelets 1/688 (0.15%) Transfusion: pRBCs 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%) Ischemia/infarction 0/688 (0.00%) Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) ",
        "premise_nums": [
            "1/688 (0.15%)",
            "0/688 (0.00%)",
            "41/688 (5.96%)",
            "86/688 (12.50%)",
            "2:Total: 86/688",
            "15/688 (2.18%)"
        ]
    },
    {
        "id": "91adb350-ab20-41a6-944d-c13b55cf33f2",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded none ",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Entailment",
        "premise_text": "Colitis 0/688 (0.00%)",
        "premise_nums": [
            "0/688 (0.00%)"
        ]
    },
    {
        "id": "78949f1f-6738-4220-a233-e7831902e6f3",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "statement_nums": [
            "719 in Combination",
            "BYL719 in"
        ],
        "premise_text": "Outcome Measurement: Dose Limiting Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 DLTs of BYL719 in combination with T-DM1 will be assessed using National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (except for hyperglycemia)  A DLT is described any grade 3 or higher  clinically significant toxicity (excluding alopecia) experienced during the first 21 days following first dose of BYL719 that is determined to be at least possibly related to study medication  Lower grades may also be considered DLTs if they lead to a dose interruption of more than 7 consecutive days of BYL719. In general adverse events (AEs) will be graded according to the following: ",
        "premise_nums": [
            "21 days following",
            "719 that is",
            "BYL719 that",
            "719 in Combination",
            "1 will be",
            "719 in combination",
            "BYL719 in",
            "7 consecutive days",
            "3 or higher",
            "1 DLTs of"
        ]
    },
    {
        "id": "78949f1f-6738-4220-a233-e7831902e6f3",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "statement_nums": [
            "719 in Combination",
            "BYL719 in"
        ],
        "premise_text": "Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AETime frame: The 1st 21 days (Cycle 1) of treatment Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes ",
        "premise_nums": [
            "4 Life-threatening or",
            "40 mg Stratified",
            "21 days (Cycle",
            "1 Mild AE",
            "3 Severe AE",
            "5 Death related",
            "2 Moderate AE",
            "20 mg or"
        ]
    },
    {
        "id": "78949f1f-6738-4220-a233-e7831902e6f3",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "label": "Contradiction",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "statement_nums": [
            "719 in Combination",
            "BYL719 in"
        ],
        "premise_text": "Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM Time frame: 4 months ",
        "premise_nums": [
            "6 alleles have",
            "4 months of",
            "10 possible allelic"
        ]
    },
    {
        "id": "0984431d-4997-41dc-9ba4-07134568c3fa",
        "primaryId": "NCT00258349",
        "secondaryId": "NCT01328249",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate With Prophylactic Filgrastim  whereas both cohorts in the secondary trial receive some ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Vorinostat +Trastuzumab Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes  every 3 weeks; Vorinostat 200 mg of SAHA orally twice a day  daily for 14 days out of a 21-day cycle INTERVENTION 1: Cohort 1: Eribulin Mesylate With Filgrastim as Needed ",
        "premise_nums": [
            "14 days out",
            "200 mg of",
            "6 mg/kg once",
            "21-day cycle"
        ]
    },
    {
        "id": "d9dc4a6d-a913-46ac-b0aa-d50823ff2305",
        "primaryId": "NCT00662129",
        "statement_text": "Patients with Platelet count over 100,000/mm¬¨‚â•, ANC smaller than 1,700/mm¬¨‚â• and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial ",
        "statement_nums": [
            "100,000/mm¬¨‚â•, ANC",
            "11 to 18",
            "1,700/mm¬¨‚â• and"
        ],
        "label": "Entailment",
        "premise_text": "PATIENT CHARACTERISTICS: ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL ",
        "premise_nums": [
            "100,000/mm³ Hemoglobin",
            "Hemoglobin 9.0 g/dL",
            "1,500/mm³ Platelet"
        ]
    },
    {
        "id": "89fdf182-7474-4e70-baf7-03c8920c4ff3",
        "primaryId": "NCT01385137",
        "secondaryId": "NCT00593346",
        "label": "Contradiction",
        "statement_text": "Placebo treatment is used in cohort 2 of the secondary trial  but there is only a test group in the primary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each patient will receive accelerated partial breast brachytherapy with multiple plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  ",
        "premise_nums": [
            "7 days with",
            "3-fatty acid",
            "10 twice-daily fractions",
            "5-7 days",
            "3400 cGy delivered",
            "3-fatty Acid",
            "6 hours separation",
            "24 weeks in"
        ]
    },
    {
        "id": "d0b9c11c-50f2-4803-a96c-fff3ca90cf36",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle)  the difference between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC ",
        "statement_nums": [
            "21 days (1",
            "2 is mBC",
            "145 mg/m¬¨‚â§",
            "1 is NSCLC"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Cohort A - Pegylated Irinotecan to Treat NSCLC Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) ",
        "premise_nums": [
            "21 days (1",
            "90 minutes every",
            "21 days in",
            "145 mg/m²"
        ]
    },
    {
        "id": "d0b9c11c-50f2-4803-a96c-fff3ca90cf36",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle)  the difference between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC ",
        "statement_nums": [
            "21 days (1",
            "2 is mBC",
            "145 mg/m¬¨‚â§",
            "1 is NSCLC"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 2:Cohort C - Pegylated Irinotecan to Treat mBC Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) ",
        "premise_nums": [
            "90 minutes every",
            "21 days in",
            "145 mg/m²",
            "21 days (1",
            "2:Cohort C"
        ]
    },
    {
        "id": "0900325b-6ecd-46f1-b3f1-a2ce1605d151",
        "primaryId": "NCT00325598",
        "statement_text": "There is no difference in results or cohort size between cohort 1 and 2 of the primary trial  the increase in Gy has no notable effect ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her  Time frame: Within 1 year of protocol registration Results 1: Arm/Group Title: Cohort 1 (36 Gy) Arm/Group Description: 36 Gy in 9 fractions BID x 4 1/2 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 Results 2: Arm/Group Title: Cohort 2 (40 Gy) ",
        "premise_nums": [
            "9 fractions BID",
            "50 Measure Type:",
            "36 Gy in",
            "1 year of",
            "100 Results 2:",
            "4 patients cannot",
            "4 1/2 treatment",
            "2 treatment days"
        ]
    },
    {
        "id": "0900325b-6ecd-46f1-b3f1-a2ce1605d151",
        "primaryId": "NCT00325598",
        "statement_text": "There is no difference in results or cohort size between cohort 1 and 2 of the primary trial  the increase in Gy has no notable effect ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: 40 Gy in 10 fractions BID over 5 treatment daysPartial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 ",
        "premise_nums": [
            "40 Gy in",
            "50 Measure Type:",
            "10 fractions BID",
            "5 treatment daysPartial"
        ]
    },
    {
        "id": "6f10e1f3-1197-464e-b574-d697fb49331d",
        "primaryId": "NCT02419807",
        "secondaryId": "NCT00777101",
        "label": "Entailment",
        "statement_text": "Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial  However  only patients with stage 1-2 breast cancer are eligible for the primary trial  and patients with stage 3-4 are eligilbe for the secondary trial ",
        "statement_nums": [
            "2 breast cancer",
            "3-4 are",
            "4 are eligilbe",
            "1-2 breast"
        ],
        "premise_text": "Inclusion Criteria: Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer Inclusion Criteria: Stage IIIB  IIIC  or IV erbB2 (HER2) positive breast cancer ",
        "premise_nums": [
            "1 or 2",
            "(HER2) positive"
        ]
    },
    {
        "id": "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response ",
        "statement_nums": [
            "27.6% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Patients With Pathological Complete Response (pCR) in Patients Who Have Fatty Acid Synthase (FASN) Expression pCR is defined as no invasive disease in the breast of axilla at the time of definitive surgery  A patient is considered to have FASN expression if the positivity was greater than or equal 15% at the baseline or after 4-7 days of Omeprazole monotherapy  FASN expression is evaluated using immunohistochemistry in core biopsy samples  The percent of patients with FASN expression that have pCR will be calculated with an exact 95% confidence interval  Time frame: Up to 6 months Results 1: ",
        "premise_nums": [
            "95% confidence",
            "6 months Results",
            "4-7 days",
            "7 days of",
            "15% at"
        ]
    },
    {
        "id": "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response ",
        "statement_nums": [
            "27.6% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: High Dose Omeprazole TreatmentArm/Group Description: Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery  Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 72.4 (52.8 to 87.3) ",
        "premise_nums": [
            "7 days prior",
            "4-7 days",
            "29 Measure Type:",
            "80 mg orally",
            "8 to 87.3)"
        ]
    },
    {
        "id": "494c1f01-5a2d-409e-b614-5871f408fbe6",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial group A has a higher percentage of patients with greater than 25% increase in tumor area at 3 months after treatment than group B ",
        "statement_nums": [
            "25% increase",
            "3 months after"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Central Nervous System (CNS) Progression-free Survival(PFS) The number of patients that are documented to have progression free survival at 3 months after treatment  Progression free is define as smaller than 25% increase in tumor area  PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death  Time frame: 3 months after treatment Results 1: Arm/Group Title: Epothilone B: Group A ",
        "premise_nums": [
            "25% increase",
            "3 months after"
        ]
    },
    {
        "id": "494c1f01-5a2d-409e-b614-5871f408fbe6",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial group A has a higher percentage of patients with greater than 25% increase in tumor area at 3 months after treatment than group B ",
        "statement_nums": [
            "25% increase",
            "3 months after"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Group A: Patients with progressive  radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT)  Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: participants 12 Results 2: Arm/Group Title: Epothilone B: Group B ",
        "premise_nums": [
            "45 Measure Type:",
            "(q3weeks) with",
            "10 mg/m2",
            "12 Results 2:"
        ]
    },
    {
        "id": "494c1f01-5a2d-409e-b614-5871f408fbe6",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial group A has a higher percentage of patients with greater than 25% increase in tumor area at 3 months after treatment than group B ",
        "statement_nums": [
            "25% increase",
            "3 months after"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Group B: an exploratory cohort of patients  with either leptomeningeal metastases (LMD) or unirradiated  asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 10 Measure Type: Number Unit of Measure: participants 2 ",
        "premise_nums": [
            "10 mg/m2",
            "(q3weeks) with",
            "10 Measure Type:"
        ]
    },
    {
        "id": "17881072-2517-483f-9c03-1edad21a58cf",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Contradiction",
        "statement_text": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial ",
        "statement_nums": [
            "3 more cases"
        ],
        "premise_text": "Adverse Events 1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 0/42 (0.00%) Influenza like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/42 (2.38%)",
            "0/42 (0.00%)",
            "7/42 (16.67%)"
        ]
    },
    {
        "id": "17881072-2517-483f-9c03-1edad21a58cf",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Contradiction",
        "statement_text": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial ",
        "statement_nums": [
            "3 more cases"
        ],
        "premise_text": "Total: 7/42 (16.67%)Febrile neutropenia 0/42 (0.00%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) ",
        "premise_nums": [
            "2/42 (4.76%)",
            "7/42 (16.67%)Febrile",
            "21/209 (10.05%)",
            "0/42 (0.00%)",
            "1/42 (2.38%)"
        ]
    },
    {
        "id": "17881072-2517-483f-9c03-1edad21a58cf",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Contradiction",
        "statement_text": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial ",
        "statement_nums": [
            "3 more cases"
        ],
        "premise_text": "Anaemia 0/209 (0.00%)Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Acute myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) ",
        "premise_nums": [
            "29/216 (13.43%)",
            "1/209 (0.48%)",
            "0/209 (0.00%)Febrile"
        ]
    },
    {
        "id": "17881072-2517-483f-9c03-1edad21a58cf",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Contradiction",
        "statement_text": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial ",
        "statement_nums": [
            "3 more cases"
        ],
        "premise_text": "Anaemia 2/216 (0.93%)Febrile neutropenia 2/216 (0.93%) Thrombocytopenia 2/216 (0.93%) Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%) Oral pain 2/216 (0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) ",
        "premise_nums": [
            "0/216 (0.00%)",
            "1/216 (0.46%)",
            "2/216 (0.93%)Febrile"
        ]
    },
    {
        "id": "58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7",
        "primaryId": "NCT00093795",
        "statement_text": "Patients with cancer cells that have metastasised into less than 3 lymph nodes  with at least one larger than 2mm, cannot enter the primary trial ",
        "statement_nums": [
            "3 lymph nodes"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: By pathologic evaluation  ipsilateral nodes must be pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b (only if due to microscopic involvement of internal mammary node detected by sentinel lymph node dissection and with more than 3 positive axillary lymph nodes)  ",
        "premise_nums": [
            "3 positive axillary"
        ]
    },
    {
        "id": "da6ce3a9-b653-47b2-9271-f831e4de3f19",
        "primaryId": "NCT00912340",
        "statement_text": "Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Pleural effusion *0/24 (0.00%) Adverse Events 2: Pleural effusion *2/30 (6.67%) ",
        "premise_nums": [
            "2/30 (6.67%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "66979ae5-a709-4adf-9067-287f0f92b9e2",
        "primaryId": "NCT00828074",
        "statement_text": "A higher number of cohort 2 participants from the primary trial experienced fever  compared to cohort 1.",
        "statement_nums": [
            "2 participants from"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Fever * 2/41 (4.88%) Adverse Events 2: Fever * 0/5 (0.00%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "0/5 (0.00%)"
        ]
    },
    {
        "id": "46ac8a9f-77ab-40cf-9421-64aad4ae6976",
        "primaryId": "NCT00537771",
        "secondaryId": "NCT00354640",
        "label": "Entailment",
        "statement_text": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD ",
        "statement_nums": [
            "1 milligram of",
            "1 in the"
        ],
        "premise_text": "INTERVENTION 1: Arimidex Group Anastrozole(ARIMIDEX): 1 mg once daily oral dose INTERVENTION 1: anastrozole : 1 milligram tablet PO QD for 14 days ",
        "premise_nums": [
            "1 mg once",
            "1 milligram tablet"
        ]
    },
    {
        "id": "9a896e4a-ae6b-468c-a7c0-32c1514c0b48",
        "primaryId": "NCT00107276",
        "secondaryId": "NCT00232505",
        "label": "Entailment",
        "statement_text": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events  in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event  and more than 30% of those in cohort 2 of the secondary trial had adverse events ",
        "statement_nums": [
            "2 of the",
            "5% of",
            "10% patients",
            "30% of",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 1: Total: 3/31 (9.68%) Adverse Events 2: Total: 8/25 (32.00%) ",
        "premise_nums": [
            "8/25 (32.00%)",
            "3/31 (9.68%)",
            "4/95 (4.21%)"
        ]
    },
    {
        "id": "70912726-ba1b-47ef-9005-9584c8caf559",
        "primaryId": "NCT00853996",
        "statement_text": "Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model   and no Family history consistent with hereditary breast cancer  are eligible for the primary trial ",
        "statement_nums": [
            "5 years by"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Gail risk greater than or equal 1.7% and/or relative risk greater than or equal 3 times that for 5-year age group Family history consistent with hereditary breast cancer  as indicated by 1 of the following criteria: ",
        "premise_nums": [
            "5-year age",
            "equal 1.7% and/or",
            "3 times that",
            "1 of the"
        ]
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "2 pm Days",
            "1000 mg/m2 pm",
            "1 and 8",
            "21 day cycle;",
            "2 tablets x",
            "2 twice daily",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)  Overall Number of Participants Analyzed: 81 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "95% Confidence",
            "2 tablets x",
            "2 twice daily",
            "30 minutes after",
            "7 day rest",
            "83 to 128)"
        ]
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "2 pm Days",
            "1000 mg/m2 pm",
            "1 and 8",
            "21 day cycle;",
            "2 tablets x",
            "2 twice daily",
            "2 tablets )",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 81 (48 to 95) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "48 to 95)",
            "95% Confidence",
            "2 twice daily",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "f1a45b47-498d-45c8-b6d9-6c8f035da30b",
        "primaryId": "NCT01201265",
        "statement_text": "1 patient in the primary trial was affected by Sepsis ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "3/40 (7.50%)",
            "1/40 (2.50%)",
            "17/40 (42.50%)",
            "5/40 (12.50%)",
            "6/40 (15.00%)"
        ]
    },
    {
        "id": "4c67a7b4-36fa-4c20-a15a-122609550973",
        "primaryId": "NCT00201773",
        "statement_text": "Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events  She is eligible for the primary trial",
        "statement_nums": [
            "6 months and",
            "85 year old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Must be female with histologically confirmed breast cancer Stage II-IV disease ER and/or PR positive ECOG Performance Status 0-1 Postmenopausal ",
        "premise_nums": [
            "0-1 Postmenopausal"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "premise_nums": [
            "1-L4) Bone"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA)  The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader  Percent change = 100*((BMD at Month 12 - Baseline BMD)/Baseline BMD))  Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method  Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward Time frame: Baseline  12 months Results 1: ",
        "premise_nums": [
            "6 were not",
            "12 were imputed",
            "6 were carried",
            "12 months Results"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Zoledronic Acid UpfrontArm/Group Description: Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 253 Mean (Standard Deviation) ",
        "premise_nums": [
            "4 mg i.v",
            "(1000-1200 mg",
            "1 and every",
            "15-minute infusion",
            "253 Mean (Standard",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "4 mg IV",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: In lieu of a placebo arm  which was considered unethical for this trial  a delayed start arm was used  Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture  or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit  were started on zoledronic acid 4 mg i.v  and for every 6 months until disease progression (recurrence) or end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  ",
        "premise_nums": [
            "36 scheduled visit",
            "4 mg i.v",
            "(1000-1200 mg",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Contradiction",
        "premise_text": "Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months Overall Number of Participants Analyzed: 256 Mean (Standard Deviation) Unit of Measure: Percentage of BMD -2.325 (3.9542) ",
        "premise_nums": [
            "6 months Overall",
            "4 mg IV",
            "256 Mean (Standard",
            "15-minute infusion"
        ]
    },
    {
        "id": "441c0760-ca4a-4f1d-864e-a77395fd1f18",
        "primaryId": "NCT00399802",
        "statement_text": "The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "5 mg group"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 u-NTx is a biochemical index of bone resorption  Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx  Time frame: Baseline and Week 4 Results 1: Arm/Group Title: Single IV Infusion of ZA 4 mg Arm/Group Description: Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks  Overall Number of Participants Analyzed: 14 Mean (95% Confidence Interval) ",
        "premise_nums": [
            "4 mg at",
            "4 mg Arm",
            "4 u-NTx is",
            "95% Confidence",
            "4 for measurement",
            "4 Results 1:"
        ]
    },
    {
        "id": "441c0760-ca4a-4f1d-864e-a77395fd1f18",
        "primaryId": "NCT00399802",
        "statement_text": "The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "5 mg group"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percentage change -73 (-80 to -62)Results 2: Arm/Group Title: Once-daily Odanacatib 5 mg Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment  Overall Number of Participants Analyzed: 27 Mean (95% Confidence Interval) Unit of Measure: Percentage change -77 (-82 to -71) ",
        "premise_nums": [
            "5 mg Arm",
            "95% Confidence",
            "5 mg tablet",
            "4 weeks and"
        ]
    },
    {
        "id": "fbe60029-8944-4e12-b4b2-3413037a10cc",
        "primaryId": "NCT00723125",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery ",
        "statement_nums": [
            "57% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Pathological Complete Response Rates at Surgery [Not Specified] Time frame: at surgery approximately 5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 ",
        "premise_nums": [
            "5 months after"
        ]
    },
    {
        "id": "fbe60029-8944-4e12-b4b2-3413037a10cc",
        "primaryId": "NCT00723125",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery ",
        "statement_nums": [
            "57% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks",
        "premise_nums": [
            "100 mg/m2 IV",
            "60 minutes cycles",
            "2 IV over",
            "10 Avastin 10",
            "30 minutes weekly",
            "14 Abraxane 100",
            "30-90 minutes",
            "12 weeks with",
            "6 over 30",
            "30-60 minutes",
            "10 mg/kg IV",
            "60 minutes q2weeks",
            "90 minutes weeks",
            "60 mg/m2*",
            "15 mg/kg IV",
            "600 mg/m2 IV",
            "4 cycles Definitive",
            "1,4,7, and",
            "90 minutes day",
            "2 IV q2weeks"
        ]
    },
    {
        "id": "fbe60029-8944-4e12-b4b2-3413037a10cc",
        "primaryId": "NCT00723125",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery ",
        "statement_nums": [
            "57% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 28 Measure Type: Number Unit of Measure: participants 16 ",
        "premise_nums": [
            "30 minutes weekly",
            "100 mg/m2 IV",
            "1 and Cohort",
            "28 Measure Type:",
            "2 IV over",
            "30-90 minutes",
            "1,4,7, and",
            "12 weeks with",
            "90 minutes weeks",
            "6 over 30",
            "15 mg/kg IV"
        ]
    },
    {
        "id": "fe1782aa-a871-4608-a7cb-8f83b7f76d8a",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "label": "Contradiction",
        "statement_text": "Gemcitabine is not used in the primary trial  and used only in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatmentINTERVENTION 2: Arm B: Nab-Paclitaxel + Carboplatin ",
        "premise_nums": [
            "1000 mg/m^2",
            "1 and 8",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "fe1782aa-a871-4608-a7cb-8f83b7f76d8a",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "label": "Contradiction",
        "statement_text": "Gemcitabine is not used in the primary trial  and used only in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment ",
        "premise_nums": [
            "21-day treatment",
            "1 and 8",
            "125 mg/m^2",
            "2 on Days"
        ]
    },
    {
        "id": "d7fa4f81-e108-491f-9b08-c147a33863e8",
        "primaryId": "NCT01953003",
        "statement_text": "Patients receiving intervention 1 of the primary trial  will be administered medication orally and intraveinously ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm A : iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest  vinflunine: intraveinous administration day 1 once every 3 weeks  280 mg/m² Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B : Capecitabine 1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² ",
        "premise_nums": [
            "1 once every",
            "1 week of",
            "1 of each",
            "825 mg/m²",
            "2500 mg/m²",
            "14 consecutive days",
            "1650 mg/m²",
            "1250 mg/m²",
            "280 mg/m²"
        ]
    },
    {
        "id": "d2d6f646-5881-42a2-b965-0c6f79e89463",
        "primaryId": "NCT00090857",
        "statement_text": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry  if the results from this are more than 2 standard deviations below normal  the study physician can still decide to let them participate ",
        "statement_nums": [
            "2 standard deviations",
            "1 month prior"
        ],
        "label": "Entailment",
        "premise_text": "Bone density scan within 2 standard deviations from normal within the past 30 days Bone density scan 2 standard deviations below normal allowed if approved by the study physician ",
        "premise_nums": [
            "30 days Bone",
            "2 standard deviations"
        ]
    },
    {
        "id": "45e6b4b6-ca31-4318-936e-5b27cbca47a2",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months ",
        "statement_nums": [
            "3 decrease in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI  the sum over all measureable lesions on the MRI was calculated at each time point  V3 was calculated by subtracting the total MRI FTV measured (i.e  the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline  For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests  Time frame: up to 3 months from start of treatment Results 1: ",
        "premise_nums": [
            "3 months from",
            "(V3) Mean",
            "3 was calculated",
            "95% confidence",
            "3 the raw"
        ]
    },
    {
        "id": "45e6b4b6-ca31-4318-936e-5b27cbca47a2",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months ",
        "statement_nums": [
            "3 decrease in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Letrozole + MRIArm/Group Description: Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. Overall Number of Participants Analyzed: 68 Mean (95% Confidence Interval) Unit of Measure: cubic centimeters -1.93 (-2.87 to -0.98) ",
        "premise_nums": [
            "of 2.5 mg/day",
            "6 months of",
            "95% Confidence",
            "3 and 6."
        ]
    },
    {
        "id": "50d119f6-a657-4619-918e-7617ac57f052",
        "primaryId": "NCT03078751",
        "statement_text": "Cohort 1 of the primary trial reported one case of AML ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) ",
        "premise_nums": [
            "4/26 (15.38%)",
            "0/26 (0.00%)",
            "1/26 (3.85%)"
        ]
    },
    {
        "id": "d63706f1-4fb8-488d-8f86-c1a19df341d4",
        "primaryId": "NCT00944047",
        "secondaryId": "NCT00228943",
        "label": "Entailment",
        "statement_text": "Patients with tumors underexpressing HER2 are excluded from the primary trial  but may be included in the secondary trial ",
        "statement_nums": [
            "2 are excluded"
        ],
        "premise_text": "Inclusion Criteria: HER-2/neu 1+ or 2+ by immunohistochemistry Inclusion Criteria: At least 18 years of age Willing and able to provide informed consent Reporting daily hot flashes Able to read  write  and speak English Postmenopausal to limit sample variability (greater than 12 months amenorrhea) Greater then 1 month but smaller than 5 years post-treatment (surgery  radiation  chemotherapy) for non-metastatic breast cancer  These criteria allow inclusion of women successfully treated for recurrent breast cancer since there is no known reason to exclude them  Menopausal status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users  Exclusion Criteria: ",
        "premise_nums": [
            "1 month but",
            "12 months amenorrhea)",
            "5 years post",
            "2/neu 1+",
            "18 years of"
        ]
    },
    {
        "id": "80a5cdbc-0721-41b6-af1a-28e3f46557ce",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had a cardiac related adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 146/573 (25.48%) Anaemia 4/573 (0.70%) Disseminated intravascular coagulation 0/573 (0.00%) Neutropenia 1/573 (0.17%) Thrombocytopenia 0/573 (0.00%) Acute coronary syndrome 1/573 (0.17%) Angina pectoris 1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) ",
        "premise_nums": [
            "0/573 (0.00%)",
            "1/573 (0.17%)",
            "146/573 (25.48%)",
            "2/573 (0.35%)",
            "101/570 (17.72%)",
            "4/573 (0.70%)"
        ]
    },
    {
        "id": "80a5cdbc-0721-41b6-af1a-28e3f46557ce",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had a cardiac related adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Anaemia 3/570 (0.53%)Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%) Thrombocytopenia 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial fibrillation 0/570 (0.00%) Atrial flutter 1/570 (0.18%) Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%) ",
        "premise_nums": [
            "1/570 (0.18%)",
            "3/570 (0.53%)Disseminated",
            "0/570 (0.00%)"
        ]
    },
    {
        "id": "18fcd396-cb03-4e80-bb2d-ee03c12ba32a",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Contradiction",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145 (1.38%) NEUTROPENIA 1/145 (0.69%) LEUKOCYTOSIS 1/145 (0.69%) THROMBOCYTOPENIA 1/145 (0.69%) FEBRILE NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2: ",
        "premise_nums": [
            "1/145 (0.69%)",
            "2/145 (1.38%)",
            "17/145 (11.72%)",
            "0/145 (0.00%)"
        ]
    },
    {
        "id": "18fcd396-cb03-4e80-bb2d-ee03c12ba32a",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Contradiction",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Total: 11/144 (7.64%)ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144 (0.00%) NEUTROPENIA 0/144 (0.00%) LEUKOCYTOSIS 0/144 (0.00%) THROMBOCYTOPENIA 0/144 (0.00%) FEBRILE NEUTROPENIA 1/144 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%) DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: ",
        "premise_nums": [
            "11/144 (7.64%)ANAEMIA",
            "0/144 (0.00%)",
            "1/144 (0.69%)"
        ]
    },
    {
        "id": "18fcd396-cb03-4e80-bb2d-ee03c12ba32a",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Contradiction",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Total: 22/79 (27.85%)Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: Total: 13/76 (17.11%) ",
        "premise_nums": [
            "2/79 (2.53%)",
            "13/76 (17.11%)",
            "0/79 (0.00%)",
            "22/79 (27.85%)Anaemia",
            "1/79 (1.27%)"
        ]
    },
    {
        "id": "18fcd396-cb03-4e80-bb2d-ee03c12ba32a",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Contradiction",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Anaemia 1/76 (1.32%)Right ventricular dysfunction 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%) ",
        "premise_nums": [
            "0/76 (0.00%)",
            "2/76 (2.63%)",
            "1/76 (1.32%)Right"
        ]
    },
    {
        "id": "b87abb47-13b6-4dbe-9cfd-e63075b676aa",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "0 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Objective Response Based on Data Review Committee's Assessment Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST)  CR is defined as disappearance of all target and non-target lesions  PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD according to RECIST  Confirmed responses are those that persist on repeat evaluation 4 weeks after initial documentation of response  Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8. Results 1: Arm/Group Title: SUNITINIB+CAPECITABINE ",
        "premise_nums": [
            "30% decrease",
            "6 weeks after",
            "1 of Cycle",
            "4 weeks after"
        ]
    },
    {
        "id": "b87abb47-13b6-4dbe-9cfd-e63075b676aa",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "0 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity  and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance  Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study Overall Number of Participants Analyzed: 63 Measure Type: Number Unit of Measure: participants Total Number of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR): 19 ",
        "premise_nums": [
            "of 2,000 mg/m",
            "19 Complete Response",
            "1 to 14",
            "63 Measure Type:",
            "0 Partial Response",
            "21-day cycles",
            "2,000 mg/m^2/day",
            "21 days at",
            "1 at the",
            "of 37.5 mg/day"
        ]
    },
    {
        "id": "eb025223-1b4a-4df7-a85e-2eeeb62a6bf5",
        "primaryId": "NCT00754845",
        "statement_text": "Patients who received over 5 years of anastrozole therapy  completed under a year ago  are eligible for the primary trial ",
        "statement_nums": [
            "5 years of"
        ],
        "label": "Contradiction",
        "premise_text": "Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g.  letrozole  anastrozole  or exemestane)  either as initial therapy or after prior tamoxifen citrate  including treatment received as part of clinical trial CAN-NCIC-MA17 Completed aromatase inhibitor therapy 2 years ago ",
        "premise_nums": [
            "6 years of",
            "17 Completed aromatase",
            "MA17 Completed",
            "2 years ago"
        ]
    },
    {
        "id": "a5486f80-69e5-4a5a-8435-f82f39cddf85",
        "primaryId": "NCT00080301",
        "statement_text": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "2 more cases",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 127/368 (34.51%) ANAEMIA 3/368 (0.82%) LEUKOPENIA 0/368 (0.00%) NEUTROPENIA 0/368 (0.00%) COAGULOPATHY 3/368 (0.82%) LYMPHADENOPATHY 0/368 (0.00%) THROMBOCYTOPENIA 2/368 (0.54%) BONE MARROW FAILURE 0/368 (0.00%) FEBRILE NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%) ",
        "premise_nums": [
            "0/368 (0.00%)",
            "127/368 (34.51%)",
            "4/368 (1.09%)",
            "2/368 (0.54%)",
            "3/368 (0.82%)"
        ]
    },
    {
        "id": "a5486f80-69e5-4a5a-8435-f82f39cddf85",
        "primaryId": "NCT00080301",
        "statement_text": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "2 more cases",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "ATRIAL FLUTTER 0/368 (0.00%)CARDIAC ARREST 0/368 (0.00%) Adverse Events 2: Total: 151/369 (40.92%) ANAEMIA 11/369 (2.98%) LEUKOPENIA 6/369 (1.63%) NEUTROPENIA 18/369 (4.88%) COAGULOPATHY 0/369 (0.00%) LYMPHADENOPATHY 1/369 (0.27%) THROMBOCYTOPENIA 7/369 (1.90%) BONE MARROW FAILURE 1/369 (0.27%) FEBRILE NEUTROPENIA 15/369 (4.07%) ",
        "premise_nums": [
            "0/369 (0.00%)",
            "6/369 (1.63%)",
            "151/369 (40.92%)",
            "15/369 (4.07%)",
            "0/368 (0.00%)CARDIAC",
            "18/369 (4.88%)",
            "11/369 (2.98%)",
            "7/369 (1.90%)",
            "1/369 (0.27%)"
        ]
    },
    {
        "id": "a5486f80-69e5-4a5a-8435-f82f39cddf85",
        "primaryId": "NCT00080301",
        "statement_text": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "2 more cases",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%)ATRIAL FLUTTER 1/369 (0.27%) CARDIAC ARREST 1/369 (0.27%) ",
        "premise_nums": [
            "1/369 (0.27%)ATRIAL"
        ]
    },
    {
        "id": "bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75",
        "primaryId": "NCT00106002",
        "statement_text": "the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression ",
        "statement_nums": [
            "600 mg of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Pemetrexed 600 mg/m2, intravenous (IV)  every 14 days until complete response or disease progression ",
        "premise_nums": [
            "600 mg/m2,",
            "14 days until"
        ]
    },
    {
        "id": "fcb195de-2143-44d8-8c46-136104554e2d",
        "primaryId": "NCT01492101",
        "statement_text": "There less than 1% of either cohort of the primary trial was effect by Pancytopenia  but just over 5% of cohort 1 patients suffered from Coagulopathy ",
        "statement_nums": [
            "5% of",
            "1% of",
            "1 patients suffered"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Pancytopenia *2/425 (0.47%) Coagulopathy *1/425 (0.24%) Adverse Events 2: Pancytopenia *0/406 (0.00%) ",
        "premise_nums": [
            "2/425 (0.47%)",
            "1/425 (0.24%)",
            "0/406 (0.00%)"
        ]
    },
    {
        "id": "70337af9-3d4a-44bc-bbfa-0d97ea88553c",
        "primaryId": "NCT00317720",
        "statement_text": "Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial ",
        "statement_nums": [
            "3 prior treatments"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: History of trastuzumab resistance  defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer  Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy)for metastatic breast cancer  Patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible  ",
        "premise_nums": [
            "2 prior trastuzumab"
        ]
    },
    {
        "id": "a289f67c-ff56-44a9-b3da-152fb0d20271",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Entailment",
        "statement_text": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 respiratory adverse"
        ],
        "premise_text": "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1: Total: 4/6 (66.67%) Anemia 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 1/6 (16.67%) Retinal vein occlusion 0/6 (0.00%) ",
        "premise_nums": [
            "5/32 (15.63%)",
            "1/32 (3.13%)",
            "1/6 (16.67%)",
            "4/6 (66.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "a289f67c-ff56-44a9-b3da-152fb0d20271",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Entailment",
        "statement_text": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 respiratory adverse"
        ],
        "premise_text": "Gastroenteritis 1/6 (16.67%)Vomiting 1/6 (16.67%) Diarrhea 0/6 (0.00%) Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Hepatic hemorrhage 0/6 (0.00%) Adverse Events 2: Total: 25/52 (48.08%) Anemia 1/52 (1.92%) Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%) Retinal vein occlusion 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "2/6 (33.33%)",
            "25/52 (48.08%)",
            "1/52 (1.92%)",
            "2/52 (3.85%)",
            "0/6 (0.00%)",
            "1/6 (16.67%)Vomiting"
        ]
    },
    {
        "id": "a289f67c-ff56-44a9-b3da-152fb0d20271",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Entailment",
        "statement_text": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 respiratory adverse"
        ],
        "premise_text": "Gastroenteritis 0/52 (0.00%)Vomiting 0/52 (0.00%) Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)Vomiting",
            "1/52 (1.92%)",
            "9/52 (17.31%)"
        ]
    },
    {
        "id": "a47e048a-56aa-49e0-9903-563f53797b6e",
        "primaryId": "NCT00600340",
        "statement_text": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency and dose than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks ",
        "premise_nums": [
            "4 weeks INTERVENTION",
            "8 and 15,",
            "1000 mg/m²",
            "10 mg/kg intravenous",
            "1-14, every",
            "90 mg/m2,",
            "1 and 15,",
            "15 mg/kg i"
        ]
    },
    {
        "id": "f5477a02-dde7-44c8-80b5-2cdb9fa66f23",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "label": "Contradiction",
        "statement_text": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Adverse Events 1: Total: 80/260 (30.77%) Anaemia * 2/260 (0.77%) Febrile neutropenia * 0/260 (0.00%) Neutropenia * 2/260 (0.77%) Thrombocytopenia * 0/260 (0.00%) Bundle branch block right * 0/260 (0.00%) Pericardial effusion * 0/260 (0.00%) Cardiopulmonary failure * 0/260 (0.00%) Aplasia * 0/260 (0.00%) Eye symptom * 1/260 (0.38%) Abdominal discomfort * 0/260 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/260 (0.38%)",
            "80/260 (30.77%)",
            "0/260 (0.00%)",
            "2/260 (0.77%)"
        ]
    },
    {
        "id": "f5477a02-dde7-44c8-80b5-2cdb9fa66f23",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "label": "Contradiction",
        "statement_text": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Total: 71/267 (26.59%)Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Neutropenia * 0/267 (0.00%) Thrombocytopenia * 1/267 (0.37%) Bundle branch block right * 1/267 (0.37%) Pericardial effusion * 5/267 (1.87%) Cardiopulmonary failure * 1/267 (0.37%) Aplasia * 1/267 (0.37%) Eye symptom * 0/267 (0.00%) Abdominal discomfort * 1/267 (0.37%) Adverse Events 1: ",
        "premise_nums": [
            "1/267 (0.37%)",
            "2/267 (0.75%)",
            "71/267 (26.59%)Anaemia",
            "5/267 (1.87%)",
            "0/267 (0.00%)"
        ]
    },
    {
        "id": "f5477a02-dde7-44c8-80b5-2cdb9fa66f23",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "label": "Contradiction",
        "statement_text": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "premise_text": "Total: 13/74 (17.57%)neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74 (1.35%) constipation and hypokalemia 1/74 (1.35%) nausea  vomiting and burning abdominal pain 2/74 (2.70%) Infection 1/74 (1.35%) febrile neutropenia 3/74 (4.05%) speech impairment 1/74 (1.35%) dyspnea  pain 1/74 (1.35%) hemorrhage/bleeding 2/74 (2.70%) ",
        "premise_nums": [
            "13/74 (17.57%)neutropenia",
            "2/74 (2.70%)",
            "1/74 (1.35%)",
            "3/74 (4.05%)"
        ]
    },
    {
        "id": "62489179-bb30-4b96-a904-ea907dd05e23",
        "primaryId": "NCT01097460",
        "secondaryId": "NCT01009918",
        "label": "Contradiction",
        "statement_text": "Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years ",
        "statement_nums": [
            "1 Treatment-emergent adverse"
        ],
        "premise_text": "Outcome Measurement: Incidence of Treatment-emergent AE's [Not Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin Arm/Group Description: MM-111 will be combined with Herceptin MM-111 and Herceptin: For Phase 1: Dose escalation cohorts  MM-111 and Herceptin are administered weekly or bi-weekly via IV Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants 16 Outcome Measurement: Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment ",
        "premise_nums": [
            "111 and Herceptin:",
            "16 Outcome Measurement:",
            "52 Weeks of",
            "16 Measure Type:",
            "2 years Results",
            "111 will be"
        ]
    },
    {
        "id": "62489179-bb30-4b96-a904-ea907dd05e23",
        "primaryId": "NCT01097460",
        "secondaryId": "NCT01009918",
        "label": "Contradiction",
        "statement_text": "Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years ",
        "statement_nums": [
            "1 Treatment-emergent adverse"
        ],
        "premise_text": "Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of Left Ventricular Ejection Fraction (LVEF)  Number of Patients who experienced a cardiotoxicity Time frame: 2 years Results 1: Arm/Group Title: Arm I Lisinopril Arm/Group Description: Patients receive oral lisinopril once daily  lisinopril: Given orally Overall Number of Participants Analyzed: 152 Measure Type: Count of Participants Unit of Measure: Participants 45 29.6% ",
        "premise_nums": [
            "52 weeks of",
            "2 years Results",
            "152 Measure Type:"
        ]
    },
    {
        "id": "9ec1e3f0-64a2-4629-aee8-cdb516fd27f3",
        "primaryId": "NCT00258349",
        "secondaryId": "NCT01328249",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate or Vorinostat  whereas both cohorts in the secondary trial receive some of both ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Vorinostat +Trastuzumab Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes  every 3 weeks; Vorinostat 200 mg of SAHA orally twice a day  daily for 14 days out of a 21-day cycle INTERVENTION 1: Cohort 1: Eribulin Mesylate With Filgrastim as Needed ",
        "premise_nums": [
            "14 days out",
            "200 mg of",
            "6 mg/kg once",
            "21-day cycle"
        ]
    },
    {
        "id": "f53c8212-6da8-470f-a392-1bb037ed90e8",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Contradiction",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all  or a placebo ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone ",
        "premise_nums": [
            "0.25 % Bupivacaine",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "f53c8212-6da8-470f-a392-1bb037ed90e8",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Contradiction",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all  or a placebo ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone  The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  ",
        "premise_nums": [
            "0.25 % bupivacaine",
            "1:100,000 epinephrine",
            "000 epinephrine and",
            "4 mg dexamethasoneadministered",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "f53c8212-6da8-470f-a392-1bb037ed90e8",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Contradiction",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all  or a placebo ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If randomized to this arm  subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively  ",
        "premise_nums": [
            "4 mg dexamethasone:",
            "0.25 % bupivacaine",
            "1:100,000 epinephrine",
            "000 epinephrine and",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "7b7e6e8b-aa62-4fcd-af1e-c243995243d1",
        "primaryId": "NCT02622074",
        "statement_text": "There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) The following events  if considered to be study-treatment-related by the Investigator  were considered a DLT: Hematologic: Grade 4 neutropenia lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48 hours  or Grade 3 asymptomatic hepatic toxicities lasting 7 days; or ",
        "premise_nums": [
            "3 thrombocytopenia with",
            "4 neutropenia lasting",
            "4 thrombocytopenia requiring",
            "3 asymptomatic hepatic",
            "3 symptomatic hepatic",
            "3 or Grade"
        ]
    },
    {
        "id": "7b7e6e8b-aa62-4fcd-af1e-c243995243d1",
        "primaryId": "NCT02622074",
        "statement_text": "There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Grade 3 non-hematologic  non-hepatic organ toxicity  with exceptionsOther: Any treatment delays for 14 days due to unresolved toxicity; Grade 5 treatment-related adverse event (AE); A dose reduction of study treatment during the DLT evaluation period  Time frame: Cycle 1 Day 1 through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 7 (Up to ~150 days from first dose of first combination regimen); Each cycle was 21 days  Results 1: Arm/Group Title: Cohort A: KNp / KAC ",
        "premise_nums": [
            "3 non-hematologic",
            "150 days from",
            "1 Day 1",
            "14 days due",
            "6 Day 1",
            "5 treatment-related adverse",
            "3 and Cycle"
        ]
    },
    {
        "id": "6b35c306-a699-44f2-8606-a58d58fc18f3",
        "primaryId": "NCT00728949",
        "statement_text": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases ",
        "statement_nums": [
            "6 adverse event",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) ",
        "premise_nums": [
            "2/56 (3.57%)",
            "1/56 (1.79%)",
            "0/56 (0.00%)",
            "16/56 (28.57%)"
        ]
    },
    {
        "id": "a1b3667f-bfa5-426a-975a-20ed350c12c0",
        "primaryId": "NCT00748553",
        "statement_text": "Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month ",
        "statement_nums": [
            "5 doses of",
            "3 doses of"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Phase 1 Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle ",
        "premise_nums": [
            "3 weeks of",
            "2 weekly for",
            "1 Azacitidine (Vidaza):",
            "100mg/m2 daily",
            "50mg/m2,",
            "2 daily for",
            "5 days for",
            "75mg/m2 or",
            "4-week cycle",
            "100mg/m2 weekly"
        ]
    },
    {
        "id": "f57403d9-7278-481e-bcb9-066bf31b6158",
        "primaryId": "NCT01201265",
        "secondaryId": "NCT00932373",
        "label": "Contradiction",
        "statement_text": "1 patient in the primary trial was affected by Sepsis  and several were affected in the secondary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) Adverse Events 1: Total: 1/3 (33.33%) ",
        "premise_nums": [
            "2/40 (5.00%)",
            "3/40 (7.50%)",
            "1/3 (33.33%)",
            "1/40 (2.50%)",
            "17/40 (42.50%)",
            "5/40 (12.50%)",
            "6/40 (15.00%)"
        ]
    },
    {
        "id": "f57403d9-7278-481e-bcb9-066bf31b6158",
        "primaryId": "NCT01201265",
        "secondaryId": "NCT00932373",
        "label": "Contradiction",
        "statement_text": "1 patient in the primary trial was affected by Sepsis  and several were affected in the secondary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Pain 0/3 (0.00%)Cellulitis 0/3 (0.00%) Influenza 0/3 (0.00%) Osteomyelitis 0/3 (0.00%) Pneumonia 0/3 (0.00%) Humerus Fracture 0/3 (0.00%) Brain Oedema 0/3 (0.00%) Cerebral Haemorrhage 0/3 (0.00%) Convulsion 0/3 (0.00%) Dysarthria 0/3 (0.00%) Hepatic Encephalopathy 0/3 (0.00%) Confusional State 0/3 (0.00%) Dyspnoea 1/3 (33.33%) Adverse Events 2: ",
        "premise_nums": [
            "1/3 (33.33%)",
            "0/3 (0.00%)Cellulitis"
        ]
    },
    {
        "id": "f57403d9-7278-481e-bcb9-066bf31b6158",
        "primaryId": "NCT01201265",
        "secondaryId": "NCT00932373",
        "label": "Contradiction",
        "statement_text": "1 patient in the primary trial was affected by Sepsis  and several were affected in the secondary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Total: 1/1 (100.00%)Pain 0/1 (0.00%) Cellulitis 0/1 (0.00%) Influenza 0/1 (0.00%) Osteomyelitis 0/1 (0.00%) Pneumonia 0/1 (0.00%) Humerus Fracture 0/1 (0.00%) Brain Oedema 0/1 (0.00%) Cerebral Haemorrhage 0/1 (0.00%) Convulsion 0/1 (0.00%) Dysarthria 0/1 (0.00%) Hepatic Encephalopathy 0/1 (0.00%) Confusional State 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)",
            "1/1 (100.00%)Pain"
        ]
    },
    {
        "id": "f57403d9-7278-481e-bcb9-066bf31b6158",
        "primaryId": "NCT01201265",
        "secondaryId": "NCT00932373",
        "label": "Contradiction",
        "statement_text": "1 patient in the primary trial was affected by Sepsis  and several were affected in the secondary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Dyspnoea 0/1 (0.00%)",
        "premise_nums": [
            "0/1 (0.00%)"
        ]
    },
    {
        "id": "420e4977-ce75-4fab-99e0-3e7db837d521",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 21 days in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "21 days in"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days Treatment continues until progression of disease at which time crossover treatment begins  Overall Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) Results 2: Arm/Group Title: Docetaxel Plus Capecitabine ",
        "premise_nums": [
            "1000 milligrams per",
            "75 mg/m2,",
            "1 every 21",
            "73 to 10.79)",
            "1 and 8",
            "95% Confidence",
            "21 days plus"
        ]
    },
    {
        "id": "420e4977-ce75-4fab-99e0-3e7db837d521",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 21 days in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "21 days in"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a day  days 1-14 every 21 days  Treatment continues until progression of disease  at which time crossover treatment begins Overall Number of Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05) ",
        "premise_nums": [
            "14 every 21",
            "75 mg/m2,",
            "1 every 21",
            "37 to 11.05)",
            "95% Confidence",
            "1000 mg/m2,",
            "1-14 every"
        ]
    },
    {
        "id": "d07b4a30-e74f-468a-8420-7ade791d372d",
        "primaryId": "NCT00096356",
        "statement_text": "the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8%",
        "statement_nums": [
            "10 reduces the",
            "CoQ10 reduces"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization POMS-F is the Profile of Mood States - fatigue scale  It ranges from 0 to 28; higher values indicate greater fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1 - CoQ10 & Vitamin E Arm/Group Description: CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day  Overall Number of Participants Analyzed: 122 Least Squares Mean (Standard Error) Unit of Measure: units on a scale 6.96 (0.71) Results 2: Arm/Group Title: Arm 2 - Placebo & Vitamin E Arm/Group Description: Placebo-Vitamin E 100 mg/day in 3 doses Overall Number of Participants Analyzed: 114 ",
        "premise_nums": [
            "24 Weeks Following",
            "10 on Fatigue",
            "3 doses Overall",
            "100 IU taken",
            "Q10 on",
            "100 mg/day in",
            "122 Least Squares",
            "24 weeks Results",
            "0 to 28;"
        ]
    },
    {
        "id": "6f5570c0-4114-47ee-9611-b2e4be91cf9a",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "label": "Contradiction",
        "statement_text": "2 patients in the primary trial suffer from DVT  0 in the secondary trial ",
        "statement_nums": [
            "0 in the",
            "2 patients in"
        ],
        "premise_text": "Deep vein thrombosis 1/28 (3.57%) Adverse Events 1: Total: 1/24 (4.17%) Pericardial effusion *1/24 (4.17%) Other cardiac disorder *0/24 (0.00%) Ejection fraction decrease *0/24 (0.00%) Hypertension *0/24 (0.00%) Salivary gland infection *0/24 (0.00%) Pleural effusion *0/24 (0.00%) Adverse Events 2: Total: 6/30 (20.00%) Pericardial effusion *1/30 (3.33%) Other cardiac disorder *1/30 (3.33%) Ejection fraction decrease *1/30 (3.33%) ",
        "premise_nums": [
            "1/24 (4.17%)",
            "6/30 (20.00%)",
            "1/28 (3.57%)",
            "1/30 (3.33%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "6f5570c0-4114-47ee-9611-b2e4be91cf9a",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "label": "Contradiction",
        "statement_text": "2 patients in the primary trial suffer from DVT  0 in the secondary trial ",
        "statement_nums": [
            "0 in the",
            "2 patients in"
        ],
        "premise_text": "Hypertension *1/30 (3.33%)Salivary gland infection *1/30 (3.33%) Pleural effusion *2/30 (6.67%) ",
        "premise_nums": [
            "1/30 (3.33%)Salivary",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef",
        "primaryId": "NCT01224678",
        "statement_text": "Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women  The percent change in breast density will be reported here  Time frame: 12 months Results 1: Arm/Group Title: Placebo Arm/Group Description: Patients receive oral placebo once daily for 12 months  Overall Number of Participants Analyzed: 46 Mean (Standard Deviation) Unit of Measure: percent change -3.4 (7.1) Results 2: Arm/Group Title: Vitamin D Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months  Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) ",
        "premise_nums": [
            "46 Mean (Standard",
            "40 Mean (Standard",
            "12 months Results"
        ]
    },
    {
        "id": "6f686de9-f110-4be0-9cd8-1ceb0ce6f073",
        "primaryId": "NCT01376349",
        "secondaryId": "NCT01912612",
        "label": "Contradiction",
        "statement_text": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects  of the two cohorts in the secondary trial only the cohort without pain recieves Duloxetine 30 mg daily ",
        "statement_nums": [
            "receive 3.25 mg of",
            "2 subjects of",
            "30 mg daily"
        ],
        "premise_text": "Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  ",
        "premise_nums": [
            "2 weeks Duloxetine:",
            "30 mg daily",
            "60 mg daily",
            "60 mg duloxetine",
            "30 mg duloxetine"
        ]
    },
    {
        "id": "ffa913b7-9875-458e-8a28-476f9e788bb0",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Contradiction",
        "premise_text": "To estimate the clinical benefit rate (defined as complete response  partial response  or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD Time frame: 24 weeks Results 1: ",
        "premise_nums": [
            "30% decrease",
            "24 weeks Results"
        ]
    },
    {
        "id": "ffa913b7-9875-458e-8a28-476f9e788bb0",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: GTx-024 9 mgArm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: participants 16 Results 2: Arm/Group Title: GTx-024 18 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg ",
        "premise_nums": [
            "50 Measure Type:",
            "16 Results 2:",
            "18 mg Arm",
            "9 mg GTx",
            "024 softgel capsules",
            "9 mgArm/Group Description"
        ]
    },
    {
        "id": "ffa913b7-9875-458e-8a28-476f9e788bb0",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial ",
        "statement_nums": [
            "18 mg group",
            "5% difference",
            "9 mg and"
        ],
        "label": "Contradiction",
        "premise_text": "GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate Overall Number of Participants Analyzed: 52 Measure Type: Number Unit of Measure: participants 15 ",
        "premise_nums": [
            "52 Measure Type:"
        ]
    },
    {
        "id": "5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5",
        "primaryId": "NCT00193206",
        "statement_text": "the primary trial records a total of 7 different types of infections ",
        "statement_nums": [
            "7 different types"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 22/123 (17.89%) Cardiac Ischemia/Infarction [1]1/123 (0.81%) Pain - Chest 2/123 (1.63%) Dehydration 2/123 (1.63%) Death [2]1/123 (0.81%) Weakness 1/123 (0.81%) Pain - Liver 1/123 (0.81%) Infection - Skin [3]3/123 (2.44%) Infection - Gastrointestinal [4]1/123 (0.81%) Infection - Vein [5]2/123 (1.63%) Infection - Pneumonia 1/123 (0.81%) ",
        "premise_nums": [
            "3/123 (2.44%)",
            "1/123 (0.81%)",
            "2/123 (1.63%)",
            "22/123 (17.89%)"
        ]
    },
    {
        "id": "c003dd08-af3b-44cc-b31c-6fbdadfa1d83",
        "primaryId": "NCT01806259",
        "statement_text": "In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years ",
        "statement_nums": [
            "85% patient"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg Arm/Group Description: Active drug to be compared with placebo Ketorolac 30 mg IV Overall Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of Measure: Participants 80 83.3% Results 2: Arm/Group Title: NaCl 0.9% 3mL Arm/Group Description: Ketorolac 30 mg IV Overall Number of Participants Analyzed: 107 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7% ",
        "premise_nums": [
            "96 Measure Type:",
            "30 mg Arm",
            "80 83.3% Results 2",
            "3 additional years",
            "2 years for",
            "30 mg IV",
            "107 Measure Type:",
            "5 years Results"
        ]
    },
    {
        "id": "8ddf49c7-316e-4c7c-b2dd-423182a37612",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Entailment",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145 (1.38%) NEUTROPENIA 1/145 (0.69%) LEUKOCYTOSIS 1/145 (0.69%) THROMBOCYTOPENIA 1/145 (0.69%) FEBRILE NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) ",
        "premise_nums": [
            "1/145 (0.69%)",
            "2/145 (1.38%)",
            "17/145 (11.72%)",
            "0/145 (0.00%)"
        ]
    },
    {
        "id": "8ddf49c7-316e-4c7c-b2dd-423182a37612",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Entailment",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 2:Total: 11/144 (7.64%) ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144 (0.00%) NEUTROPENIA 0/144 (0.00%) LEUKOCYTOSIS 0/144 (0.00%) THROMBOCYTOPENIA 0/144 (0.00%) FEBRILE NEUTROPENIA 1/144 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%) DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) ",
        "premise_nums": [
            "11/144 (7.64%)",
            "0/144 (0.00%)",
            "2:Total: 11/144",
            "1/144 (0.69%)"
        ]
    },
    {
        "id": "8ddf49c7-316e-4c7c-b2dd-423182a37612",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Entailment",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1:Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: ",
        "premise_nums": [
            "2/79 (2.53%)",
            "22/79 (27.85%)",
            "1:Total: 22/79",
            "0/79 (0.00%)",
            "1/79 (1.27%)"
        ]
    },
    {
        "id": "8ddf49c7-316e-4c7c-b2dd-423182a37612",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "label": "Entailment",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Total: 13/76 (17.11%)Anaemia 1/76 (1.32%) Right ventricular dysfunction 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%) ",
        "premise_nums": [
            "2/76 (2.63%)",
            "0/76 (0.00%)",
            "13/76 (17.11%)Anaemia",
            "1/76 (1.32%)"
        ]
    },
    {
        "id": "9ae51f9c-8544-4764-b731-e4efe9ae0ba6",
        "primaryId": "NCT00452673",
        "statement_text": "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1/7 patients",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Safety was assessed from first dose of study drug through at least 30 days after the last dose  until resolution of drug-related toxicity or when toxicity was deemed irreversible  whichever was longer  An adverse event (AE) was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days and was at least possibly related to study drugs and were: Clinically-evident toxicity of Grade greater than or equal 3, or of Grade 2 which required interruption of treatment for greater than or equal 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory value of Grade greater than or equal 3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which in the judgment of the investigator required a dose reduction or removal from further study therapy Time frame: Day 1 to 30 days post last dose ",
        "premise_nums": [
            "21 days and",
            "2 which required",
            "30 days after",
            "1 to 30",
            "7 days (consecutive"
        ]
    },
    {
        "id": "9ae51f9c-8544-4764-b731-e4efe9ae0ba6",
        "primaryId": "NCT00452673",
        "statement_text": "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1/7 patients",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Results 1:Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine ",
        "premise_nums": [
            "825 mg/m^2Capecitabine",
            "50 mg Dasatinib",
            "1:Arm/Group Title:"
        ]
    },
    {
        "id": "5b1915da-1819-4504-81bd-3f44a83b5e95",
        "primaryId": "NCT00320541",
        "statement_text": "Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Leukopenia 1/94 (1.06%) Adverse Events 2: Leukopenia 3/93 (3.23%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "3/93 (3.23%)"
        ]
    },
    {
        "id": "edb1e4c0-7669-4b8c-878b-ea8ca060c350",
        "primaryId": "NCT00074152",
        "statement_text": "Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/77 (0.00%) Neutropenia [1]0/77 (0.00%) Left ventricular dysfunction 0/77 (0.00%) Cardiac ischemia 0/77 (0.00%) Gastrointestinal pain 0/77 (0.00%) Colitis 0/77 (0.00%) Febrile neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection 0/77 (0.00%) Diverticulitis 0/77 (0.00%) Motor neuropathy 0/77 (0.00%) Endometrial mucosa thinkening 0/77 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/77 (0.00%)"
        ]
    },
    {
        "id": "edb1e4c0-7669-4b8c-878b-ea8ca060c350",
        "primaryId": "NCT00074152",
        "statement_text": "Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 12/85 (14.12%)Neutropenia [1]1/85 (1.18%) Left ventricular dysfunction 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%) Pulmonary/upper respiratory infection 1/85 (1.18%) Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) ",
        "premise_nums": [
            "12/85 (14.12%)Neutropenia",
            "2/85 (2.35%)",
            "3/85 (3.53%)",
            "1/85 (1.18%)"
        ]
    },
    {
        "id": "126c1169-b375-4f89-95b2-52e971d19565",
        "primaryId": "NCT00856492",
        "statement_text": "Cohort 1 of the primary trial recorded no deaths and no cases of Enterocolitis infectious ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%) Mucositis oral 1/96 (1.04%) Nausea 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96 (0.00%) ",
        "premise_nums": [
            "1/96 (1.04%)",
            "0/96 (0.00%)",
            "22/96 (22.92%)",
            "2/96 (2.08%)",
            "4/96 (4.17%)"
        ]
    },
    {
        "id": "79362f6d-ef2c-4b93-8719-be361d0b5acc",
        "primaryId": "NCT03096847",
        "secondaryId": "NCT01840163",
        "label": "Contradiction",
        "statement_text": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial  but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english ",
        "statement_nums": [
            "1 to 2"
        ],
        "premise_text": "Exclusion Criteria Patient who received any CDK4/6 inhibitor or any mTOR inhibitor  Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male ",
        "premise_nums": [
            "CDK4/6 inhibitor",
            "6 inhibitor or",
            "2 invasive breast",
            "1-2 invasive"
        ]
    },
    {
        "id": "6f342205-ef33-482a-b74a-74644537538b",
        "primaryId": "NCT00077857",
        "statement_text": "Patients must be older than 18, female  have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial ",
        "statement_nums": [
            "2 regiments of"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: women greater than or equal 18 years of age; greater than or equal 1 target lesion; greater than or equal 2 regimens of chemotherapy for advanced/metastatic disease  ",
        "premise_nums": [
            "1 target lesion;",
            "18 years of",
            "2 regimens of"
        ]
    },
    {
        "id": "5b63fffb-0a75-414f-8744-5fea78395f28",
        "primaryId": "NCT00950742",
        "statement_text": "100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities ",
        "statement_nums": [
            "100 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days Results 1: Arm/Group Title: Afatinib 20mg + Herceptin Arm/Group Description: Patients received continuous daily dosing with Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit  This group includes patients from the dose-escalation cohort and from the expansion cohort  Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Participants 4 ",
        "premise_nums": [
            "13 Measure Type:",
            "28 days Results"
        ]
    },
    {
        "id": "55eaae8d-611c-4dbb-b162-de664902e059",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.",
        "statement_nums": [
            "1 than in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Small Intestinal Obstruction 1/31 (3.23%) Adverse Events 2: Small Intestinal Obstruction 0/31 (0.00%) ",
        "premise_nums": [
            "0/31 (0.00%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "8f505cec-6ad4-4142-a861-1771e3ae5cdd",
        "primaryId": "NCT00821964",
        "statement_text": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle ",
        "statement_nums": [
            "13 days every",
            "28 day cycle"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Treatment (Biological Therapy  Chemo) Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity  imiquimod: Given topically Abraxane: Given IV laboratory biomarker analysis: Correlative studies RNA analysis: Correlative studies immunoenzyme technique: Correlative studies ",
        "premise_nums": [
            "22-25. Treatment",
            "15 and apply",
            "30 minutes on",
            "15-18, and",
            "1-4, 8-11,",
            "3 cycles in",
            "28 days for"
        ]
    },
    {
        "id": "bad4d3e7-a05a-44fd-937a-c94a23655c03",
        "primaryId": "NCT01712009",
        "secondaryId": "NCT00343382",
        "label": "Contradiction",
        "statement_text": "Cohort 2 patients in the primary trial receive naproxen at the same frequency and dosage as cohort 2 patients in the secondary trial receive Pilocarpine ",
        "statement_nums": [
            "2 patients in"
        ],
        "premise_text": "INTERVENTION 2: Naproxen 500 mg BID Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles  beginning on the day of pegfilgrastim administration  INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  ",
        "premise_nums": [
            "500 mg orally",
            "500 mg BID",
            "5 days in",
            "2 Times Per",
            "2 times per"
        ]
    },
    {
        "id": "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "label": "Contradiction",
        "statement_text": "There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41 (2.44%) Femoral Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Fatigue 2/41 (4.88%) Headache 1/41 (2.44%) Nausea 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) ",
        "premise_nums": [
            "27/41 (65.85%)",
            "2/41 (4.88%)",
            "4/41 (9.76%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "label": "Contradiction",
        "statement_text": "There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1:Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31 (6.45%) Ascites 0/31 (0.00%) Ileus 1/31 (3.23%) Small Intestinal Obstruction 1/31 (3.23%) Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%) ",
        "premise_nums": [
            "0/31 (0.00%)",
            "2/31 (6.45%)",
            "15/31 (48.39%)",
            "1:Total: 15/31",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "0c435231-a09c-4424-924a-13840c6b7068",
        "primaryId": "NCT00191789",
        "statement_text": "In the primary trial there was 1 case of jaundice ",
        "statement_nums": [
            "1 case of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Jaundice 1/65 (1.54%) ",
        "premise_nums": [
            "1/65 (1.54%)"
        ]
    },
    {
        "id": "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049",
        "primaryId": "NCT00418457",
        "statement_text": "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "10 days prior"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Primary breast cancer without known extension beyond the breast and axillary nodes (i.e  believed to be Tumor Stage 1-3, Nodes 0-2) Scheduled for unilateral or bilateral mastectomy with or without implant (isolated \"lumpectomy\" will not qualify) Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes) Written informed consent  including willingness to be randomized to morphine or regional analgesia Exclusion Criteria: Previous surgery for breast cancer (except diagnostic biopsies) Inflammatory breast cancer Age smaller than 18 or greater than 85 years old Scheduled free flap reconstruction ASA Physical Status 4 Any contraindication to epidural or paravertebral anesthesia and analgesia (including coagulopathy  abnormal anatomy) ",
        "premise_nums": [
            "18 or greater",
            "85 years old",
            "0-2) Scheduled",
            "1-3, Nodes",
            "4 Any contraindication"
        ]
    },
    {
        "id": "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049",
        "primaryId": "NCT00418457",
        "statement_text": "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "10 days prior"
        ],
        "label": "Contradiction",
        "premise_text": "Any contraindication to midazolam  propofol  sevoflurane  fentanyl  or morphineOther cancer not believed by the attending surgeon to be in long-term remission Systemic disease believed by the attending surgeon to present 25% two-year mortality ",
        "premise_nums": [
            "25% two-year"
        ]
    },
    {
        "id": "e9824c27-bb70-4707-9599-ff20281f873e",
        "primaryId": "NCT00357110",
        "statement_text": "Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins ",
        "statement_nums": [
            "20% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Varicose Vein 1/6 (16.67%) ",
        "premise_nums": [
            "1/6 (16.67%)"
        ]
    },
    {
        "id": "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial  compared to cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10 Overall survival (OS) was defined as the time from randomization to death due to any cause  Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) Results 1: Arm/Group Title: Pembrolizumab Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)  Overall Number of Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 12.7 (9.9 to 16.3) Results 2: ",
        "premise_nums": [
            "200 mg IV",
            "10 Overall survival",
            "35 administrations (up",
            "95% Confidence",
            "11-April-2019) Results",
            "36 months (through",
            "9 to 16.3)"
        ]
    },
    {
        "id": "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial  compared to cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: ChemotherapyArm/Group Description: Participants received capecitabine  eribulin  gemcitabine  or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice  TPC) in accordance with local regulations and guidelines  Overall Number of Participants Analyzed: 98 Median (95% Confidence Interval) Unit of Measure: Months 11.6 (8.3 to 13.7) ",
        "premise_nums": [
            "95% Confidence",
            "3 to 13.7)"
        ]
    },
    {
        "id": "27e0b995-b3d1-46a6-900a-d6e513504ff3",
        "primaryId": "NCT00398567",
        "statement_text": "3/4 patients in the primary trial did not suffer any adverse events ",
        "statement_nums": [
            "4 patients in",
            "3/4 patients"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 1/4 (25.00%) ",
        "premise_nums": [
            "1/4 (25.00%)"
        ]
    },
    {
        "id": "c876167f-fe1e-4c3b-9183-dd3c1069ed0b",
        "primaryId": "NCT00024102",
        "statement_text": "A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Transfusion: pRBCs 1/181 (0.55%) ",
        "premise_nums": [
            "1/181 (0.55%)"
        ]
    },
    {
        "id": "d6989b67-ae99-4c2a-a67d-c2285cc57058",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 11 months in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "11 months in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days Treatment continues until progression of disease at which time crossover treatment begins  Overall Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) Results 2: Arm/Group Title: Docetaxel Plus Capecitabine ",
        "premise_nums": [
            "1000 milligrams per",
            "75 mg/m2,",
            "1 every 21",
            "73 to 10.79)",
            "1 and 8",
            "95% Confidence",
            "21 days plus"
        ]
    },
    {
        "id": "d6989b67-ae99-4c2a-a67d-c2285cc57058",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 11 months in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "11 months in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a day  days 1-14 every 21 days  Treatment continues until progression of disease  at which time crossover treatment begins Overall Number of Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05) ",
        "premise_nums": [
            "14 every 21",
            "75 mg/m2,",
            "1 every 21",
            "37 to 11.05)",
            "95% Confidence",
            "1000 mg/m2,",
            "1-14 every"
        ]
    },
    {
        "id": "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1",
        "primaryId": "NCT00320385",
        "secondaryId": "NCT00075270",
        "label": "Contradiction",
        "statement_text": "Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) PFS was defined as the time from randomization until the first documented sign of disease progression or death due to any cause  Time frame: Baseline to disease progression or death due to any cause or 30 days after last dose (up to 216 weeks) Results 1: Arm/Group Title: Trastuzumab + Lapatinib Arm/Group Description: Participants received Lapatinib 1000 milligram (mg) tablets orally daily 1 hour before or after breakfast along with Trastuzumab infusion at a loading dose of 4 milligrams/kilogram (mg/kg) body weight intravenously (IV) over 90 minutes on Day 1, followed by 2 mg/kg IV over 30 minutes weekly  in a 4 week cycle  ",
        "premise_nums": [
            "30 minutes weekly",
            "1000 milligram (mg)",
            "4 week cycle",
            "1 hour before",
            "2 mg/kg IV",
            "30 days after",
            "4 milligrams/kilogram",
            "90 minutes on"
        ]
    },
    {
        "id": "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1",
        "primaryId": "NCT00320385",
        "secondaryId": "NCT00075270",
        "label": "Contradiction",
        "statement_text": "Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Overall Number of Participants Analyzed: 146Median (95% Confidence Interval) Unit of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib Arm/Group Description: Participants received Lapatinib 1500 mg tablets orally daily 1 hour before or after breakfast  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of Measure: weeks 8.1 (7.6 to 9.0) Outcome Measurement: Time to Progression as Evaluated by the Investigator ",
        "premise_nums": [
            "1500 mg tablets",
            "1 to 16.0)",
            "1 hour before",
            "95% Confidence",
            "6 to 9.0)"
        ]
    },
    {
        "id": "b881b717-1c8a-41b8-9554-6ed9e8ee7c77",
        "primaryId": "NCT00193206",
        "statement_text": "the primary trial records a total of 7 patients suffering from various infections ",
        "statement_nums": [
            "7 patients suffering"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 22/123 (17.89%) Cardiac Ischemia/Infarction [1]1/123 (0.81%) Pain - Chest 2/123 (1.63%) Dehydration 2/123 (1.63%) Death [2]1/123 (0.81%) Weakness 1/123 (0.81%) Pain - Liver 1/123 (0.81%) Infection - Skin [3]3/123 (2.44%) Infection - Gastrointestinal [4]1/123 (0.81%) Infection - Vein [5]2/123 (1.63%) Infection - Pneumonia 1/123 (0.81%) ",
        "premise_nums": [
            "3/123 (2.44%)",
            "1/123 (0.81%)",
            "2/123 (1.63%)",
            "22/123 (17.89%)"
        ]
    },
    {
        "id": "20530faf-addb-47bf-896d-b9666e149223",
        "primaryId": "NCT01439282",
        "statement_text": "In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2.",
        "statement_nums": [
            "20% more",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 14/67 (20.90%) Adverse Events 2: Total: 1/10 (10.00%) ",
        "premise_nums": [
            "1/10 (10.00%)",
            "14/67 (20.90%)"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "DISEASE CHARACTERISTICS: Histologically confirmed stage IV breast cancer Inclusion Criteria: Male and Female patients must be at least 18 years of age Pathologically confirmed diagnosis of breast cancer Metastatic or advanced stage breast cancer Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy) Patients with HER2+ disease must have received prior treatment with Trastuzumab Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) 3 weeks Measurable disease by RECIST 1.1 ",
        "premise_nums": [
            "18 years of",
            "3 weeks Measurable"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of at least 3 months Adequate hematologic function as defined by: Absolute neutrophil count 1,500 cells/μL Platelets 100,000/μL Hemoglobin 9.0g/dL Adequate hepatic function as defined by: Serum bilirubin 1.5 X upper limit of normal (ULN); Adequate renal function as defined by a serum creatinine 1.5 x ULN AST  ALT  and alkaline phosphatase 3 × ULN except for: ",
        "premise_nums": [
            "bilirubin 1.5 X upper",
            "0 or 1",
            "Hemoglobin 9.0g/dL",
            "creatinine 1.5 x ULN",
            "100,000/μL Hemoglobin",
            "1,500 cells/",
            "4 weeks prior",
            "3 months Adequate"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "Patients with hepatic metastases: ALT and AST 5 × ULNPatients with hepatic and/or bone metastases: alkaline phosphatase 5 × ULN Patients with Gilbert's disease: serum bilirubin smaller than 5 mg/dL Willingness and ability to comply with scheduled visits  treatment plans  laboratory tests  and other study procedures Female subjects of childbearing potential and males must agree to use adequate contraception (e.g.  hormonal or barrier method of birth control; abstinence) for the duration of study treatment Female subjects of childbearing age must have a negative serum pregnancy test at study entry  Exclusion Criteria: Surgery  radiotherapy  or lesion ablative procedure to the only area of measurable disease ",
        "premise_nums": [
            "5 mg/dL Willingness"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "Major surgery within 4 weeks prior to first dose of STA-9090Poor peripheral venous access for study drug administration  Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material  History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g.  Polyethylene glycol [PEG] 300 and Polysorbate 80) Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than 50% at baseline Treatment with chronic immunosuppressants (e.g.  cyclosporine following transplantation) Women who are pregnant or lactating ",
        "premise_nums": [
            "4 weeks prior",
            "470 msec Ventricular",
            "50% at",
            "300 and Polysorbate",
            "3 or 4)"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "Uncontrolled intercurrent illness including  but not limited to  human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  ventricular arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirementsOther medications  or severe acute/chronic medical or psychiatric condition  or laboratory abnormality that may increase the risk associated with study participation or study drug administration  or may interfere with the interpretation of study results in the judgment of the investigator Seizure disorder or requirement for seizure medication Prior treatment with an HSP90 inhibitor persistent adverse events of prior therapies that are greater than 1 grade 1 in severity ",
        "premise_nums": [
            "HSP90 inhibitor",
            "1 grade 1",
            "90 inhibitor persistent"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Contradiction",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive stage",
            "4 tumors may"
        ],
        "premise_text": "history of or current coronary artery disease  myocardial infarction  angina pectoris  angioplasty or coronary bypass surgeryhistory of or current uncontrolled dysrhythmias  or requirement for antiarrhythmic medications  or Grade 2 or greater left bundle branch block New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea  orthopnea  or edema that requires current treatment with angiotensin converting enzyme inhibitors  angiotensin II receptor blockers  beta blockers or diuretics ",
        "premise_nums": [
            "2 or greater"
        ]
    },
    {
        "id": "11472413-533f-45f9-9aac-c46bca318aab",
        "primaryId": "NCT00373256",
        "statement_text": "Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death  and the median PFS for this group was just under 7 and a half months ",
        "statement_nums": [
            "200 patients being",
            "18 months or",
            "1 of the",
            "7 and a"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Time from date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS = (first event date minus randomization date +1) divided by 30.4 Time frame: From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death Results 1: Arm/Group Title: Sunitinib + Paclitaxel ",
        "premise_nums": [
            "1 and every",
            "4 Time frame:",
            "8 weeks thereafter",
            "by 30.4 Time frame",
            "18 months or"
        ]
    },
    {
        "id": "11472413-533f-45f9-9aac-c46bca318aab",
        "primaryId": "NCT00373256",
        "statement_text": "Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death  and the median PFS for this group was just under 7 and a half months ",
        "statement_nums": [
            "200 patients being",
            "18 months or",
            "1 of the",
            "7 and a"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Starting sunitinib doses of 25 mg daily  After Cycle 1, escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia and if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 mg/m^2, at discretion of the investigator  Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted Overall Number of Participants Analyzed: 242 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 8.5) ",
        "premise_nums": [
            "to 37.5 mg daily",
            "80 or 90",
            "2 upon recovery",
            "2 based on",
            "9 to 8.5)",
            "3 Cycle 1",
            "95% Confidence",
            "90 mg/m^2,",
            "25 mg daily",
            "65 mg/m^2"
        ]
    },
    {
        "id": "6446f085-c6b0-43ce-82ed-16d6952b549e",
        "primaryId": "NCT00880022",
        "secondaryId": "NCT00916578",
        "label": "Contradiction",
        "statement_text": "Only patients in cohort 2 of the primary trial undergo Trunk compression  However all patients in the secondary trial are treated with Trunk compression ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm Compression Only [Not Specified] INTERVENTION 2: Arm  Trunck and Chest Compression [Not Specified] INTERVENTION 1: Single Arm Institution  Open Label  Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will be administered when patients receives radiation therapy  Radiation therapy doses will be 50-57 Gy to the initial clinical target volume  ",
        "premise_nums": [
            "2 bid of",
            "2 hours before",
            "825 mg/m2 bid",
            "57 Gy to",
            "50-57 Gy"
        ]
    },
    {
        "id": "8809cc5e-36d5-4f7e-b06d-b1915a421f71",
        "primaryId": "NCT00759785",
        "statement_text": "Only one adverse event  a Breast abscess  is observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 1/25 (4.00%) Diarrhoea 0/25 (0.00%) Breast abscess 0/25 (0.00%) Breast cellulitis 0/25 (0.00%) Syncope 1/25 (4.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "1/25 (4.00%)"
        ]
    },
    {
        "id": "48ccd744-abf1-4e98-bc86-8ecd625e6279",
        "primaryId": "NCT00654836",
        "statement_text": "Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial ",
        "statement_nums": [
            "2-negative adenocarcinoma"
        ],
        "label": "Entailment",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally recurrent or metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past No known CNS disease ",
        "premise_nums": [
            "2-positive, must",
            "2-negative breast"
        ]
    },
    {
        "id": "1882de62-2df2-4b73-a3d2-81811f85f661",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy ",
        "statement_nums": [
            "2% of",
            "3 years of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Recurrence-free Survival Recurrence-free survival curves will be plotted for subjects treated with stage I and II disease  Time frame: Time from the start of treatment to recurrence  second malignancy  or death as a first event  assessed up to 3 years Results 1: Arm/Group Title: Treatment (Chemotherapy With or Without Maintenance Therapy) Arm/Group Description: SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "3 hours on",
            "6 courses in",
            "1 hour and",
            "14 days for",
            "3 years Results"
        ]
    },
    {
        "id": "1882de62-2df2-4b73-a3d2-81811f85f661",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy ",
        "statement_nums": [
            "2% of",
            "3 years of"
        ],
        "label": "Contradiction",
        "premise_text": "MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity cyclophosphamide  paclitaxel  trastuzumab: Given IV Overall Number of Participants Analyzed: 100 Measure Type: Number Unit of Measure: percentage of subjects 98 (92.2 to 99.5) ",
        "premise_nums": [
            "21 days for",
            "2 to 99.5)",
            "14 days for",
            "30 minutes on",
            "5 courses and",
            "100 Measure Type:",
            "2 neu positive",
            "14 courses in"
        ]
    },
    {
        "id": "eb152d1b-a0d6-428c-8d1d-eb5d862a8147",
        "primaryId": "NCT01120184",
        "statement_text": "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia  a rare coagulation disorder ",
        "statement_nums": [
            "1 patient in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 81/353 (22.95%) Febrile neutropenia * 13/353 (3.68%) Anaemia * 21/353 (0.28%) Neutropenia * 25/353 (1.42%) Thrombocytopenia * 20/353 (0.00%) Hypercoagulation * 21/353 (0.28%) Leukopenia * 21/353 (0.28%) Atrial fibrillation * 1/353 (0.28%) Cardiac failure * 0/353 (0.00%) Cardiac failure congestive * 0/353 (0.00%) ",
        "premise_nums": [
            "20/353 (0.00%)",
            "25/353 (1.42%)",
            "81/353 (22.95%)",
            "13/353 (3.68%)",
            "21/353 (0.28%)"
        ]
    },
    {
        "id": "eb152d1b-a0d6-428c-8d1d-eb5d862a8147",
        "primaryId": "NCT01120184",
        "statement_text": "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia  a rare coagulation disorder ",
        "statement_nums": [
            "1 patient in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Myocardial infarction * 1/353 (0.28%)",
        "premise_nums": [
            "1/353 (0.28%)"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "55 more Participants",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions  Time frame: Baseline visit and then every 8 weeks to 12 months  then every 3 months until disease progression Results 1: Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg ",
        "premise_nums": [
            "8 weeks to",
            "3 months until",
            "30% reduction",
            "16 mg/m^2",
            "10 mg/kg"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "55 more Participants",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity  Bevacizumab  10 mg/kg  administered after ixabepilone as IV infusion every 2 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 46 Measure Type: Number ",
        "premise_nums": [
            "46 Measure Type:",
            "1-hour intravenous",
            "15 of a",
            "10 mg/kg",
            "28-day cycle",
            "90 minutes for",
            "30 minutes for"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "55 more Participants",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percentage of participants 47.8 (32.9 to 63.1)Results 2: Arm/Group Title: Ixabepilone  40 mg/m^2 + Bevacizumab  15 mg/kg ",
        "premise_nums": [
            "9 to 63.1)Results",
            "15 mg/kg",
            "40 mg/m^2"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "55 more Participants",
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Ixabepilone  40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 implemented for all subsequent cycles  Bevacizumab  15 mg/kg  administered after ixabepilone as IV infusion every 3 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 45 Measure Type: Number ",
        "premise_nums": [
            "15 mg/kg",
            "45 Measure Type:",
            "40 mg/m^2,",
            "32 mg/m^2",
            "2 implemented for",
            "3-hour IV",
            "1 of a",
            "90 minutes for",
            "30 minutes for",
            "21-day cycle"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "Inclusion Criteria: Women aged 45-69, according to the target age of the screening centres involved; New invited women in mammography screening programme  Exclusion Criteria: None DISEASE CHARACTERISTICS: Histologically or cytologically confirmed infiltrating breast cancer Clinical evidence of metastatic disease Measurable disease  defined as at least one measurable lesion per RECIST criteria No non-measurable disease only  defined as all other lesions  including small lesions (longest diameter smaller than 2 cm) and truly non-measurable lesions  including any of the following: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal masses that are not confirmed and followed by imaging techniques Cystic lesions ",
        "premise_nums": [
            "45-69, according"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "Patients with HER-2/neu positive tumors  must have received prior treatment with trastuzumab (Herceptin®) or have a contraindication for trastuzumabNo evidence of active brain metastasis  including leptomeningeal involvement  on MRI or CT scan CNS metastasis controlled by prior surgery and/or radiotherapy allowed Must be asymptomatic for 2 months with no evidence of progression prior to study entry Hormone receptor status not specified PATIENT CHARACTERISTICS: Menopausal status not specified Life expectancy 12 weeks ECOG performance status 0-1 ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL ",
        "premise_nums": [
            "100,000/mm³ Hemoglobin",
            "2 months with",
            "Hemoglobin 9.0 g/dL",
            "0-1 ANC",
            "2/neu positive",
            "12 weeks ECOG",
            "1,500/mm³ Platelet"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "AST and ALT 2.5 times upper limit of normal (ULN)Alkaline phosphatase 2.5 times ULN Total bilirubin 1.5 times ULN Creatinine 1.5 mg/dL Urine protein:creatinine ratio smaller than 1 or urinalysis smaller than 1+ protein Patients discovered to have 1+ proteinuria at baseline must demonstrate 24-hour urine protein smaller than 1 g Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 30 days after completion of study therapy Able to complete questionnaires alone or with assistance No peripheral neuropathy greater than grade 1 ",
        "premise_nums": [
            "Creatinine 1.5 mg/dL",
            "bilirubin 1.5 times ULN",
            "30 days after",
            "phosphatase 2.5 times ULN",
            "24-hour urine",
            "ALT 2.5 times upper",
            "1 g Not",
            "1 or urinalysis"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "No history of allergy or hypersensitivity to albumin-bound paclitaxel  paclitaxel  gemcitabine hydrochloride  bevacizumab  albumin  drug product excipients  or chemically similar agentsNo stage III or IV invasive  non-breast malignancy within the past 5 years No other active malignancy  except nonmelanoma skin cancer or carcinoma in situ of the cervix Patient must not be receiving other specific treatment for a prior malignancy No uncontrolled hypertension (i.e.  blood pressure [BP] greater than 160/90 mm Hg on 2 occasions at least 5 minutes apart) ",
        "premise_nums": [
            "2 occasions at",
            "90 mm Hg",
            "160/90 mm",
            "5 minutes apart)",
            "5 years No"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "Patients who have recently started or adjusted antihypertensive medications are eligible providing that BP is smaller than 140/90 mm Hg on any new regimen for 3 different observations in 14 daysNo bleeding diathesis or uncontrolled coagulopathy No hemoptysis within the past 6 months No prior arterial or venous thrombosis within the past 12 months No history of cerebrovascular accident No history of hypertensive crisis or hypertensive encephalopathy No abdominal fistula or gastrointestinal perforation within the past 6 months No serious non-healing wound  ulcer  or fracture No clinically significant cardiac disease  defined as any of the following: Congestive heart failure Symptomatic coronary artery disease Unstable angina ",
        "premise_nums": [
            "90 mm Hg",
            "6 months No",
            "14 daysNo bleeding",
            "3 different observations",
            "12 months No",
            "140/90 mm"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "Cardiac arrhythmias not well controlled with medicationMyocardial infarction within the past 12 months No comorbid systemic illnesses or other severe concurrent disease which  in the judgment of the investigator  would make the patient inappropriate for study entry or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior chemotherapy for metastatic disease May have received one prior adjuvant chemotherapy regimen Prior neoadjuvant chemotherapy allowed More than 6 months since prior adjuvant or neoadjuvant taxane (i.e.  docetaxel or paclitaxel) therapy Prior hormonal therapy in either adjuvant or metastatic setting allowed ",
        "premise_nums": [
            "6 months since",
            "12 months No"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "More than 4 weeks since prior radiotherapy (except if to a non-target lesion only  or single dose radiation for palliation)Prior radiotherapy to a target lesion is allowed provided there has been clear progression of the lesion since radiotherapy was completed More than 4 weeks since prior cytotoxic chemotherapeutic agent or investigational drug More than 2 weeks since prior and no concurrent acetylsalicylic acid  anticoagulants  or thrombolytic agents (except for once-daily 81 mg acetylsalicylic acid) More than 6 weeks since prior major surgery  chemotherapy  or immunologic therapy More than 1 week since prior minor surgery (e.g.  core biopsy) Placement of a vascular access device within 7 days is allowed ",
        "premise_nums": [
            "2 weeks since",
            "6 weeks since",
            "4 weeks since",
            "81 mg acetylsalicylic",
            "7 days is",
            "1 week since"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Contradiction",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "18-25 with",
            "25 with stable"
        ],
        "premise_text": "More than 3 months since prior neurosurgeryNo concurrent treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered Trials related to symptom management (Cancer Control) which do not employ hormonal treatments or treatments that may block the path of the targeted agents used in this study may be allowed ",
        "premise_nums": [
            "3 months since"
        ]
    },
    {
        "id": "c3f01101-2259-4677-add1-1b1f48a0202b",
        "primaryId": "NCT00528567",
        "secondaryId": "NCT01196052",
        "label": "Contradiction",
        "statement_text": "The total number of patients affected by adverse events in cohort 2 the primary trial is more than 1000.",
        "statement_nums": [
            "2 the primary"
        ],
        "premise_text": "Adverse Events 2: Total: 250/1271 (19.67%) Adverse Events 1: Total: 15/148 (10.14%) Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Pyrexia 2/148 (1.35%) Cellulitis 1/148 (0.68%) Device related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%) ",
        "premise_nums": [
            "2/148 (1.35%)",
            "15/148 (10.14%)",
            "1/148 (0.68%)",
            "250/1271 (19.67%)"
        ]
    },
    {
        "id": "33b827a0-ada5-4204-abb8-d5239ea16f0b",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group ",
        "statement_nums": [
            "3 days difference"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Time to Progression (TTP) - Expert Evaluation Committee Assessment Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer  whichever comes first  Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started  For participants with bone metastasis only  at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition)  Time frame: Up to 2008 days of the treatment Results 1: Arm/Group Title: Exemestane ",
        "premise_nums": [
            "2008 days of",
            "25% increase",
            "version 1.0 as an",
            "20% increase"
        ]
    },
    {
        "id": "33b827a0-ada5-4204-abb8-d5239ea16f0b",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group ",
        "statement_nums": [
            "3 days difference"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) Results 2: Arm/Group Title: Anastrozole Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) ",
        "premise_nums": [
            "25 mg and",
            "95% Confidence",
            "8 to 16.5)",
            "1 mg and"
        ]
    },
    {
        "id": "22bff413-a1bd-419b-b19b-2157dedc9948",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Entailment",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort ",
        "statement_nums": [
            "14 Day cohort",
            "21 Days cohort",
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: Up to 2 years  Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) ",
        "premise_nums": [
            "30% decrease",
            "102 given on",
            "q14 day",
            "35 Measure Type:",
            "6 to 46.3)",
            "14 Day Arm",
            "14 day schedule"
        ]
    },
    {
        "id": "22bff413-a1bd-419b-b19b-2157dedc9948",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Entailment",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort ",
        "statement_nums": [
            "14 Day cohort",
            "21 Days cohort",
            "1 of the"
        ],
        "premise_text": "Results 2:Arm/Group Title: NKTR-102 21 Days Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 35 (14.6 to 46.3) Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) ",
        "premise_nums": [
            "102 given on",
            "21 Days Arm",
            "2:Arm/Group Title:",
            "q21 day",
            "35 Measure Type:",
            "21 day schedule",
            "6 to 46.3)"
        ]
    },
    {
        "id": "22bff413-a1bd-419b-b19b-2157dedc9948",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Entailment",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort ",
        "statement_nums": [
            "14 Day cohort",
            "21 Days cohort",
            "1 of the"
        ],
        "premise_text": "Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: ",
        "premise_nums": [
            "30% decrease",
            "15 months Results",
            "RECIST 1.0 for target"
        ]
    },
    {
        "id": "22bff413-a1bd-419b-b19b-2157dedc9948",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "label": "Entailment",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort ",
        "statement_nums": [
            "14 Day cohort",
            "21 Days cohort",
            "1 of the"
        ],
        "premise_text": "Arm/Group Title: Everolimus + LetrozoleArm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol  Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 ",
        "premise_nums": [
            "2 tablets (5",
            "43 Measure Type:",
            "1 tablet of"
        ]
    },
    {
        "id": "2ea80a50-0db3-4ff2-8ca0-71eb048649f7",
        "primaryId": "NCT01875367",
        "statement_text": "More than 3 patients in the primary trial had a common cold ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/81 (2.47%) Heart failure 0/81 (0.00%) Fever 1/81 (1.23%) Cold 0/81 (0.00%) Catheter related infection (Bacteriemia) 0/81 (0.00%) Lack of strength in left leg 0/81 (0.00%) Ostenecrosis produced by biphosphonates 0/81 (0.00%) Gastric cancer 0/81 (0.00%) Stroke 0/81 (0.00%) Hematuria 1/81 (1.23%) Nodule in left breast 0/81 (0.00%) Adverse Events 2: Total: 10/85 (11.76%) Heart failure 1/85 (1.18%) ",
        "premise_nums": [
            "1/85 (1.18%)",
            "0/81 (0.00%)",
            "2/81 (2.47%)",
            "1/81 (1.23%)",
            "10/85 (11.76%)"
        ]
    },
    {
        "id": "2ea80a50-0db3-4ff2-8ca0-71eb048649f7",
        "primaryId": "NCT01875367",
        "statement_text": "More than 3 patients in the primary trial had a common cold ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Fever 0/85 (0.00%)Cold 1/85 (1.18%) Catheter related infection (Bacteriemia) 1/85 (1.18%) Lack of strength in left leg 1/85 (1.18%) Ostenecrosis produced by biphosphonates 1/85 (1.18%) Gastric cancer 1/85 (1.18%) Stroke 1/85 (1.18%) Hematuria 0/85 (0.00%) Nodule in left breast 1/85 (1.18%) ",
        "premise_nums": [
            "0/85 (0.00%)Cold",
            "1/85 (1.18%)"
        ]
    },
    {
        "id": "6e1955b8-e6fa-42b2-a498-7ada9e733304",
        "primaryId": "NCT01593020",
        "secondaryId": "NCT00834678",
        "label": "Entailment",
        "statement_text": "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [
            "3 times the"
        ],
        "premise_text": "Exclusion Criteria: AST or ALT greater than 2.5 times the upper limit of normal (ULN) ALT and AST 2.5 times ULN ( 5 times ULN in the presence of documented liver metastases) ",
        "premise_nums": [
            "than 2.5 times the",
            "AST 2.5 times ULN"
        ]
    },
    {
        "id": "b7936bbc-f0c0-444c-a199-2db323c30396",
        "primaryId": "NCT00313170",
        "secondaryId": "NCT00305448",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had",
            "33% higher"
        ],
        "premise_text": "Outcome Measurement: Objective Response (ORR) Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions)  All patients were to be followed up every 12 weeks for progression  defined by response evaluation criteria in solid tumors (RECIST v1.1). Time frame: The planned data cut-off for this study was when all patients  except withdrawals  had been followed up for at least 24 weeks  Patients received treatment up to approximately 2 years  Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 47 Measure Type: Number ",
        "premise_nums": [
            "30% decrease",
            "12 weeks for",
            "250 mg Overall",
            "47 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "b7936bbc-f0c0-444c-a199-2db323c30396",
        "primaryId": "NCT00313170",
        "secondaryId": "NCT00305448",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had",
            "33% higher"
        ],
        "premise_text": "Unit of Measure: Percentage of patients 8.5 (2.4 to 20.4)Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of patients 5.9 (1.2 to 16.2) Outcome Measurement: Objective Response Rate (ORR) ",
        "premise_nums": [
            "51 Measure Type:",
            "4 to 20.4)Results",
            "2 to 16.2)"
        ]
    },
    {
        "id": "b7936bbc-f0c0-444c-a199-2db323c30396",
        "primaryId": "NCT00313170",
        "secondaryId": "NCT00305448",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had",
            "33% higher"
        ],
        "premise_text": "Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 17.6 ",
        "premise_nums": [
            "45 Measure Type:",
            "1 Results 2:",
            "250 mg Overall",
            "participants 11.1 Results 2",
            "51 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "6d6625ec-26b7-4157-a38c-87c770201323",
        "primaryId": "NCT01373671",
        "secondaryId": "NCT00686127",
        "label": "Entailment",
        "statement_text": "Lidoderm products are used in intervention arm 1 of the secondary trial  and a Siemens product is used in arm 1 of the primary trial",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  ",
        "premise_nums": [
            "1 patch was",
            "12 hours each"
        ]
    },
    {
        "id": "c94ad26b-1f5e-4446-a4fe-bb949c5dc561",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Contradiction",
        "statement_text": "Patients must have BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "3 to be",
            "8,000/mm3 to",
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "5,000/mm3 to"
        ],
        "premise_text": "Inclusion Criteria: Biopsy-diagnosed breast cancer with metastasis in multiple organs Performance Status (World Health Organization :WHO) 0-2 Functions below are maintained in major organs: Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater than 9.5 g/dL Total bilirubin: greater than 1.5 mg/dL AST(GOT): within twice a normal upper value in an institution ",
        "premise_nums": [
            "2,000/mm3 or",
            "2 Functions below",
            "than 9.5 g/dL",
            "4,000/mm3 to",
            "12,000/mm3 Neutrophil",
            "3 Neutrophil count:",
            "100,000/mm3 or",
            "3 or more",
            "than 1.5 mg/dL",
            "0-2 Functions"
        ]
    },
    {
        "id": "c94ad26b-1f5e-4446-a4fe-bb949c5dc561",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Contradiction",
        "statement_text": "Patients must have BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "3 to be",
            "8,000/mm3 to",
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "5,000/mm3 to"
        ],
        "premise_text": "AST(GPT): within twice a normal upper value in an institutionBUN: smaller than 25 mg/dL Creatinine: within a normal upper value in the institution 24 hours creatinine clearance: greater than 50 mL/min (using the Cockcroft-Gault formula) Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 Inclusion Criteria: Histologically- or cytologically-proven diagnosis of breast adenocarcinoma that is not amenable to surgery  radiation  or combined modality therapy with curative intent ",
        "premise_nums": [
            "72 x Serum",
            "25 mg/dL Creatinine",
            "x 0.85 Inclusion Criteria",
            "(140-Age)/(72 x",
            "24 hours creatinine",
            "85 Inclusion Criteria:",
            "50 mL/min"
        ]
    },
    {
        "id": "c94ad26b-1f5e-4446-a4fe-bb949c5dc561",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Contradiction",
        "statement_text": "Patients must have BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "3 to be",
            "8,000/mm3 to",
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "5,000/mm3 to"
        ],
        "premise_text": "Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/ Sunfural (tegafur)  UFT/UFT-E (tegafur/uracil)  TS-1 (tegafur/gimeracil/oteracil) or Mifurol (carmofur) in metastatic disease setting",
        "premise_nums": [
            "(5-FU) and",
            "5-FU derivatives"
        ]
    },
    {
        "id": "4e31e4f8-a6da-49fc-8bfe-1309674ec2ee",
        "primaryId": "NCT00244881",
        "statement_text": "30% of the primary trial participants had an increased level of CECs after 42 days of treatment ",
        "statement_nums": [
            "30% of",
            "42 days of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Fraction of Patients With Increased Levels of Circulating Endothelial Cells An exact 95% confidence interval (CI) will be calculated for the CEC response rate  With 26 patients  this CI will be no wider than 40% (e.g.  if 13 of 26 patients respond  the CI is 30% to 70%). Time frame: After 3 weeks of treatment Results 1: Arm/Group Title: Treatment (Cediranib Maleate) Arm/Group Description: Patients receive oral AZD2171 once daily for 42 days  Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage of participants 30 ",
        "premise_nums": [
            "3 weeks of",
            "42 days in",
            "26 Measure Type:",
            "AZD2171 once",
            "30% to",
            "2171 once daily",
            "95% confidence",
            "13 of 26"
        ]
    },
    {
        "id": "5c00f992-5066-42f2-88d7-566b8b9104b5",
        "primaryId": "NCT00089661",
        "statement_text": "On average cohort 1 participants in the primary trial had an increased Rate of Acute Toxicity   whereas those in cohort 2 did not experience any Acute Toxicities ",
        "statement_nums": [
            "2 did not",
            "1 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  Time frame: 12 months Results 1: Arm/Group Title: Denosumab 60 mg Q6M Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results 2: Arm/Group Title: Placebo Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 122 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline -.7 (-1.3 to -.1) ",
        "premise_nums": [
            "12 Bone Mineral",
            "12 months Results",
            "123 Least Squares",
            "95% Confidence",
            "122 Least Squares",
            "60 mg Q6M",
            "3 to 5.4)"
        ]
    },
    {
        "id": "4e3379b9-f971-4ab6-8846-c395f1162bf2",
        "primaryId": "NCT00810797",
        "secondaryId": "NCT00828074",
        "label": "Entailment",
        "statement_text": "Skin infections were more common in patients in cohort 1 of the secondary trial  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Skin infection * 1/36 (2.78%) Adverse Events 1: Skin infection * 2/41 (4.88%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "1/36 (2.78%)"
        ]
    },
    {
        "id": "adf3bb50-ec36-467a-987a-f33c10380c60",
        "primaryId": "NCT01771666",
        "secondaryId": "NCT01256567",
        "label": "Contradiction",
        "statement_text": "Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "2 are eligible"
        ],
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2. Inclusion Criteria: The participant is Japanese The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ",
        "premise_nums": [
            "0,1,2. Inclusion",
            "0 or 1"
        ]
    },
    {
        "id": "03cb39e4-1d21-47e5-9b09-ebe508eb2a17",
        "primaryId": "NCT00477464",
        "statement_text": "59 patients from Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "59 patients from"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Clinical Benefit Response (Independent Reviewer-assessed) CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months (24 weeks)  A \"complete response\" is defined as the disappearance of all target or non-target lesions  \"partial response\" and \"disease progression\" as at least a 30% decrease and at least a 20% increase  respectively  in the sum of the longest diameter of target lesions  and \"stable disease\" as neither \"partial response\" nor \"disease progression.\" Time frame: Baseline  every 6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119) Results 1: ",
        "premise_nums": [
            "30% decrease",
            "6 weeks until",
            "6 months (24",
            "12 weeks until",
            "24 and then",
            "20% increase"
        ]
    },
    {
        "id": "03cb39e4-1d21-47e5-9b09-ebe508eb2a17",
        "primaryId": "NCT00477464",
        "statement_text": "59 patients from Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "59 patients from"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Lapatinib 1250 mg and Capecitabine 2000 mg/m^2Arm/Group Description: Participants took lapatinib and capecitabine  Lapatinib was orally administered at 1250 milligrams (mg) once daily  Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle  Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 59 ",
        "premise_nums": [
            "1250 milligrams (mg)",
            "1250 mg and",
            "1000 mg per",
            "2000 mg/m^2Arm/Group",
            "51 Measure Type:",
            "21-day cycle"
        ]
    },
    {
        "id": "dca6ba74-441e-482f-b667-6c45800ed8c1",
        "primaryId": "NCT00425672",
        "statement_text": "Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle  for a total of 6 courses  unless death occurs  ",
        "statement_nums": [
            "21 day treatment",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity  ONTAK: Given IV flow cytometry: Correlative studies immunohistochemistry staining method: Correlative studies enzyme-linked immunosorbent assay: Correlative studies laboratory biomarker analysis: Correlative studies protein expression analysis: Correlative studies ",
        "premise_nums": [
            "6 courses in",
            "1-5. Treatment",
            "21 days for",
            "1 hour on"
        ]
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis  whichever occurred earlier  Tumor responses were assessed every 6 weeks using  Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir ",
        "premise_nums": [
            "30% decrease",
            "6 weeks using",
            "20% increase"
        ]
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A  34 months for Arm B and 35 months for Arm CResults 1: Arm/Group Title: Arm A: Nab-Paclitaxel + Gemcitabine ",
        "premise_nums": [
            "16 December 2016;",
            "31 months for",
            "35 months for",
            "34 months for"
        ]
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatmentOverall Number of Participants Analyzed: 61 Median (95% Confidence Interval) Unit of Measure: months 5.5 (4.1 to 7.0) ",
        "premise_nums": [
            "1 to 7.0)",
            "1000 mg/m^2",
            "1 and 8",
            "95% Confidence",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "2 months shorter"
        ],
        "label": "Entailment",
        "premise_text": "Results 2:Arm/Group Title: Arm B: Nab-Paclitaxel + Carboplatin Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment  Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) ",
        "premise_nums": [
            "2:Arm/Group Title:",
            "1 and 8",
            "95% Confidence",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "8d3378f7-caaf-4654-b12a-382a0e911eb1",
        "primaryId": "NCT02429427",
        "statement_text": "Patients with a platelet count of 50 x 109/l are not eligible for the primary trial",
        "statement_nums": [
            "50 x 109",
            "109/l are"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Pre-treatment haematology and biochemistry values within acceptable local limits: Haemoglobin  white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than 1.5 x upper normal limit   Alkaline phosphatase less or equal to 1.5 x upper normal limit   Serum creatinine less than 1.5 x upper normal limit ",
        "premise_nums": [
            "to 3.0 x 109",
            "than 1.5 x upper",
            "100 x 109",
            "to 1.5 x upper",
            "to 1.51 x 109",
            "109/l, Serum",
            "109/l or",
            "109/l, Platelets"
        ]
    },
    {
        "id": "3889cecd-aa2d-4f58-857e-11d7209f9cf4",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment  than cohort 2.",
        "statement_nums": [
            "1 has a",
            "3 months after"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Central Nervous System (CNS) Progression-free Survival(PFS) The number of patients that are documented to have progression free survival at 3 months after treatment  Progression free is define as smaller than 25% increase in tumor area  PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death  Time frame: 3 months after treatment Results 1: Arm/Group Title: Epothilone B: Group A ",
        "premise_nums": [
            "25% increase",
            "3 months after"
        ]
    },
    {
        "id": "3889cecd-aa2d-4f58-857e-11d7209f9cf4",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment  than cohort 2.",
        "statement_nums": [
            "1 has a",
            "3 months after"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Group A: Patients with progressive  radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT)  Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: participants 12 Results 2: Arm/Group Title: Epothilone B: Group B ",
        "premise_nums": [
            "45 Measure Type:",
            "(q3weeks) with",
            "10 mg/m2",
            "12 Results 2:"
        ]
    },
    {
        "id": "3889cecd-aa2d-4f58-857e-11d7209f9cf4",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment  than cohort 2.",
        "statement_nums": [
            "1 has a",
            "3 months after"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Group B: an exploratory cohort of patients  with either leptomeningeal metastases (LMD) or unirradiated  asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 10 Measure Type: Number Unit of Measure: participants 2 ",
        "premise_nums": [
            "10 mg/m2",
            "(q3weeks) with",
            "10 Measure Type:"
        ]
    },
    {
        "id": "1d0ce237-70eb-45b4-9c77-f0b70d410387",
        "primaryId": "NCT00193180",
        "statement_text": "A female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial ",
        "statement_nums": [
            "18 suffering from"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Age 18 years or older Exclusion Criteria: Known chronic liver disease ",
        "premise_nums": [
            "18 years or"
        ]
    },
    {
        "id": "dad5ecc6-afcf-496c-8193-778a100c0318",
        "primaryId": "NCT00436917",
        "statement_text": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine  or with a prior surgery at the lumbosacral spine are excluded from the primary trial  as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA) ",
        "statement_nums": [
            "20 degrees at"
        ],
        "label": "Entailment",
        "premise_text": "No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following: History of surgery at the lumbosacral spine  with or without implantable devices Scoliosis with a Cobb angle greater than 15 degrees at the lumbar spine ",
        "premise_nums": [
            "15 degrees at"
        ]
    },
    {
        "id": "63ec91be-7e12-431e-84b0-ca401bfb157b",
        "primaryId": "NCT01048099",
        "secondaryId": "NCT02502864",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 2.38% more total adverse events than the secondary trial",
        "statement_nums": [
            "recorded 2.38% more total"
        ],
        "premise_text": "Adverse Events 1: Total: 5/14 (35.71%) Adverse Events 1: Total: 3/9 (33.33%) ",
        "premise_nums": [
            "3/9 (33.33%)",
            "5/14 (35.71%)"
        ]
    },
    {
        "id": "fd5af11f-7270-49d5-924a-755ff399c463",
        "primaryId": "NCT00373256",
        "statement_text": "Cohort 1 of the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death  and the mean PFS for this group was just under 7 and a half months ",
        "statement_nums": [
            "250 patients being",
            "18 months or",
            "1 of the",
            "7 and a"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Time from date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS = (first event date minus randomization date +1) divided by 30.4 Time frame: From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death Results 1: Arm/Group Title: Sunitinib + Paclitaxel Overall Number of Participants Analyzed: 242 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 8.5) ",
        "premise_nums": [
            "1 and every",
            "9 to 8.5)",
            "95% Confidence",
            "8 weeks thereafter",
            "4 Time frame:",
            "by 30.4 Time frame",
            "18 months or"
        ]
    },
    {
        "id": "f07e932e-1d79-4e1f-9ac2-ed9e2db1c276",
        "primaryId": "NCT02186015",
        "statement_text": "Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol ",
        "statement_nums": [
            "30 ng/ml did"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Cholecalciferol Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks  INTERVENTION 2: No Cholecalciferol Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention  ",
        "premise_nums": [
            "received 50,000 IUs weekly",
            "30 ng/ml received"
        ]
    },
    {
        "id": "a495df61-260d-479c-8d5f-d586f295c672",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "label": "Contradiction",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups  receiving a placebo tablet PO BID ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Minocycline Hydrochloride) Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 2: Arm II (Placebo) Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  ",
        "premise_nums": [
            "12 courses in",
            "1-7. Treatment",
            "7 days for"
        ]
    },
    {
        "id": "a495df61-260d-479c-8d5f-d586f295c672",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "label": "Contradiction",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups  receiving a placebo tablet PO BID ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherenceINTERVENTION 2: Control Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR  Control: Web-based resource lists and text-based study adherence reminders ",
        "premise_nums": [
            "24 weeks of"
        ]
    },
    {
        "id": "917afeec-5152-4424-89e3-7f3ffad6378f",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered IL-2 3 times per week for 6 doses ",
        "statement_nums": [
            "3 times per",
            "45 kg receive",
            "4 million units",
            "1 of the",
            "2 less of"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm 1: CsA Fludarabine: Administered intravenously  25 mg/m^2, days -6 through -2 (5 days)  Cyclophosphamide: Administered intravenously  60 mg/kg  days -5 and -4. Cyclosporine (CsA): Administered intravenously  1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14 Natural Killer cells: Administered by infusion over less than 1 hour; no more than 8.0 x 10^7 cells/kg will be given  ",
        "premise_nums": [
            "10^7 cells",
            "60 mg/kg",
            "25 mg/m^2,",
            "14 Natural Killer",
            "1.5 mg/kg",
            "150-250 ng/mL",
            "than 8.0 x 10",
            "3 through day"
        ]
    },
    {
        "id": "917afeec-5152-4424-89e3-7f3ffad6378f",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered IL-2 3 times per week for 6 doses ",
        "statement_nums": [
            "3 times per",
            "45 kg receive",
            "4 million units",
            "1 of the",
            "2 less of"
        ],
        "label": "Entailment",
        "premise_text": "Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of 6 doses  beginning 4 hours after NK cell infusion  (For patients weighing less than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses) ",
        "premise_nums": [
            "3 times per",
            "2 will be",
            "3 times a",
            "9 million units",
            "5 million units",
            "4 hours after"
        ]
    },
    {
        "id": "94cd9451-35a4-4035-a7de-2d385f771607",
        "primaryId": "NCT01671319",
        "statement_text": "1/42 patients in cohort 2 of the primary trial fainted ",
        "statement_nums": [
            "2 of the",
            "42 patients in",
            "1/42 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 4/42 (9.52%) Perforation  GI 1/42 (2.38%) Febrile neutropenia 1/42 (2.38%) Syncope 1/42 (2.38%) Rash/desquamation 1/42 (2.38%) ",
        "premise_nums": [
            "1/42 (2.38%)",
            "4/42 (9.52%)"
        ]
    },
    {
        "id": "18310f83-54ca-4530-92f1-7c41419ab69e",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15 (0.00%) Severe Dehydration * 1/15 (6.67%) hypokalemia * 1/15 (6.67%) pain  swelling  mastectomy site cellulitis * 0/15 (0.00%) death progressive disease * 0/15 (0.00%) divetricular abscess * 0/15 (0.00%) fever * 1/15 (6.67%) febrile neutropenia * 3/15 (20.00%) Neutropenia * 0/15 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/15 (0.00%)",
            "3/15 (20.00%)",
            "1/15 (6.67%)",
            "6/15 (40.00%)"
        ]
    },
    {
        "id": "18310f83-54ca-4530-92f1-7c41419ab69e",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 4/14 (28.57%)diarrhea and dehydration * 0/14 (0.00%) Severe Dehydration * 0/14 (0.00%) hypokalemia * 0/14 (0.00%) pain  swelling  mastectomy site cellulitis * 0/14 (0.00%) death progressive disease * 1/14 (7.14%) divetricular abscess * 0/14 (0.00%) fever * 0/14 (0.00%) febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%) ",
        "premise_nums": [
            "2/14 (14.29%)",
            "1/14 (7.14%)",
            "0/14 (0.00%)",
            "4/14 (28.57%)diarrhea"
        ]
    },
    {
        "id": "85210693-996a-4ab9-92f4-62060571da21",
        "primaryId": "NCT01847001",
        "statement_text": "Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial ",
        "statement_nums": [
            "50 beats per"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: English or Spanish speaking women age 18 Heart Rate greater than 60 bpm ",
        "premise_nums": [
            "18 Heart Rate"
        ]
    },
    {
        "id": "f0fbdbf4-af12-4cde-a5f1-a56cc60658f4",
        "primaryId": "NCT00148668",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 5/41 (12.20%) Neutropenia 4/41 (9.76%) Febrile Neutropenia 0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT (ALT) 0/40 (0.00%) ",
        "premise_nums": [
            "0/41 (0.00%)",
            "4/41 (9.76%)",
            "5/41 (12.20%)",
            "4/40 (10.00%)",
            "1/41 (2.44%)",
            "1/40 (2.50%)",
            "5/40 (12.50%)",
            "0/40 (0.00%)"
        ]
    },
    {
        "id": "6a37e999-4b7e-4654-b9ac-7776a0720040",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Entailment",
        "statement_text": "1 patient in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Adverse Events 1: Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia with urinary tract infection 0/22 (0.00%) dyspnoea 1/22 (4.55%) hypoxia 0/22 (0.00%) thromboembolism 0/22 (0.00%) Adverse Events 2: Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) ",
        "premise_nums": [
            "4/17 (23.53%)",
            "3/22 (13.64%)",
            "0/22 (0.00%)",
            "1/17 (5.88%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "6a37e999-4b7e-4654-b9ac-7776a0720040",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Entailment",
        "statement_text": "1 patient in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "febrile neutropenia with respiratory infection 0/17 (0.00%)urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%) hypoxia 1/17 (5.88%) thromboembolism 1/17 (5.88%) Adverse Events 1: Total: 9/46 (19.57%) Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) Upper gastrointestinal hemorrhage 1/46 (2.17%) ",
        "premise_nums": [
            "0/17 (0.00%)urosepsis",
            "9/46 (19.57%)",
            "1/46 (2.17%)",
            "1/17 (5.88%)"
        ]
    },
    {
        "id": "6a37e999-4b7e-4654-b9ac-7776a0720040",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Entailment",
        "statement_text": "1 patient in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "1 patient in"
        ],
        "premise_text": "Chest pain 1/46 (2.17%)Fatigue 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%) Anorexia 1/46 (2.17%) Dehydration 1/46 (2.17%) Serum potassium increased 1/46 (2.17%) ",
        "premise_nums": [
            "1/46 (2.17%)Fatigue",
            "2/46 (4.35%)"
        ]
    },
    {
        "id": "25f1f3b8-15ed-4339-bf56-1cf1e0c2909f",
        "primaryId": "NCT00856492",
        "statement_text": "Cohort 1 of the primary trial recorded no deaths and no cases of Anemia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%) Mucositis oral 1/96 (1.04%) Nausea 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96 (0.00%) ",
        "premise_nums": [
            "1/96 (1.04%)",
            "0/96 (0.00%)",
            "22/96 (22.92%)",
            "2/96 (2.08%)",
            "4/96 (4.17%)"
        ]
    },
    {
        "id": "64dcb690-ef14-4cf2-85e5-670eb0645d7f",
        "primaryId": "NCT01073865",
        "statement_text": "Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial ",
        "statement_nums": [
            "2 weeks prior"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation  and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of randomisation  ",
        "premise_nums": [
            "10 pg/mL and",
            "1 year of",
            "30 mIU/mL within",
            "4 weeks of",
            "20 years and"
        ]
    },
    {
        "id": "cacd1b1b-510e-421b-9adb-c5715f281794",
        "primaryId": "NCT01566721",
        "statement_text": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "1 Adverse Event"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period Participants were planned to receive a total of 18 cycles of SC Herceptin  An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin  Examples included unfavorable/unintended signs and symptoms  new or exacerbated disease  recurrence of intermittent condition  deterioration in laboratory value or other clinical test  or adverse procedure-related events  The percentage of participants with at least 1 AE during the treatment period (regardless of severity or seriousness) was reported  Time frame: From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year) Results 1: ",
        "premise_nums": [
            "19 cycles (cycle",
            "1 AE during",
            "18 cycles of",
            "1 up to",
            "1 Adverse Event"
        ]
    },
    {
        "id": "cacd1b1b-510e-421b-9adb-c5715f281794",
        "primaryId": "NCT01566721",
        "statement_text": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "1 Adverse Event"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Cohort A: SC Herceptin by Needle/SyringeArm/Group Description: Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe  Overall Number of Participants Analyzed: 1864 Measure Type: Number Unit of Measure: percentage of participants 88.6 Results 2: Arm/Group Title: Cohort B: SC Herceptin by SID ",
        "premise_nums": [
            "1864 Measure Type:",
            "18 doses/cycles",
            "3 weeks for",
            "6 Results 2:",
            "600 mg every",
            "participants 88.6 Results 2"
        ]
    },
    {
        "id": "cacd1b1b-510e-421b-9adb-c5715f281794",
        "primaryId": "NCT01566721",
        "statement_text": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "statement_nums": [
            "2 of the",
            "1 Adverse Event"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was administered from a pre-filled SID  The first administration was performed by an HCP  Subsequent doses were self-administered by participants who were willing and judged competent by the HCP Overall Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants 89.0 ",
        "premise_nums": [
            "18 doses/cycles",
            "3 weeks for",
            "600 mg every",
            "709 Measure Type:"
        ]
    },
    {
        "id": "7926bfa3-cf49-4589-8143-0a0826336b67",
        "primaryId": "NCT01401166",
        "statement_text": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants by Preferred Method of Drug Administration The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant  Participants were asked  \"All things considered  which method of administration did you prefer?\" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported  Time frame: Week 24 Results 1: Arm/Group Title: Cohort 1: SC (SID) Then IV Herceptin ",
        "premise_nums": [
            "24 Results 1:"
        ]
    },
    {
        "id": "7926bfa3-cf49-4589-8143-0a0826336b67",
        "primaryId": "NCT01401166",
        "statement_text": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles  During Cycles 1 to 4 of the crossover period  SC Herceptin was administered via SID  and during Cycles 5 to 8, IV Herceptin was given  In the continuation period  participants received IV Herceptin for up to 10 remaining cycles  Administration was performed by HCP  Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP  The SC dose was 600 mg for all cycles where SC Herceptin was given  and the IV dose was 6 mg/kg for all cycles where IV Herceptin was given Overall Number of Participants Analyzed: 117 ",
        "premise_nums": [
            "5 to 8,",
            "1 of each",
            "1 to 4",
            "10 remaining cycles",
            "3-week cycle",
            "600 mg for",
            "2 treatment cycles",
            "6 mg/kg for",
            "18-cycle treatment"
        ]
    },
    {
        "id": "7926bfa3-cf49-4589-8143-0a0826336b67",
        "primaryId": "NCT01401166",
        "statement_text": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Measure Type: NumberUnit of Measure: percentage of participants SC Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0 ",
        "premise_nums": [
            "7 IV Herceptin:",
            "3 No Preference:"
        ]
    },
    {
        "id": "a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42",
        "primaryId": "NCT00887575",
        "secondaryId": "NCT01610284",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 3/41 (7.32%) Adverse Events 1: Total: 146/573 (25.48%) ",
        "premise_nums": [
            "146/573 (25.48%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "36957dd8-fe28-4b70-b651-8f6ea7d1d0e9",
        "primaryId": "NCT01269346",
        "secondaryId": "NCT01597193",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial have the same total number of adverse events ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 15/52 (28.85%) Adverse Events 1: Total: 2/7 (28.57%) ",
        "premise_nums": [
            "15/52 (28.85%)",
            "2/7 (28.57%)"
        ]
    },
    {
        "id": "1aee22c7-96f2-4ea6-909a-48741f87ba07",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) Stomatitis 0/8 (0.00%) ",
        "premise_nums": [
            "0/8 (0.00%)",
            "1/8 (12.50%)",
            "3/8 (37.50%)"
        ]
    },
    {
        "id": "1aee22c7-96f2-4ea6-909a-48741f87ba07",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Upper gastrointestinal haemorrhage 0/8 (0.00%)Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "0/8 (0.00%)Vomiting",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "1aee22c7-96f2-4ea6-909a-48741f87ba07",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Diarrhoea 0/6 (0.00%)Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) ",
        "premise_nums": [
            "0/6 (0.00%)Nausea",
            "1/6 (16.67%)"
        ]
    },
    {
        "id": "e6c0f7af-b549-4aad-8f3c-15f367a04a50",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "10% more"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response Rate Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab ",
        "premise_nums": [
            "30% decrease",
            "6 months Results"
        ]
    },
    {
        "id": "e6c0f7af-b549-4aad-8f3c-15f367a04a50",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "10% more"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: ",
        "premise_nums": [
            "100 mg/m2 X",
            "9 to 45.0)",
            "2 X 3",
            "15 at 28",
            "1 and 15",
            "39 Measure Type:",
            "5 mg/kg for",
            "10 mg/kg loading",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "e6c0f7af-b549-4aad-8f3c-15f367a04a50",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "30% decrease",
            "10% more"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Abraxane AloneArm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) ",
        "premise_nums": [
            "2 weekly X",
            "18 to 61.1)",
            "2 cycles (every",
            "21 Measure Type:",
            "15 at 28",
            "100 mg/m2 weekly",
            "3 doses on",
            "28-day intervals"
        ]
    },
    {
        "id": "9e664bcb-38cc-4ca6-9738-28d96248b7f2",
        "primaryId": "NCT00320411",
        "statement_text": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily ",
        "statement_nums": [
            "(1500g) PO",
            "6 tablets of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Lapatinib Monotherapy Lapatinib: 1500 mg (six 250 mg tablets) orally once daily ",
        "premise_nums": [
            "1500 mg (six",
            "250 mg tablets)"
        ]
    },
    {
        "id": "ad853675-40ed-4a65-a401-d09ac3153570",
        "primaryId": "NCT03004534",
        "statement_text": "Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "0 breast carcinoma"
        ],
        "label": "Entailment",
        "premise_text": "Tumor must be confined to either the breast or to the breast and ipsilateral axilla (Note: patinets with multifocal/multicentric tumors are eligible)  Patient must have (according to TNM 7th edition rules): T1 with T 1.0cm, T2 or T3 by at least one radiographic or clinical measurement Either clinically positive (N1 only) or clinically negative axillary nodes (N0) M0 ",
        "premise_nums": [
            "2 or T3",
            "1 with T",
            "(N0) M"
        ]
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "2 pm Days",
            "1000 mg/m2 pm",
            "1 and 8",
            "21 day cycle;",
            "2 tablets x",
            "2 twice daily",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 81 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "95% Confidence",
            "2 twice daily",
            "30 minutes after",
            "7 day rest",
            "83 to 128)"
        ]
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine)Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "2 pm Days",
            "1000 mg/m2 pm",
            "1 and 8",
            "21 day cycle;",
            "2 tablets x",
            "2 twice daily",
            "2 tablets )",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 81 (48 to 95) ",
        "premise_nums": [
            "of 1,000 mg/m2",
            "14 days followed",
            "48 to 95)",
            "95% Confidence",
            "2 twice daily",
            "30 minutes after",
            "7 day rest"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "premise_nums": [
            "1-L4) Bone"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA)  The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader  Percent change = 100*((BMD at Month 12 - Baseline BMD)/Baseline BMD))  Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method  Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward Time frame: Baseline  12 months Results 1: ",
        "premise_nums": [
            "6 were not",
            "12 were imputed",
            "6 were carried",
            "12 months Results"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Zoledronic Acid UpfrontArm/Group Description: Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 253 Mean (Standard Deviation) ",
        "premise_nums": [
            "4 mg i.v",
            "(1000-1200 mg",
            "1 and every",
            "15-minute infusion",
            "253 Mean (Standard",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "4 mg IV",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: In lieu of a placebo arm  which was considered unethical for this trial  a delayed start arm was used  Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture  or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit  were started on zoledronic acid 4 mg i.v  and for every 6 months until disease progression (recurrence) or end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  ",
        "premise_nums": [
            "36 scheduled visit",
            "4 mg i.v",
            "(1000-1200 mg",
            "(400-800 IU",
            "Letrozole 2.5 daily plus",
            "6 months until",
            "received 2.5 mg daily"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "1-L4) Bone"
        ],
        "label": "Entailment",
        "premise_text": "Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months Overall Number of Participants Analyzed: 256 Mean (Standard Deviation) Unit of Measure: Percentage of BMD -2.325 (3.9542) ",
        "premise_nums": [
            "6 months Overall",
            "4 mg IV",
            "256 Mean (Standard",
            "15-minute infusion"
        ]
    },
    {
        "id": "d23eb56e-c232-4754-94aa-903bc174cb35",
        "primaryId": "NCT00524303",
        "statement_text": "The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm ",
        "statement_nums": [
            "9% better"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed)  A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus)  Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and 12 weeks of treatment with Paclitaxel  Time frame: Week 26 ",
        "premise_nums": [
            "26 Weeks of",
            "2-week run-in",
            "12 weeks of",
            "26 weeks of"
        ]
    },
    {
        "id": "d23eb56e-c232-4754-94aa-903bc174cb35",
        "primaryId": "NCT00524303",
        "statement_text": "The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm ",
        "statement_nums": [
            "9% better"
        ],
        "label": "Entailment",
        "premise_text": "Results 1:Arm/Group Title: Trastuzumab ",
        "premise_nums": [
            "1:Arm/Group Title:"
        ]
    },
    {
        "id": "b1a17048-dfe8-4173-ae80-6ec273244848",
        "primaryId": "NCT01298193",
        "statement_text": "More than 20% of patients in cohort 1 of the primary trial experienced adverse events ",
        "statement_nums": [
            "20% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 31/185 (16.76%) ",
        "premise_nums": [
            "31/185 (16.76%)"
        ]
    },
    {
        "id": "5344044c-127d-4a39-80dc-277538b5ad33",
        "primaryId": "NCT02131064",
        "statement_text": "less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples ",
        "statement_nums": [
            "60 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples tpCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy  tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes ( that is [i.e.]  ypT0/is, ypN0 in the American Joint Committee on Cancer [AJCC] staging system  7th edition)  Percentage of participants with tpCR was reported  Time frame: Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months) Results 1: ",
        "premise_nums": [
            "6 weeks after",
            "0 in the",
            "0/is, ypN0"
        ]
    },
    {
        "id": "ed43519d-9954-4e0f-9d42-39a3ed81e4a5",
        "primaryId": "NCT00820872",
        "statement_text": "Hyperglycemia was the most common adverse event in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage 1/30 (3.33%) Fatigue 1/30 (3.33%) Skin infection 1/30 (3.33%) Neutrophil count decreased 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%) ",
        "premise_nums": [
            "10/30 (33.33%)",
            "3/30 (10.00%)",
            "7/30 (23.33%)",
            "1/30 (3.33%)",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "1a32e1c1-31b1-40e5-bbb6-84041ef796fe",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2",
            "3 patients that"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Congestive Heart Failure Rate Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN)  or symptomatic diastolic dysfunction  223 treated patients were included in the analysis  Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment  then every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry Results 1: Arm/Group Title: Arm A (ddBAC greater than BT greater than B) ",
        "premise_nums": [
            "3 years from",
            "2 years and",
            "17 and 25,",
            "6 months for",
            "3 months for",
            "223 treated patients",
            "2-3 years",
            "1 of cycles"
        ]
    },
    {
        "id": "1a32e1c1-31b1-40e5-bbb6-84041ef796fe",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "1 and 2",
            "3 patients that"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Dose dense bevacizumab  cyclophosphamide and doxorubicin  followed by paclitaxel and bevacizumab  followed by bevacizumabOverall Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.9 (0.6 to 8.3) Results 2: Arm/Group Title: Arm B (ddAC greater than BT greater than B) Arm/Group Description: Dose dense doxorubicin and cyclophosphamide  followed by paclitaxel and bevacizumab  followed by bevacizumab Overall Number of Participants Analyzed: 120 Measure Type: Number ",
        "premise_nums": [
            "120 Measure Type:",
            "6 to 8.3)",
            "103 Measure Type:"
        ]
    },
    {
        "id": "382747d3-69df-41be-a771-4218407ce5d3",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy  Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA)  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid 4 mg Upfront ",
        "premise_nums": [
            "2-L4) at",
            "12 months Results",
            "2-L4) as",
            "12 Months of",
            "4 mg Upfront"
        ]
    },
    {
        "id": "382747d3-69df-41be-a771-4218407ce5d3",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 423 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Delayed ",
        "premise_nums": [
            "tablets 2.5 mg/day",
            "15 minute infusion",
            "423 Mean (Standard",
            "6 months for",
            "5 years beginning",
            "4 mg Delayed",
            "4 mg Intravenous"
        ]
    },
    {
        "id": "382747d3-69df-41be-a771-4218407ce5d3",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score smaller than = -2.0 SD at either the lumbar spine or total hip  any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit  All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 418 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD -3.617 (4.2151) ",
        "premise_nums": [
            "tablets 2.5 mg/day",
            "15 minute infusion",
            "5 years beginning",
            "6 months beginning",
            "418 Mean (Standard",
            "0 SD at",
            "4 mg Intravenous"
        ]
    },
    {
        "id": "646959e4-25d0-4eb1-b7b0-2d7b1e02e132",
        "primaryId": "NCT01262027",
        "statement_text": "Less than 5% of patients in the primary trial suffered an adverse event ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) ",
        "premise_nums": [
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "a781374c-99e1-47ee-a266-bff9267c2ed1",
        "primaryId": "NCT00950742",
        "statement_text": "100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities ",
        "statement_nums": [
            "100% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days Results 2: Arm/Group Title: Afatinib 30mg + Herceptin Arm/Group Description: Patients received continuous daily dosing with Afatinib 30mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit  Overall Number of Participants Analyzed: 2 Measure Type: Number Unit of Measure: Participants 2 ",
        "premise_nums": [
            "2 Measure Type:",
            "28 days Results"
        ]
    },
    {
        "id": "deb77d34-76a5-4e6e-bc9d-176cc30eca07",
        "primaryId": "NCT00917735",
        "statement_text": "One patient in cohort 2 of the primary trial died in a motorcycle crash ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) ",
        "premise_nums": [
            "8/537 (1.49%)",
            "1/537 (0.19%)",
            "2/537 (0.37%)",
            "0/537 (0.00%)"
        ]
    },
    {
        "id": "bfe97430-fcec-4c4a-9621-51f6ec05d8d3",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15 (0.00%) Severe Dehydration * 1/15 (6.67%) hypokalemia * 1/15 (6.67%) pain  swelling  mastectomy site cellulitis * 0/15 (0.00%) death progressive disease * 0/15 (0.00%) divetricular abscess * 0/15 (0.00%) fever * 1/15 (6.67%) febrile neutropenia * 3/15 (20.00%) Neutropenia * 0/15 (0.00%) Adverse Events 2: Total: 4/14 (28.57%) ",
        "premise_nums": [
            "3/15 (20.00%)",
            "0/15 (0.00%)",
            "6/15 (40.00%)",
            "4/14 (28.57%)",
            "1/15 (6.67%)"
        ]
    },
    {
        "id": "bfe97430-fcec-4c4a-9621-51f6ec05d8d3",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "diarrhea and dehydration * 0/14 (0.00%)Severe Dehydration * 0/14 (0.00%) hypokalemia * 0/14 (0.00%) pain  swelling  mastectomy site cellulitis * 0/14 (0.00%) death progressive disease * 1/14 (7.14%) divetricular abscess * 0/14 (0.00%) fever * 0/14 (0.00%) febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%) ",
        "premise_nums": [
            "2/14 (14.29%)",
            "1/14 (7.14%)",
            "0/14 (0.00%)Severe"
        ]
    },
    {
        "id": "568beebd-b350-4ba1-b8fc-c43f4d6ed517",
        "primaryId": "NCT01421017",
        "statement_text": "the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment ",
        "statement_nums": [
            "9 weeks after"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Systemic Tumor Response Rates (Complete Response+Partial Response) The systemic tumor response refers to the response at the time of best overall response  The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok  et al.  2009). Time frame: 9 weeks from the start of the treatment of RT ",
        "premise_nums": [
            "9 weeks from"
        ]
    },
    {
        "id": "dfa2ecee-96cf-4551-875e-aedd8aac5df9",
        "primaryId": "NCT01519700",
        "statement_text": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "1 of Chemotherapy",
            "4 Neutropenia During"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L) Time frame: 21 days (Cycle 1 of chemotherapy treatment) Results 1: Arm/Group Title: EP2006 + EP2006 & Neupogen Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1 Overall Number of Participants Analyzed: 101 Mean (Standard Deviation) Unit of Measure: Days 1.17 (1.11) Results 2: Arm/Group Title: Neupogen + Neupogen & EP2006 ",
        "premise_nums": [
            "1 of Chemotherapy",
            "21 days (Cycle",
            "1 of chemotherapy",
            "4 Neutropenia During",
            "1 Overall Number",
            "2006 in Cycle",
            "EP2006 in",
            "101 Mean (Standard",
            "4 neutropenia (ANC"
        ]
    },
    {
        "id": "dfa2ecee-96cf-4551-875e-aedd8aac5df9",
        "primaryId": "NCT01519700",
        "statement_text": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "1 of Chemotherapy",
            "4 Neutropenia During"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: All subjects randomized to receive Neupogen in Cycle 1Overall Number of Participants Analyzed: 103 Mean (Standard Deviation) Unit of Measure: Days 1.2 (1.02) ",
        "premise_nums": [
            "103 Mean (Standard"
        ]
    },
    {
        "id": "81c85a29-d449-4f79-a3b3-682ba5f288ca",
        "primaryId": "NCT00190671",
        "secondaryId": "NCT00455533",
        "label": "Entailment",
        "statement_text": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia ",
        "statement_nums": [
            "1 had more",
            "2 of the",
            "2 had more"
        ],
        "premise_text": "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144 (0.00%) ",
        "premise_nums": [
            "2/61 (3.28%)",
            "0/42 (0.00%)",
            "2/145 (1.38%)",
            "0/144 (0.00%)"
        ]
    },
    {
        "id": "b250a17c-9d4d-405d-ba64-40f7eda16707",
        "primaryId": "NCT00368875",
        "statement_text": "the primary trial results indicate that the Recommended Phase II Dose for paclitaxel  as Assessed by NCI Common Terminology Criteria for Adverse Events  is 90 mg/m2  ",
        "statement_nums": [
            "90 mg/m2"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I) Dose-limiting toxcities (DLT) were defined as grade 3-4 febrile neutropenia  thrombocytopenia and non-hemtological toxicity attributed to therapy (nausea  vomiting and diarrhea would be considered dose limiting only if not adequately controlled with therapy)  Any toxicity occurring during cycle 1 that resulted in dose reduction of vorinostat or paclitaxel or failure to complete all protocol specificed doses in the first cycle was also considered a DLT Time frame: 28 days Results 1: Arm/Group Title: Phase I ",
        "premise_nums": [
            "4 febrile neutropenia",
            "1 that resulted",
            "3-4 febrile",
            "28 days Results"
        ]
    },
    {
        "id": "b250a17c-9d4d-405d-ba64-40f7eda16707",
        "primaryId": "NCT00368875",
        "statement_text": "the primary trial results indicate that the Recommended Phase II Dose for paclitaxel  as Assessed by NCI Common Terminology Criteria for Adverse Events  is 90 mg/m2  ",
        "statement_nums": [
            "90 mg/m2"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at the time of registration  Vorinostat was administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle All patients also received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2, 9, and 16 of every 28-day cycle  Bevacizumab was administered on day 2 and day 16 of the 28 day cycle at 10 mg/kg dose  Vorinostat dose escalation was carried out in the standard 3 + 3 phase I trial design based upon toxicity observed during the first cycle of therapy  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: mg 300 ",
        "premise_nums": [
            "2 and day",
            "16 of the",
            "1-hour infusion",
            "10 mg/kg dose",
            "90 mg/m2 as",
            "3 phase I",
            "200 or 300",
            "17 of each",
            "28 day cycle",
            "1-3, 8-10,",
            "28-day cycle",
            "16 of every",
            "6 Measure Type:",
            "300 mg BID",
            "15-17 of"
        ]
    },
    {
        "id": "4b4e6ac7-107c-46f4-adbb-c77c01f51935",
        "primaryId": "NCT00075764",
        "statement_text": "The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%) Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%) Cardiac-ischemia/infarction 1/337 (0.30%) Left ventricular diastolic dysfunction 0/337 (0.00%) Left ventricular systolic dysfunction 1/337 (0.30%) Restrictive cardiomyopathy 1/337 (0.30%) ",
        "premise_nums": [
            "0/337 (0.00%)",
            "1/337 (0.30%)",
            "2/337 (0.59%)",
            "21/337 (6.23%)"
        ]
    },
    {
        "id": "2a1d9064-fde9-4645-95ab-7ddaea4ad322",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1.",
        "statement_nums": [
            "2 of the",
            "3 had more"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (CR Plus PR Plus SD) Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0 CR = disappearance of all target lesions PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease SD is defined as lack of disease progression by 24 weeks  Time frame: 24 weeks after start of treatment Results 1: Arm/Group Title: Arm 1 (6 mg Estradiol) Arm/Group Description: 6 mg of estradiol daily (2 mg tid)  Overall Number of Participants Analyzed: 34 Measure Type: Number ",
        "premise_nums": [
            "30% decrease",
            "0 CR =",
            "24 weeks after",
            "2 mg tid)",
            "34 Measure Type:",
            "6 mg of",
            "6 mg Estradiol)"
        ]
    },
    {
        "id": "2a1d9064-fde9-4645-95ab-7ddaea4ad322",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1.",
        "statement_nums": [
            "2 of the",
            "3 had more"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: participants Complete response (CR): 0Partial response (PR): 3 Stable disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 32 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 1 Stable disease (SD): 8 CR+PR+SD: 9 ",
        "premise_nums": [
            "30 mg Estradiol)",
            "1 Stable disease",
            "3 Stable disease",
            "0 Partial response",
            "32 Measure Type:",
            "30 mg of",
            "10 Results 2:",
            "10 mg tid)"
        ]
    },
    {
        "id": "847de3fe-b584-4d43-b82d-93263ce88830",
        "primaryId": "NCT00509587",
        "statement_text": "Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day  continuing until disease progression or unacceptable toxicity ",
        "statement_nums": [
            "300 mg pazopanib"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Treatment (Pazopanib Hydrochloride) Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  pazopanib hydrochloride: Given orally pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies ",
        "premise_nums": [
            "28 days in",
            "1-28. Courses"
        ]
    },
    {
        "id": "3c798991-6366-43e2-94ca-0523629930c2",
        "primaryId": "NCT00149214",
        "secondaryId": "NCT01004744",
        "label": "Contradiction",
        "statement_text": "Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in the primary trial  but not for patients in the secondary trial ",
        "statement_nums": [
            "6 months for"
        ],
        "premise_text": "Exclusion Criteria: Prior anthracyclines as part of prior anticancer therapy  Inclusion Criteria: No prior chemotherapy  radiation therapy  or surgery within 6 months of study entry ",
        "premise_nums": [
            "6 months of"
        ]
    },
    {
        "id": "64fe54a2-8897-4324-af88-f627c1c208ed",
        "primaryId": "NCT01764022",
        "statement_text": "Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Anemia with trombocytopenia 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "d5ea3443-103f-4d29-9be3-522210b84152",
        "primaryId": "NCT00618826",
        "secondaryId": "NCT02040857",
        "label": "Contradiction",
        "statement_text": "the primary trial and the secondary trial only record 2 of the same adverse events ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Adverse Events 1: Lymphopenia 1/14 (7.14%) Diarrhea 1/14 (7.14%) Fatigue (asthenia  lethargy  malaise) 2/14 (14.29%) Hypertension 2/14 (14.29%) Adverse Events 1: Lymphocyte count decreased 2/162 (1.23%) Diarrhea 1/162 (0.62%) Fatigue 6/162 (3.70%) Hypertension 1/162 (0.62%) ",
        "premise_nums": [
            "2/14 (14.29%)",
            "6/162 (3.70%)",
            "2/162 (1.23%)",
            "1/162 (0.62%)",
            "1/14 (7.14%)"
        ]
    },
    {
        "id": "d54cae08-3ac9-4460-bf6d-7338b45d8cd7",
        "primaryId": "NCT00193050",
        "statement_text": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial ",
        "statement_nums": [
            "6 months to",
            "18 and have"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female Patients greater than 18 years of age Exclusion Criteria: Life expectancy of smaller than than 6 months ",
        "premise_nums": [
            "18 years of"
        ]
    },
    {
        "id": "608c5521-c9a6-47de-9ebf-791ce317a02d",
        "primaryId": "NCT00086957",
        "statement_text": "All of the patients in cohort 1 of the primary trial experienced an adverse event ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/2 (100.00%) Febrile neutropenia * 2/2 (100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%) Diarrhea * 0/2 (0.00%) Melaena * 0/2 (0.00%) Mucositis oral * 0/2 (0.00%) Nausea * 0/2 (0.00%) Vomiting * 0/2 (0.00%) Catheter related infection * 0/2 (0.00%) Infection NOS * 0/2 (0.00%) Leukopenia * 1/2 (50.00%) ",
        "premise_nums": [
            "1/2 (50.00%)",
            "0/2 (0.00%)",
            "2/2 (100.00%)"
        ]
    },
    {
        "id": "14a8e9e9-0a46-4537-bc07-53c786bcbe97",
        "primaryId": "NCT00593827",
        "secondaryId": "NCT00478257",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "2 negative MBC"
        ],
        "premise_text": "Inclusion Criteria: Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) 50 Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - ",
        "premise_nums": [
            "(HER2) negative",
            "18 pregnancy metastatic",
            "50 Has Human"
        ]
    },
    {
        "id": "2d97bfa0-336f-4976-95e5-1262327a730b",
        "primaryId": "NCT01048099",
        "secondaryId": "NCT02502864",
        "label": "Contradiction",
        "statement_text": "the primary trial recorded 2 more total adverse events than the secondary trial",
        "statement_nums": [
            "2 more total"
        ],
        "premise_text": "Adverse Events 1: Total: 5/14 (35.71%) Adverse Events 1: Total: 3/9 (33.33%) ",
        "premise_nums": [
            "3/9 (33.33%)",
            "5/14 (35.71%)"
        ]
    },
    {
        "id": "4613834d-c178-475c-b9fd-c9c66d5681eb",
        "primaryId": "NCT04080297",
        "secondaryId": "NCT02780713",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants ",
        "statement_nums": [
            "2 of the",
            "AZD9496 variants",
            "122 than either"
        ],
        "premise_text": "INTERVENTION 2: 200 mg Q-122 Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days  INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  ",
        "premise_nums": [
            "122 administered orally",
            "2 Participants received",
            "200 mg Q",
            "50 mg capsules",
            "1 Participants received",
            "122 Dosage was"
        ]
    },
    {
        "id": "c1b90c18-45f4-4e28-b50a-a00b0eadc523",
        "primaryId": "NCT00290732",
        "secondaryId": "NCT02748213",
        "label": "Contradiction",
        "statement_text": "Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial  but not the primary trial ",
        "statement_nums": [
            "is 0.1 cm across"
        ],
        "premise_text": "T1-3, any N disease No inflammatory breast cancer or other T4 features Inclusion Criteria: Histologically confirmed  HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy ",
        "premise_nums": [
            "4 features Inclusion",
            "2-positive advanced",
            "1-3, any"
        ]
    },
    {
        "id": "33ef3abf-97c0-4d15-909d-258fb47ac54a",
        "primaryId": "NCT00232479",
        "statement_text": "Only patients with HER2 positive breast carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: HER-2 overexpressing breast cancer ",
        "premise_nums": [
            "2 overexpressing breast"
        ]
    },
    {
        "id": "5feefe8b-ddca-4eb8-af68-d1e211963d1f",
        "primaryId": "NCT02748213",
        "statement_text": "2 patients  in cohort 1 of the primary trial was recorded as having an overactive pituitary gland ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 52/112 (46.43%) Febrile neutropenia * 16/112 (14.29%) Neutropenia * 7/112 (6.25%) Anaemia * 1/112 (0.89%) Cardiac failure * 1/112 (0.89%) Coronary artery disease * 1/112 (0.89%) Left ventricular dysfunction * 1/112 (0.89%) Pericardial effusion * 0/112 (0.00%) Hyperthyroidism * 1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse Events 2: ",
        "premise_nums": [
            "0/112 (0.00%)",
            "16/112 (14.29%)",
            "7/112 (6.25%)",
            "1/112 (0.89%)",
            "3/112 (2.68%)",
            "52/112 (46.43%)",
            "5/112 (4.46%)"
        ]
    },
    {
        "id": "5feefe8b-ddca-4eb8-af68-d1e211963d1f",
        "primaryId": "NCT02748213",
        "statement_text": "2 patients  in cohort 1 of the primary trial was recorded as having an overactive pituitary gland ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 51/110 (46.36%)Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%) Coronary artery disease * 0/110 (0.00%) Left ventricular dysfunction * 0/110 (0.00%) Pericardial effusion * 1/110 (0.91%) Hyperthyroidism * 0/110 (0.00%) Diarrhoea * 0/110 (0.00%) Vomiting * 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)",
            "26/110 (23.64%)",
            "7/110 (6.36%)",
            "51/110 (46.36%)Febrile",
            "0/110 (0.00%)"
        ]
    },
    {
        "id": "178c50cc-49ee-4083-bc8e-b5832037498a",
        "primaryId": "NCT00258960",
        "statement_text": "4 patients in the primary trial experienced a grade 3 or above adverse event ",
        "statement_nums": [
            "4 patients in",
            "3 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 16/48 (33.33%) Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%) ",
        "premise_nums": [
            "2/48 (4.17%)",
            "3/48 (6.25%)",
            "1/48 (2.08%)",
            "16/48 (33.33%)"
        ]
    },
    {
        "id": "92ace4fa-4426-4f34-af52-ee62913e60aa",
        "primaryId": "NCT01026142",
        "secondaryId": "NCT00846027",
        "label": "Contradiction",
        "statement_text": "There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial ",
        "statement_nums": [
            "10% more",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Left Ventricular Dysfunction 4/218 (1.83%) Adverse Events 2: Left Ventricular Dysfunction 13/228 (5.70%) Adverse Events 1: Left ventricular systolic dysfunction 1/82 (1.22%) ",
        "premise_nums": [
            "1/82 (1.22%)",
            "13/228 (5.70%)",
            "4/218 (1.83%)"
        ]
    },
    {
        "id": "7dbde84d-f1c9-4197-9d44-500fd337bebd",
        "primaryId": "NCT01823107",
        "statement_text": "At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events ",
        "statement_nums": [
            "12 Patients implanted"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Rate of Breast Related Adverse Events Investigators evaluated each subject and each reconstructed breast for the occurrence of an adverse event from the first stage of reconstruction through the final follow-up visit  A breast related adverse event was defined as any untoward medical occurrence related to a reconstructed breast  Time frame: 18 months Results 1: Arm/Group Title: Meso BioMatrix Acellular Peritoneum Matrix Arm/Group Description: All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction  After tissue expansion  the tissue expander was replaced with a breast implant during the second stage of reconstruction  Overall Number of Participants Analyzed: 25 Overall Number of Units Analyzed ",
        "premise_nums": [
            "18 months Results",
            "25 Overall Number"
        ]
    },
    {
        "id": "824da29f-b2ff-440e-8b78-7a8291cbd6d2",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 89 patients in the primary trial had Supraventricular tachycardia ",
        "statement_nums": [
            "89 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213 (0.00%) Supraventricular tachycardia 0/213 (0.00%) Diarrhoea 0/213 (0.00%) Colitis 0/213 (0.00%) Vomiting 1/213 (0.47%) Nausea 1/213 (0.47%) Enterocolitis 0/213 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "0/213 (0.00%)",
            "1/213 (0.47%)",
            "19/213 (8.92%)"
        ]
    },
    {
        "id": "824da29f-b2ff-440e-8b78-7a8291cbd6d2",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 89 patients in the primary trial had Supraventricular tachycardia ",
        "statement_nums": [
            "89 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 133/416 (31.97%)Pancytopenia 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416 (0.24%) Supraventricular tachycardia 1/416 (0.24%) Diarrhoea 32/416 (7.69%) Colitis 14/416 (3.37%) Vomiting 4/416 (0.96%) Nausea 3/416 (0.72%) Enterocolitis 2/416 (0.48%) ",
        "premise_nums": [
            "0/416 (0.00%)",
            "133/416 (31.97%)Pancytopenia",
            "32/416 (7.69%)",
            "4/416 (0.96%)",
            "3/416 (0.72%)",
            "2/416 (0.48%)",
            "1/416 (0.24%)",
            "14/416 (3.37%)"
        ]
    },
    {
        "id": "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1",
        "primaryId": "NCT02748213",
        "statement_text": "1 patient  in cohort 1 of the primary trial was recorded as having an overactive thyroid gland ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 52/112 (46.43%) Febrile neutropenia * 16/112 (14.29%) Neutropenia * 7/112 (6.25%) Anaemia * 1/112 (0.89%) Cardiac failure * 1/112 (0.89%) Coronary artery disease * 1/112 (0.89%) Left ventricular dysfunction * 1/112 (0.89%) Pericardial effusion * 0/112 (0.00%) Hyperthyroidism * 1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse Events 2: ",
        "premise_nums": [
            "0/112 (0.00%)",
            "16/112 (14.29%)",
            "7/112 (6.25%)",
            "1/112 (0.89%)",
            "3/112 (2.68%)",
            "52/112 (46.43%)",
            "5/112 (4.46%)"
        ]
    },
    {
        "id": "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1",
        "primaryId": "NCT02748213",
        "statement_text": "1 patient  in cohort 1 of the primary trial was recorded as having an overactive thyroid gland ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 51/110 (46.36%)Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%) Coronary artery disease * 0/110 (0.00%) Left ventricular dysfunction * 0/110 (0.00%) Pericardial effusion * 1/110 (0.91%) Hyperthyroidism * 0/110 (0.00%) Diarrhoea * 0/110 (0.00%) Vomiting * 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)",
            "26/110 (23.64%)",
            "7/110 (6.36%)",
            "51/110 (46.36%)Febrile",
            "0/110 (0.00%)"
        ]
    },
    {
        "id": "1d7dbb44-049d-4887-8bd6-6aefc77aa1e9",
        "primaryId": "NCT00444587",
        "statement_text": "A total of 7 patients in the primary trial were observed with either Leukopenia  Cardiopulmonary failure or Diarrhoea ",
        "statement_nums": [
            "7 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Leukopenia 2/93 (2.15%) Cardiopulmonary failure 2/93 (2.15%) Diarrhoea 3/93 (3.23%) ",
        "premise_nums": [
            "2/93 (2.15%)",
            "3/93 (3.23%)"
        ]
    },
    {
        "id": "95345dbe-446f-4999-8f3e-a429b77ea554",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "label": "Entailment",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN  These conditions are not explicitly required for the secondary trial ",
        "statement_nums": [
            "hemoglobin 11.5 g/dL",
            "than 1.7x ULN"
        ],
        "premise_text": "White Blood Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L. Demonstrate adequate renal  hepatic function (Liver function tests (ALT  AST  alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN)  Serum creatinine should be less than 1.7x ULN  Inclusion Criteria: Signed informed consent ",
        "premise_nums": [
            "than 1.7x ULN",
            "than 2.5x upper",
            "109/L, hemoglobin",
            "hemoglobin 11.5 g/dL",
            "109/L. Demonstrate"
        ]
    },
    {
        "id": "95345dbe-446f-4999-8f3e-a429b77ea554",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "label": "Entailment",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN  These conditions are not explicitly required for the secondary trial ",
        "statement_nums": [
            "hemoglobin 11.5 g/dL",
            "than 1.7x ULN"
        ],
        "premise_text": "At least 19 years oldGlomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category c or d)  Exclusion Criteria: History of iodinated contrast allergy Pregnant or lactating as determined by routine standard practice Personal history of breast cancer History of prior breast excisional biopsy (Patients with a history of core needle biopsy will not be excluded) History of prior breast reduction mammoplasty surgery History of prior breast augmentation surgery ",
        "premise_nums": [
            "60 Heterogeneously or",
            "19 years oldGlomerular"
        ]
    },
    {
        "id": "b05fde86-4004-427f-8baf-2ea4a0a535c7",
        "primaryId": "NCT00376597",
        "statement_text": "the primary trial all undergo surgery twice  first at 2 weeks and then again a month later ",
        "statement_nums": [
            "2 weeks and"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I (Lymphedema Education) Six weeks after surgery  patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials  Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months  Patients are also contacted by telephone at 9 and 15 months  INTERVENTION 2: Arm II (Lymphedema Education  Physical Therapy) Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I  Patients also complete a personalized physical therapy intervention  receive a refrigerator magnet  and a 15-minute video that reinforces information and exercises  ",
        "premise_nums": [
            "9 and 15",
            "15-minute video",
            "6 weeks and"
        ]
    },
    {
        "id": "21e24c6c-d282-48fb-8d68-3e723458794e",
        "primaryId": "NCT00825734",
        "statement_text": "Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection  unstable angina or a grade 4 hemorrhage within the last month ",
        "statement_nums": [
            "4 hemorrhage within"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection greater than grade 2. Unstable angina (anginal symptoms at rest) or new onset angina Pulmonary hemorrhage or bleeding event grade 2 within 4 weeks of the first dose of study treatment  or any other hemorrhage or bleeding event grade 3 within 4 weeks of the first dose of study treatment  ",
        "premise_nums": [
            "2 within 4",
            "3 within 4"
        ]
    },
    {
        "id": "d1e579e2-b057-43da-8a2f-64dad964b789",
        "primaryId": "NCT00821964",
        "statement_text": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle ",
        "statement_nums": [
            "14 days every",
            "28 day cycle"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Treatment (Biological Therapy  Chemo) Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity  imiquimod: Given topically Abraxane: Given IV laboratory biomarker analysis: Correlative studies RNA analysis: Correlative studies immunoenzyme technique: Correlative studies ",
        "premise_nums": [
            "22-25. Treatment",
            "15 and apply",
            "30 minutes on",
            "15-18, and",
            "1-4, 8-11,",
            "3 cycles in",
            "28 days for"
        ]
    },
    {
        "id": "d130c981-f602-4f17-b1cb-11a7ad632b92",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial more than 6 different types of cardiac related adverse events ",
        "statement_nums": [
            "6 different types"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "0/49 (0.00%)",
            "1/52 (1.92%)",
            "0/52 (0.00%)"
        ]
    },
    {
        "id": "d130c981-f602-4f17-b1cb-11a7ad632b92",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial more than 6 different types of cardiac related adverse events ",
        "statement_nums": [
            "6 different types"
        ],
        "label": "Entailment",
        "premise_text": "Pericardial effusion 4/49 (8.16%)Right ventricular failure 0/49 (0.00%) ",
        "premise_nums": [
            "0/49 (0.00%)",
            "4/49 (8.16%)Right"
        ]
    },
    {
        "id": "c1f9982f-c4c9-48dc-887a-7ae05f508c21",
        "primaryId": "NCT03329937",
        "statement_text": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle  for 2 cycles",
        "statement_nums": [
            "28 day cycle",
            "200 milligrams (mg)"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Niraparib 200 mg Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles  After 2 cycles  participants either underwent surgery  received additional cycles of niraparib (maximum of 6 cycles total)  or received neoadjuvant chemotherapy  at physician's discretion  A breast magnetic resonance imaging (MRI) was performed at the end of cycle 2 and breast ultrasounds were performed at the end of each cycle  including any additional cycles beyond cycle 2. After completion of all neoadjuvant therapy participants proceeded to surgery  at which time pathological complete response (pCR) was assessed  ",
        "premise_nums": [
            "200 mg Participants",
            "6 cycles total)",
            "200 milligrams (mg)",
            "2 and breast",
            "28-day treatment"
        ]
    },
    {
        "id": "92acd36d-ea44-4b98-acbc-e51382233089",
        "primaryId": "NCT00820872",
        "statement_text": "Diarrhea was the most common adverse event in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage 1/30 (3.33%) Fatigue 1/30 (3.33%) Skin infection 1/30 (3.33%) Neutrophil count decreased 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%) ",
        "premise_nums": [
            "10/30 (33.33%)",
            "3/30 (10.00%)",
            "7/30 (23.33%)",
            "1/30 (3.33%)",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "01280892-ca31-4e46-831b-a076426f65e5",
        "primaryId": "NCT01401062",
        "statement_text": "A patient who underwent T-cell transfer therapy in the past 6 months prior  and has fully recovered from the associated toxicities  would be excluded from the primary trial ",
        "statement_nums": [
            "6 months prior"
        ],
        "label": "Contradiction",
        "premise_text": "Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia): immunotherapy; ",
        "premise_nums": [
            "4 weeks since"
        ]
    },
    {
        "id": "959bd67a-1b2a-48da-ae44-211cbab4b665",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Month 33 Results 1: Arm/Group Title: Docetaxel + Sunitinib ",
        "premise_nums": [
            "33 Results 1:"
        ]
    },
    {
        "id": "959bd67a-1b2a-48da-ae44-211cbab4b665",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib) Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) ",
        "premise_nums": [
            "2 every 3",
            "2 weeks followed",
            "75 milligrams per",
            "100 mg/m^2",
            "95% Confidence",
            "2/1) with",
            "sunitinib 37.5 mg daily",
            "1-week off-treatment",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "959bd67a-1b2a-48da-ae44-211cbab4b665",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "95% Confidence"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: months Independent radiology assessment: 8.6 (8.2 to 10.3)Investigator's assessment: 8.2 (7.3 to 8.6) Results 2: Arm/Group Title: Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 297 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 8.3 (7.7 to 9.6) Investigator's assessment: 6.9 (6.5 to 7.3) ",
        "premise_nums": [
            "2 every 3",
            "3 to 8.6)",
            "3 weeks Overall",
            "5 to 7.3)",
            "7 to 9.6)",
            "100 mg/m^2",
            "95% Confidence"
        ]
    },
    {
        "id": "5a5695e8-9b84-42ad-9f34-6dd043153943",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "label": "Contradiction",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial and the secondary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN ",
        "statement_nums": [
            "hemoglobin 11.5 g/dL",
            "than 1.7x ULN"
        ],
        "premise_text": "White Blood Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L. Demonstrate adequate renal  hepatic function (Liver function tests (ALT  AST  alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN)  Serum creatinine should be less than 1.7x ULN  Inclusion Criteria: Signed informed consent At least 19 years old ",
        "premise_nums": [
            "than 1.7x ULN",
            "than 2.5x upper",
            "109/L, hemoglobin",
            "hemoglobin 11.5 g/dL",
            "109/L. Demonstrate",
            "19 years old"
        ]
    },
    {
        "id": "33634c51-0fb9-4de1-966d-14784bca93f8",
        "primaryId": "NCT01847001",
        "statement_text": "Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial ",
        "statement_nums": [
            "60 beats per"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: English or Spanish speaking women age 18 Heart Rate greater than 60 bpm ",
        "premise_nums": [
            "18 Heart Rate"
        ]
    },
    {
        "id": "8e46dc77-fa36-4231-a124-0ff6392891a1",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Minocycline Hydrochloride) Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 2: Arm II (Placebo) Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  ",
        "premise_nums": [
            "12 courses in",
            "1-7. Treatment",
            "7 days for"
        ]
    },
    {
        "id": "8e46dc77-fa36-4231-a124-0ff6392891a1",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherenceINTERVENTION 2: Control Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR  Control: Web-based resource lists and text-based study adherence reminders ",
        "premise_nums": [
            "24 weeks of"
        ]
    },
    {
        "id": "d11b0673-42a9-46c0-887f-d5a9b038264f",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "12 times in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity  Beginning 1 week later  patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity  Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity ",
        "premise_nums": [
            "1 week later",
            "30 minutes once",
            "30-90 minutes",
            "7 days for",
            "90 minutes once",
            "15 minutes on",
            "12 weeks in",
            "2/neu positive",
            "2-7. Courses",
            "10-15 minutes",
            "1 year in",
            "1-7, and"
        ]
    },
    {
        "id": "83511f04-e07c-438d-bf1e-f680fa49b384",
        "primaryId": "NCT01901146",
        "secondaryId": "NCT00209092",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Febrile neutropenia 3/364 (0.82%) Adverse Events 1: Febrile Neutropenia *0/25 (0.00%) ",
        "premise_nums": [
            "0/25 (0.00%)",
            "3/364 (0.82%)"
        ]
    },
    {
        "id": "72bb3c6e-66b0-4380-9da2-5a5867d715fd",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%) Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) Lymphoedema * 0/3 (0.00%) Adverse Events 2: Total: 6/41 (14.63%) Febrile Neutropenia * 1/41 (2.44%) Neutropenia * 1/41 (2.44%) Sudden Death * 1/41 (2.44%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "6/41 (14.63%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "72bb3c6e-66b0-4380-9da2-5a5867d715fd",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Bacterial Infection * 1/41 (2.44%)Bronchitis * 1/41 (2.44%) Sepsis * 1/41 (2.44%) Lymphoedema * 1/41 (2.44%) ",
        "premise_nums": [
            "1/41 (2.44%)Bronchitis"
        ]
    },
    {
        "id": "1b433096-f36a-4205-b16e-f9a370be3d05",
        "primaryId": "NCT01365845",
        "statement_text": "More than 18 participants in the primary trial had radiation dermatitis ",
        "statement_nums": [
            "18 participants in"
        ],
        "label": "Contradiction",
        "premise_text": "Radiation dermatitis 2 [1]4/18 (22.22%) ",
        "premise_nums": [
            "4/18 (22.22%)"
        ]
    },
    {
        "id": "f25adbc7-c0a0-44ed-af93-02f4bced7208",
        "primaryId": "NCT00343382",
        "secondaryId": "NCT00798135",
        "label": "Contradiction",
        "statement_text": "Cohort 2 of the primary trial recieves the same dose of Pilocarpine as cohort 2 of the secondary trial recieves of oral itraconazole ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  INTERVENTION 1: Itraconazole oral itraconazole 200mg a day until disease progression or unacceptable toxicities  ",
        "premise_nums": [
            "2 Times Per",
            "2 times per"
        ]
    },
    {
        "id": "2b182323-9357-486a-87aa-09ddc6230bf1",
        "primaryId": "NCT02481050",
        "statement_text": "There is only 1 adverse event in the primary trial that occurred more than once ",
        "statement_nums": [
            "1 adverse event"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 14/58 (24.14%) Constipation 1/58 (1.72%) Vomiting 1/58 (1.72%) Upper gastrointestinal haemorrhage 1/58 (1.72%) Asthenia 1/58 (1.72%) Chest pain 1/58 (1.72%) Pain 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture 1/58 (1.72%) Neutrophil count decreased 1/58 (1.72%) Dehydration 1/58 (1.72%) Hypovolaemia 1/58 (1.72%) ",
        "premise_nums": [
            "14/58 (24.14%)",
            "2/58 (3.45%)",
            "1/58 (1.72%)"
        ]
    },
    {
        "id": "171d0a20-8943-4994-a48a-7dff124e62ee",
        "primaryId": "NCT00046891",
        "statement_text": "cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily ",
        "statement_nums": [
            "60 mg of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Ginkgo Biloba Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID) ",
        "premise_nums": [
            "120 mg per",
            "60 mg BID)"
        ]
    },
    {
        "id": "25cc9a6e-656d-44ee-a301-93f5879407a0",
        "primaryId": "NCT01923168",
        "statement_text": "Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days ",
        "statement_nums": [
            "150 mg alpelisib",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Alpelisib + Letrozole Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily  ",
        "premise_nums": [
            "300 mg once",
            "letrozole 2.5 mg once"
        ]
    },
    {
        "id": "d9b4d4aa-0094-405e-83a3-cf2978cfda38",
        "primaryId": "NCT00347919",
        "statement_text": "56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "statement_nums": [
            "1500 mg had",
            "56.9% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Progressive Disease at Week 12 in Cohort 1 The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured  Per Response Evaluation Criteria In Solid Tumors (RECIST)  a response of PD is defined as a greater than or equal 20% increase in target lesions  Participants were also classified as having PD if their response at Week 12 was unknown or missing  Response was determined by an independent radiologist and by an investigator  Time frame: Week 12 Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day Overall Number of Participants Analyzed: 72 Measure Type: Number Unit of Measure: percentage of participants Independently Evaluated: 38.9 Investigator Evaluated: 43.1 ",
        "premise_nums": [
            "1500 milligrams (mg)",
            "72 Measure Type:",
            "12 Results 1:",
            "9 Investigator Evaluated:",
            "12 was unknown",
            "12 weeks after",
            "1500 mg Arm",
            "12 in Cohort",
            "1 The percentage",
            "20% increase"
        ]
    },
    {
        "id": "6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0",
        "primaryId": "NCT02525718",
        "secondaryId": "NCT02606708",
        "label": "Contradiction",
        "statement_text": "Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) ",
        "premise_nums": [
            "of 40.5 Gy to",
            "3 weeks delivered",
            "in 2.7 Gy/fraction",
            "of 0.50 Gy will",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "label": "Entailment",
        "statement_text": "In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients  Whereas all the primary trial participants receive the same treatment ",
        "statement_nums": [
            "2 neu positive"
        ],
        "premise_text": "INTERVENTION 1: Vorinostat Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid)  with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or biopsy)  INTERVENTION 1: Treatment (Chemotherapy With or Without Maintenance Therapy) SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "3 hours on",
            "2 hours before",
            "6 courses in",
            "1 hour and",
            "14 days for",
            "6 doses of",
            "300 mg twice"
        ]
    },
    {
        "id": "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "label": "Entailment",
        "statement_text": "In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients  Whereas all the primary trial participants receive the same treatment ",
        "statement_nums": [
            "2 neu positive"
        ],
        "premise_text": "MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity cyclophosphamide  paclitaxel  trastuzumab: Given IV ",
        "premise_nums": [
            "21 days for",
            "14 days for",
            "30 minutes on",
            "5 courses and",
            "2 neu positive",
            "14 courses in"
        ]
    },
    {
        "id": "ee7fe82e-de91-45c7-bd12-bff5d6c887a3",
        "primaryId": "NCT00320411",
        "statement_text": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily ",
        "statement_nums": [
            "(250mg) PO",
            "6 tablets of"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Lapatinib Monotherapy Lapatinib: 1500 mg (six 250 mg tablets) orally once daily ",
        "premise_nums": [
            "1500 mg (six",
            "250 mg tablets)"
        ]
    },
    {
        "id": "13466cbb-9f78-46ff-a983-09e2e9ad5a2c",
        "primaryId": "NCT00679211",
        "statement_text": "1 patient in the primary trial presented a fever  in addition to either a cough or a sore throat ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Influenza like illness 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "8e45da73-f016-4ca0-b106-a3fabc960b36",
        "primaryId": "NCT01432145",
        "statement_text": "the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate ",
        "statement_nums": [
            "6-Mercaptopurine more"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day (od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given continuously until disease progression  Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week  in the morning  One cycle is 28 days  Treatment is given continuously until disease progression  Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression  ",
        "premise_nums": [
            "1 hour after",
            "75mg/m2 body",
            "6-Mercaptopurine: 6MP",
            "2 will be",
            "2012 due to",
            "2 body surface",
            "6-Mercaptopurine and",
            "20mg/m2 will"
        ]
    },
    {
        "id": "8e45da73-f016-4ca0-b106-a3fabc960b36",
        "primaryId": "NCT01432145",
        "statement_text": "the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate ",
        "statement_nums": [
            "6-Mercaptopurine more"
        ],
        "label": "Entailment",
        "premise_text": "The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week ",
        "premise_nums": [
            "2 of 6MP",
            "2 of Methotrexate",
            "15mg/m2 of",
            "55mg/m2 of"
        ]
    },
    {
        "id": "65e370b7-7726-477e-8730-8cea734d1609",
        "primaryId": "NCT02115607",
        "secondaryId": "NCT01823107",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix ",
        "statement_nums": [
            "3 ml Perflutren",
            "3ml/min,"
        ],
        "premise_text": "INTERVENTION 1: Definity Infusion Infusion of Definity (Perflutren Lipid Microspheres) Definity infusion: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min INTERVENTION 1: Meso BioMatrix Acellular Peritoneum Matrix ",
        "premise_nums": [
            "3 ml of",
            "50 ml of",
            "4ml/min INTERVENTION"
        ]
    },
    {
        "id": "a7903e59-9620-457a-8d83-eb6eb5dd8a2b",
        "primaryId": "NCT01300351",
        "statement_text": "At least 1 participant in each cohort of the primary trial showed signs of poor liver function ",
        "statement_nums": [
            "1 participant in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Hepatic function abnormal * 1/109 (0.92%) ",
        "premise_nums": [
            "1/109 (0.92%)"
        ]
    },
    {
        "id": "da00532d-57a8-4fe2-a2de-acc525161fd9",
        "primaryId": "NCT01120184",
        "statement_text": "At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder ",
        "statement_nums": [
            "1 patient in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Hypercoagulation * 21/353 (0.28%) ",
        "premise_nums": [
            "21/353 (0.28%)"
        ]
    },
    {
        "id": "a06d1ca5-c890-4157-b1d2-0b70fd0092bd",
        "primaryId": "NCT00591851",
        "statement_text": "There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial ",
        "statement_nums": [
            "4 different cardiac",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 19/70 (27.14%) Febrile Neutropenia 24/70 (5.71%) Pericarditis 21/70 (1.43%) Sinus bradycardia 21/70 (1.43%) Abdominal Pain 2/70 (2.86%) Diarrhea 21/70 (1.43%) Lower gastrointestinal hemorrhage 21/70 (1.43%) Nausea 21/70 (1.43%) Non Cardiac-Chest pain 22/70 (2.86%) Fever 24/70 (5.71%) Skin infection 41/70 (1.43%) Neutrophil count decreased 31/70 (1.43%) ",
        "premise_nums": [
            "41/70 (1.43%)",
            "24/70 (5.71%)",
            "19/70 (27.14%)",
            "22/70 (2.86%)",
            "31/70 (1.43%)",
            "21/70 (1.43%)"
        ]
    },
    {
        "id": "9bcbadcc-ae56-4254-ac8b-ab5d35e80eba",
        "primaryId": "NCT00952731",
        "secondaryId": "NCT00956813",
        "label": "Entailment",
        "statement_text": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses ",
        "statement_nums": [
            "2 in the"
        ],
        "premise_text": "INTERVENTION 2: Placebo Gel + Oral Treatment Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  ",
        "premise_nums": [
            "4-10 weeks"
        ]
    },
    {
        "id": "73d323e7-1a38-49d4-97f4-a15f1664fb3e",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months  almost 1cm3 less than average ",
        "statement_nums": [
            "3 less than",
            "3 increase in"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI  the sum over all measureable lesions on the MRI was calculated at each time point  V3 was calculated by subtracting the total MRI FTV measured (i.e  the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline  For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests  ",
        "premise_nums": [
            "3 months from",
            "(V3) Mean",
            "3 was calculated",
            "95% confidence",
            "3 the raw"
        ]
    },
    {
        "id": "73d323e7-1a38-49d4-97f4-a15f1664fb3e",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months  almost 1cm3 less than average ",
        "statement_nums": [
            "3 less than",
            "3 increase in"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: up to 3 months from start of treatmentResults 1: Arm/Group Title: Letrozole + MRI Arm/Group Description: Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. Overall Number of Participants Analyzed: 68 Mean (95% Confidence Interval) Unit of Measure: cubic centimeters -1.93 (-2.87 to -0.98) ",
        "premise_nums": [
            "3 months from",
            "of 2.5 mg/day",
            "6 months of",
            "95% Confidence",
            "3 and 6."
        ]
    },
    {
        "id": "4c8a124b-f015-42e2-8ad3-6168f21fe705",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  before T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: Cycle 1 Day 1, pre-dose (Baseline); Cycle 1 Day 1, 15 and 60 minutes post-dose; Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60 minutes post-dose Results 1: Arm/Group Title: T-DM1 Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg  Overall Number of Participants Analyzed: 51 Mean (Standard Deviation) ",
        "premise_nums": [
            "1 Day 8;",
            "3 Day 1,",
            "51 Mean (Standard",
            "3 week cycle",
            "1 of every",
            "of 3.6 mg/kg",
            "15 and 60",
            "15 minutes pre",
            "1 Day 1,"
        ]
    },
    {
        "id": "4c8a124b-f015-42e2-8ad3-6168f21fe705",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  before T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3)Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 1, Day 8 [N=43]: -4.0 (13.4) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 3, Day 1, 15 minutes post-dose [N=37]: 4.7 (9.6) ",
        "premise_nums": [
            "15 minutes post",
            "60 minutes post",
            "15 minutes pre"
        ]
    },
    {
        "id": "4c8a124b-f015-42e2-8ad3-6168f21fe705",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  before T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Contradiction",
        "premise_text": "Cycle 3, Day 1, 60 minutes post-dose [N=37]: 4.7 (10.9)",
        "premise_nums": [
            "60 minutes post"
        ]
    },
    {
        "id": "fb43432d-6c1b-4ff7-aea8-72bc2519a12d",
        "primaryId": "NCT00130533",
        "statement_text": "Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Hyperbilirrubinemia [1]1/436 (0.23%) ",
        "premise_nums": [
            "1/436 (0.23%)"
        ]
    },
    {
        "id": "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Contradiction",
        "premise_text": "DISEASE CHARACTERISTICS: Confirmed diagnosis of prior operable  noninflammatory breast cancer meeting the following criteria: Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor)  determined by immunohistochemistry  after primary surgery and before commencement of prior endocrine therapy Prior local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease Following primary surgery  eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes  but not supraclavicular nodes Clinically disease-free Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs)  aromatase inhibitors (AIs)  or a sequential combination of both ",
        "premise_nums": [
            "4-6 years",
            "6 years of"
        ]
    },
    {
        "id": "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Contradiction",
        "premise_text": "When calculating 4-6 years  neoadjuvant endocrine therapy should not be includedNo evidence of recurrent disease or distant metastatic disease No prior bilateral breast cancer PATIENT CHARACTERISTICS: Female Must be postmenopausal by any of the following criteria: Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for greater than 3 months) Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol  luteinizing hormone [LH]  and follicle-stimulating hormone [FSH] in the postmenopausal range) ",
        "premise_nums": [
            "4-6 years",
            "56 years old"
        ]
    },
    {
        "id": "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Contradiction",
        "premise_text": "Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol  LH  and FSH in the postmenopausal range)Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above Clinically adequate hepatic function No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy No prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin  in situ carcinoma of the cervix or bladder  or contra- or ipsilateral in situ breast carcinoma ",
        "premise_nums": [
            "4-6 years",
            "55 years old",
            "6 years of"
        ]
    },
    {
        "id": "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Contradiction",
        "premise_text": "No other nonmalignant systemic diseases (cardiovascular  renal  lung  etc.) that would prevent prolonged follow-upNo psychiatric  addictive  or any other disorder that compromises compliance with protocol requirements PRIOR CONCURRENT THERAPY: See Disease Characteristics More than 12 months since prior and no other concurrent endocrine SERM/AI therapy Any type of prior adjuvant therapy allowed including  but not limited to  any of the following: Neoadjuvant chemotherapy Neoadjuvant endocrine therapy Adjuvant chemotherapy Trastuzumab (Herceptin®) Ovarian ablation Gonadotropin releasing hormone analogues Lapatinib ditosylate No concurrent hormone-replacement therapy  bisphosphonates (except for treatment of bone loss)  or any other investigational agent ",
        "premise_nums": [
            "12 months since"
        ]
    },
    {
        "id": "f7410166-82a7-4d15-8a04-47287ef6884c",
        "primaryId": "NCT00448591",
        "statement_text": "Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial ",
        "statement_nums": [
            "1% of",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 672/2264 (29.68%) Febrile neutropenia * 117/2264 (5.17%) Neutropenia * 98/2264 (4.33%) Febrile bone marrow aplasia * 14/2264 (0.62%) Anaemia * 8/2264 (0.35%) Leukopenia * 8/2264 (0.35%) Thrombocytopenia * 6/2264 (0.27%) Disseminated intravascular coagulation * 3/2264 (0.13%) Agranulocytosis * 1/2264 (0.04%) Bone marrow failure * 1/2264 (0.04%) ",
        "premise_nums": [
            "14/2264 (0.62%)",
            "6/2264 (0.27%)",
            "117/2264 (5.17%)",
            "1/2264 (0.04%)",
            "8/2264 (0.35%)",
            "98/2264 (4.33%)",
            "3/2264 (0.13%)",
            "672/2264 (29.68%)"
        ]
    },
    {
        "id": "d42054cd-deb6-4436-941c-9e3a06c713cc",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years Number of events (disease relapse or death) to time of observation for DFS  DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal  receptor positive  node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years  Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC)  Intercurrent death: death without disease relapse  Time frame: Baseline (Month 0) up to 2.75 years Results 1: ",
        "premise_nums": [
            "to 2.75 years Results",
            "to 2.75 Years Number"
        ]
    },
    {
        "id": "d42054cd-deb6-4436-941c-9e3a06c713cc",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "10% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: ExemestaneArm/Group Description: Exemestane (Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4898 Measure Type: Number Unit of Measure: Events (disease relapse or death) 352 Results 2: Arm/Group Title: Tamoxifen Followed by Exemestane Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen  participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy  Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events (disease relapse or death) 388 ",
        "premise_nums": [
            "4868 Measure Type:",
            "completing 2.5 years to",
            "5 years endocrine",
            "20 mg QD;",
            "25 mg QD",
            "352 Results 2:",
            "4898 Measure Type:",
            "3 years of"
        ]
    },
    {
        "id": "49ecc5a6-89be-48b6-85c5-c809c83f5baf",
        "primaryId": "NCT00825734",
        "statement_text": "Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection  unstable angina or a grade 4 hemorrhage within the last month ",
        "statement_nums": [
            "4 hemorrhage within"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection greater than grade 2. Unstable angina (anginal symptoms at rest) or new onset angina Pulmonary hemorrhage or bleeding event grade 2 within 4 weeks of the first dose of study treatment  or any other hemorrhage or bleeding event grade 3 within 4 weeks of the first dose of study treatment  ",
        "premise_nums": [
            "2 within 4",
            "3 within 4"
        ]
    },
    {
        "id": "68792f63-d7b5-4570-bf8e-95e4cb8094e9",
        "primaryId": "NCT00343382",
        "secondaryId": "NCT00798135",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial recieves a lower dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  INTERVENTION 1: Itraconazole oral itraconazole 200mg a day until disease progression or unacceptable toxicities  ",
        "premise_nums": [
            "2 Times Per",
            "2 times per"
        ]
    },
    {
        "id": "b7f3e657-638b-4463-9639-4fb0da2be042",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "label": "Contradiction",
        "statement_text": "In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients ",
        "statement_nums": [
            "2 neu positive"
        ],
        "premise_text": "INTERVENTION 1: Vorinostat Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid)  with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or biopsy)  INTERVENTION 1: Treatment (Chemotherapy With or Without Maintenance Therapy) SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "3 hours on",
            "2 hours before",
            "6 courses in",
            "1 hour and",
            "14 days for",
            "6 doses of",
            "300 mg twice"
        ]
    },
    {
        "id": "b7f3e657-638b-4463-9639-4fb0da2be042",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "label": "Contradiction",
        "statement_text": "In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients ",
        "statement_nums": [
            "2 neu positive"
        ],
        "premise_text": "MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity cyclophosphamide  paclitaxel  trastuzumab: Given IV ",
        "premise_nums": [
            "21 days for",
            "14 days for",
            "30 minutes on",
            "5 courses and",
            "2 neu positive",
            "14 courses in"
        ]
    },
    {
        "id": "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd",
        "primaryId": "NCT00418457",
        "statement_text": "antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "10 days prior"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Primary breast cancer without known extension beyond the breast and axillary nodes (i.e  believed to be Tumor Stage 1-3, Nodes 0-2) Scheduled for unilateral or bilateral mastectomy with or without implant (isolated \"lumpectomy\" will not qualify) Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes) Written informed consent  including willingness to be randomized to morphine or regional analgesia Exclusion Criteria: Previous surgery for breast cancer (except diagnostic biopsies) Inflammatory breast cancer Age smaller than 18 or greater than 85 years old Scheduled free flap reconstruction ASA Physical Status 4 Any contraindication to epidural or paravertebral anesthesia and analgesia (including coagulopathy  abnormal anatomy) ",
        "premise_nums": [
            "18 or greater",
            "85 years old",
            "0-2) Scheduled",
            "1-3, Nodes",
            "4 Any contraindication"
        ]
    },
    {
        "id": "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd",
        "primaryId": "NCT00418457",
        "statement_text": "antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "10 days prior"
        ],
        "label": "Entailment",
        "premise_text": "Any contraindication to midazolam  propofol  sevoflurane  fentanyl  or morphineOther cancer not believed by the attending surgeon to be in long-term remission Systemic disease believed by the attending surgeon to present 25% two-year mortality ",
        "premise_nums": [
            "25% two-year"
        ]
    },
    {
        "id": "a12a46de-9d3e-4c6a-becb-d43653040bf0",
        "primaryId": "NCT00089973",
        "statement_text": "the primary trial uses a 3 week cycle for SB-715992 administration  and the study lasts for 21 cycles ",
        "statement_nums": [
            "3 week cycle"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: SB-715992 The eligible participants were administered Ispinesib  intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle  at a dose of 18 mg/m^2. The dosing was repeated for up to multiple cycles  until disease progression or removal from treatment due to an unacceptable toxicity or withdrawal of consent  ",
        "premise_nums": [
            "21-day treatment",
            "715992 The eligible",
            "1 of every",
            "18 mg/m^2."
        ]
    },
    {
        "id": "66ee10ac-1bfe-44d6-9b91-8a2bb1983606",
        "primaryId": "NCT01017549",
        "secondaryId": "NCT01390064",
        "label": "Contradiction",
        "statement_text": "the secondary trial has 5 more patients cohorts than the primary trial ",
        "statement_nums": [
            "5 more patients"
        ],
        "premise_text": "INTERVENTION 1: Electronic Brachytherapy Radiation therapy was delivered using the 510(k) cleared Xoft Axxent System  Accelerated partial breast irradiation is the method of radiation therapy administration that has been commonly used by physicians using Iridium-192, but was FDA cleared for use prior to commencing study enrollment using an electronic source  INTERVENTION 1: Initial Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: ",
        "premise_nums": [
            "300 micrograms Vaccination",
            "5 doses of",
            "51 VG vaccine",
            "51 VG Subcutaneous"
        ]
    },
    {
        "id": "66ee10ac-1bfe-44d6-9b91-8a2bb1983606",
        "primaryId": "NCT01017549",
        "secondaryId": "NCT01390064",
        "label": "Contradiction",
        "statement_text": "the secondary trial has 5 more patients cohorts than the primary trial ",
        "statement_nums": [
            "5 more patients"
        ],
        "premise_text": "Escalation CohortVaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule ",
        "premise_nums": [
            "5 doses of",
            "51 VG vaccine",
            "500 micrograms Vaccination",
            "51 VG Subcutaneous"
        ]
    },
    {
        "id": "714c540c-1fa1-47c7-ac13-1e8f056d1e31",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "3 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) ",
        "premise_nums": [
            "9/33 (27.27%)",
            "23/23 (100.00%)",
            "0/33 (0.00%)",
            "57/57 (100.00%)",
            "15/33 (45.45%)",
            "3/11 (27.27%)",
            "9/11 (81.82%)",
            "2/11 (18.18%)",
            "13/33 (39.39%)"
        ]
    },
    {
        "id": "714c540c-1fa1-47c7-ac13-1e8f056d1e31",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "3 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Alopecia 23/23 (100.00%)",
        "premise_nums": [
            "23/23 (100.00%)"
        ]
    },
    {
        "id": "3948b30d-934d-485c-b324-b3571e2957a3",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Entailment",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Adverse Events 1: Total: 267/744 (35.89%) Neutropenia *2/744 (0.27%) Anaemia *1/744 (0.13%) Leukopenia *1/744 (0.13%) Thrombocytopenia *1/744 (0.13%) Thrombotic thrombocytopenic purpura *1/744 (0.13%) Atrial flutter *1/744 (0.13%) Cardiac arrest *1/744 (0.13%) Myocardial ischaemia *1/744 (0.13%) Arrhythmia *0/744 (0.00%) ",
        "premise_nums": [
            "0/744 (0.00%)",
            "2/744 (0.27%)",
            "1/744 (0.13%)",
            "267/744 (35.89%)"
        ]
    },
    {
        "id": "3948b30d-934d-485c-b324-b3571e2957a3",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Entailment",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Cardiac failure congestive *0/744 (0.00%)Adverse Events 2: Total: 67/736 (9.10%) Neutropenia *1/736 (0.14%) Anaemia *0/736 (0.00%) Leukopenia *0/736 (0.00%) Thrombocytopenia *0/736 (0.00%) Thrombotic thrombocytopenic purpura *0/736 (0.00%) Atrial flutter *0/736 (0.00%) Cardiac arrest *0/736 (0.00%) Myocardial ischaemia *0/736 (0.00%) ",
        "premise_nums": [
            "0/744 (0.00%)Adverse",
            "0/736 (0.00%)",
            "1/736 (0.14%)",
            "67/736 (9.10%)"
        ]
    },
    {
        "id": "3948b30d-934d-485c-b324-b3571e2957a3",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Entailment",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Arrhythmia *2/736 (0.27%)Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) ",
        "premise_nums": [
            "6 Atrial fibrillation",
            "1/67 (1.49%)",
            "1/736 (0.14%)",
            "2/736 (0.27%)Cardiac"
        ]
    },
    {
        "id": "3948b30d-934d-485c-b324-b3571e2957a3",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Entailment",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Pleurisy 1/67 (1.49%)",
        "premise_nums": [
            "1/67 (1.49%)"
        ]
    },
    {
        "id": "45cf29ce-25f5-4719-8468-69d94893c9e7",
        "primaryId": "NCT01166763",
        "statement_text": "the primary trial recorded 4 life-threatening adverse events ",
        "statement_nums": [
            "4 life-threatening adverse"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/30 (10.00%) Cholecystitis * [1]1/30 (3.33%) Increase in diarrhea * [2]1/30 (3.33%) Flank pain * [3]1/30 (3.33%) ",
        "premise_nums": [
            "1/30 (3.33%)",
            "3/30 (10.00%)"
        ]
    },
    {
        "id": "79dbf7bf-e08d-4eae-a804-0daeb83d6f01",
        "primaryId": "NCT00930930",
        "statement_text": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) lymphopenia 1/96 (1.04%) cardiac ischemia/infarction 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96 (1.04%) diarrhea 5/96 (5.21%) ileus 1/96 (1.04%) nausea 2/96 (2.08%) vomiting 1/96 (1.04%) distal small bowel obstruction 1/96 (1.04%) edema 1/96 (1.04%) ",
        "premise_nums": [
            "5/96 (5.21%)",
            "1/96 (1.04%)",
            "2/96 (2.08%)",
            "22/96 (22.92%)"
        ]
    },
    {
        "id": "79dbf7bf-e08d-4eae-a804-0daeb83d6f01",
        "primaryId": "NCT00930930",
        "statement_text": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "fatigue 2/96 (2.08%)Adverse Events 2: Total: 6/49 (12.24%) Anemia 0/49 (0.00%) lymphopenia 0/49 (0.00%) cardiac ischemia/infarction 0/49 (0.00%) sinus tachycardia 0/49 (0.00%) Dehydration 1/49 (2.04%) colitis 0/49 (0.00%) diarrhea 0/49 (0.00%) ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "0/49 (0.00%)",
            "2/96 (2.08%)Adverse",
            "6/49 (12.24%)"
        ]
    },
    {
        "id": "79dbf7bf-e08d-4eae-a804-0daeb83d6f01",
        "primaryId": "NCT00930930",
        "statement_text": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "edema 0/49 (0.00%)fatigue 0/49 (0.00%) ",
        "premise_nums": [
            "0/49 (0.00%)fatigue"
        ]
    },
    {
        "id": "23040754-d1ad-4660-aacf-3298aefa5dae",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Contradiction",
        "statement_text": "There were no depressed patients in either the primary trial or the secondary trial  however there was one suicide attempt in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) ",
        "premise_nums": [
            "1/116 (0.86%)",
            "31/116 (26.72%)",
            "3/116 (2.59%)",
            "0/116 (0.00%)"
        ]
    },
    {
        "id": "23040754-d1ad-4660-aacf-3298aefa5dae",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Contradiction",
        "statement_text": "There were no depressed patients in either the primary trial or the secondary trial  however there was one suicide attempt in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Nausea 2/116 (1.72%)Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115 (0.87%) Abdominal pain 0/115 (0.00%) Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) ",
        "premise_nums": [
            "24/115 (20.87%)",
            "1/115 (0.87%)",
            "2/116 (1.72%)Adverse",
            "4/115 (3.48%)",
            "0/115 (0.00%)"
        ]
    },
    {
        "id": "23040754-d1ad-4660-aacf-3298aefa5dae",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Contradiction",
        "statement_text": "There were no depressed patients in either the primary trial or the secondary trial  however there was one suicide attempt in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Intestinal haemorrhage 0/115 (0.00%)Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) ",
        "premise_nums": [
            "3/115 (2.61%)",
            "8/54 (14.81%)",
            "1/54 (1.85%)",
            "0/115 (0.00%)Nausea"
        ]
    },
    {
        "id": "23040754-d1ad-4660-aacf-3298aefa5dae",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "label": "Contradiction",
        "statement_text": "There were no depressed patients in either the primary trial or the secondary trial  however there was one suicide attempt in cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Dyspnoea 1/54 (1.85%)",
        "premise_nums": [
            "1/54 (1.85%)"
        ]
    },
    {
        "id": "e7899445-9b80-4429-b4c3-d47bd36a2347",
        "primaryId": "NCT00232479",
        "statement_text": "Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: HER-2 overexpressing breast cancer ",
        "premise_nums": [
            "2 overexpressing breast"
        ]
    },
    {
        "id": "2a50cc2a-281b-4bc6-9f18-6bd9686c682d",
        "primaryId": "NCT00754845",
        "statement_text": "Patients who received over 5 years of anastrozole therapy  completed 2 years prior  are eligible for the primary trial ",
        "statement_nums": [
            "5 years of",
            "2 years prior"
        ],
        "label": "Entailment",
        "premise_text": "Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g.  letrozole  anastrozole  or exemestane)  either as initial therapy or after prior tamoxifen citrate  including treatment received as part of clinical trial CAN-NCIC-MA17 Completed aromatase inhibitor therapy 2 years ago ",
        "premise_nums": [
            "6 years of",
            "17 Completed aromatase",
            "MA17 Completed",
            "2 years ago"
        ]
    },
    {
        "id": "f5d50d87-b419-4537-87ec-7c9d23b765db",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a smaller  but still positive change in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy  Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA)  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid 4 mg Upfront ",
        "premise_nums": [
            "2-L4) at",
            "12 months Results",
            "2-L4) as",
            "12 Months of",
            "4 mg Upfront"
        ]
    },
    {
        "id": "f5d50d87-b419-4537-87ec-7c9d23b765db",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a smaller  but still positive change in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 423 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Delayed ",
        "premise_nums": [
            "tablets 2.5 mg/day",
            "15 minute infusion",
            "423 Mean (Standard",
            "6 months for",
            "5 years beginning",
            "4 mg Delayed",
            "4 mg Intravenous"
        ]
    },
    {
        "id": "f5d50d87-b419-4537-87ec-7c9d23b765db",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a smaller  but still positive change in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "4 mg Delayed",
            "4 mg Upfront"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score smaller than = -2.0 SD at either the lumbar spine or total hip  any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit  All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 418 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD -3.617 (4.2151) ",
        "premise_nums": [
            "tablets 2.5 mg/day",
            "15 minute infusion",
            "5 years beginning",
            "6 months beginning",
            "418 Mean (Standard",
            "0 SD at",
            "4 mg Intravenous"
        ]
    },
    {
        "id": "f52ab54b-7a78-4449-9dfe-5fc67323e5c2",
        "primaryId": "NCT01797120",
        "statement_text": "Cohort 2 of the primary trial is only receiving placebo tablets  and no other medications ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 2: Fulvestrant & Placebo Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles  Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles)  If no evidence of disease progression after 12 cycles  unblind and continue same dose and schedule until progression or unacceptable toxicity  Placebo: Placebo for Everolimus (2 tablets) daily x 12 cycles  Placebo manufactured to mimic everolimus tablet  ",
        "premise_nums": [
            "15 of Cycle",
            "500 mg Day",
            "28 days for",
            "1 of all"
        ]
    },
    {
        "id": "c0277198-6eef-4cf3-9527-dea5d01a4000",
        "primaryId": "NCT00426556",
        "statement_text": "There were more than 3 cases of Febrile neutropenia  Leukopenia and Neutropenia across all cohorts in the primary trial ",
        "statement_nums": [
            "3 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/6 (50.00%) Febrile neutropenia 0/6 (0.00%) Leukopenia 0/6 (0.00%) Neutropenia 0/6 (0.00%) Adverse Events 2: Total: 6/17 (35.29%) Febrile neutropenia 0/17 (0.00%) Leukopenia 0/17 (0.00%) Neutropenia 0/17 (0.00%) ",
        "premise_nums": [
            "6/17 (35.29%)",
            "3/6 (50.00%)",
            "0/6 (0.00%)",
            "0/17 (0.00%)"
        ]
    },
    {
        "id": "fea87f74-c8ef-4efd-944a-053f5e5a752f",
        "primaryId": "NCT01582971",
        "statement_text": "In order to participate in the primary trial  participants must have 20/20 vision and a hiistologically confirmed  measurable  invasive breast carcinoma ",
        "statement_nums": [
            "20/20 vision",
            "20 vision and"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Age 21 Diagnosis of breast cancer  Stage III  IV  or Stage I or II with metastasis or recurrence Able to perform basic ADLs Undergoing chemotherapy and/or hormonal therapy for breast cancer Able to speak and understand English Have access to a telephone Able to hear normal conversation Cognitively oriented to time  place  and person (determined via nurse recruiter) Exclusion Criteria: Diagnosis of major mental illness on the medical record and verified by the recruiter Residing in a nursing home Bedridden Currently receiving regular reflexology Diagnosis of symptoms of deep vein thrombosis or painful foot neuropathy  which will require medical approval ",
        "premise_nums": [
            "21 Diagnosis of"
        ]
    },
    {
        "id": "2417fea2-7c8e-4f03-a918-c3cfcbe97425",
        "primaryId": "NCT01998906",
        "statement_text": "The same number of cases of Neutropenia  Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile neutropenia * 7/115 (6.09%) Neutropenia * 1/115 (0.87%) Pancytopenia * 1/115 (0.87%) ",
        "premise_nums": [
            "1/115 (0.87%)",
            "7/115 (6.09%)"
        ]
    },
    {
        "id": "55391bc6-41a8-4686-82d6-6814166d32b8",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "label": "Entailment",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial ",
        "statement_nums": [
            "50% to"
        ],
        "premise_text": "LVEF smaller than 50% and 40% documented in echocardiogram done within the last 30 days Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease ",
        "premise_nums": [
            "40% documented",
            "2-negative adenocarcinoma",
            "0 or 1",
            "3 weeks from",
            "50% and",
            "2-positive status",
            "30 days Inclusion"
        ]
    },
    {
        "id": "55391bc6-41a8-4686-82d6-6814166d32b8",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "label": "Entailment",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial ",
        "statement_nums": [
            "50% to"
        ],
        "premise_text": "Prior hormonal therapy smaller than 2 weeks prior to randomizationPrior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death ",
        "premise_nums": [
            "12 weeks Inadequate",
            "5 years prior",
            "28 days of",
            "12 months prior",
            "2 weeks prior"
        ]
    },
    {
        "id": "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b",
        "primaryId": "NCT00091832",
        "statement_text": "cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur) ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100. Time frame: Baseline and Week 13 Results 1: Arm/Group Title: Bisphosphonate IV Q4W Arm/Group Description: Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion Overall Number of Participants Analyzed: 38 Mean (Standard Deviation) ",
        "premise_nums": [
            "38 Mean (Standard",
            "4 weeks (Q4W)",
            "13 Results 1:",
            "13 in Creatinine",
            "13 in Urinary",
            "(Q4W) by"
        ]
    },
    {
        "id": "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b",
        "primaryId": "NCT00091832",
        "statement_text": "cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur) ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percent change -10.19 (208.84)Results 2: Arm/Group Title: Denosumab 30 mg Q4W Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: Percent change -52.87 (95.14) ",
        "premise_nums": [
            "(Q4W) Overall",
            "30 mg by",
            "4 weeks (Q4W)",
            "40 Mean (Standard",
            "30 mg Q4W"
        ]
    },
    {
        "id": "58838d25-bf87-44e7-a604-23468d67a1e3",
        "primaryId": "NCT02606708",
        "secondaryId": "NCT02504424",
        "label": "Entailment",
        "statement_text": "Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy  patients in the secondary trial receive no radiotherapy whatsoever ",
        "statement_nums": [
            "receive 40.5 Gy of"
        ],
        "premise_text": "INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  ",
        "premise_nums": [
            "of 40.5 Gy to",
            "3 weeks delivered",
            "in 2.7 Gy/fraction",
            "of 0.50 Gy will"
        ]
    },
    {
        "id": "02426c34-ebf9-4bd4-9d55-86fad89baf20",
        "primaryId": "NCT01959490",
        "statement_text": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [
            "20% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) ",
        "premise_nums": [
            "30 days after",
            "2 positive or"
        ]
    },
    {
        "id": "02426c34-ebf9-4bd4-9d55-86fad89baf20",
        "primaryId": "NCT01959490",
        "statement_text": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [
            "20% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) ",
        "premise_nums": [
            "840 mg IV",
            "4 80.0% Results 2",
            "60 minutes on",
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "5 Measure Type:",
            "14 followed by",
            "30-60 minutes"
        ]
    },
    {
        "id": "02426c34-ebf9-4bd4-9d55-86fad89baf20",
        "primaryId": "NCT01959490",
        "statement_text": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [
            "20% of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% ",
        "premise_nums": [
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "8 mg/kg IV",
            "14 followed by",
            "6 Measure Type:",
            "30-60 minutes",
            "90 minutes on"
        ]
    },
    {
        "id": "9e28c807-8d88-4eea-87ee-48a42bd002ab",
        "primaryId": "NCT00618826",
        "secondaryId": "NCT02040857",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial only record 4 of the same adverse events ",
        "statement_nums": [
            "4 of the"
        ],
        "premise_text": "Adverse Events 1: Lymphopenia 1/14 (7.14%) Diarrhea 1/14 (7.14%) Fatigue (asthenia  lethargy  malaise) 2/14 (14.29%) Hypertension 2/14 (14.29%) Adverse Events 1: Lymphocyte count decreased 2/162 (1.23%) Diarrhea 1/162 (0.62%) Fatigue 6/162 (3.70%) Hypertension 1/162 (0.62%) ",
        "premise_nums": [
            "2/14 (14.29%)",
            "6/162 (3.70%)",
            "2/162 (1.23%)",
            "1/162 (0.62%)",
            "1/14 (7.14%)"
        ]
    },
    {
        "id": "341156fc-9cbd-492f-8e9e-8fbf98191625",
        "primaryId": "NCT00291577",
        "statement_text": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours ",
        "statement_nums": [
            "24 or 12"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation  Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose ",
        "premise_nums": [
            "011248 and SU012662",
            "SU011248 and",
            "24 hours postdose"
        ]
    },
    {
        "id": "523a44a3-6b90-4be7-ab46-6b6addd7b5b9",
        "primaryId": "NCT00080301",
        "statement_text": "There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "5 more cases",
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: THROMBOCYTOPENIA 2/368 (0.54%) Adverse Events 2: THROMBOCYTOPENIA 7/369 (1.90%) ",
        "premise_nums": [
            "7/369 (1.90%)",
            "2/368 (0.54%)"
        ]
    },
    {
        "id": "1a451f2e-0818-4a86-8808-0e4cce700aef",
        "primaryId": "NCT00391092",
        "statement_text": "In total there were 32 cases of Febrile neutropenia in the primary trial  and only one case of anemia ",
        "statement_nums": [
            "32 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile neutropenia * 14/206 (6.80%) Anaemia * 1/206 (0.49%) Adverse Events 2: Febrile neutropenia * 18/215 (8.37%) Anaemia * 1/215 (0.47%) ",
        "premise_nums": [
            "1/206 (0.49%)",
            "14/206 (6.80%)",
            "18/215 (8.37%)",
            "1/215 (0.47%)"
        ]
    },
    {
        "id": "14a32a42-424b-4b97-bae9-05f4bb2b415b",
        "primaryId": "NCT00246090",
        "secondaryId": "NCT00266799",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the",
            "trial 0.0015% less total",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 88/291 (30.24%) Adverse Events 2: Total: 46/102 (45.10%) ",
        "premise_nums": [
            "88/291 (30.24%)",
            "46/102 (45.10%)"
        ]
    },
    {
        "id": "4fd230f2-caf1-44d6-81f2-4f51dda6da3a",
        "primaryId": "NCT03371732",
        "statement_text": "Any patients with Karnofsky Index smaller than 80 are eligible for the primary trial ",
        "statement_nums": [
            "80 are eligible"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  Individuals able to consent to benefit of intervention focused on substance use  (Karnofsky Index greater than 70). ",
        "premise_nums": [
            "1 or more"
        ]
    },
    {
        "id": "7a3d1ca7-8776-4ace-bbc0-107635b93583",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months ",
        "statement_nums": [
            "6 ng/mL over"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes ",
        "premise_nums": [
            "40 mg Stratified",
            "20 mg or"
        ]
    },
    {
        "id": "7a3d1ca7-8776-4ace-bbc0-107635b93583",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months ",
        "statement_nums": [
            "6 ng/mL over"
        ],
        "label": "Entailment",
        "premise_text": "Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM Time frame: 4 months Results 1: Arm/Group Title: Ultra-rapid Metabolizers ",
        "premise_nums": [
            "6 alleles have",
            "4 months of",
            "10 possible allelic",
            "4 months Results"
        ]
    },
    {
        "id": "7a3d1ca7-8776-4ace-bbc0-107635b93583",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months ",
        "statement_nums": [
            "6 ng/mL over"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Those with the highest transformation of the CYP2D6 genotype to allelic activityOverall Number of Participants Analyzed: 5 Mean (Standard Deviation) Unit of Measure: ng/mL Baseline endoxifen concentration: 5 participants 8.4 (4.59) 4-Month endoxifen concentration: 4 participants 15.35 (5.48) ",
        "premise_nums": [
            "5 Mean (Standard",
            "6 genotype to",
            "4 participants 15.35",
            "5 participants 8.4",
            "4-Month endoxifen"
        ]
    },
    {
        "id": "7e629f62-2981-4462-a4c1-f0cc9c24777a",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) ",
        "premise_nums": [
            "3/24 (12.50%)",
            "1/24 (4.17%)",
            "13/24 (54.17%)",
            "5/24 (20.83%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "7e629f62-2981-4462-a4c1-f0cc9c24777a",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "PATHOLOGICAL FRACTURE 1/24 (4.17%)Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%) NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) ",
        "premise_nums": [
            "1/24 (4.17%)Adverse",
            "6/24 (25.00%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "7e629f62-2981-4462-a4c1-f0cc9c24777a",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.",
        "statement_nums": [
            "25% more",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "CHOLECYSTITIS 0/24 (0.00%)PATHOLOGICAL FRACTURE 0/24 (0.00%) ",
        "premise_nums": [
            "0/24 (0.00%)PATHOLOGICAL"
        ]
    },
    {
        "id": "c660faec-58d8-4ba9-8e18-1775b1135819",
        "primaryId": "NCT00600340",
        "statement_text": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks ",
        "premise_nums": [
            "4 weeks INTERVENTION",
            "8 and 15,",
            "1000 mg/m²",
            "10 mg/kg intravenous",
            "1-14, every",
            "90 mg/m2,",
            "1 and 15,",
            "15 mg/kg i"
        ]
    },
    {
        "id": "a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2",
        "primaryId": "NCT03078751",
        "statement_text": "Cohort 2 of the primary trial reported one case of AML ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%) Cardiac failure congestive 0/24 (0.00%) Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%) Acute myeloid leukaemia 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%) ",
        "premise_nums": [
            "2/24 (8.33%)",
            "0/24 (0.00%)",
            "1/24 (4.17%)"
        ]
    },
    {
        "id": "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3",
        "primaryId": "NCT00118157",
        "secondaryId": "NCT01401959",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial ",
        "statement_nums": [
            "2 Year Disease"
        ],
        "premise_text": "Outcome Measurement: Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) [Not Specified] Time frame: 4 weeks Results 1: Arm/Group Title: Arm 1 Arm/Group Description: Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28. lapatinib ditosylate: Given orally tamoxifen citrate: Given orally Overall Number of Participants Analyzed: 17 Measure Type: Number Unit of Measure: participants 1 (1 to 27) Outcome Measurement: Percentage of Patients With a 2 Year Disease-Free Survival (DFS) as a Measure of Efficacy ",
        "premise_nums": [
            "1 Arm/Group Description",
            "1-28. lapatinib",
            "2 Year Disease",
            "17 Measure Type:",
            "1 to 27)",
            "4 weeks Results"
        ]
    },
    {
        "id": "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3",
        "primaryId": "NCT00118157",
        "secondaryId": "NCT01401959",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial ",
        "statement_nums": [
            "2 Year Disease"
        ],
        "premise_text": "The percentage of patients that are without evidence of disease recurrence at the 2 year timepoint  as measured from date of first protocol treatment date to first documented disease progression date or date of death from any cause  whichever comes first  Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions Time frame: Up to 2 years Results 1: Arm/Group Title: Cohort A: Triple-negative Breast Cancer Patients ",
        "premise_nums": [
            "2 year timepoint",
            "2 years Results",
            "20% increase"
        ]
    },
    {
        "id": "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3",
        "primaryId": "NCT00118157",
        "secondaryId": "NCT01401959",
        "label": "Contradiction",
        "statement_text": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial ",
        "statement_nums": [
            "2 Year Disease"
        ],
        "premise_text": "Arm/Group Description: Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route Overall Number of Participants Analyzed: 53 Measure Type: Number Unit of Measure: percentage of patients 56 (42 to 69) ",
        "premise_nums": [
            "21 days for",
            "6 cycles via",
            "42 to 69)",
            "eribulin 1.4 mg/m",
            "1 and 8",
            "2 on Days",
            "53 Measure Type:"
        ]
    },
    {
        "id": "e0b7a120-8735-413d-9a47-8508b2feffb3",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 20 the primary trial participants achieved partial response (PR) ",
        "statement_nums": [
            "20 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics  Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole ",
        "premise_nums": [
            "30% decrease",
            "15 months Results",
            "RECIST 1.0 for target"
        ]
    },
    {
        "id": "e0b7a120-8735-413d-9a47-8508b2feffb3",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 20 the primary trial participants achieved partial response (PR) ",
        "statement_nums": [
            "20 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 ",
        "premise_nums": [
            "2 tablets (5",
            "43 Measure Type:",
            "1 tablet of"
        ]
    },
    {
        "id": "abfa5699-2863-4319-9386-4b359f2062f2",
        "primaryId": "NCT00195013",
        "secondaryId": "NCT00620373",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial is a placebo group  the secondary trial does not have a placebo group ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "INTERVENTION 1: Glutamine 10 grams three times a day (orally) for four days and then stop glutamine: 10 grams three times a day (orally) for four days and then stop INTERVENTION 2: Placebo 10 grams three times a day (orally) for four days and then stop Placebo: 10 grams three times a day (orally) for four days and then stop INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 2: Gamma Imaging For this reporting arm  the interpretation and analysis was done with gamma imaging only  ",
        "premise_nums": [
            "10 grams three"
        ]
    },
    {
        "id": "d11dd4ae-28be-4ad2-a452-4374c48f08d1",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  may increase OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Overall Survival (OS) Overall survival was defined as the time in months from randomization until the date of death  For those patients who had not died  survival duration was censored at the last date the patient was known to be alive  Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method  Time frame: from date of randomization until death Results 1: Arm/Group Title: Ixabepilone + Capecitabine ",
        "premise_nums": [
            "95% CI"
        ]
    },
    {
        "id": "d11dd4ae-28be-4ad2-a452-4374c48f08d1",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  may increase OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "95 to 17.91)",
            "1 week of",
            "40 mg/m2 administered",
            "1000 mg/m2 twice",
            "1 of each",
            "2 daily dose)",
            "2 twice a",
            "95% Confidence",
            "2 administered as",
            "3-hour intravenous"
        ]
    },
    {
        "id": "d11dd4ae-28be-4ad2-a452-4374c48f08d1",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  may increase OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02) ",
        "premise_nums": [
            "1 week of",
            "86 to 17.02)",
            "2 daily dose)",
            "95% Confidence",
            "1250 mg/m2 BID",
            "2 BID (2500"
        ]
    },
    {
        "id": "3b6229a9-00a1-4d26-9285-6d9f6a25fd77",
        "primaryId": "NCT02273973",
        "statement_text": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Diarrhoea 5/167 (2.99%) Erysipelas 2/167 (1.20%) ",
        "premise_nums": [
            "2/167 (1.20%)",
            "5/167 (2.99%)"
        ]
    },
    {
        "id": "553d7721-289e-4ab1-a9b9-7b2c939f47c1",
        "primaryId": "NCT01997333",
        "statement_text": "The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year ",
        "statement_nums": [
            "1 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions  or progression in a non-target lesion  or the appearance of new lesions  The primary analysis of PFS was based on PFS events determined retrospectively by the central independent review committee  blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria  Time frame: Evaluated every 6 - 9 weeks following treatment initiation Results 1: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "9 weeks following",
            "20% increase"
        ]
    },
    {
        "id": "553d7721-289e-4ab1-a9b9-7b2c939f47c1",
        "primaryId": "NCT01997333",
        "statement_text": "The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year ",
        "statement_nums": [
            "1 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Capecitabine administered on Days 1 through 14 of each 21 day cycle until disease progression  discontinuation due to toxicity  withdrawal of consent  or end of study Overall Number of Participants Analyzed: 109 Median (95% Confidence Interval) Unit of Measure: months 2.8 (1.6 to 3.2) ",
        "premise_nums": [
            "6 to 3.2)",
            "1 through 14",
            "95% Confidence",
            "21 day cycle"
        ]
    },
    {
        "id": "5501dae3-0d3c-4812-96c2-35ca863e24a5",
        "primaryId": "NCT00343863",
        "statement_text": "On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV  oral cyclophosphamide  dexamethasone IV or orally and ondansetron IV ",
        "statement_nums": [
            "1 Cohort 1"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Dexamethasone + Ondansetron IV All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)  ",
        "premise_nums": [
            "1 and oral",
            "1-7. Patients"
        ]
    },
    {
        "id": "8df8e2c0-a0ca-4ea2-ba83-494f250c4bef",
        "primaryId": "NCT00509769",
        "statement_text": "3/112 patients (2.68%) in the primary trial had Diabetes insipidus",
        "statement_nums": [
            "3/112 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 30/112 (26.79%) Thrombocytopenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112 (0.89%) Upper gastrointestinal haemorrhage 1/112 (0.89%) Asthenia 1/112 (0.89%) Disease progression 1/112 (0.89%) Hepatotoxicity 1/112 (0.89%) Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) Osteomyelitis 1/112 (0.89%) ",
        "premise_nums": [
            "30/112 (26.79%)",
            "2/112 (1.79%)",
            "3/112 (2.68%)",
            "1/112 (0.89%)"
        ]
    },
    {
        "id": "1d4a385f-1c72-4c61-8d49-9ada0e3b716a",
        "primaryId": "NCT02556632",
        "statement_text": "Both cohorts the primary trial apply the same topical intervention for approximately every 4-6 hours every day for a week of the study ",
        "statement_nums": [
            "4-6 hours",
            "6 hours every"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies ",
        "premise_nums": [
            "1 week after",
            "6 hours beginning",
            "4-6 hours"
        ]
    },
    {
        "id": "b15aa13a-fbd9-4b2e-9dd2-b16628084d07",
        "primaryId": "NCT01091428",
        "statement_text": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel  supported by results from cohort 2 of the primary trial  is 40 mg/m^2 orally  twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "statement_nums": [
            "2 of the",
            "2 Dose (RP2D)",
            "40 mg/m^2",
            "1-3, 8-10",
            "(RP2D) for"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel ",
        "premise_nums": [
            "2 Dose (RP2D)",
            "(RP2D) for"
        ]
    },
    {
        "id": "c9214d06-2733-4c78-99e5-a42015908eae",
        "primaryId": "NCT00246571",
        "statement_text": "Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment ",
        "statement_nums": [
            "of 2.5 months by"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause  PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from adverse event (AE) data (where the outcome was \"Death\")  Time frame: Baseline  every 6 weeks until disease progression or death (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib ",
        "premise_nums": [
            "3 years from",
            "6 weeks until"
        ]
    },
    {
        "id": "c9214d06-2733-4c78-99e5-a42015908eae",
        "primaryId": "NCT00246571",
        "statement_text": "Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment ",
        "statement_nums": [
            "of 2.5 months by"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: SU011248 (Sutent [sunitinib malate  hereafter referred to as sunitinib]) oral capsules  37.5 milligrams (mg) once daily (QD) in a continuous regimen  expressed in 3-week cycles  1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities Overall Number of Participants Analyzed: 113 Median (95% Confidence Interval) Unit of Measure: Months Core radiology laboratory assessment: 2.0 (1.5 to 2.8) Investigator's assessment: 1.7 (1.5 to 2.6) Results 2: Arm/Group Title: Standard of Care ",
        "premise_nums": [
            "3-week cycles",
            "5 to 2.6)",
            "5 to 2.8)",
            "50 mg QD",
            "95% Confidence",
            "1-week treatment",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "a318fc31-4f28-4356-b09a-59741bb7c97a",
        "primaryId": "NCT02660788",
        "secondaryId": "NCT01490892",
        "label": "Entailment",
        "statement_text": "the primary trial is investigating different ways to communicate with women aged 51-73 years old   whereas the secondary trial is not ",
        "statement_nums": [
            "73 years old",
            "51-73 years"
        ],
        "premise_text": "INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) ",
        "premise_nums": [
            "25 ml followed",
            "20 micro-l/kg"
        ]
    },
    {
        "id": "a1a421cc-01c9-4afb-8f09-6b10b0ff5094",
        "primaryId": "NCT01663727",
        "secondaryId": "NCT00072293",
        "label": "Contradiction",
        "statement_text": "Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "13 and 76"
        ],
        "premise_text": "Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease Prior hormonal therapy smaller than 2 weeks prior to randomization ",
        "premise_nums": [
            "0 or 1",
            "2-negative adenocarcinoma",
            "3 weeks from",
            "2-positive status",
            "2 weeks prior"
        ]
    },
    {
        "id": "a1a421cc-01c9-4afb-8f09-6b10b0ff5094",
        "primaryId": "NCT01663727",
        "secondaryId": "NCT00072293",
        "label": "Contradiction",
        "statement_text": "Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "13 and 76"
        ],
        "premise_text": "Prior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomizationInvestigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death PATIENT CHARACTERISTICS: Age Any age ",
        "premise_nums": [
            "28 days of",
            "12 months prior",
            "12 weeks Inadequate",
            "5 years prior"
        ]
    },
    {
        "id": "9316ef0d-55b0-4547-88ae-887e0132a263",
        "primaryId": "NCT00246571",
        "statement_text": "Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment ",
        "statement_nums": [
            "of 2.7months by"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression-Free Survival (PFS) Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause  PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from adverse event (AE) data (where the outcome was \"Death\")  Time frame: Baseline  every 6 weeks until disease progression or death (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib ",
        "premise_nums": [
            "3 years from",
            "6 weeks until"
        ]
    },
    {
        "id": "9316ef0d-55b0-4547-88ae-887e0132a263",
        "primaryId": "NCT00246571",
        "statement_text": "Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment ",
        "statement_nums": [
            "of 2.7months by"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: SU011248 (Sutent [sunitinib malate  hereafter referred to as sunitinib]) oral capsules  37.5 milligrams (mg) once daily (QD) in a continuous regimen  expressed in 3-week cycles  1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities Overall Number of Participants Analyzed: 113 Median (95% Confidence Interval) Unit of Measure: Months Core radiology laboratory assessment: 2.0 (1.5 to 2.8) Investigator's assessment: 1.7 (1.5 to 2.6) Results 2: Arm/Group Title: Standard of Care ",
        "premise_nums": [
            "3-week cycles",
            "5 to 2.6)",
            "5 to 2.8)",
            "50 mg QD",
            "95% Confidence",
            "1-week treatment",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "c330f152-c64e-47ab-8568-5129a1a2099e",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events ",
        "statement_nums": [
            "2 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%) Nausea 0/3 (0.00%) Vomiting 0/3 (0.00%) Abdominal pain 0/3 (0.00%) Colitis 0/3 (0.00%) Diarrhoea 0/3 (0.00%) Gastritis 0/3 (0.00%) Ileus 0/3 (0.00%) Fatigue 0/3 (0.00%) Pyrexia 0/3 (0.00%) Pain 0/3 (0.00%) Hepatic cirrhosis 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)"
        ]
    },
    {
        "id": "c330f152-c64e-47ab-8568-5129a1a2099e",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events ",
        "statement_nums": [
            "2 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Cellulitis 0/3 (0.00%)Adverse Events 2: Total: 22/64 (34.38%) Pericardial effusion 1/64 (1.56%) Tachycardia 1/64 (1.56%) Nausea 2/64 (3.13%) Vomiting 2/64 (3.13%) Abdominal pain 2/64 (3.13%) Colitis 1/64 (1.56%) Diarrhoea 1/64 (1.56%) Gastritis 1/64 (1.56%) Ileus 1/64 (1.56%) Fatigue 1/64 (1.56%) Pyrexia 1/64 (1.56%) Pain 1/64 (1.56%) ",
        "premise_nums": [
            "1/64 (1.56%)",
            "22/64 (34.38%)",
            "0/3 (0.00%)Adverse",
            "2/64 (3.13%)"
        ]
    },
    {
        "id": "c330f152-c64e-47ab-8568-5129a1a2099e",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events ",
        "statement_nums": [
            "2 the primary"
        ],
        "label": "Contradiction",
        "premise_text": "Hepatic cirrhosis 1/64 (1.56%)Cellulitis 3/64 (4.69%) ",
        "premise_nums": [
            "3/64 (4.69%)",
            "1/64 (1.56%)Cellulitis"
        ]
    },
    {
        "id": "e621f354-dea0-4d0f-a252-5480028c1712",
        "primaryId": "NCT00022516",
        "statement_text": "At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 1/473 (0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) ",
        "premise_nums": [
            "0/0 Leukopenia",
            "1/473 (0.21%)",
            "0/0 Neurologic-other",
            "0/0 Radiation",
            "2/473 (0.42%)",
            "0 CNS hemorrhage",
            "0/0 Adverse",
            "0/0 Neutropenia",
            "0 Elevated SGPT",
            "0 Adverse Events",
            "11/473 (2.33%)",
            "0/0 Arthralgia",
            "0/0 Ocular-other",
            "0 Radiation dermatitis",
            "0/0 CNS",
            "0/0 Elevated",
            "5/473 (1.06%)"
        ]
    },
    {
        "id": "e621f354-dea0-4d0f-a252-5480028c1712",
        "primaryId": "NCT00022516",
        "statement_text": "At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Neurologic-other 1/473 (0.21%)Radiation dermatitis 1/473 (0.21%) ",
        "premise_nums": [
            "1/473 (0.21%)Radiation"
        ]
    },
    {
        "id": "ee209156-74dc-475e-87af-ae51160982ef",
        "primaryId": "NCT00244881",
        "statement_text": "30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment ",
        "statement_nums": [
            "3 weeks of",
            "30% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Fraction of Patients With Increased Levels of Circulating Endothelial Cells An exact 95% confidence interval (CI) will be calculated for the CEC response rate  With 26 patients  this CI will be no wider than 40% (e.g.  if 13 of 26 patients respond  the CI is 30% to 70%). Time frame: After 3 weeks of treatment Results 1: Arm/Group Title: Treatment (Cediranib Maleate) Arm/Group Description: Patients receive oral AZD2171 once daily for 42 days  Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage of participants 30 ",
        "premise_nums": [
            "3 weeks of",
            "42 days in",
            "26 Measure Type:",
            "AZD2171 once",
            "30% to",
            "2171 once daily",
            "95% confidence",
            "13 of 26"
        ]
    },
    {
        "id": "edf813c0-2271-49ca-a040-a355bf71d8b4",
        "primaryId": "NCT01519700",
        "statement_text": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "36 hours difference",
            "1 of Chemotherapy",
            "4 Neutropenia During"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L) Time frame: 21 days (Cycle 1 of chemotherapy treatment) Results 1: Arm/Group Title: EP2006 + EP2006 & Neupogen Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1 Overall Number of Participants Analyzed: 101 Mean (Standard Deviation) Unit of Measure: Days 1.17 (1.11) Results 2: Arm/Group Title: Neupogen + Neupogen & EP2006 ",
        "premise_nums": [
            "1 of Chemotherapy",
            "21 days (Cycle",
            "1 of chemotherapy",
            "4 Neutropenia During",
            "1 Overall Number",
            "2006 in Cycle",
            "EP2006 in",
            "101 Mean (Standard",
            "4 neutropenia (ANC"
        ]
    },
    {
        "id": "edf813c0-2271-49ca-a040-a355bf71d8b4",
        "primaryId": "NCT01519700",
        "statement_text": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "36 hours difference",
            "1 of Chemotherapy",
            "4 Neutropenia During"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: All subjects randomized to receive Neupogen in Cycle 1Overall Number of Participants Analyzed: 103 Mean (Standard Deviation) Unit of Measure: Days 1.2 (1.02) ",
        "premise_nums": [
            "103 Mean (Standard"
        ]
    },
    {
        "id": "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin ",
        "statement_nums": [
            "receiving 1.4 mg/m2",
            "2 of Eribulin"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Overall Response Rate (ORR) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment  Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  ",
        "premise_nums": [
            "30% decrease",
            "RECIST 1.1 criteria on",
            "RECIST 1.1 for target"
        ]
    },
    {
        "id": "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin ",
        "statement_nums": [
            "receiving 1.4 mg/m2",
            "2 of Eribulin"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: Disease was evaluated radiologically at baseline and every 9 weeks on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months (Cohort 2)Results 1: Arm/Group Title: Cohort 1: HR+/HER2- Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 35.6 (24 to 49) Results 2: ",
        "premise_nums": [
            "2-5 minutes",
            "17 cycles/12 months",
            "12 months (Cohort",
            "26 months (Cohort",
            "45 Measure Type:",
            "2 administered intravenously",
            "21 day cycle",
            "24 to 49)",
            "38 cycles/26 months",
            "1 and 8",
            "5 minutes on",
            "1.4 mg/m",
            "9 weeks on"
        ]
    },
    {
        "id": "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin ",
        "statement_nums": [
            "receiving 1.4 mg/m2",
            "2 of Eribulin"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: Cohort 2: TNBCArm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: percentage of participants 13.2 (5 to 26) ",
        "premise_nums": [
            "2-5 minutes",
            "2 administered intravenously",
            "5 to 26)",
            "1 and 8",
            "5 minutes on",
            "1.4 mg/m",
            "38 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "e1782960-8d44-4acc-aaae-bfa4f8e38de0",
        "primaryId": "NCT00254592",
        "statement_text": "Patients must have an ECOG score below 3 to participate in the primary trial ",
        "statement_nums": [
            "3 to participate"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients must have a performance status of 0-2 by Zubrod criteria ",
        "premise_nums": [
            "0-2 by",
            "2 by Zubrod"
        ]
    },
    {
        "id": "6ce047b6-c18f-4f63-90ec-8643f5145efe",
        "primaryId": "NCT00305448",
        "statement_text": "At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "11 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants 17.6 ",
        "premise_nums": [
            "45 Measure Type:",
            "1 Results 2:",
            "250 mg Overall",
            "participants 11.1 Results 2",
            "51 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "d647aad0-47f7-4b77-a265-e77dcf5e0983",
        "primaryId": "NCT02781051",
        "secondaryId": "NCT01067976",
        "label": "Contradiction",
        "statement_text": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit  in contrast a full year of daily physical exercise is explicitly required for the secondary trial ",
        "statement_nums": [
            "12 weeks while"
        ],
        "premise_text": "INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management  ",
        "premise_nums": [
            "12 weekly group",
            "6 month follow",
            "12 weeks with"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response  According to the Miller&Payne Criteria  pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D. Time frame: Up to 16 weeks Results 1: Arm/Group Title: Arm 1: EC -greater than D + Lapatinib Arm/Group Description: EC -greater than D + Lapatinib Drugs plus Biological ",
        "premise_nums": [
            "5-D). Within",
            "5-A and",
            "5-D. Time",
            "3-4 weeks",
            "4 weeks after",
            "16 weeks Results"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + lapatinib each 21 days for 4 cycles)Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants with pCR 23.5 (11.9 to 35.1) Results 2: Arm/Group Title: Arm 2: EC -greater than D + Trastuzumab Arm/Group Description: EC -greater than D + Trastuzumab Drug plus Biological ",
        "premise_nums": [
            "51 Measure Type:",
            "21 days for",
            "9 to 35.1)"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + Trastuzumab each 21 days for 4 cyclesOverall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants with pCR 47.9 (33.8 to 62.0) Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  ",
        "premise_nums": [
            "21 days for",
            "4 cyclesOverall Number",
            "8 to 62.0)",
            "48 Measure Type:"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) ",
        "premise_nums": [
            "30 days after",
            "2 positive or"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) ",
        "premise_nums": [
            "840 mg IV",
            "4 80.0% Results 2",
            "60 minutes on",
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "5 Measure Type:",
            "14 followed by",
            "30-60 minutes"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Entailment",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% ",
        "premise_nums": [
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "8 mg/kg IV",
            "14 followed by",
            "6 Measure Type:",
            "30-60 minutes",
            "90 minutes on"
        ]
    },
    {
        "id": "11138479-1666-4973-84c2-c6779b5444f5",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "label": "Contradiction",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the same intervention ",
        "statement_nums": [
            "1 cohort is"
        ],
        "premise_text": "INTERVENTION 1: Arm 1 (Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  INTERVENTION 1: Monotherapy: Alobresib 0.6 mg ",
        "premise_nums": [
            "60 mg daily",
            "60 mg duloxetine",
            "30 mg daily",
            "30 mg duloxetine"
        ]
    },
    {
        "id": "11138479-1666-4973-84c2-c6779b5444f5",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "label": "Contradiction",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the same intervention ",
        "statement_nums": [
            "1 cohort is"
        ],
        "premise_text": "Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  ",
        "premise_nums": [
            "of 0.6 mg orally",
            "Alobresib 1.4 mg Participants",
            "28 days cycle",
            "D28 of",
            "of 1.4 mg orally",
            "1 through C1D28"
        ]
    },
    {
        "id": "59ff0501-f6af-4739-bd07-71e12e8cd8a7",
        "primaryId": "NCT02244580",
        "secondaryId": "NCT01901146",
        "label": "Entailment",
        "statement_text": "Patients with undetermined human epidermal growth factor receptor 2 expression cannot be accepted by either the primary trial or the secondary trial ",
        "statement_nums": [
            "2 expression cannot"
        ],
        "premise_text": "Inclusion Criteria: Estrogen receptor (ER)  PgR and HER2 expression have been determined Inclusion Criteria: HER2 positive disease ",
        "premise_nums": [
            "2 expression have",
            "2 positive disease"
        ]
    },
    {
        "id": "5bb09d7b-622f-4bdd-8dfd-809ea014a278",
        "primaryId": "NCT00559754",
        "secondaryId": "NCT02924883",
        "label": "Entailment",
        "statement_text": "A higher percent of patients in cohort 1 of the secondary trial experienced adverse events  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 13/72 (18.06%) Adverse Events 1: Total: 52/133 (39.10%) ",
        "premise_nums": [
            "13/72 (18.06%)",
            "52/133 (39.10%)"
        ]
    },
    {
        "id": "bda2752e-082e-4d06-926a-04ade3f61c26",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "label": "Entailment",
        "statement_text": "11 patients in the primary trial suffer from a liver disease  0 in the secondary trial ",
        "statement_nums": [
            "0 in the",
            "11 patients in"
        ],
        "premise_text": "Hepatitis acute 1/28 (3.57%) Adverse Events 1: Total: 1/24 (4.17%) Pericardial effusion *1/24 (4.17%) Other cardiac disorder *0/24 (0.00%) Ejection fraction decrease *0/24 (0.00%) Hypertension *0/24 (0.00%) Salivary gland infection *0/24 (0.00%) Pleural effusion *0/24 (0.00%) Adverse Events 2: Total: 6/30 (20.00%) Pericardial effusion *1/30 (3.33%) Other cardiac disorder *1/30 (3.33%) Ejection fraction decrease *1/30 (3.33%) ",
        "premise_nums": [
            "1/24 (4.17%)",
            "6/30 (20.00%)",
            "1/28 (3.57%)",
            "1/30 (3.33%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "bda2752e-082e-4d06-926a-04ade3f61c26",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "label": "Entailment",
        "statement_text": "11 patients in the primary trial suffer from a liver disease  0 in the secondary trial ",
        "statement_nums": [
            "0 in the",
            "11 patients in"
        ],
        "premise_text": "Hypertension *1/30 (3.33%)Salivary gland infection *1/30 (3.33%) Pleural effusion *2/30 (6.67%) ",
        "premise_nums": [
            "1/30 (3.33%)Salivary",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "f418c027-439a-4b19-bfb0-e1c1241886d8",
        "primaryId": "NCT01127763",
        "statement_text": "There were 4 more cases of Dyspnea than Dehydration in the primary trial ",
        "statement_nums": [
            "4 more cases"
        ],
        "label": "Contradiction",
        "premise_text": "Dehydration 1/25 (4.00%) Dyspnea (Shortness Of Breath) 2/25 (8.00%) ",
        "premise_nums": [
            "1/25 (4.00%)",
            "2/25 (8.00%)"
        ]
    },
    {
        "id": "9a3cb836-66a8-4c68-980c-97e5841f331f",
        "primaryId": "NCT01091428",
        "statement_text": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel  supported by the primary trial results  is 40 mg orally  twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "statement_nums": [
            "40 mg orally",
            "1-3, 8-10",
            "(RP2D) for",
            "2 Dose (RP2D)"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel ",
        "premise_nums": [
            "2 Dose (RP2D)",
            "(RP2D) for"
        ]
    },
    {
        "id": "45d4f78f-04d4-434c-9679-fd92291e97b6",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Entailment",
        "premise_text": "Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs)  aromatase inhibitors (AIs)  or a sequential combination of bothWhen calculating 4-6 years  neoadjuvant endocrine therapy should not be included No evidence of recurrent disease or distant metastatic disease No prior bilateral breast cancer PATIENT CHARACTERISTICS: Female Must be postmenopausal by any of the following criteria: Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for greater than 3 months) ",
        "premise_nums": [
            "4-6 years",
            "6 years of"
        ]
    },
    {
        "id": "45d4f78f-04d4-434c-9679-fd92291e97b6",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Entailment",
        "premise_text": "Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol  luteinizing hormone [LH]  and follicle-stimulating hormone [FSH] in the postmenopausal range)Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol  LH  and FSH in the postmenopausal range) Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above Clinically adequate hepatic function ",
        "premise_nums": [
            "56 years old",
            "55 years old"
        ]
    },
    {
        "id": "45d4f78f-04d4-434c-9679-fd92291e97b6",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up ",
        "statement_nums": [
            "55 year old"
        ],
        "label": "Entailment",
        "premise_text": "No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapyNo prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin  in situ carcinoma of the cervix or bladder  or contra- or ipsilateral in situ breast carcinoma No other nonmalignant systemic diseases (cardiovascular  renal  lung  etc.) that would prevent prolonged follow-up No psychiatric  addictive  or any other disorder that compromises compliance with protocol requirements PRIOR CONCURRENT THERAPY: See Disease Characteristics More than 12 months since prior and no other concurrent endocrine SERM/AI therapy Any type of prior adjuvant therapy allowed including  but not limited to  any of the following: ",
        "premise_nums": [
            "4-6 years",
            "6 years of",
            "12 months since"
        ]
    },
    {
        "id": "2cebae78-f4a3-4e09-ac54-cd2388670274",
        "primaryId": "NCT01953003",
        "statement_text": "Patients receiving intervention 1 of the primary trial  will be administered medication topically and intraveinously ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm A : iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest  vinflunine: intraveinous administration day 1 once every 3 weeks  280 mg/m² Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B : Capecitabine 1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² ",
        "premise_nums": [
            "1 once every",
            "1 week of",
            "1 of each",
            "825 mg/m²",
            "2500 mg/m²",
            "14 consecutive days",
            "1650 mg/m²",
            "1250 mg/m²",
            "280 mg/m²"
        ]
    },
    {
        "id": "57cf3760-1692-439f-bbe2-82a6bc8862ce",
        "primaryId": "NCT01376349",
        "secondaryId": "NCT01912612",
        "label": "Entailment",
        "statement_text": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects  of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily ",
        "statement_nums": [
            "1 recieves Duloxetine",
            "2 subjects of",
            "30 mg daily",
            "receive 3.25 mg of"
        ],
        "premise_text": "Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  ",
        "premise_nums": [
            "2 weeks Duloxetine:",
            "30 mg daily",
            "60 mg daily",
            "60 mg duloxetine",
            "30 mg duloxetine"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Outcome Measurement: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF)  myocardial infarction or arrhythmia  or probable cardiac death defined as sudden  unexpected death within 24 hours of a definite or probable cardiac event  or severe symptomatic HF  concomitant with a left ventricular ejection fraction (LVEF) drop of greater than 10 percentage points from baseline and to 50% LVEF ",
        "premise_nums": [
            "8 Cycles of",
            "10 percentage points",
            "50% LVEF",
            "1 Year Cardiac",
            "1 or 2),",
            "24 hours of"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of greater than 10 percentage points from baseline and to smaller than 50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks Time frame: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment Results 1: Arm/Group Title: Pegylated Liposomal Doxorubicin (PLD) Based Regimen ",
        "premise_nums": [
            "8 cycles of",
            "4 weeks Time",
            "10 percentage points",
            "50% LVEF",
            "3-4 weeks"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Arm/Group Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: Doxorubicin Based Regimen ",
        "premise_nums": [
            "80 mg/m^2",
            "2 IV over",
            "4 courses (12",
            "30 minutes (first",
            "120 Measure Type:",
            "600 mg/m^2",
            "30-90 minutes",
            "4 mg/kg IV",
            "5 Results 2:",
            "12 weeks (4",
            "35 mg/m^2",
            "60 minutes with",
            "90 minutes given",
            "30 minutes given",
            "2 mg/kg IV"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 59 Measure Type: Number Unit of Measure: Participants 11 Outcome Measurement: Time to Progression (TTP) - Expert Evaluation Committee Assessment ",
        "premise_nums": [
            "60 mg/m^2",
            "80 mg/m^2",
            "2 IV over",
            "4 courses (12",
            "30 minutes (first",
            "600 mg/m^2",
            "30-90 minutes",
            "4 mg/kg IV",
            "59 Measure Type:",
            "12 weeks (4",
            "2 intravenous (IV)",
            "21 days for",
            "60 minutes with",
            "90 minutes given",
            "2 mg/kg IV",
            "11 Outcome Measurement:"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer  whichever comes first  Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started  For participants with bone metastasis only  at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition) Time frame: Up to 2008 days of the treatment Results 1: Arm/Group Title: Exemestane ",
        "premise_nums": [
            "2008 days of",
            "25% increase",
            "version 1.0 as an",
            "20% increase"
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "label": "Contradiction",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "20% of"
        ],
        "premise_text": "Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) Results 2: Arm/Group Title: Anastrozole Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) ",
        "premise_nums": [
            "25 mg and",
            "95% Confidence",
            "8 to 16.5)",
            "1 mg and"
        ]
    },
    {
        "id": "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Contradiction",
        "statement_text": "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial ",
        "statement_nums": [
            "1 in the",
            "0 cases of"
        ],
        "premise_text": "Adverse Events 1: Total: 19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth  Atrial flutter 1/3761 (0.03%) Ventric.arrhyth  Trigeminy 1/3761 (0.03%) Hypothyroidism 0/3761 (0.00%) Blurred vision 1/3761 (0.03%) Nyctalopia 0/3761 (0.00%) ",
        "premise_nums": [
            "19/3761 (0.51%)",
            "3/3761 (0.08%)",
            "0/3761 (0.00%)",
            "1/3761 (0.03%)"
        ]
    },
    {
        "id": "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Contradiction",
        "statement_text": "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial ",
        "statement_nums": [
            "1 in the",
            "0 cases of"
        ],
        "premise_text": "Ocular - Other 1/3761 (0.03%)Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%) Ventric.arrhyth  Trigeminy 0/3759 (0.00%) Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%) ",
        "premise_nums": [
            "1/3759 (0.03%)",
            "0/3759 (0.00%)",
            "1/3761 (0.03%)Adverse",
            "7/3759 (0.19%)"
        ]
    },
    {
        "id": "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Contradiction",
        "statement_text": "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial ",
        "statement_nums": [
            "1 in the",
            "0 cases of"
        ],
        "premise_text": "Ocular - Other 0/3759 (0.00%)Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) ",
        "premise_nums": [
            "29/48 (60.42%)",
            "7/48 (14.58%)",
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "2/48 (4.17%)",
            "1/48 (2.08%)",
            "0/3759 (0.00%)Adverse"
        ]
    },
    {
        "id": "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Contradiction",
        "statement_text": "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial ",
        "statement_nums": [
            "1 in the",
            "0 cases of"
        ],
        "premise_text": "Mucosal infection 1/48 (2.08%)",
        "premise_nums": [
            "1/48 (2.08%)"
        ]
    },
    {
        "id": "3050bca2-a8bc-412e-b679-5be1055e3749",
        "primaryId": "NCT03061175",
        "secondaryId": "NCT03098550",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study  whereas Cohort 1 of the primary trial recieves a consistent dose of Daratumumab for the full study ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)",
        "premise_nums": [
            "1 to 8),",
            "16 mg/kg Q",
            "3 to 24)",
            "240 mg Q2W"
        ]
    },
    {
        "id": "c8ef1457-63a9-4eac-a98b-edb805afd35b",
        "primaryId": "NCT02660788",
        "secondaryId": "NCT01490892",
        "label": "Contradiction",
        "statement_text": "the primary trial is investigating different ways to communicate with women aged 51-73 years old   whereas the secondary trial is evaluating the impact of regular exercise and dieting ",
        "statement_nums": [
            "73 years old",
            "51-73 years"
        ],
        "premise_text": "INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) ",
        "premise_nums": [
            "25 ml followed",
            "20 micro-l/kg"
        ]
    },
    {
        "id": "515d0710-429b-4c28-b881-8a6531ee973e",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "label": "Entailment",
        "statement_text": "Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "25 with Bone",
            "18-25 with"
        ],
        "premise_text": "Inclusion Criteria: Women aged 45-69, according to the target age of the screening centres involved; New invited women in mammography screening programme  Exclusion Criteria: None No non-measurable disease only  defined as all other lesions  including small lesions (longest diameter smaller than 2 cm) and truly non-measurable lesions  including any of the following: Bone lesions Leptomeningeal disease ",
        "premise_nums": [
            "45-69, according"
        ]
    },
    {
        "id": "93fc76a9-5f3d-490b-8802-21d0fa806728",
        "primaryId": "NCT00633464",
        "statement_text": "Cohort 2 of the primary trial reported worse results than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator  CR: Disappearance of all evidence of target and non-target lesions  PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions  Confidence interval (CI) was Computed using Clopper-Pearson method  Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) Results 1: Arm/Group Title: Ixabepilone 40 mg/m^2 ",
        "premise_nums": [
            "3 months until",
            "6 weeks for",
            "40 mg/m^2",
            "12 months from",
            "30% reduction"
        ]
    },
    {
        "id": "93fc76a9-5f3d-490b-8802-21d0fa806728",
        "primaryId": "NCT00633464",
        "statement_text": "Cohort 2 of the primary trial reported worse results than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeksOverall Number of Participants Analyzed: 40 Measure Type: Number Unit of Measure: percentage of participants 30.0 (16.6 to 46.5) Results 2: Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 35.9 (21.2 to 52.8) ",
        "premise_nums": [
            "400 mg/m^2",
            "3 weeks Overall",
            "250 mg/m^2",
            "2 every 3",
            "40 Measure Type:",
            "40 mg/m^2",
            "39 Measure Type:",
            "3 weeksOverall Number",
            "2 to 52.8)",
            "6 to 46.5)",
            "2 loading dose"
        ]
    },
    {
        "id": "75da6329-e8a1-4808-bb0f-78fd3a2dde9c",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "was 10.3% higher in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Best Overall Response (BOR) Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST)  Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized  20 June 2007, until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and Cetuximab ",
        "premise_nums": [
            "6 weeks until",
            "31 July 2009",
            "20 June 2007,"
        ]
    },
    {
        "id": "75da6329-e8a1-4808-bb0f-78fd3a2dde9c",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "was 10.3% higher in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly  Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity Overall Number of Participants Analyzed: 115 Measure Type: Number Unit of Measure: percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatin ",
        "premise_nums": [
            "3 weeks with",
            "1 until every",
            "2 IV infusion",
            "400 mg/m^2",
            "250 mg/m^2",
            "6 cycles of",
            "6 cycles and",
            "1 to 28.5)",
            "75 milligram per",
            "2 followed by",
            "115 Measure Type:"
        ]
    },
    {
        "id": "75da6329-e8a1-4808-bb0f-78fd3a2dde9c",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "was 10.3% higher in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD  unacceptable toxicity or withdrawal of consent Overall Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 10.3 (3.9 to 21.2) ",
        "premise_nums": [
            "3 weeks with",
            "1 until every",
            "6 cycles until",
            "2 IV infusion",
            "58 Measure Type:",
            "9 to 21.2)",
            "75 mg/m^2"
        ]
    },
    {
        "id": "3194a043-d156-49d6-97bb-81867ed188f0",
        "primaryId": "NCT00712985",
        "secondaryId": "NCT02038010",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719 by IV ",
        "statement_nums": [
            "BYL719 by",
            "719 by IV"
        ],
        "premise_text": "INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)  INTERVENTION 1: Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1) ",
        "premise_nums": [
            "12 for serum",
            "5 mg IV",
            "2 months to",
            "15 minutes as",
            "3.6mg/kg"
        ]
    },
    {
        "id": "3194a043-d156-49d6-97bb-81867ed188f0",
        "primaryId": "NCT00712985",
        "secondaryId": "NCT02038010",
        "label": "Contradiction",
        "statement_text": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719 by IV ",
        "statement_nums": [
            "BYL719 by",
            "719 by IV"
        ],
        "premise_text": "Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity PI3K inhibitor BYL719: Given PO Ado-trastuzumab emtansine: Given IV Pharmacological study: Correlative studies Laboratory biomarker analysis: Optional correlative studies ",
        "premise_nums": [
            "1-21 and",
            "250 mg PO",
            "21 days in",
            "30-90 minutes",
            "1 ado-trastuzumab emtansine",
            "and 3.6mg/kg",
            "719 on days",
            "BYL719 on",
            "90 minutes on"
        ]
    },
    {
        "id": "3058d104-172e-41be-b641-9f0f9cb172be",
        "primaryId": "NCT00240071",
        "statement_text": "At least one participant of the primary trial survived over 200 days without documented disease progression ",
        "statement_nums": [
            "200 days without"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) Progression free survival is defined as time from date of registration until the date of first documented disease progression or date of death from any cause  whichever occurs first  Time frame: From date of registration until disease progression or death  whichever occurs first Results 1: Arm/Group Title: Avastin (Bevacizumab) Plus Hormone Arm/Group Description: All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking  Overall Number of Participants Analyzed: 30 Median (95% Confidence Interval) Unit of Measure: days 125.5 (90 to 256) ",
        "premise_nums": [
            "90 to 256)",
            "95% Confidence",
            "15 mg/kg IV"
        ]
    },
    {
        "id": "bc845a3d-1f69-41a3-bf84-36a62e8127a4",
        "primaryId": "NCT01439282",
        "statement_text": "In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2.",
        "statement_nums": [
            "1 of the",
            "10 times the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 14/67 (20.90%) Adverse Events 2: Total: 1/10 (10.00%) ",
        "premise_nums": [
            "1/10 (10.00%)",
            "14/67 (20.90%)"
        ]
    },
    {
        "id": "69ced998-f3c9-460a-a272-b2c95421b89d",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "label": "Entailment",
        "statement_text": "Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial",
        "statement_nums": [
            "6 months pregnant"
        ],
        "premise_text": "Inclusion Criteria: All subjects must be female  Postmenopausal status  defined as any one of the following criteria: Documented history of bilateral oophorectomy  Age 60 years or more  Age 45 to 59 and satisfying one or more of the following criteria: Amenorrhea for at least 12 months and intact uterus  Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range including: patients who have had a hysterectomy and patients who have received hormone replacement  Exclusion Criteria: Pregnant or breast feeding females ",
        "premise_nums": [
            "12 months and",
            "60 years or",
            "45 to 59"
        ]
    },
    {
        "id": "45fb84a3-674c-40f5-ac8c-26a3c7844e7b",
        "primaryId": "NCT00354640",
        "statement_text": "Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole ",
        "statement_nums": [
            "4 times as",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Anastrozole and Simvastatin adjuvant therapy : laboratory analysis pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD for 14 days ",
        "premise_nums": [
            "40 milligram tablet",
            "1 milligram tablet",
            "14 days anastrozole"
        ]
    },
    {
        "id": "c349cad6-8b63-4e5e-9b87-4fc08bb6fc30",
        "primaryId": "NCT00146172",
        "statement_text": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of Neratinb ",
        "statement_nums": [
            "60% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd ",
        "premise_nums": [
            "80 mg Neratinib",
            "80 mg qd",
            "40 mg Neratinb",
            "40 mg qd"
        ]
    },
    {
        "id": "f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9",
        "primaryId": "NCT00912340",
        "statement_text": "More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Pleural effusion *0/24 (0.00%) Adverse Events 2: Pleural effusion *2/30 (6.67%) ",
        "premise_nums": [
            "2/30 (6.67%)",
            "0/24 (0.00%)"
        ]
    },
    {
        "id": "9026c2ff-2dd8-4aa9-b2fb-f6bef856189d",
        "primaryId": "NCT03106077",
        "statement_text": "Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks ",
        "statement_nums": [
            "IMGN853 by",
            "853 by IV"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W ",
        "premise_nums": [
            "6 mg/kg IMGN",
            "853 IV Q3W",
            "IMGN853 IV"
        ]
    },
    {
        "id": "88b13330-b937-4bbc-80ea-4bf8ccc17bd1",
        "primaryId": "NCT00699491",
        "statement_text": "3/4 participants in the primary trial suffered from Dose-limiting toxicities ",
        "statement_nums": [
            "4 participants in",
            "3/4 participants"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Recommended Dose Level for Phase II Testing (RPTD) (Phase I) The RPTD is defined as the highest dose level at which at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the next highest dose level has 2 or more DLTs  The number of patients in each cohort reporting a DLT is reported  Dose-limiting toxicities (DLTs) are defined as any of the following adverse events (AEs) that are related to study agent with an attribution of possible  probably  or definite and fulfilling one of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot be stably controlled with diabetic medication ",
        "premise_nums": [
            "4 hematologic toxicity",
            "2 or more",
            "6 patients develops"
        ]
    },
    {
        "id": "88b13330-b937-4bbc-80ea-4bf8ccc17bd1",
        "primaryId": "NCT00699491",
        "statement_text": "3/4 participants in the primary trial suffered from Dose-limiting toxicities ",
        "statement_nums": [
            "4 participants in",
            "3/4 participants"
        ],
        "label": "Entailment",
        "premise_text": "Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such as hyperlipidemia  hypophosphatemia  and hypokalemia)Time frame: During first course Results 1: Arm/Group Title: Dose Level 1 Arm/Group Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 3 Measure Type: Number Unit of Measure: DLTs 2 Results 2: Arm/Group Title: Dose Level -1 ",
        "premise_nums": [
            "1 Arm/Group Description",
            "3 mg/ks cixutumumab",
            "3 or 4",
            "22 Courses repeat",
            "28 days in",
            "60 minutes on",
            "30 minutes on",
            "25 mg temsirolimus",
            "2 Results 2:",
            "3 Measure Type:",
            "4 non-hematologic toxicity"
        ]
    },
    {
        "id": "88b13330-b937-4bbc-80ea-4bf8ccc17bd1",
        "primaryId": "NCT00699491",
        "statement_text": "3/4 participants in the primary trial suffered from Dose-limiting toxicities ",
        "statement_nums": [
            "4 participants in",
            "3/4 participants"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 223 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 1 Measure Type: Number Unit of Measure: DLTs 1 ",
        "premise_nums": [
            "1 Measure Type:",
            "28 days in",
            "22 Courses repeat",
            "60 minutes on",
            "30 minutes on",
            "223 mg/ks cixutumumab",
            "20 mg temsirolimus"
        ]
    },
    {
        "id": "eea73ae4-0985-4f74-957d-e2aad7ab453c",
        "primaryId": "NCT00248170",
        "secondaryId": "NCT01299038",
        "label": "Contradiction",
        "statement_text": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer  she is too old to participate in both the secondary trial and the primary trial ",
        "statement_nums": [
            "32 year old"
        ],
        "premise_text": "Inclusion Criteria: Recent primary surgery for breast cancer Early stage breast cancer Postmenopausal Hormone receptor positive Positive lymph node involvement Exclusion Criteria: Metastatic disease Presence of contralateral breast cancer including DCIS Progression Other protocol-defined inclusion/exclusion criteria may apply  Inclusion Criteria: Metastatic adenocarcinoma of the breast (Stage IV) Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1 or 2 Normal organ and marrow function as defined in the protocol Exclusion Criteria: Participants may not be receiving any other study agents Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks ",
        "premise_nums": [
            "6 weeks (with",
            "2 therapy )",
            "5 weeks Any",
            "1 or 2",
            "18 years ECOG"
        ]
    },
    {
        "id": "6550c068-14e6-4e93-8f98-756338c91e35",
        "primaryId": "NCT00313170",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response (ORR) Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions)  All patients were to be followed up every 12 weeks for progression  defined by response evaluation criteria in solid tumors (RECIST v1.1). Time frame: The planned data cut-off for this study was when all patients  except withdrawals  had been followed up for at least 24 weeks  Patients received treatment up to approximately 2 years  Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 47 Measure Type: Number ",
        "premise_nums": [
            "30% decrease",
            "12 weeks for",
            "250 mg Overall",
            "47 Measure Type:",
            "250 mg Arm"
        ]
    },
    {
        "id": "6550c068-14e6-4e93-8f98-756338c91e35",
        "primaryId": "NCT00313170",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "250 mg had"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Percentage of patients 8.5 (2.4 to 20.4)Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of patients 5.9 (1.2 to 16.2) ",
        "premise_nums": [
            "51 Measure Type:",
            "4 to 20.4)Results",
            "2 to 16.2)"
        ]
    },
    {
        "id": "de71f285-4382-465f-9e7e-d163662f6d9c",
        "primaryId": "NCT01446159",
        "statement_text": "the primary trial only had a total of 66 patients in across both its cohorts ",
        "statement_nums": [
            "66 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/3 (66.67%) Adverse Events 2: Total: 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "2/3 (66.67%)"
        ]
    },
    {
        "id": "594c9a79-d601-46b4-ae30-0b48a1117693",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "label": "Entailment",
        "statement_text": "The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)"
        ]
    },
    {
        "id": "594c9a79-d601-46b4-ae30-0b48a1117693",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "label": "Entailment",
        "statement_text": "The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons ",
        "statement_nums": [
            "2 of the"
        ],
        "premise_text": "Intestinal obstruction 0/1 (0.00%)Nausea 0/1 (0.00%) Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) ",
        "premise_nums": [
            "2/537 (0.37%)",
            "1/537 (0.19%)",
            "0/1 (0.00%)Nausea",
            "0/537 (0.00%)",
            "8/537 (1.49%)"
        ]
    },
    {
        "id": "99e8ee0e-d72d-4e19-9424-20e5891bb2b6",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "label": "Contradiction",
        "statement_text": "It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2 the primary trial  despite the difference in cohort size ",
        "statement_nums": [
            "2 of the",
            "2 the primary"
        ],
        "premise_text": "Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) ",
        "premise_nums": [
            "0/1 (0.00%)"
        ]
    },
    {
        "id": "99e8ee0e-d72d-4e19-9424-20e5891bb2b6",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "label": "Contradiction",
        "statement_text": "It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2 the primary trial  despite the difference in cohort size ",
        "statement_nums": [
            "2 of the",
            "2 the primary"
        ],
        "premise_text": "Intestinal obstruction 0/1 (0.00%)Nausea 0/1 (0.00%) Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) ",
        "premise_nums": [
            "2/537 (0.37%)",
            "1/537 (0.19%)",
            "0/1 (0.00%)Nausea",
            "0/537 (0.00%)",
            "8/537 (1.49%)"
        ]
    },
    {
        "id": "f1b0653f-b5ce-4558-b325-56244940c0cd",
        "primaryId": "NCT01273896",
        "statement_text": "There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Cardiac General  other1/22 (4.55%) Dyspnea (shortness of breath)2/22 (9.09%) ",
        "premise_nums": [
            "2/22 (9.09%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "24b24d36-2500-4841-99a3-13cba905d77d",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial at least 8 different types of cardiac related adverse events ",
        "statement_nums": [
            "8 different types"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) ",
        "premise_nums": [
            "1/49 (2.04%)",
            "0/49 (0.00%)",
            "1/52 (1.92%)",
            "0/52 (0.00%)"
        ]
    },
    {
        "id": "24b24d36-2500-4841-99a3-13cba905d77d",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial at least 8 different types of cardiac related adverse events ",
        "statement_nums": [
            "8 different types"
        ],
        "label": "Contradiction",
        "premise_text": "Pericardial effusion 4/49 (8.16%)Right ventricular failure 0/49 (0.00%) ",
        "premise_nums": [
            "0/49 (0.00%)",
            "4/49 (8.16%)Right"
        ]
    },
    {
        "id": "0797ff90-f847-4442-92fd-017c539bb38f",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their trachea ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Anorexia 1/31 (3.23%) ",
        "premise_nums": [
            "2/31 (6.45%)",
            "10/31 (32.26%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "0797ff90-f847-4442-92fd-017c539bb38f",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their trachea ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Dyspnea 2/31 (6.45%)",
        "premise_nums": [
            "2/31 (6.45%)"
        ]
    },
    {
        "id": "e802b1f6-62fb-4759-b261-c69dbdc1d7ef",
        "primaryId": "NCT04080297",
        "secondaryId": "NCT02780713",
        "label": "Contradiction",
        "statement_text": "Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants ",
        "statement_nums": [
            "AZD9496 variants",
            "122 than either"
        ],
        "premise_text": "INTERVENTION 1: 100 mg Q-122 Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days  INTERVENTION 2: 200 mg Q-122 Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days  INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  ",
        "premise_nums": [
            "100 mg Q",
            "122 administered orally",
            "2 Participants received",
            "122 Dosage was",
            "50 mg capsules",
            "1 Participants received",
            "200 mg Q"
        ]
    },
    {
        "id": "97d0bbf0-c2c5-409b-820b-6e14a6326b06",
        "primaryId": "NCT02322814",
        "secondaryId": "NCT00356148",
        "label": "Contradiction",
        "statement_text": "A patient with Histologically confirmed estrogen receptor-negative  progesterone receptor-negative  and human epidermal growth factor 2 positive breast cancer  with no known Brain metastases and no prior history of cardiac dysfunction  could be eligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "premise_text": "Inclusion Criteria: Histologically confirmed estrogen receptor (ER)-negative  progesterone receptor (PR)-negative  and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease History of autoimmune disease Brain metastases (symptomatic or nonsymptomatic) that have not been treated previously  are progressive  or require any type of therapy (e.g.  radiation  surgery  or steroids) to control symptoms from brain metastases within 30 days prior to first study treatment dose History of clinically significant cardiac dysfunction ",
        "premise_nums": [
            "30 days prior"
        ]
    },
    {
        "id": "620106e8-2a7f-4078-80b6-d5f1840c66e1",
        "primaryId": "NCT00699491",
        "statement_text": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab ",
        "statement_nums": [
            "3 mg/ks cixutumumab"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Recommended Dose Level for Phase II Testing (RPTD) (Phase I) The RPTD is defined as the highest dose level at which at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the next highest dose level has 2 or more DLTs  The number of patients in each cohort reporting a DLT is reported  Dose-limiting toxicities (DLTs) are defined as any of the following adverse events (AEs) that are related to study agent with an attribution of possible  probably  or definite and fulfilling one of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot be stably controlled with diabetic medication ",
        "premise_nums": [
            "4 hematologic toxicity",
            "2 or more",
            "6 patients develops"
        ]
    },
    {
        "id": "620106e8-2a7f-4078-80b6-d5f1840c66e1",
        "primaryId": "NCT00699491",
        "statement_text": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab ",
        "statement_nums": [
            "3 mg/ks cixutumumab"
        ],
        "label": "Contradiction",
        "premise_text": "Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such as hyperlipidemia  hypophosphatemia  and hypokalemia)Time frame: During first course Results 1: Arm/Group Title: Dose Level 1 Arm/Group Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 3 Measure Type: Number Unit of Measure: DLTs 2 Results 2: Arm/Group Title: Dose Level -1 ",
        "premise_nums": [
            "1 Arm/Group Description",
            "3 mg/ks cixutumumab",
            "3 or 4",
            "22 Courses repeat",
            "28 days in",
            "60 minutes on",
            "30 minutes on",
            "25 mg temsirolimus",
            "2 Results 2:",
            "3 Measure Type:",
            "4 non-hematologic toxicity"
        ]
    },
    {
        "id": "620106e8-2a7f-4078-80b6-d5f1840c66e1",
        "primaryId": "NCT00699491",
        "statement_text": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab ",
        "statement_nums": [
            "3 mg/ks cixutumumab"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 223 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 1 Measure Type: Number Unit of Measure: DLTs 1 ",
        "premise_nums": [
            "1 Measure Type:",
            "28 days in",
            "22 Courses repeat",
            "60 minutes on",
            "30 minutes on",
            "223 mg/ks cixutumumab",
            "20 mg temsirolimus"
        ]
    },
    {
        "id": "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35",
        "primaryId": "NCT00992225",
        "statement_text": "Only 2 of the 12 adverse event types recorded in the primary trial  occurred more than once ",
        "statement_nums": [
            "2 of the",
            "12 adverse event"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 10/33 (30.30%) Constipation 1/33 (3.03%) Dysphagia 1/33 (3.03%) Ileus 1/33 (3.03%) Nausea 1/33 (3.03%) Vomiting 1/33 (3.03%) Fatigue 1/33 (3.03%) Pain 1/33 (3.03%) Sepsis 2/33 (6.06%) Urinary tract infection 1/33 (3.03%) Alanine aminotransferase increased 1/33 (3.03%) Aspartate aminotransferase increased 1/33 (3.03%) Dehydration 2/33 (6.06%) ",
        "premise_nums": [
            "1/33 (3.03%)",
            "2/33 (6.06%)",
            "10/33 (30.30%)"
        ]
    },
    {
        "id": "01a57096-0278-4c70-be43-acd57010cd6f",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "label": "Entailment",
        "statement_text": "There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 6/21 (28.57%) Hypertension 3/21 (14.29%) Edema 3/21 (14.29%) Nausea 2/21 (9.52%) Fracture 1/21 (4.76%) Dizziness 3/21 (14.29%) Syncope 2/21 (9.52%) Headache 2/21 (9.52%) Dyspnea 2/21 (9.52%) Hypoxia 3/21 (14.29%) Adverse Events 1: Total: 1/40 (2.50%) Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) ",
        "premise_nums": [
            "6/21 (28.57%)",
            "1/21 (4.76%)",
            "1/40 (2.50%)",
            "2/21 (9.52%)",
            "3/21 (14.29%)",
            "0/40 (0.00%)"
        ]
    },
    {
        "id": "01a57096-0278-4c70-be43-acd57010cd6f",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "label": "Entailment",
        "statement_text": "There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Death 0/40 (0.00%)Headache 0/40 (0.00%) Dyspnea 0/40 (0.00%) Sinusitis 0/40 (0.00%) Wound Dehiscence 0/40 (0.00%) ",
        "premise_nums": [
            "0/40 (0.00%)Headache"
        ]
    },
    {
        "id": "7c12676c-7973-4e9d-b1fc-3b14d241d0c8",
        "primaryId": "NCT00696072",
        "statement_text": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [
            "20 patients treated"
        ],
        "label": "Entailment",
        "premise_text": "CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than  equal to 6 months  CR= Disappearance of all target lesions  No new lesions  PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD  SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started  Physical examination,radiological assessment  and bone scans (if applicable) were used to assess outcome Time frame: First dose of study drug to last dose plus 7 days  up to study completion (approximately 6 years) Results 1: ",
        "premise_nums": [
            "30% decrease"
        ]
    },
    {
        "id": "7c12676c-7973-4e9d-b1fc-3b14d241d0c8",
        "primaryId": "NCT00696072",
        "statement_text": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [
            "20 patients treated"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Dasatinib Plus LetrozoleArm/Group Description: Dasatinib + Letrozole: Tablets  Oral  once daily  up to 2 years Dasatinib 100 mg + Letrozole 2.5 mg Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity  If the intolerable toxicity was determined to be related to dasatinib  dasatinib was discontinued and the patient continued on single-agent letrozole  Although drugs were taken daily  cycle length was 28-days Overall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: participants CBR (CR+PR+SD): 40 CBR  DFI smaller than = 2 Years: 20 ",
        "premise_nums": [
            "Letrozole 2.5 mg Patients",
            "2 years Dasatinib",
            "56 Measure Type:",
            "28-days Overall"
        ]
    },
    {
        "id": "cd645637-0a31-4f54-bc75-4a52349cf100",
        "primaryId": "NCT00748553",
        "statement_text": "Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle",
        "statement_nums": [
            "80mg/m2 daily",
            "75mg/m2 and",
            "50mg/m2,",
            "5 days for",
            "2 daily every",
            "4-week cycle"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Phase 1 Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle ",
        "premise_nums": [
            "3 weeks of",
            "2 weekly for",
            "1 Azacitidine (Vidaza):",
            "100mg/m2 daily",
            "50mg/m2,",
            "2 daily for",
            "5 days for",
            "75mg/m2 or",
            "4-week cycle",
            "100mg/m2 weekly"
        ]
    },
    {
        "id": "adfc79ba-2996-47ce-9986-7d287931df89",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) ",
        "premise_nums": [
            "9/33 (27.27%)",
            "23/23 (100.00%)",
            "0/33 (0.00%)",
            "57/57 (100.00%)",
            "15/33 (45.45%)",
            "3/11 (27.27%)",
            "9/11 (81.82%)",
            "2/11 (18.18%)",
            "13/33 (39.39%)"
        ]
    },
    {
        "id": "adfc79ba-2996-47ce-9986-7d287931df89",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Alopecia 23/23 (100.00%)",
        "premise_nums": [
            "23/23 (100.00%)"
        ]
    },
    {
        "id": "60bff573-0251-4f05-b2b7-dec74c7363cc",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there was at least 2 fatigued patients ",
        "statement_nums": [
            "2 fatigued patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 0/6 (0.00%) Thrombocytopenia * 1/6 (16.67%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 1/6 (16.67%) Cholecystitis * 1/6 (16.67%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "1/6 (16.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "60bff573-0251-4f05-b2b7-dec74c7363cc",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there was at least 2 fatigued patients ",
        "statement_nums": [
            "2 fatigued patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2:Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 1/6 (16.67%) Thrombocytopenia * 0/6 (0.00%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 0/6 (0.00%) Cholecystitis * 0/6 (0.00%) ",
        "premise_nums": [
            "0/6 (0.00%)",
            "2/6 (33.33%)",
            "1/6 (16.67%)",
            "2:Total: 2/6"
        ]
    },
    {
        "id": "f3a03aec-194d-4538-9be3-cea8281d995c",
        "primaryId": "NCT00693719",
        "statement_text": "the primary trial recorded less than 3 different Adverse Events  ",
        "statement_nums": [
            "3 different Adverse"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 4/31 (12.90%) Bleeding 1/31 (3.23%) Pain 2/31 (6.45%) Dehydration 1/31 (3.23%) Dyspnea 1/31 (3.23%) ",
        "premise_nums": [
            "4/31 (12.90%)",
            "2/31 (6.45%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "c8df3461-4063-4fb0-ae48-f57062eb0a68",
        "primaryId": "NCT03329937",
        "statement_text": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle  for 3 cycles  after which all participants undergo neoadjuvant chemotherapy ",
        "statement_nums": [
            "28 day cycle",
            "200 milligrams (mg)"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Niraparib 200 mg Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles  After 2 cycles  participants either underwent surgery  received additional cycles of niraparib (maximum of 6 cycles total)  or received neoadjuvant chemotherapy  at physician's discretion  A breast magnetic resonance imaging (MRI) was performed at the end of cycle 2 and breast ultrasounds were performed at the end of each cycle  including any additional cycles beyond cycle 2. After completion of all neoadjuvant therapy participants proceeded to surgery  at which time pathological complete response (pCR) was assessed  ",
        "premise_nums": [
            "200 mg Participants",
            "6 cycles total)",
            "200 milligrams (mg)",
            "2 and breast",
            "28-day treatment"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "2 cohorts of",
            "20% difference"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions  Time frame: Baseline visit and then every 8 weeks to 12 months  then every 3 months until disease progression Results 1: Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg ",
        "premise_nums": [
            "8 weeks to",
            "3 months until",
            "30% reduction",
            "16 mg/m^2",
            "10 mg/kg"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "2 cohorts of",
            "20% difference"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity  Bevacizumab  10 mg/kg  administered after ixabepilone as IV infusion every 2 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 46 Measure Type: Number ",
        "premise_nums": [
            "46 Measure Type:",
            "1-hour intravenous",
            "15 of a",
            "10 mg/kg",
            "28-day cycle",
            "90 minutes for",
            "30 minutes for"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "2 cohorts of",
            "20% difference"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Percentage of participants 47.8 (32.9 to 63.1)Results 2: Arm/Group Title: Ixabepilone  40 mg/m^2 + Bevacizumab  15 mg/kg ",
        "premise_nums": [
            "9 to 63.1)Results",
            "15 mg/kg",
            "40 mg/m^2"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "2 cohorts of",
            "20% difference"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Ixabepilone  40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 implemented for all subsequent cycles  Bevacizumab  15 mg/kg  administered after ixabepilone as IV infusion every 3 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 45 Measure Type: Number ",
        "premise_nums": [
            "15 mg/kg",
            "45 Measure Type:",
            "40 mg/m^2,",
            "32 mg/m^2",
            "2 implemented for",
            "3-hour IV",
            "1 of a",
            "90 minutes for",
            "30 minutes for",
            "21-day cycle"
        ]
    },
    {
        "id": "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had Acute coronary syndrome ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 30/98 (30.61%) NEUTROPENIA 1/98 (1.02%) ATRIAL FIBRILLATION 1/98 (1.02%) CARDIAC FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) ABDOMINAL PAIN 0/98 (0.00%) COLITIS 0/98 (0.00%) DIARRHOEA 2/98 (2.04%) FEMORAL HERNIA 0/98 (0.00%) HAEMATEMESIS 0/98 (0.00%) ILEUS 0/98 (0.00%) ",
        "premise_nums": [
            "1/98 (1.02%)",
            "2/98 (2.04%)",
            "30/98 (30.61%)",
            "0/98 (0.00%)"
        ]
    },
    {
        "id": "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had Acute coronary syndrome ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "NAUSEA 0/98 (0.00%)",
        "premise_nums": [
            "0/98 (0.00%)"
        ]
    },
    {
        "id": "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "0 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Objective Response Based on Data Review Committee's Assessment Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST)  CR is defined as disappearance of all target and non-target lesions  PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD according to RECIST  Confirmed responses are those that persist on repeat evaluation 4 weeks after initial documentation of response  Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8. Results 1: Arm/Group Title: SUNITINIB+CAPECITABINE ",
        "premise_nums": [
            "30% decrease",
            "6 weeks after",
            "1 of Cycle",
            "4 weeks after"
        ]
    },
    {
        "id": "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "0 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity  and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance  Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study Overall Number of Participants Analyzed: 63 Measure Type: Number Unit of Measure: participants Total Number of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR): 19 ",
        "premise_nums": [
            "of 2,000 mg/m",
            "19 Complete Response",
            "1 to 14",
            "63 Measure Type:",
            "0 Partial Response",
            "21-day cycles",
            "2,000 mg/m^2/day",
            "21 days at",
            "1 at the",
            "of 37.5 mg/day"
        ]
    },
    {
        "id": "aef2367d-78a5-4dc7-a6f7-d96415082362",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "label": "Entailment",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) Renal Failure * 1/33 (3.03%) Pneumonia * 1/33 (3.03%) Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) ",
        "premise_nums": [
            "12/76 (15.79%)",
            "5/33 (15.15%)",
            "1/33 (3.03%)",
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "aef2367d-78a5-4dc7-a6f7-d96415082362",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "label": "Entailment",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Cardiopulmonary failure 1/76 (1.32%)Optic ischaemic neuropathy 1/76 (1.32%) Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 1/76 (1.32%) ",
        "premise_nums": [
            "0/76 (0.00%)",
            "1/76 (1.32%)Optic"
        ]
    },
    {
        "id": "985c4cb3-2684-4a67-a479-998602044a0d",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  other than sudden death  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%) Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) Lymphoedema * 0/3 (0.00%) Adverse Events 2: Total: 6/41 (14.63%) Febrile Neutropenia * 1/41 (2.44%) Neutropenia * 1/41 (2.44%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "6/41 (14.63%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "985c4cb3-2684-4a67-a479-998602044a0d",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  other than sudden death  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Sudden Death * 1/41 (2.44%)Bacterial Infection * 1/41 (2.44%) Bronchitis * 1/41 (2.44%) Sepsis * 1/41 (2.44%) Lymphoedema * 1/41 (2.44%) ",
        "premise_nums": [
            "1/41 (2.44%)Bacterial"
        ]
    },
    {
        "id": "39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3",
        "primaryId": "NCT00107276",
        "secondaryId": "NCT00232505",
        "label": "Contradiction",
        "statement_text": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events  in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event  and less than a 1/3 of those in cohort 2 of the secondary trial had adverse events ",
        "statement_nums": [
            "2 of the",
            "5% of",
            "10% patients",
            "3 of those",
            "1/3 of",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 1: Total: 3/31 (9.68%) Adverse Events 2: Total: 8/25 (32.00%) ",
        "premise_nums": [
            "8/25 (32.00%)",
            "3/31 (9.68%)",
            "4/95 (4.21%)"
        ]
    },
    {
        "id": "5319ac1a-07ae-4531-bf93-5fce83016c87",
        "primaryId": "NCT00941330",
        "statement_text": "Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan ",
        "statement_nums": [
            "2 patients receive",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  ",
        "premise_nums": [
            "6 cycles (6",
            "25 mg daily",
            "3 weeks for",
            "6 to 12"
        ]
    },
    {
        "id": "087aba29-40c6-4453-a44b-e63c3867e5b4",
        "primaryId": "NCT00388726",
        "statement_text": "A 75 year old female patient  with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial ",
        "statement_nums": [
            "3 and an",
            "75 year old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Age greater than or equal 18 years  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of greater than or equal 3 months  ",
        "premise_nums": [
            "0 to 2."
        ]
    },
    {
        "id": "122b1aef-4506-464d-9852-47caa508b047",
        "primaryId": "NCT00879086",
        "statement_text": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia  but Cohort 1 had 8 more cases of Leukopenia than cohort 2.",
        "statement_nums": [
            "1 and 2",
            "1 had 8"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Adverse Events 2: Anaemia 1/50 (2.00%) Leukopenia 0/50 (0.00%) Neutropenia 1/50 (2.00%) ",
        "premise_nums": [
            "0/50 (0.00%)",
            "1/51 (1.96%)",
            "1/50 (2.00%)"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response  According to the Miller&Payne Criteria  pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D. Time frame: Up to 16 weeks Results 1: Arm/Group Title: Arm 1: EC -greater than D + Lapatinib Arm/Group Description: EC -greater than D + Lapatinib Drugs plus Biological ",
        "premise_nums": [
            "5-D). Within",
            "5-A and",
            "5-D. Time",
            "3-4 weeks",
            "4 weeks after",
            "16 weeks Results"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + lapatinib each 21 days for 4 cycles)Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants with pCR 23.5 (11.9 to 35.1) Results 2: Arm/Group Title: Arm 2: EC -greater than D + Trastuzumab Arm/Group Description: EC -greater than D + Trastuzumab Drug plus Biological ",
        "premise_nums": [
            "51 Measure Type:",
            "21 days for",
            "9 to 35.1)"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + Trastuzumab each 21 days for 4 cyclesOverall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants with pCR 47.9 (33.8 to 62.0) Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  ",
        "premise_nums": [
            "21 days for",
            "4 cyclesOverall Number",
            "8 to 62.0)",
            "48 Measure Type:"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) ",
        "premise_nums": [
            "30 days after",
            "2 positive or"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) ",
        "premise_nums": [
            "840 mg IV",
            "4 80.0% Results 2",
            "60 minutes on",
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "5 Measure Type:",
            "14 followed by",
            "30-60 minutes"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "label": "Contradiction",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% ",
        "premise_nums": [
            "6 courses in",
            "60 minutes and",
            "3 weeks for",
            "8 mg/kg IV",
            "14 followed by",
            "6 Measure Type:",
            "30-60 minutes",
            "90 minutes on"
        ]
    },
    {
        "id": "9f7dc38b-1945-4035-a0ff-e08ead55145b",
        "primaryId": "NCT00297596",
        "secondaryId": "NCT00580333",
        "label": "Entailment",
        "statement_text": "Patients who completed a trastuzumab regiment  to treat the current breast cancer greater than 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "2 weeks before"
        ],
        "premise_text": "Inclusion Criteria: Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab  All prior chemotherapy  trastuzumab and radiation therapy should be completed greater than 2 weeks before enrollment  Exclusion Criteria: Any prior cytotoxic chemotherapy or radiation for the current breast cancer ",
        "premise_nums": [
            "2 weeks before"
        ]
    },
    {
        "id": "b259774e-410a-49aa-b5d4-31b8d9505fc3",
        "primaryId": "NCT01525589",
        "statement_text": "People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial ",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1) ",
        "premise_nums": [
            "1/2 (Patients"
        ]
    },
    {
        "id": "893d5684-03f8-4acd-86e4-6d38eea3ce16",
        "primaryId": "NCT00129935",
        "statement_text": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the",
            "80% more"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin * [2]0/669 (0.00%) CNS cerebrovascular ischemia * [1]0/669 (0.00%) CNS cerebrovascular ischemia * [3]0/669 (0.00%) Heart Failure * [1]3/669 (0.45%) Thrombosis/embolism * [1]1/669 (0.15%) ",
        "premise_nums": [
            "0/669 (0.00%)",
            "3/669 (0.45%)",
            "111/669 (16.59%)",
            "1/669 (0.15%)"
        ]
    },
    {
        "id": "893d5684-03f8-4acd-86e4-6d38eea3ce16",
        "primaryId": "NCT00129935",
        "statement_text": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the",
            "80% more"
        ],
        "label": "Contradiction",
        "premise_text": "Thrombosis/embolism * [3]0/669 (0.00%)Adverse Events 2: Total: 138/715 (19.30%) Leukocytes * [1]0/715 (0.00%) Hemoglobin * [1]0/715 (0.00%) Hemoglobin * [2]1/715 (0.14%) CNS cerebrovascular ischemia * [1]1/715 (0.14%) CNS cerebrovascular ischemia * [3]1/715 (0.14%) Heart Failure * [1]1/715 (0.14%) ",
        "premise_nums": [
            "0/669 (0.00%)Adverse",
            "0/715 (0.00%)",
            "138/715 (19.30%)",
            "1/715 (0.14%)"
        ]
    },
    {
        "id": "893d5684-03f8-4acd-86e4-6d38eea3ce16",
        "primaryId": "NCT00129935",
        "statement_text": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "2 of the",
            "80% more"
        ],
        "label": "Contradiction",
        "premise_text": "Thrombosis/embolism * [1]3/715 (0.42%)Thrombosis/embolism * [3]2/715 (0.28%) ",
        "premise_nums": [
            "3/715 (0.42%)Thrombosis/embolism",
            "2/715 (0.28%)"
        ]
    },
    {
        "id": "4b46164d-a4c2-4738-be36-588ab231ceb1",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "label": "Entailment",
        "statement_text": "There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts ",
        "statement_nums": [
            "0 patients with"
        ],
        "premise_text": "Dysphagia 0/5 (0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110 (0.91%) Nausea/Vomiting 1/110 (0.91%) Nausea 1/110 (0.91%) Fever 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%) Infection - Pneumonia 1/110 (0.91%) Dyspnea 2/110 (1.82%) ",
        "premise_nums": [
            "2/110 (1.82%)",
            "1/110 (0.91%)",
            "11/110 (10.00%)",
            "17/110 (15.45%)",
            "0/5 (0.00%)"
        ]
    },
    {
        "id": "4b46164d-a4c2-4738-be36-588ab231ceb1",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "label": "Entailment",
        "statement_text": "There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts ",
        "statement_nums": [
            "0 patients with"
        ],
        "premise_text": "Hypoxia 1/110 (0.91%)",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "d9236874-7f3d-4402-9699-2889db9f5c61",
        "primaryId": "NCT00320541",
        "statement_text": "Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1.",
        "statement_nums": [
            "2 of the",
            "10% more"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Leukopenia 1/94 (1.06%) Adverse Events 2: Leukopenia 3/93 (3.23%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "3/93 (3.23%)"
        ]
    },
    {
        "id": "3658f2f7-a497-4abb-badb-c877036456f2",
        "primaryId": "NCT00077857",
        "statement_text": "Patients must be older than 18, female  have three or more target lesions and more than 1 regiment of chemotherapy to participate in the primary trial ",
        "statement_nums": [
            "1 regiment of"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: women greater than or equal 18 years of age; greater than or equal 1 target lesion; greater than or equal 2 regimens of chemotherapy for advanced/metastatic disease  ",
        "premise_nums": [
            "1 target lesion;",
            "18 years of",
            "2 regimens of"
        ]
    },
    {
        "id": "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c",
        "primaryId": "NCT02781051",
        "secondaryId": "NCT01067976",
        "label": "Entailment",
        "statement_text": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit  no physical activity is explicitly required for the secondary trial ",
        "statement_nums": [
            "12 weeks while"
        ],
        "premise_text": "INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management  ",
        "premise_nums": [
            "12 weekly group",
            "6 month follow",
            "12 weeks with"
        ]
    },
    {
        "id": "52610141-321d-4e3d-8660-ebc14b9f1696",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  triples patient OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Overall Survival (OS) Overall survival was defined as the time in months from randomization until the date of death  For those patients who had not died  survival duration was censored at the last date the patient was known to be alive  Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method  Time frame: from date of randomization until death Results 1: Arm/Group Title: Ixabepilone + Capecitabine ",
        "premise_nums": [
            "95% CI"
        ]
    },
    {
        "id": "52610141-321d-4e3d-8660-ebc14b9f1696",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  triples patient OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "95 to 17.91)",
            "1 week of",
            "40 mg/m2 administered",
            "1000 mg/m2 twice",
            "1 of each",
            "2 daily dose)",
            "2 twice a",
            "95% Confidence",
            "2 administered as",
            "3-hour intravenous"
        ]
    },
    {
        "id": "52610141-321d-4e3d-8660-ebc14b9f1696",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  triples patient OS  compared to Capecitabine alone ",
        "statement_nums": [
            "40 mg/m2 administered",
            "1 of each",
            "2 administered as",
            "3-hour intravenous"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02) ",
        "premise_nums": [
            "1 week of",
            "86 to 17.02)",
            "2 daily dose)",
            "95% Confidence",
            "1250 mg/m2 BID",
            "2 BID (2500"
        ]
    },
    {
        "id": "90203158-6477-4486-b8d9-09dcaca63617",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "label": "Contradiction",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) Renal Failure * 1/33 (3.03%) Pneumonia * 1/33 (3.03%) Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) ",
        "premise_nums": [
            "5/33 (15.15%)",
            "10/76 (13.16%)",
            "1/33 (3.03%)",
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "14/76 (18.42%)"
        ]
    },
    {
        "id": "90203158-6477-4486-b8d9-09dcaca63617",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "label": "Contradiction",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Cardiopulmonary failure 0/76 (0.00%)Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 0/76 (0.00%) ",
        "premise_nums": [
            "0/76 (0.00%)Optic",
            "1/76 (1.32%)"
        ]
    },
    {
        "id": "a847cfc1-9556-4a55-9698-69c22696148f",
        "primaryId": "NCT02370238",
        "statement_text": "There were 2 cases of Angina in the primary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 13/61 (21.31%) Anaemia 1/61 (1.64%) Febrile neutropenia 1/61 (1.64%) Cardiac failure congestive 0/61 (0.00%) Pericardial effusion 0/61 (0.00%) Constipation 1/61 (1.64%) Intestinal perforation 1/61 (1.64%) Stomatitis 0/61 (0.00%) Non-cardiac chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2: Total: 12/60 (20.00%) ",
        "premise_nums": [
            "12/60 (20.00%)",
            "1/61 (1.64%)",
            "0/61 (0.00%)",
            "13/61 (21.31%)",
            "2/61 (3.28%)"
        ]
    },
    {
        "id": "a847cfc1-9556-4a55-9698-69c22696148f",
        "primaryId": "NCT02370238",
        "statement_text": "There were 2 cases of Angina in the primary trial ",
        "statement_nums": [
            "2 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Anaemia 1/60 (1.67%)Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) Intestinal perforation 0/60 (0.00%) Stomatitis 1/60 (1.67%) Non-cardiac chest pain 0/60 (0.00%) Condition aggravated 0/60 (0.00%) General physical health deterioration 1/60 (1.67%) ",
        "premise_nums": [
            "0/60 (0.00%)",
            "1/60 (1.67%)Febrile"
        ]
    },
    {
        "id": "e5379a89-f880-44c1-bee0-a0d8ad2abfce",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "label": "Entailment",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is not specified in the intervention section ",
        "statement_nums": [
            "5 year long"
        ],
        "premise_text": "INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS  INTERVENTION 1: Single Drain ",
        "premise_nums": [
            "5 years INTERVENTION",
            "q28 days",
            "75 mg by",
            "5 years plus",
            "28 days for"
        ]
    },
    {
        "id": "3cbf2726-ddb0-460c-9dd2-082b8dda495d",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 in the primary trial experienced adverse events  but more than 45% of patients cohort 2 did experience adverse events ",
        "statement_nums": [
            "1 in the",
            "45% of",
            "2 did experience"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Infection-ulcer 20/11 (0.00%) Hemoglobin 20/11 (0.00%) Hypoglycemia 20/11 (0.00%) Pain-rib cage due to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11 (9.09%) Pain-breast 21/11 (9.09%) ",
        "premise_nums": [
            "5/11 (45.45%)",
            "21/11 (9.09%)",
            "20/11 (0.00%)"
        ]
    },
    {
        "id": "3cbf2726-ddb0-460c-9dd2-082b8dda495d",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 in the primary trial experienced adverse events  but more than 45% of patients cohort 2 did experience adverse events ",
        "statement_nums": [
            "1 in the",
            "45% of",
            "2 did experience"
        ],
        "label": "Contradiction",
        "premise_text": "Pleural effusion 22/11 (18.18%)Adverse Events 2: Total: 0/6 (0.00%) ",
        "premise_nums": [
            "22/11 (18.18%)Adverse",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "e7741151-2b2c-4e78-a4df-fe998c580714",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "label": "Entailment",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the intervention  but cohort 2 recieves more than double the dose of cohort 1.",
        "statement_nums": [
            "1 cohort is",
            "2 recieves more"
        ],
        "premise_text": "INTERVENTION 1: Arm 1 (Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  INTERVENTION 1: Monotherapy: Alobresib 0.6 mg ",
        "premise_nums": [
            "60 mg daily",
            "60 mg duloxetine",
            "30 mg daily",
            "30 mg duloxetine"
        ]
    },
    {
        "id": "e7741151-2b2c-4e78-a4df-fe998c580714",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "label": "Entailment",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the intervention  but cohort 2 recieves more than double the dose of cohort 1.",
        "statement_nums": [
            "1 cohort is",
            "2 recieves more"
        ],
        "premise_text": "Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  ",
        "premise_nums": [
            "of 0.6 mg orally",
            "Alobresib 1.4 mg Participants",
            "28 days cycle",
            "D28 of",
            "of 1.4 mg orally",
            "1 through C1D28"
        ]
    },
    {
        "id": "8cff36b0-a022-4469-8d14-7120be891cb1",
        "primaryId": "NCT00376688",
        "statement_text": "Less than 1/10 the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [
            "10 the primary",
            "1/10 the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Clinical Benefit Rate (Complete Response  Partial Response  or Stable Disease) Response evaluation criteria in solid tumors (RECIST) criteria version 1.0 was used for response evaluation  Clinical benefit rate is defined as the proportion of subjects experiencing a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks  ",
        "premise_nums": [
            "version 1.0 was used"
        ]
    },
    {
        "id": "8cff36b0-a022-4469-8d14-7120be891cb1",
        "primaryId": "NCT00376688",
        "statement_text": "Less than 1/10 the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [
            "10 the primary",
            "1/10 the"
        ],
        "label": "Entailment",
        "premise_text": "Evaluation of target lesions: Complete Response (CR)-- Disappearance of all target lesions; Partial Response (PR)-- At least a 30% decrease in the sum of the LD of target lesions  taking as reference the baseline sum LD; Stable Disease (SD)-- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD  taking as reference the smallest sum LD since the treatment started;Evaluation of non-target lesions: Complete Response (CR)-- Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/ Stable Disease (SD)-- Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits ",
        "premise_nums": [
            "30% decrease"
        ]
    },
    {
        "id": "8cff36b0-a022-4469-8d14-7120be891cb1",
        "primaryId": "NCT00376688",
        "statement_text": "Less than 1/10 the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [
            "10 the primary",
            "1/10 the"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Up to 24 monthsResults 1: Arm/Group Title: Treatment (Temsirolimus) Arm/Group Description: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Temsirolimus: Given IV Overall Number of Participants Analyzed: 31 Measure Type: Number Unit of Measure: percentage of participants 9.7 ",
        "premise_nums": [
            "28 days in",
            "30 minutes on",
            "24 monthsResults 1:",
            "31 Measure Type:"
        ]
    },
    {
        "id": "2514da19-b30a-44bb-8853-4545e97295da",
        "primaryId": "NCT00633464",
        "statement_text": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group ",
        "statement_nums": [
            "40 mg/m^2",
            "250 mg/m^2",
            "2 group in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator  CR: Disappearance of all evidence of target and non-target lesions  PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions  Confidence interval (CI) was Computed using Clopper-Pearson method  ",
        "premise_nums": [
            "30% reduction"
        ]
    },
    {
        "id": "2514da19-b30a-44bb-8853-4545e97295da",
        "primaryId": "NCT00633464",
        "statement_text": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group ",
        "statement_nums": [
            "40 mg/m^2",
            "250 mg/m^2",
            "2 group in"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks)Results 1: Arm/Group Title: Ixabepilone 40 mg/m^2 Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40 Measure Type: Number Unit of Measure: percentage of participants 30.0 (16.6 to 46.5) Results 2: Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 ",
        "premise_nums": [
            "2 every 3",
            "3 months until",
            "250 mg/m^2",
            "3 weeks Overall",
            "40 Measure Type:",
            "6 weeks for",
            "40 mg/m^2",
            "12 months from",
            "6 to 46.5)"
        ]
    },
    {
        "id": "2514da19-b30a-44bb-8853-4545e97295da",
        "primaryId": "NCT00633464",
        "statement_text": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group ",
        "statement_nums": [
            "40 mg/m^2",
            "250 mg/m^2",
            "2 group in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeksOverall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 35.9 (21.2 to 52.8) ",
        "premise_nums": [
            "400 mg/m^2",
            "2 every 3",
            "250 mg/m^2",
            "40 mg/m^2",
            "39 Measure Type:",
            "3 weeksOverall Number",
            "2 to 52.8)",
            "2 loading dose"
        ]
    },
    {
        "id": "cb9f8a52-b88e-4b04-bb28-a0eabead1439",
        "primaryId": "NCT00728949",
        "statement_text": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case ",
        "statement_nums": [
            "6 adverse event",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) ",
        "premise_nums": [
            "2/56 (3.57%)",
            "1/56 (1.79%)",
            "0/56 (0.00%)",
            "16/56 (28.57%)"
        ]
    },
    {
        "id": "bd3055c6-09aa-47f0-89ed-67ad3798a580",
        "primaryId": "NCT00090857",
        "statement_text": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry  if the results from this are more than 2 standard deviations below normal  they must be excluded ",
        "statement_nums": [
            "2 standard deviations",
            "1 month prior"
        ],
        "label": "Contradiction",
        "premise_text": "Bone density scan within 2 standard deviations from normal within the past 30 days Bone density scan 2 standard deviations below normal allowed if approved by the study physician ",
        "premise_nums": [
            "30 days Bone",
            "2 standard deviations"
        ]
    },
    {
        "id": "9a8157a9-82fc-4d7e-9254-295123459430",
        "primaryId": "NCT00054132",
        "statement_text": "The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above ",
        "statement_nums": [
            "0 patients had",
            "3 or above"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Level of EGFR Expression Estimated at the end of the trial Immunoreactivity will be evaluated qualitatively with regard to intensity as follows: Measured on a scale  ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+ = positive: faint immunoreactivity (weak staining) intense immunoreactivity (strong staining) Immunohistochemical studies will be performed on the tumor specimen to correlate the anti-tumor efficacy of OSI-774 and bevacizumab with pre-treatment molecular characteristics  Time frame: Up to 12 years Results 1: ",
        "premise_nums": [
            "0-3+ 0=negative",
            "12 years Results",
            "774 and bevacizumab"
        ]
    },
    {
        "id": "9a8157a9-82fc-4d7e-9254-295123459430",
        "primaryId": "NCT00054132",
        "statement_text": "The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above ",
        "statement_nums": [
            "0 patients had",
            "3 or above"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: Treatment (Erlotinib Hydrochloride  Bevacizumab)Arm/Group Description: Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants EGFR 0: 24 EGFR 1+: 8 EGFR 2+: 4 EGFR 3+: 0 Insufficient tumor tissue: 2 ",
        "premise_nums": [
            "2+: 4",
            "3+: 0",
            "8 EGFR 2",
            "1-21 and",
            "4 EGFR 3",
            "21 days in",
            "0 Insufficient tumor",
            "30-90 minutes",
            "21 and bevacizumab",
            "24 EGFR 1",
            "38 Measure Type:",
            "1+: 8",
            "90 minutes on"
        ]
    },
    {
        "id": "eb00b609-f17b-4595-87bd-d0843ec9e39a",
        "primaryId": "NCT01857882",
        "secondaryId": "NCT01439945",
        "label": "Contradiction",
        "statement_text": "the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does ",
        "statement_nums": [
            "150 mg/Day more"
        ],
        "premise_text": "INTERVENTION 1: Decision Support Workshop The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology  Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients  Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications  advantages / disadvantages  expected post-operative course  aesthetic result and complications with probabilities Registered nurse (30 mins): preparing for surgery  postoperative recovery and how to navigate the health care system Social worker (30 mins): values clarification exercise Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education INTERVENTION 1: ",
        "premise_nums": [
            "2 hours in"
        ]
    },
    {
        "id": "eb00b609-f17b-4595-87bd-d0843ec9e39a",
        "primaryId": "NCT01857882",
        "secondaryId": "NCT01439945",
        "label": "Contradiction",
        "statement_text": "the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does ",
        "statement_nums": [
            "150 mg/Day more"
        ],
        "premise_text": "Low Dose Magnesium Oxide (800 mg/Day)Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD)  ",
        "premise_nums": [
            "400 mg tablet",
            "4-9: Patients"
        ]
    },
    {
        "id": "0864493d-9f64-49d1-a585-21be71704c59",
        "primaryId": "NCT01684215",
        "statement_text": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in the primary trial suffered grade 4 or above thrombocytopenia ",
        "statement_nums": [
            "4 or above",
            "100 mg vs",
            "125 mg of",
            "0% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1 ",
        "premise_nums": [
            "1 Phase 1"
        ]
    },
    {
        "id": "884ba067-d3fe-4837-ad2a-a802b671b53c",
        "primaryId": "NCT00295867",
        "statement_text": "Patients with an ECOG score between 3-5 are eligible for the primary trial ",
        "statement_nums": [
            "5 are eligible",
            "3-5 are"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria Women greater than 18 years of age with histologically or cytologically confirmed stage I  II or III breast cancer  If adjuvant chemotherapy is recommended  it must be completed before study start  Bone marrow aspirate positive by IC/FC assay a  Definition of positive: greater than 4 MM/ml b  Timing of bone marrow aspiration to determine study eligibility: i  If patient is to receive either no adjuvant therapy or hormonal therapy alone  the aspiration may be performed at diagnosis as part of the large MM study at University of California  San Francisco  or following diagnosis if the patient received initial surgery elsewhere  This is also true for patients who have surgery following neoadjuvant therapy for breast cancer  ",
        "premise_nums": [
            "4 MM/ml b",
            "18 years of"
        ]
    },
    {
        "id": "884ba067-d3fe-4837-ad2a-a802b671b53c",
        "primaryId": "NCT00295867",
        "statement_text": "Patients with an ECOG score between 3-5 are eligible for the primary trial ",
        "statement_nums": [
            "5 are eligible",
            "3-5 are"
        ],
        "label": "Contradiction",
        "premise_text": "History of allergy to bisphosphonates  Acute phase reactions occur in up to 24% of patients and disappear with subsequent dosing  An acute phase reaction does not qualify as an allergic reaction History of renal insufficiency  Renal insufficiency is defined by a serum creatinine greater than the upper limit of normal or a creatinine clearance smaller than 50 mL/min due to any underlying cause  Karnofsky Performance status smaller than 90%. Any significant medical condition that might interfere with treatment  Women participating in this study are not allowed to receive other bisphosphonate therapy during the study period  either oral or intravenous  Patients who are pregnant ",
        "premise_nums": [
            "50 mL/min due",
            "24% of"
        ]
    },
    {
        "id": "6d8b4720-e600-47d7-b6c5-3b8627f2358f",
        "primaryId": "NCT00320710",
        "statement_text": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients ",
        "statement_nums": [
            "2 of the",
            "than 0.5% of patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2: Anaemia 3/202 (1.49%) Febrile neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202 (0.00%) Pancytopenia 1/202 (0.50%) Atrial fibrillation 1/202 (0.50%) Cardiac failure congestive 1/202 (0.50%) Palpitations 1/202 (0.50%) Pericardial effusion 1/202 (0.50%) Supraventricular tachycardia 1/202 (0.50%) ",
        "premise_nums": [
            "3/202 (1.49%)",
            "2/202 (0.99%)",
            "1/202 (0.50%)",
            "0/202 (0.00%)"
        ]
    },
    {
        "id": "dc7c4409-32e5-4211-83fe-0a97b6176ca0",
        "primaryId": "NCT01007942",
        "statement_text": "Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "5 times more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Febrile neutropenia 30/280 (10.71%) Adverse Events 2: Febrile neutropenia 4/282 (1.42%) ",
        "premise_nums": [
            "4/282 (1.42%)",
            "30/280 (10.71%)"
        ]
    },
    {
        "id": "f4f50a05-9d63-4006-9680-b7ef68dbb5fe",
        "primaryId": "NCT00952731",
        "secondaryId": "NCT00956813",
        "label": "Contradiction",
        "statement_text": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses PO ",
        "statement_nums": [
            "2 in the"
        ],
        "premise_text": "INTERVENTION 2: Placebo Gel + Oral Treatment Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  ",
        "premise_nums": [
            "4-10 weeks"
        ]
    },
    {
        "id": "f34760f4-965e-4bbb-b88f-8b63a7045808",
        "primaryId": "NCT00741260",
        "statement_text": "Patients with HER2 positive tumors are ineligible for the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "label": "Contradiction",
        "premise_text": "INCLUSION CRITERIA erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)  based on local testing  or based on centralized FISH testing prior to day 1. ",
        "premise_nums": [
            "2 gene amplified",
            "3+, or",
            "2 overexpression (IHC"
        ]
    },
    {
        "id": "f4a33395-7e6b-46b9-b222-af3bbfff1591",
        "primaryId": "NCT00866905",
        "statement_text": "Less than 2% of patients in the primary trial experienced an adverse event ",
        "statement_nums": [
            "2% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 6/168 (3.57%) ",
        "premise_nums": [
            "6/168 (3.57%)"
        ]
    },
    {
        "id": "e7d00591-381f-45e2-abdb-2ae1e568b193",
        "primaryId": "NCT01421472",
        "statement_text": "More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Febrile Neutropenia * 5/67 (7.46%) ",
        "premise_nums": [
            "5/67 (7.46%)"
        ]
    },
    {
        "id": "f144c34b-9428-4836-bf01-5f7030eb579c",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Entailment",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial are for the control groups ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone ",
        "premise_nums": [
            "0.25 % Bupivacaine",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "f144c34b-9428-4836-bf01-5f7030eb579c",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Entailment",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial are for the control groups ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone  The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  ",
        "premise_nums": [
            "0.25 % bupivacaine",
            "1:100,000 epinephrine",
            "000 epinephrine and",
            "4 mg dexamethasoneadministered",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "f144c34b-9428-4836-bf01-5f7030eb579c",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "label": "Entailment",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial are for the control groups ",
        "statement_nums": [
            "1 for the"
        ],
        "premise_text": "0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If randomized to this arm  subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively  ",
        "premise_nums": [
            "4 mg dexamethasone:",
            "0.25 % bupivacaine",
            "1:100,000 epinephrine",
            "000 epinephrine and",
            "(2.5 mg/ml"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Inclusion Criteria: Female gender; Age 18 years; Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination and mammography or ultrasound  Any N  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization  Known hormone receptor status  Hematopoietic status: ",
        "premise_nums": [
            "1 cm diameter",
            "1 Histologically confirmed",
            "0-1 Histologically",
            "2 in the"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl Hepatic status: ",
        "premise_nums": [
            "75 of institutional",
            "count 1,5 x 10",
            "9 g/dl Hepatic",
            "100 x 10",
            "9/L, Hemoglobin",
            "9/L, Platelet"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Serum total bilirubin 2 x upper limit of normal (ULN)  In the case of known Gilbert's syndrome  a higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan  ",
        "premise_nums": [
            "50% measured",
            "than 1.5 x ULN",
            "Creatinine 1.5mg/dL",
            "5 x ULN)",
            "phosphatase 2.5 times ULN",
            "2 x upper"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Previous (less than 5 years) or current history of malignant neoplasms  except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina  clinically significant arrhythmias  congestive heart failure  transmural myocardial infarction  uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at rest  or chronic therapy with oxygen; ",
        "premise_nums": [
            "180/110), unstable",
            "2 Known history",
            "5 years prior"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine  trastuzumab  lapatinib  paclitaxel  abraxane or their components;Pregnant or lactating women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g  active or uncontrolled infection  uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol Patients have an active infection and require IV or oral antibiotics  Pregnant or breast-feeding women Patients unwilling or unable to comply with the protocol ",
        "premise_nums": [
            "4 inhibitors or"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "label": "Contradiction",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "5 cigarettes smoked"
        ],
        "premise_text": "Inclusion Criteria :women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  ",
        "premise_nums": [
            "1 or more"
        ]
    },
    {
        "id": "f078c722-b879-40f2-ac72-c733001b93dd",
        "primaryId": "NCT01740323",
        "secondaryId": "NCT00127205",
        "label": "Contradiction",
        "statement_text": "the secondary trial and the primary trial only accept 18 year olds ",
        "statement_nums": [
            "18 year olds"
        ],
        "premise_text": "Inclusion Criteria: Female breast cancer patients over the age of 18 will be recruited for this study  Patients enrolled in the study will meet standard criteria for whole breast XRT  PATIENT CHARACTERISTICS: Age 18 and over ",
        "premise_nums": [
            "18 and over",
            "18 will be"
        ]
    },
    {
        "id": "8fee5ce4-3e46-4731-842e-a5b1df451c7d",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "40% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics  Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole ",
        "premise_nums": [
            "30% decrease",
            "15 months Results",
            "RECIST 1.0 for target"
        ]
    },
    {
        "id": "8fee5ce4-3e46-4731-842e-a5b1df451c7d",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "40% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 ",
        "premise_nums": [
            "2 tablets (5",
            "43 Measure Type:",
            "1 tablet of"
        ]
    },
    {
        "id": "def4199f-a22d-4939-b15d-66fd073fb280",
        "primaryId": "NCT02518191",
        "statement_text": "Cohort 2 of the primary trial is the control group ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy  INTERVENTION 2: None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated without GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  ",
        "premise_nums": [
            "2 weeks before",
            "leuprorelin 3.75mg subcutaneous",
            "1-2 weeks",
            "4-8 weeks",
            "8 weeks after"
        ]
    },
    {
        "id": "c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2",
        "primaryId": "NCT00871858",
        "statement_text": "1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis 0/58 (0.00%) Endometrial atrophy 1/58 (1.72%) ",
        "premise_nums": [
            "2/60 (3.33%)",
            "3/58 (5.17%)",
            "1/60 (1.67%)",
            "0/60 (0.00%)",
            "1/58 (1.72%)",
            "0/58 (0.00%)"
        ]
    },
    {
        "id": "86c1430c-553b-4388-a034-b82f78afdc0d",
        "primaryId": "NCT01028352",
        "statement_text": "Patients with aromatase inhibitor associated musculoskeletal symptoms  such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy  are eligible for the primary trial ",
        "statement_nums": [
            "0 sensory neuropathy",
            "1 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: AI-associated musculoskeletal symptoms  defined as: Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy; ",
        "premise_nums": [
            "6 or 7",
            "7 on CGICS",
            "1 or higher"
        ]
    },
    {
        "id": "b7cef0e1-7bd8-4c0e-a044-b11708cf927c",
        "primaryId": "NCT01905592",
        "statement_text": "both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies ",
        "statement_nums": [
            "4 standard of"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Physician's Choice Physician selection from 4 standard of care metastatic breast cancer chemotherapies (eribulin or vinorelbine or gemcitabine or capecitabine)  until progression or unacceptable toxicity develops  INTERVENTION 2: Niraparib Niraparib 300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops ",
        "premise_nums": [
            "x100 mg",
            "300 mg (3x100",
            "4 standard of"
        ]
    },
    {
        "id": "0b55d5b7-5e71-497f-96ad-9dc2f872c4aa",
        "primaryId": "NCT00444587",
        "statement_text": "A total of 2/93 patients in the primary trial were observed with either Leukopenia  Cardiopulmonary failure or Diarrhoea ",
        "statement_nums": [
            "2/93 patients",
            "93 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Leukopenia 2/93 (2.15%) Cardiopulmonary failure 2/93 (2.15%) Diarrhoea 3/93 (3.23%) ",
        "premise_nums": [
            "2/93 (2.15%)",
            "3/93 (3.23%)"
        ]
    },
    {
        "id": "5464e8a7-159c-4e00-8710-45a44ceaeda3",
        "primaryId": "NCT03061175",
        "secondaryId": "NCT03098550",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study  whereas Cohort 1 of the primary trial has the same intervention for the full study ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)",
        "premise_nums": [
            "1 to 8),",
            "16 mg/kg Q",
            "3 to 24)",
            "240 mg Q2W"
        ]
    },
    {
        "id": "98965d07-e2db-41bf-ac3e-a5c130513275",
        "primaryId": "NCT00382018",
        "secondaryId": "NCT03012477",
        "label": "Contradiction",
        "statement_text": "Between the patients in the primary trial and the secondary trial  only 1.56% suffered from sepsis ",
        "statement_nums": [
            "only 1.56% suffered from"
        ],
        "premise_text": "Adverse Events 1: Total: 0/161 (0.00%) Gastrointestinal-Other 0/161 (0.00%) Dehydration 0/161 (0.00%) Renal/Genitourinary-Other 0/161 (0.00%) Adverse Events 2: Total: 1/64 (1.56%) Gastrointestinal-Other 1/64 (1.56%) Dehydration 1/64 (1.56%) Renal/Genitourinary-Other 1/64 (1.56%) Sepsis 1/34 (2.94%) ",
        "premise_nums": [
            "1/64 (1.56%)",
            "0/161 (0.00%)",
            "1/34 (2.94%)"
        ]
    },
    {
        "id": "d1080199-2591-44bd-bdad-0dea3830e657",
        "primaryId": "NCT00106002",
        "statement_text": "the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression ",
        "statement_nums": [
            "2 weeks until",
            "600 mg/m2 of",
            "2 of Pemetrexed"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Pemetrexed 600 mg/m2, intravenous (IV)  every 14 days until complete response or disease progression ",
        "premise_nums": [
            "600 mg/m2,",
            "14 days until"
        ]
    },
    {
        "id": "c37c21f5-19a0-4fcc-af92-89690fb64091",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "label": "Contradiction",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "3 Fatty Acid"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty Acid) Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies ",
        "premise_nums": [
            "3 fatty acid",
            "3 Fatty Acid:",
            "3 Fatty Acid)"
        ]
    },
    {
        "id": "c37c21f5-19a0-4fcc-af92-89690fb64091",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "label": "Contradiction",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "3 Fatty Acid"
        ],
        "premise_text": "INTERVENTION 1:Cohort A 750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settings INTERVENTION 2: Cohort B 750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings  ",
        "premise_nums": [
            "2 and/or more",
            "2 prior trastuzumab",
            "0-1, and",
            "1:Cohort A"
        ]
    },
    {
        "id": "bea7f10e-09d6-42c3-9e89-dfd1112a33d5",
        "primaryId": "NCT01276041",
        "secondaryId": "NCT00688909",
        "label": "Contradiction",
        "statement_text": "0 patients in the primary trial or the secondary trial died ",
        "statement_nums": [
            "0 patients in"
        ],
        "premise_text": "Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) Adverse Events 1: Total: 5/261 (1.92%) ",
        "premise_nums": [
            "5/70 (7.14%)",
            "1/70 (1.43%)",
            "2/70 (2.86%)",
            "5/261 (1.92%)",
            "3/70 (4.29%)",
            "18/70 (25.71%)"
        ]
    },
    {
        "id": "bea7f10e-09d6-42c3-9e89-dfd1112a33d5",
        "primaryId": "NCT01276041",
        "secondaryId": "NCT00688909",
        "label": "Contradiction",
        "statement_text": "0 patients in the primary trial or the secondary trial died ",
        "statement_nums": [
            "0 patients in"
        ],
        "premise_text": "Cholecystitis chronic 1/261 (0.38%)Post procedural bile leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) ",
        "premise_nums": [
            "1/261 (0.38%)Post"
        ]
    },
    {
        "id": "3d41d86b-f53f-4bf9-a4dd-eae2412c485e",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive letrozole  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) ",
        "premise_nums": [
            "3 weeks plus",
            "15mg/kg every"
        ]
    },
    {
        "id": "3d41d86b-f53f-4bf9-a4dd-eae2412c485e",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive letrozole  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent Letrozole Bevacizumab Fulvestrant ",
        "premise_nums": [
            "15mg/kg i",
            "1 every 3"
        ]
    },
    {
        "id": "f1108cbc-db27-431d-9154-1a267278bda4",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%) Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) ",
        "premise_nums": [
            "1/1634 (0.06%)",
            "3/1634 (0.18%)",
            "331/1634 (20.26%)",
            "0/1634 (0.00%)",
            "18/1634 (1.10%)"
        ]
    },
    {
        "id": "f1108cbc-db27-431d-9154-1a267278bda4",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Cardiomyopathy 1/1634 (0.06%)Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%) Lymphedema 2/1635 (0.12%) Pancytopenia 1/1635 (0.06%) Thrombocytopenia 1/1635 (0.06%) Arrhythmia 3/1635 (0.18%) ",
        "premise_nums": [
            "5/1635 (0.31%)",
            "520/1635 (31.80%)",
            "0/1635 (0.00%)",
            "2/1635 (0.12%)",
            "1/1635 (0.06%)",
            "56/1635 (3.43%)",
            "1/1634 (0.06%)Adverse",
            "3/1635 (0.18%)"
        ]
    },
    {
        "id": "f1108cbc-db27-431d-9154-1a267278bda4",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arrhythmia Ventricular 1/1635 (0.06%)Cardiomyopathy 0/1635 (0.00%) ",
        "premise_nums": [
            "0/1635 (0.00%)",
            "1/1635 (0.06%)Cardiomyopathy"
        ]
    },
    {
        "id": "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "label": "Entailment",
        "statement_text": "There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41 (2.44%) Femoral Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Fatigue 2/41 (4.88%) Headache 1/41 (2.44%) Nausea 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) ",
        "premise_nums": [
            "27/41 (65.85%)",
            "2/41 (4.88%)",
            "4/41 (9.76%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "label": "Entailment",
        "statement_text": "There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1:Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31 (6.45%) Ascites 0/31 (0.00%) Ileus 1/31 (3.23%) Small Intestinal Obstruction 1/31 (3.23%) Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%) ",
        "premise_nums": [
            "0/31 (0.00%)",
            "2/31 (6.45%)",
            "15/31 (48.39%)",
            "1:Total: 15/31",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "afc4a45b-6592-4ca8-b174-033fb6a0624a",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "label": "Contradiction",
        "statement_text": "Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial ",
        "statement_nums": [
            "12 weeks to"
        ],
        "premise_text": "Exclusion Criteria: Life expectancy of less than 12 weeks Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease) HER2-positive metastatic or locally advanced breast cancer For MBC participants: Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease  amenable for treatment with docetaxel History of disease progression within 3 months prior to study entry For LABC participants: Newly diagnosed locally advanced breast cancer  Stage IIA-IIIC (American Joint Committee on Cancer [AJCC] staging system) Exclusion Criteria: Significant cardiac disease Inadequate bone marrow  liver or renal function For MBC participants: ",
        "premise_nums": [
            "3 months prior",
            "12 weeks Inclusion",
            "2 will be",
            "2-positive metastatic"
        ]
    },
    {
        "id": "afc4a45b-6592-4ca8-b174-033fb6a0624a",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "label": "Contradiction",
        "statement_text": "Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial ",
        "statement_nums": [
            "12 weeks to"
        ],
        "premise_text": "Participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastasesBrain metastases that are untreated  symptomatic or require therapy to control symptoms; or any radiation  surgery  or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment  For LABC participants: Clinically or radiologically detectable metastasis (M1 disease) Participants for whom surgery as primary intent procedure is the best option to treat their disease Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease ",
        "premise_nums": [
            "2 months of"
        ]
    },
    {
        "id": "2e1d4811-ae58-4b81-b53a-dbcb8c980a08",
        "primaryId": "NCT00033514",
        "statement_text": "Elizabeth has HER2 positive breast cancer  she is eligible for the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Women aged greater than 18 years Histologically documents metastatic breast cancer HER2 positive using Fluorescence In Situ Hybridization (FISH) ",
        "premise_nums": [
            "18 years Histologically",
            "2 positive using"
        ]
    },
    {
        "id": "f27b25bd-c28e-4aac-8ad6-951fd7381ce4",
        "primaryId": "NCT01262027",
        "statement_text": "More than 1 patient in the primary trial suffered an adverse event ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) ",
        "premise_nums": [
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "11617367-193f-4f6b-bc3e-e58ea76d1052",
        "primaryId": "NCT00485953",
        "secondaryId": "NCT00068601",
        "label": "Contradiction",
        "statement_text": "the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD ",
        "statement_nums": [
            "4 weeks and"
        ],
        "premise_text": "INTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication once weekly INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing chemotherapy alone  cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy  Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity  cyclophosphamide: Part of planned chemotherapy regimen goserelin acetate: Given subcutaneously ",
        "premise_nums": [
            "35 mg weekly",
            "4 weeks beginning",
            "1 week before"
        ]
    },
    {
        "id": "4e42302d-2cd9-4a91-9338-8e3b0ffb9292",
        "primaryId": "NCT00654836",
        "statement_text": "Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial ",
        "statement_nums": [
            "2 positive adenocarcinoma"
        ],
        "label": "Contradiction",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally recurrent or metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past No known CNS disease ",
        "premise_nums": [
            "2-positive, must",
            "2-negative breast"
        ]
    },
    {
        "id": "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c",
        "primaryId": "NCT00270894",
        "statement_text": "60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60% of",
            "85% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Subjects Able to Complete greater than 85% of the Planned Dose on Schedule Feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with greater than 85% of the protocol-specified dose  Time frame: From the start of treatment through the neoadjuvant treatment period (approximately 20 weeks) Results 1: Arm/Group Title: Neoadjuvant Therapy ",
        "premise_nums": [
            "85% of"
        ]
    },
    {
        "id": "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c",
        "primaryId": "NCT00270894",
        "statement_text": "60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60% of",
            "85% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: percentage of participants 60 ",
        "premise_nums": [
            "4 treatments Overall",
            "4 mg/kg",
            "30 Measure Type:",
            "2 weeks for",
            "3-week break"
        ]
    },
    {
        "id": "c77c8e02-7abb-4b63-8917-01babe5cd372",
        "primaryId": "NCT00863655",
        "statement_text": "There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "statement_nums": [
            "5 more cases",
            "1 of the",
            "1 more case"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238 (0.84%) Disseminated intravascular coagulation 0/238 (0.00%) ",
        "premise_nums": [
            "37/238 (15.55%)",
            "1/482 (0.21%)",
            "2/238 (0.84%)",
            "158/482 (32.78%)",
            "0/238 (0.00%)",
            "7/482 (1.45%)"
        ]
    },
    {
        "id": "adae7d81-bc8e-48e4-b966-27c2633eb72d",
        "primaryId": "NCT02131064",
        "statement_text": "over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples ",
        "statement_nums": [
            "100 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples tpCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy  tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes ( that is [i.e.]  ypT0/is, ypN0 in the American Joint Committee on Cancer [AJCC] staging system  7th edition)  Percentage of participants with tpCR was reported  Time frame: Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months) Results 1: ",
        "premise_nums": [
            "6 weeks after",
            "0 in the",
            "0/is, ypN0"
        ]
    },
    {
        "id": "4cbb7f8f-ea60-453d-b4ab-e967944426d3",
        "primaryId": "NCT00992225",
        "statement_text": "Only 2 of the 16 adverse event types recorded in the primary trial  occurred more than once ",
        "statement_nums": [
            "2 of the",
            "16 adverse event"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 10/33 (30.30%) Constipation 1/33 (3.03%) Dysphagia 1/33 (3.03%) Ileus 1/33 (3.03%) Nausea 1/33 (3.03%) Vomiting 1/33 (3.03%) Fatigue 1/33 (3.03%) Pain 1/33 (3.03%) Sepsis 2/33 (6.06%) Urinary tract infection 1/33 (3.03%) Alanine aminotransferase increased 1/33 (3.03%) Aspartate aminotransferase increased 1/33 (3.03%) Dehydration 2/33 (6.06%) ",
        "premise_nums": [
            "1/33 (3.03%)",
            "2/33 (6.06%)",
            "10/33 (30.30%)"
        ]
    },
    {
        "id": "47f11df7-6c82-4c50-9249-5085313a5064",
        "primaryId": "NCT00209092",
        "secondaryId": "NCT00631852",
        "label": "Entailment",
        "statement_text": "A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for the primary trial  but not for the secondary trial ",
        "statement_nums": [
            "5 millimeter greatest"
        ],
        "premise_text": "Inclusion Criteria: Histologically or cytologically confirmed breast carcinoma  Inclusion Criteria: Patients with cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging ",
        "premise_nums": [
            "least 1.0 cm greatest"
        ]
    },
    {
        "id": "3114ff0f-184c-48ba-b33d-631505cffeef",
        "primaryId": "NCT01961544",
        "statement_text": "the primary trial reported a combined total of 3 cases of Ascites  Asthenia and Gastritis in cohort 1.",
        "statement_nums": [
            "3 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Ascites * 1/101 (0.99%) Gastritis * 1/101 (0.99%) Asthenia * 1/101 (0.99%) ",
        "premise_nums": [
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "edf31a43-a774-4f2a-8a02-89b84de941bb",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response ",
        "statement_nums": [
            "27.6% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage of Patients With Pathological Complete Response (pCR) in Patients Who Have Fatty Acid Synthase (FASN) Expression pCR is defined as no invasive disease in the breast of axilla at the time of definitive surgery  A patient is considered to have FASN expression if the positivity was greater than or equal 15% at the baseline or after 4-7 days of Omeprazole monotherapy  FASN expression is evaluated using immunohistochemistry in core biopsy samples  The percent of patients with FASN expression that have pCR will be calculated with an exact 95% confidence interval  Time frame: Up to 6 months Results 1: ",
        "premise_nums": [
            "95% confidence",
            "6 months Results",
            "4-7 days",
            "7 days of",
            "15% at"
        ]
    },
    {
        "id": "edf31a43-a774-4f2a-8a02-89b84de941bb",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response ",
        "statement_nums": [
            "27.6% of"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Title: High Dose Omeprazole TreatmentArm/Group Description: Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery  Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 72.4 (52.8 to 87.3) ",
        "premise_nums": [
            "7 days prior",
            "4-7 days",
            "29 Measure Type:",
            "80 mg orally",
            "8 to 87.3)"
        ]
    },
    {
        "id": "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "label": "Contradiction",
        "statement_text": "There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts ",
        "statement_nums": [
            "15 patients with"
        ],
        "premise_text": "Dysphagia 0/5 (0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110 (0.91%) Nausea/Vomiting 1/110 (0.91%) Nausea 1/110 (0.91%) Fever 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%) Infection - Pneumonia 1/110 (0.91%) Dyspnea 2/110 (1.82%) ",
        "premise_nums": [
            "2/110 (1.82%)",
            "1/110 (0.91%)",
            "11/110 (10.00%)",
            "17/110 (15.45%)",
            "0/5 (0.00%)"
        ]
    },
    {
        "id": "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "label": "Contradiction",
        "statement_text": "There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts ",
        "statement_nums": [
            "15 patients with"
        ],
        "premise_text": "Hypoxia 1/110 (0.91%)",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with patients body weight ",
        "statement_nums": [
            "1000 mg PO"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib ",
        "premise_nums": [
            "LBH589 With",
            "10 additional patients",
            "589 and will",
            "589 with Capecitabine",
            "14 of every",
            "589 With Capecitabine",
            "589 will be",
            "589 and Lapatinib",
            "LBH589 with",
            "LBH589 and",
            "LBH589 will",
            "2 orally BID",
            "21 days in",
            "14 days out",
            "825 mg/m2 to",
            "2 to 1250",
            "1250 mg/m2 orally"
        ]
    },
    {
        "id": "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with patients body weight ",
        "statement_nums": [
            "1000 mg PO"
        ],
        "label": "Contradiction",
        "premise_text": "LBH589 and LapatinibLBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  ",
        "premise_nums": [
            "1000 mg PO",
            "589 will be",
            "21 days in",
            "2 to 1250",
            "10 additional patients",
            "14 of every",
            "825 mg/m2 to",
            "589 and will",
            "589 and LapatinibLBH589:",
            "LBH589 will",
            "1250 mg/m2 orally",
            "LBH589 and",
            "2 orally BID"
        ]
    },
    {
        "id": "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62",
        "primaryId": "NCT02995980",
        "statement_text": "A patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligilbe for the primary trial ",
        "statement_nums": [
            "63 and with"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Glomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category c or d)  ",
        "premise_nums": [
            "60 Heterogeneously or"
        ]
    },
    {
        "id": "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial the majority of patients had Stable Disease  none of them had complete or partial response ",
        "statement_nums": [
            "48 of the"
        ],
        "label": "Contradiction",
        "premise_text": "The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.Time frame: At 48 weeks Results 1: Arm/Group Title: Everolimus and Exemestane ",
        "premise_nums": [
            "4 weeks apart",
            "48 weeks Results"
        ]
    },
    {
        "id": "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial the majority of patients had Stable Disease  none of them had complete or partial response ",
        "statement_nums": [
            "48 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o  and exemestane 25mg daily p.o Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: participants Patients with measurable disease at baseline: 39 Patients with non-measurable disease at baseline: 10 Best at WK 48 - Complete Response (CR): 0 Best at WK 48 - Partial Response (PR): 7 Best at WK 48 - Stable Disease (SD): 18 Best at WK 48 - Progressive Disease (PD): 15 Unknown: 1 Missing: 8 ",
        "premise_nums": [
            "39 Patients with",
            "18 Best at",
            "49 Measure Type:",
            "7 Best at",
            "10 Best at"
        ]
    },
    {
        "id": "01236718-14da-450c-8051-0207d31743a5",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause  was a month longer for patients in cohort 1 of the primary trial  compared to those in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10 Overall survival (OS) was defined as the time from randomization to death due to any cause  Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) Results 1: Arm/Group Title: Pembrolizumab Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)  Overall Number of Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 12.7 (9.9 to 16.3) Results 2: ",
        "premise_nums": [
            "200 mg IV",
            "10 Overall survival",
            "35 administrations (up",
            "95% Confidence",
            "11-April-2019) Results",
            "36 months (through",
            "9 to 16.3)"
        ]
    },
    {
        "id": "01236718-14da-450c-8051-0207d31743a5",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause  was a month longer for patients in cohort 1 of the primary trial  compared to those in cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: ChemotherapyArm/Group Description: Participants received capecitabine  eribulin  gemcitabine  or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice  TPC) in accordance with local regulations and guidelines  Overall Number of Participants Analyzed: 98 Median (95% Confidence Interval) Unit of Measure: Months 11.6 (8.3 to 13.7) ",
        "premise_nums": [
            "95% Confidence",
            "3 to 13.7)"
        ]
    },
    {
        "id": "d72c45e5-6654-4afe-91a0-1f47b0c13dc0",
        "primaryId": "NCT00464646",
        "statement_text": "Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast  with ipsilateral nodes pN2. She is eligible for the primary trial ",
        "statement_nums": [
            "2-positive invasive",
            "57 year old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients must be female  The patient must be greater than or equal to 18 years old  The patient's ECOG performance status must be 0 or 1. The tumor must be invasive adenocarcinoma of the breast on histologic examination  The breast cancer must be determined to be HER2-positive prior to study entry  Assays performed using FISH require gene amplification  Assays using IHC require a strongly positive (3+) staining score  By pathologic evaluation  ipsilateral nodes must be pN2 or pN3. ",
        "premise_nums": [
            "2-positive prior",
            "2 or pN3.",
            "(3+) staining",
            "18 years old",
            "0 or 1."
        ]
    },
    {
        "id": "e1417a26-2f40-4dd6-b598-e66e57312595",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Contradiction",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER  0% of the secondary trial patients were recorded as having LACRIMAL DISORDER ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "Adverse Events 1: Total: 6/22 (27.27%) Thrombocytopenia 1/22 (4.55%) leucocytopenia 1/22 (4.55%) neutropenia 1/22 (4.55%) papilledema 1/22 (4.55%) Nausea 1/22 (4.55%) hyperglycemia 1/22 (4.55%) Adverse Events 1: Total: 24/101 (23.76%) LYMPHADENOPATHY 0/101 (0.00%) FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ",
        "premise_nums": [
            "24/101 (23.76%)",
            "6/22 (27.27%)",
            "1/101 (0.99%)",
            "20/101 (0.00%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "e1417a26-2f40-4dd6-b598-e66e57312595",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Contradiction",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER  0% of the secondary trial patients were recorded as having LACRIMAL DISORDER ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "ARRHYTHMIA 20/101 (0.00%)CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%) Adverse Events 2: Total: 22/103 (21.36%) LYMPHADENOPATHY 1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ",
        "premise_nums": [
            "21/103 (0.97%)",
            "22/103 (21.36%)",
            "21/101 (0.99%)",
            "20/101 (0.00%)CARDIAC",
            "22/101 (1.98%)"
        ]
    },
    {
        "id": "e1417a26-2f40-4dd6-b598-e66e57312595",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "label": "Contradiction",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER  0% of the secondary trial patients were recorded as having LACRIMAL DISORDER ",
        "statement_nums": [
            "5% of",
            "1 of the",
            "0% of"
        ],
        "premise_text": "ATRIAL FIBRILLATION 1/103 (0.97%)ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) CORONARY OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%) ",
        "premise_nums": [
            "21/103 (0.97%)",
            "1/103 (0.97%)ARRHYTHMIA",
            "20/103 (0.00%)"
        ]
    },
    {
        "id": "4d776c28-8ed1-4f3f-9837-0821029d3775",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 were constipated ",
        "statement_nums": [
            "2 were constipated",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Febrile neutropenia 4/52 (7.69%) Pancytopenia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain 1/52 (1.92%) Constipation 1/52 (1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%) Sepsis 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "4/52 (7.69%)",
            "17 Anaemia 2",
            "1/52 (1.92%)",
            "2/52 (3.85%)"
        ]
    },
    {
        "id": "4d776c28-8ed1-4f3f-9837-0821029d3775",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 were constipated ",
        "statement_nums": [
            "2 were constipated",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 7 Anaemia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%) Pyrexia 1/21 (4.76%) Hepatic failure 0/21 (0.00%) Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%) Sepsis 0/21 (0.00%) ",
        "premise_nums": [
            "7 Anaemia 0",
            "2:Total: 7",
            "0/21 (0.00%)",
            "1/21 (4.76%)"
        ]
    },
    {
        "id": "9f23f617-b8ec-4665-ad0b-9a9bc8b19691",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Contradiction",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Adverse Events 1: Total: 267/744 (35.89%) Neutropenia *2/744 (0.27%) Anaemia *1/744 (0.13%) Leukopenia *1/744 (0.13%) Thrombocytopenia *1/744 (0.13%) Thrombotic thrombocytopenic purpura *1/744 (0.13%) Atrial flutter *1/744 (0.13%) Cardiac arrest *1/744 (0.13%) Myocardial ischaemia *1/744 (0.13%) Arrhythmia *0/744 (0.00%) ",
        "premise_nums": [
            "0/744 (0.00%)",
            "2/744 (0.27%)",
            "1/744 (0.13%)",
            "267/744 (35.89%)"
        ]
    },
    {
        "id": "9f23f617-b8ec-4665-ad0b-9a9bc8b19691",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Contradiction",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Cardiac failure congestive *0/744 (0.00%)Adverse Events 2: Total: 67/736 (9.10%) Neutropenia *1/736 (0.14%) Anaemia *0/736 (0.00%) Leukopenia *0/736 (0.00%) Thrombocytopenia *0/736 (0.00%) Thrombotic thrombocytopenic purpura *0/736 (0.00%) Atrial flutter *0/736 (0.00%) Cardiac arrest *0/736 (0.00%) Myocardial ischaemia *0/736 (0.00%) ",
        "premise_nums": [
            "0/744 (0.00%)Adverse",
            "0/736 (0.00%)",
            "1/736 (0.14%)",
            "67/736 (9.10%)"
        ]
    },
    {
        "id": "9f23f617-b8ec-4665-ad0b-9a9bc8b19691",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Contradiction",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Arrhythmia *2/736 (0.27%)Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) ",
        "premise_nums": [
            "6 Atrial fibrillation",
            "1/67 (1.49%)",
            "1/736 (0.14%)",
            "2/736 (0.27%)Cardiac"
        ]
    },
    {
        "id": "9f23f617-b8ec-4665-ad0b-9a9bc8b19691",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "label": "Contradiction",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "3 cases across"
        ],
        "premise_text": "Pleurisy 1/67 (1.49%)",
        "premise_nums": [
            "1/67 (1.49%)"
        ]
    },
    {
        "id": "92da8d30-a7e9-4fb4-95e4-484b53279ad7",
        "primaryId": "NCT01570036",
        "secondaryId": "NCT00021255",
        "label": "Entailment",
        "statement_text": "the primary trial and the secondary trial monitor the DFS of their patient cohorts  however the secondary trial reports the % of patients with DFS greater than or equal 5 years whereas the primary trial reports % of participants with DFS greater than or equal 2 years ",
        "statement_nums": [
            "5 years whereas"
        ],
        "premise_text": "Disease-free Survival (DFS) Disease-free survival (DFS) for all patients regardless of randomization will be determined by patients' own physicians at the individual study sites during routine follow-up screening  This will occur every three months for the first 24 months after completion of primary therapies and every six months thereafter with clinical exam  and laboratory and radiographic surveillance  The primary objective of the study is disease-free survival (DFS) at 24 months  Time frame: Disease-free survival at 24 months Outcome Measurement: Percentage of Participants With Disease Free Survival at 5 Years ",
        "premise_nums": [
            "24 months Outcome",
            "24 months after"
        ]
    },
    {
        "id": "762c3b23-547a-40cb-86c9-767294f4a142",
        "primaryId": "NCT02165605",
        "statement_text": "A 56 year old patient with a masectomy would not be eligible for the primary trial  due to her age ",
        "statement_nums": [
            "56 year old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female  age 18 or older Intact breast (not surgically absent) ",
        "premise_nums": [
            "18 or older"
        ]
    },
    {
        "id": "95a509d6-2990-49ac-b36c-aedf842f17ee",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) Stomatitis 0/8 (0.00%) ",
        "premise_nums": [
            "0/8 (0.00%)",
            "1/8 (12.50%)",
            "3/8 (37.50%)"
        ]
    },
    {
        "id": "95a509d6-2990-49ac-b36c-aedf842f17ee",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Upper gastrointestinal haemorrhage 0/8 (0.00%)Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "0/8 (0.00%)Vomiting",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "95a509d6-2990-49ac-b36c-aedf842f17ee",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Diarrhoea 0/6 (0.00%)Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) ",
        "premise_nums": [
            "0/6 (0.00%)Nausea",
            "1/6 (16.67%)"
        ]
    },
    {
        "id": "9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6",
        "primaryId": "NCT00258960",
        "statement_text": "One patient in the primary trial experienced a grade 4 adverse event ",
        "statement_nums": [
            "4 adverse event"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 16/48 (33.33%) Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%) ",
        "premise_nums": [
            "2/48 (4.17%)",
            "3/48 (6.25%)",
            "1/48 (2.08%)",
            "16/48 (33.33%)"
        ]
    },
    {
        "id": "19c2c2d7-4c33-4842-9ed4-02cfae663ce2",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Entailment",
        "statement_text": "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial ",
        "statement_nums": [
            "1 case of",
            "0 in the"
        ],
        "premise_text": "Adverse Events 1: Total: 19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth  Atrial flutter 1/3761 (0.03%) Ventric.arrhyth  Trigeminy 1/3761 (0.03%) Hypothyroidism 0/3761 (0.00%) Blurred vision 1/3761 (0.03%) Nyctalopia 0/3761 (0.00%) ",
        "premise_nums": [
            "19/3761 (0.51%)",
            "3/3761 (0.08%)",
            "0/3761 (0.00%)",
            "1/3761 (0.03%)"
        ]
    },
    {
        "id": "19c2c2d7-4c33-4842-9ed4-02cfae663ce2",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Entailment",
        "statement_text": "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial ",
        "statement_nums": [
            "1 case of",
            "0 in the"
        ],
        "premise_text": "Ocular - Other 1/3761 (0.03%)Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%) Ventric.arrhyth  Trigeminy 0/3759 (0.00%) Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%) ",
        "premise_nums": [
            "1/3759 (0.03%)",
            "0/3759 (0.00%)",
            "1/3761 (0.03%)Adverse",
            "7/3759 (0.19%)"
        ]
    },
    {
        "id": "19c2c2d7-4c33-4842-9ed4-02cfae663ce2",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Entailment",
        "statement_text": "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial ",
        "statement_nums": [
            "1 case of",
            "0 in the"
        ],
        "premise_text": "Ocular - Other 0/3759 (0.00%)Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) ",
        "premise_nums": [
            "29/48 (60.42%)",
            "7/48 (14.58%)",
            "3/48 (6.25%)",
            "4/48 (8.33%)",
            "2/48 (4.17%)",
            "1/48 (2.08%)",
            "0/3759 (0.00%)Adverse"
        ]
    },
    {
        "id": "19c2c2d7-4c33-4842-9ed4-02cfae663ce2",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "label": "Entailment",
        "statement_text": "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial ",
        "statement_nums": [
            "1 case of",
            "0 in the"
        ],
        "premise_text": "Mucosal infection 1/48 (2.08%)",
        "premise_nums": [
            "1/48 (2.08%)"
        ]
    },
    {
        "id": "94a54cdf-4c1c-4994-929a-ced7a33f2b43",
        "primaryId": "NCT00866905",
        "statement_text": "Less than 1% of patients in the primary trial became depressed ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: DEPRESSION 1/168 (0.60%) ",
        "premise_nums": [
            "1/168 (0.60%)"
        ]
    },
    {
        "id": "d0d4e184-0764-4c28-9af7-4535c7ed1aad",
        "primaryId": "NCT00303108",
        "statement_text": "Cohort 2 of the primary trial produced marginally better results than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR  Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity  whichever came first  assessed up to 54 months  Results 1: Arm/Group Title: D+C and Taxane Naive Arm/Group Description: Doxil  Carboplatin and Taxane naive Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 30.8 (17.0 to 47.6) ",
        "premise_nums": [
            "30% decrease",
            "0 to 47.6)",
            "39 Measure Type:"
        ]
    },
    {
        "id": "d0d4e184-0764-4c28-9af7-4535c7ed1aad",
        "primaryId": "NCT00303108",
        "statement_text": "Cohort 2 of the primary trial produced marginally better results than cohort 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Results 2:Arm/Group Title: D+C and Taxane Pretreated Arm/Group Description: Doxil  Carboplatin and Taxane pretreated Overall Number of Participants Analyzed: 42 Measure Type: Number Unit of Measure: percentage of participants 31.0 (17.6 to 47.1) ",
        "premise_nums": [
            "42 Measure Type:",
            "2:Arm/Group Title:",
            "6 to 47.1)"
        ]
    },
    {
        "id": "c207ff16-b7d0-49e4-9177-0597044f3008",
        "primaryId": "NCT03374995",
        "statement_text": "Some the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks  others participants may have it administered by ubcutaneous injection ",
        "statement_nums": [
            "3-6 weeks"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Group I (Topical Keratin) Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks)  Quality-of-Life Assessment: Ancillary studies Topical Keratin: Given topically INTERVENTION 2: Group II (Standard of Care) Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks)  Best Practice: Receive standard of care Quality-of-Life Assessment: Ancillary studies ",
        "premise_nums": [
            "3-6 weeks"
        ]
    },
    {
        "id": "35234f08-cf01-478f-b739-600b5a6ea3d9",
        "primaryId": "NCT00550771",
        "statement_text": "16/179 patients in the primary trial Experienced Cardiac Events  with the majority of those coming from cohort 2.",
        "statement_nums": [
            "16/179 patients",
            "179 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF)  myocardial infarction or arrhythmia  or probable cardiac death defined as sudden  unexpected death within 24 hours of a definite or probable cardiac event  or severe symptomatic HF  concomitant with a left ventricular ejection fraction (LVEF) drop of greater than 10 percentage points from baseline and to 50% LVEF ",
        "premise_nums": [
            "8 Cycles of",
            "10 percentage points",
            "50% LVEF",
            "1 Year Cardiac",
            "1 or 2),",
            "24 hours of"
        ]
    },
    {
        "id": "35234f08-cf01-478f-b739-600b5a6ea3d9",
        "primaryId": "NCT00550771",
        "statement_text": "16/179 patients in the primary trial Experienced Cardiac Events  with the majority of those coming from cohort 2.",
        "statement_nums": [
            "16/179 patients",
            "179 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of greater than 10 percentage points from baseline and to smaller than 50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks Time frame: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment Results 1: Arm/Group Title: Pegylated Liposomal Doxorubicin (PLD) Based Regimen ",
        "premise_nums": [
            "8 cycles of",
            "4 weeks Time",
            "10 percentage points",
            "50% LVEF",
            "3-4 weeks"
        ]
    },
    {
        "id": "35234f08-cf01-478f-b739-600b5a6ea3d9",
        "primaryId": "NCT00550771",
        "statement_text": "16/179 patients in the primary trial Experienced Cardiac Events  with the majority of those coming from cohort 2.",
        "statement_nums": [
            "16/179 patients",
            "179 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: Doxorubicin Based Regimen ",
        "premise_nums": [
            "80 mg/m^2",
            "2 IV over",
            "4 courses (12",
            "30 minutes (first",
            "120 Measure Type:",
            "600 mg/m^2",
            "30-90 minutes",
            "4 mg/kg IV",
            "5 Results 2:",
            "12 weeks (4",
            "35 mg/m^2",
            "60 minutes with",
            "90 minutes given",
            "30 minutes given",
            "2 mg/kg IV"
        ]
    },
    {
        "id": "35234f08-cf01-478f-b739-600b5a6ea3d9",
        "primaryId": "NCT00550771",
        "statement_text": "16/179 patients in the primary trial Experienced Cardiac Events  with the majority of those coming from cohort 2.",
        "statement_nums": [
            "16/179 patients",
            "179 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 59 Measure Type: Number Unit of Measure: Participants 11 ",
        "premise_nums": [
            "21 days for",
            "60 mg/m^2",
            "80 mg/m^2",
            "60 minutes with",
            "2 IV over",
            "600 mg/m^2",
            "30-90 minutes",
            "4 mg/kg IV",
            "90 minutes given",
            "30 minutes (first",
            "12 weeks (4",
            "2 mg/kg IV",
            "2 intravenous (IV)",
            "4 courses (12",
            "59 Measure Type:"
        ]
    },
    {
        "id": "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6",
        "primaryId": "NCT00452673",
        "statement_text": "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Safety was assessed from first dose of study drug through at least 30 days after the last dose  until resolution of drug-related toxicity or when toxicity was deemed irreversible  whichever was longer  An adverse event (AE) was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days and was at least possibly related to study drugs and were: Clinically-evident toxicity of Grade greater than or equal 3, or of Grade 2 which required interruption of treatment for greater than or equal 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory value of Grade greater than or equal 3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which in the judgment of the investigator required a dose reduction or removal from further study therapy Time frame: Day 1 to 30 days post last dose Results 1: ",
        "premise_nums": [
            "21 days and",
            "2 which required",
            "30 days after",
            "1 to 30",
            "7 days (consecutive"
        ]
    },
    {
        "id": "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6",
        "primaryId": "NCT00452673",
        "statement_text": "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine",
        "premise_nums": [
            "825 mg/m^2Capecitabine",
            "50 mg Dasatinib"
        ]
    },
    {
        "id": "011991a5-724d-4b95-b9ab-9e1371d77368",
        "primaryId": "NCT00086957",
        "statement_text": "All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 2/2 (100.00%) Febrile neutropenia * 2/2 (100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%) Diarrhea * 0/2 (0.00%) Melaena * 0/2 (0.00%) Mucositis oral * 0/2 (0.00%) Nausea * 0/2 (0.00%) Vomiting * 0/2 (0.00%) Catheter related infection * 0/2 (0.00%) Infection NOS * 0/2 (0.00%) Leukopenia * 1/2 (50.00%) ",
        "premise_nums": [
            "1/2 (50.00%)",
            "0/2 (0.00%)",
            "2/2 (100.00%)"
        ]
    },
    {
        "id": "d09091f1-3fc5-498b-8c59-4678590c8464",
        "primaryId": "NCT03176238",
        "secondaryId": "NCT01498458",
        "label": "Contradiction",
        "statement_text": "Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial  no robust comparisons can be made due to the significant differences in cohort sizes ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 59/199 (29.65%) Anaemia 7/199 (3.52%) Thrombocytopenia 2/199 (1.01%) Acute myocardial infarction 0/199 (0.00%) Atrial fibrillation 1/199 (0.50%) Cardiac arrest 1/199 (0.50%) Cardiac failure 1/199 (0.50%) Cardiopulmonary failure 1/199 (0.50%) Left ventricular failure 1/199 (0.50%) Supraventricular tachycardia 0/199 (0.00%) ",
        "premise_nums": [
            "2/199 (1.01%)",
            "7/199 (3.52%)",
            "1/199 (0.50%)",
            "0/199 (0.00%)",
            "59/199 (29.65%)"
        ]
    },
    {
        "id": "d09091f1-3fc5-498b-8c59-4678590c8464",
        "primaryId": "NCT03176238",
        "secondaryId": "NCT01498458",
        "label": "Contradiction",
        "statement_text": "Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial  no robust comparisons can be made due to the significant differences in cohort sizes ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Ventricular tachycardia 1/199 (0.50%)Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8 (12.50%) Hepatotoxicity 3/8 (37.50%) Pancreatectomy * 1/8 (12.50%) ",
        "premise_nums": [
            "6/8 (75.00%)",
            "1/199 (0.50%)Adverse",
            "1/8 (12.50%)",
            "3/8 (37.50%)"
        ]
    },
    {
        "id": "f4909215-5b14-42d9-bda4-4d112cf2a108",
        "primaryId": "NCT02574455",
        "statement_text": "More than 1/3 patients in cohort 1 of the primary trial experienced an adverse event ",
        "statement_nums": [
            "1/3 patients",
            "3 patients in",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 69/258 (26.74%) ",
        "premise_nums": [
            "69/258 (26.74%)"
        ]
    },
    {
        "id": "fc7d8ffd-9896-4806-a095-d435cde83c88",
        "primaryId": "NCT00528567",
        "secondaryId": "NCT01196052",
        "label": "Entailment",
        "statement_text": "The total number of patients affected by adverse events in cohort 2 the primary trial  is larger than the cohort size of the secondary trial ",
        "statement_nums": [
            "2 the primary"
        ],
        "premise_text": "Adverse Events 2: Total: 250/1271 (19.67%) Adverse Events 1: Total: 15/148 (10.14%) Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Pyrexia 2/148 (1.35%) Cellulitis 1/148 (0.68%) Device related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%) ",
        "premise_nums": [
            "2/148 (1.35%)",
            "15/148 (10.14%)",
            "1/148 (0.68%)",
            "250/1271 (19.67%)"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "DISEASE CHARACTERISTICS: Current random fine needle breast aspiration (FNA) evidence of 1 of the following: Hyperplasia with atypia Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4% Hyperplasia without atypia but with a BRCAPRO risk of at least 25% Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2 Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women ",
        "premise_nums": [
            "25% Hyperplasia",
            "14 of the",
            "1 or BRCA2",
            "4% Hyperplasia",
            "10-year modified",
            "1-14 of",
            "1 of the"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries  must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausalNo ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2 No active cancer (e.g.  detectable disease) Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female ",
        "premise_nums": [
            "13 mm premenopausal",
            "1 and BRCA2",
            "6 months showing",
            "8 mm postmenopausalNo",
            "6 months If",
            "18 and over"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "Menopausal status:Any Performance status: Not specified Life expectancy: At least 12 months Hematopoietic: Hemoglobin greater than 10 g/dL Granulocyte count greater than 1,000/mm^3 No deficiencies in protein C  protein S  or antithrombin III No activated protein C resistance Hepatic: Albumin greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than 200 U/L Renal: Creatinine less than 1.5 mg/dL Cardiovascular: No history of deep venous thrombosis not related to trauma or pregnancy No severe coronary artery disease ",
        "premise_nums": [
            "10 g/dL Granulocyte",
            "1,000/mm^3 No",
            "3 No deficiencies",
            "than 3.0 g/dL",
            "200 U/L Renal",
            "12 months Hematopoietic:",
            "100 U/L Alkaline",
            "than 1.5 mg/dL"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "No history of prior strokeOther: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study No other active cancer No retinal vein thrombosis No concurrent severe poorly controlled migraine No factor V Leiden mutation carrier PRIOR CONCURRENT THERAPY: Biologic therapy: At least 12 months since prior immunotherapy Chemotherapy: At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration At least 12 months since prior chemotherapy Endocrine therapy: Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration ",
        "premise_nums": [
            "3 months between",
            "6 months of",
            "3 months after",
            "12 months since"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspirationAt least 12 months since prior tamoxifen  raloxifene  or other antihormonal therapy Radiotherapy: At least 3 months since prior radiotherapy Surgery: At least 6 months between prior oophorectomy and baseline aspiration Other: At least 2 weeks since the start of other new medication that would be ingested for 1 or more months Inclusion Criteria Pathologically confirmed diagnosis of invasive breast cancer  determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy; Tumor size greater than 2cm, measured on imaging or estimated by physical exam; ",
        "premise_nums": [
            "3 months since",
            "2 weeks since",
            "1 or more",
            "6 months between",
            "12 months since"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "No contraindications for primary chemotherapy;Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant therapy; Age 18 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II); Normal organ and marrow function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; total bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) 2.5 times the institutional upper limit of normal; creatinine within normal institutional limits; OR ",
        "premise_nums": [
            "100,000/μl; total",
            "5 times the",
            "3,000/μl; absolute",
            "1,500/μl; platelets",
            "18 years or"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "label": "Contradiction",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "21 and british"
        ],
        "premise_text": "creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal;If female  postmenopausal for a minimum of one year  OR surgically sterile  OR not pregnant  confirmed by a pregnancy test as per institutional Standard of Care (SOC)  and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation; Able to understand and willing to sign a written informed consent document and a HIPAA authorization in accordance with institutional guidelines; Exclusion Criteria Previous treatment (chemotherapy  radiation  or surgery) to involved breast; including hormone therapy; ",
        "premise_nums": [
            "2 for patients",
            "30 mL/min/1.73"
        ]
    },
    {
        "id": "98850daf-738c-4005-b476-8c5479ad3b79",
        "primaryId": "NCT00033514",
        "statement_text": "Mark has HER2 positive breast cancer  he is eligible for the primary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Women aged greater than 18 years Histologically documents metastatic breast cancer HER2 positive using Fluorescence In Situ Hybridization (FISH) ",
        "premise_nums": [
            "18 years Histologically",
            "2 positive using"
        ]
    },
    {
        "id": "790047b1-43e3-486e-b41c-eaa89026eae7",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11.1% of patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients had Unexpected adverse events ",
        "statement_nums": [
            "trial 11.1% of patients"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions) Percentage of patients with AEs  Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient  Results 1: Arm/Group Title: Single Arm Arm/Group Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81 Measure Type: Number Unit of Measure: Percentage of participants Adverse Events(AE): 81.5 (71.3 to 89.3) ADR; based on current South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to 20.1) Serious ADR: 0 (0 to 4.4) ",
        "premise_nums": [
            "7 to 49.7)",
            "6 months for",
            "81 Measure Type:",
            "2 to 20.1)",
            "3 to 89.3)",
            "0 to 4.4)"
        ]
    },
    {
        "id": "790047b1-43e3-486e-b41c-eaa89026eae7",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11.1% of patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients had Unexpected adverse events ",
        "statement_nums": [
            "trial 11.1% of patients"
        ],
        "label": "Entailment",
        "premise_text": "Unexpected AE: 71.6 (60.5 to 81.1)Unexpected ADR: 24.7 (15.8 to 35.5) ",
        "premise_nums": [
            "8 to 35.5)",
            "5 to 81.1)Unexpected"
        ]
    },
    {
        "id": "fc8ed290-e2b3-4eea-a837-d369dcd9b5da",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 3 patients in cohort 1 of the primary trial experienced any adverse events ",
        "statement_nums": [
            "3 patients in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%) Nausea 0/3 (0.00%) Vomiting 0/3 (0.00%) Abdominal pain 0/3 (0.00%) Colitis 0/3 (0.00%) Diarrhoea 0/3 (0.00%) Gastritis 0/3 (0.00%) Ileus 0/3 (0.00%) Fatigue 0/3 (0.00%) Pyrexia 0/3 (0.00%) Pain 0/3 (0.00%) Hepatic cirrhosis 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)"
        ]
    },
    {
        "id": "fc8ed290-e2b3-4eea-a837-d369dcd9b5da",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 3 patients in cohort 1 of the primary trial experienced any adverse events ",
        "statement_nums": [
            "3 patients in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Cellulitis 0/3 (0.00%)",
        "premise_nums": [
            "0/3 (0.00%)"
        ]
    },
    {
        "id": "1340769c-b55c-480c-a4c4-130034e128ce",
        "primaryId": "NCT00317720",
        "statement_text": "Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial ",
        "statement_nums": [
            "1 prior treatment"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: History of trastuzumab resistance  defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer  Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy)for metastatic breast cancer  Patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible  ",
        "premise_nums": [
            "2 prior trastuzumab"
        ]
    },
    {
        "id": "3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43",
        "primaryId": "NCT00887575",
        "secondaryId": "NCT01610284",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 3/41 (7.32%) Adverse Events 1: Total: 146/573 (25.48%) ",
        "premise_nums": [
            "146/573 (25.48%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "030eded8-6513-4028-b1fe-fefd6dd388ad",
        "primaryId": "NCT02429427",
        "statement_text": "Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial",
        "statement_nums": [
            "of 50,0000 x 109",
            "109/l are"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Pre-treatment haematology and biochemistry values within acceptable local limits: Haemoglobin  white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than 1.5 x upper normal limit   Alkaline phosphatase less or equal to 1.5 x upper normal limit   Serum creatinine less than 1.5 x upper normal limit ",
        "premise_nums": [
            "to 3.0 x 109",
            "than 1.5 x upper",
            "100 x 109",
            "to 1.5 x upper",
            "to 1.51 x 109",
            "109/l, Serum",
            "109/l or",
            "109/l, Platelets"
        ]
    },
    {
        "id": "d1d77877-9c85-41c8-9eca-6fd75b254a15",
        "primaryId": "NCT00768222",
        "statement_text": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan  she cannot take part in the primary trial due to her age ",
        "statement_nums": [
            "19 years old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: 18 years of age or older with written informed consent Exclusion Criteria: Has inflammatory cancers or skin ulceration Has known allergy or intolerance to triclosan ",
        "premise_nums": [
            "18 years of"
        ]
    },
    {
        "id": "ba0c0dc6-826b-426f-8738-eec23e47f6b0",
        "primaryId": "NCT03045653",
        "statement_text": "Sharone had a hip replacement 2 months prior  she is not elgible for the primary trial ",
        "statement_nums": [
            "2 months prior"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases  including uncontrolled hypertension  active bleeding diatheses  or active infection including hepatitis B  hepatitis C and HIV With the exception of alopecia  any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia  altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures  including inability to take regular oral medication ",
        "premise_nums": [
            "1 before study",
            "30 days Inability",
            "4 weeks before"
        ]
    },
    {
        "id": "77982c81-d147-48d9-909c-18b9a98224e9",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Contradiction",
        "statement_text": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 type of"
        ],
        "premise_text": "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1: Total: 4/6 (66.67%) Anemia 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 1/6 (16.67%) Retinal vein occlusion 0/6 (0.00%) ",
        "premise_nums": [
            "5/32 (15.63%)",
            "1/32 (3.13%)",
            "1/6 (16.67%)",
            "4/6 (66.67%)",
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "77982c81-d147-48d9-909c-18b9a98224e9",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Contradiction",
        "statement_text": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 type of"
        ],
        "premise_text": "Gastroenteritis 1/6 (16.67%)Vomiting 1/6 (16.67%) Diarrhea 0/6 (0.00%) Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Hepatic hemorrhage 0/6 (0.00%) Adverse Events 2: Total: 25/52 (48.08%) Anemia 1/52 (1.92%) Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%) Retinal vein occlusion 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)",
            "2/6 (33.33%)",
            "25/52 (48.08%)",
            "1/52 (1.92%)",
            "2/52 (3.85%)",
            "0/6 (0.00%)",
            "1/6 (16.67%)Vomiting"
        ]
    },
    {
        "id": "77982c81-d147-48d9-909c-18b9a98224e9",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "label": "Contradiction",
        "statement_text": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "1 type of"
        ],
        "premise_text": "Gastroenteritis 0/52 (0.00%)Vomiting 0/52 (0.00%) Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%) ",
        "premise_nums": [
            "0/52 (0.00%)Vomiting",
            "1/52 (1.92%)",
            "9/52 (17.31%)"
        ]
    },
    {
        "id": "2e03f6f1-0d4f-4ebf-8781-20918d70d78f",
        "primaryId": "NCT02165605",
        "statement_text": "A 56 year old patient with a masectomy would not be eligible for the primary trial",
        "statement_nums": [
            "56 year old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Female  age 18 or older Intact breast (not surgically absent) ",
        "premise_nums": [
            "18 or older"
        ]
    },
    {
        "id": "142cc983-b0cc-4f9f-b3ef-4eb57e2a317b",
        "primaryId": "NCT00486525",
        "statement_text": "The difference between the two cohorts of the primary trial is that cohort 1 received higher doses of IMGN853, whereas cohort 2 received lower doses more frequently ",
        "statement_nums": [
            "1 received higher",
            "2 received lower"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Arm I: Yoga Therapy Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs  INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  ",
        "premise_nums": [
            "90 minutes twice"
        ]
    },
    {
        "id": "f57350c2-ac90-47ea-92b4-d903509bf07a",
        "primaryId": "NCT03252431",
        "statement_text": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time  There was no recorded difference whatsoever ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 ",
        "premise_nums": [
            "4 Neutropenia in"
        ]
    },
    {
        "id": "f57350c2-ac90-47ea-92b4-d903509bf07a",
        "primaryId": "NCT03252431",
        "statement_text": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time  There was no recorded difference whatsoever ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Contradiction",
        "premise_text": "Eligible subjects were randomized in a 1:1 ratio  Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle  Subjects remained in their assigned treatment arm throughout the study  Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles)  Grade 4 (severe) neutropenia was defined as ANC smaller than 0.5 × 109/L within the first 12 days of chemotherapy ",
        "premise_nums": [
            "6 mg/dose as",
            "109/L within",
            "1:1 ratio",
            "12 days of",
            "24 to 28",
            "600 mg/m2 cyclophosphamide",
            "20 mg/dose PFS",
            "2 of each"
        ]
    },
    {
        "id": "f57350c2-ac90-47ea-92b4-d903509bf07a",
        "primaryId": "NCT03252431",
        "statement_text": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time  There was no recorded difference whatsoever ",
        "statement_nums": [
            "4 Neutropenia for"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks)Results 1: Arm/Group Title: F-627 Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe  administered on Day 2 of each of 4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 197 Mean (Standard Deviation) Unit of Measure: days 0.2 (0.51) Results 2: Arm/Group Title: Neulasta Arm/Group Description: 6 mg fixed dose Neulasta   administered on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe Overall Number of Participants Analyzed: 196 Mean (Standard Deviation) ",
        "premise_nums": [
            "20 mg fixed",
            "197 Mean (Standard",
            "196 Mean (Standard",
            "6 mg fixed",
            "21-day chemotherapy",
            "4 chemotherapy cycles",
            "2 of each"
        ]
    },
    {
        "id": "35dd977f-53d8-4400-b5cb-34caaa938e78",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months ",
        "statement_nums": [
            "6 mg/m2 over",
            "2 over 4"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes ",
        "premise_nums": [
            "40 mg Stratified",
            "20 mg or"
        ]
    },
    {
        "id": "35dd977f-53d8-4400-b5cb-34caaa938e78",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months ",
        "statement_nums": [
            "6 mg/m2 over",
            "2 over 4"
        ],
        "label": "Contradiction",
        "premise_text": "Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM Time frame: 4 months Results 1: Arm/Group Title: Ultra-rapid Metabolizers ",
        "premise_nums": [
            "6 alleles have",
            "4 months of",
            "10 possible allelic",
            "4 months Results"
        ]
    },
    {
        "id": "35dd977f-53d8-4400-b5cb-34caaa938e78",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months ",
        "statement_nums": [
            "6 mg/m2 over",
            "2 over 4"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Those with the highest transformation of the CYP2D6 genotype to allelic activityOverall Number of Participants Analyzed: 5 Mean (Standard Deviation) Unit of Measure: ng/mL Baseline endoxifen concentration: 5 participants 8.4 (4.59) 4-Month endoxifen concentration: 4 participants 15.35 (5.48) ",
        "premise_nums": [
            "5 Mean (Standard",
            "6 genotype to",
            "4 participants 15.35",
            "5 participants 8.4",
            "4-Month endoxifen"
        ]
    },
    {
        "id": "54554da5-e67f-4da5-819b-a85b7bc5d52c",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment ",
        "statement_nums": [
            "12 Weeks of",
            "1/3 participants",
            "3 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment The PFS rate is defined as the percentage of subjects who have shown no evidence of disease progression or death from any cause following 12 weeks of treatment  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Since there is no independent reviewer  only the investigator response was reported  Time frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab ",
        "premise_nums": [
            "12 Weeks of",
            "12 Results 1:",
            "12 weeks of",
            "20% increase"
        ]
    },
    {
        "id": "54554da5-e67f-4da5-819b-a85b7bc5d52c",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment ",
        "statement_nums": [
            "12 Weeks of",
            "1/3 participants",
            "3 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks)Overall Number of Participants Analyzed: 52 Measure Type: Count of Participants Unit of Measure: Participants No disease progression by Week 12: 36 69.2% Disease progression or death by Week 12: 16 30.8% ",
        "premise_nums": [
            "36 69.2% Disease progression",
            "1500 mg once",
            "52 Measure Type:"
        ]
    },
    {
        "id": "592edd64-7841-4c19-ba75-583066308137",
        "primaryId": "NCT00343863",
        "statement_text": "On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV  oral cyclophosphamide  dexamethasone IV or orally and ondansetron IV ",
        "statement_nums": [
            "7 Cohort 1",
            "1-7 Cohort",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Dexamethasone + Ondansetron IV All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)  ",
        "premise_nums": [
            "1 and oral",
            "1-7. Patients"
        ]
    },
    {
        "id": "04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4",
        "primaryId": "NCT02491892",
        "secondaryId": "NCT00887575",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: DIARRHEA 1/41 (2.44%) DYSPEPSIA 1/41 (2.44%) ",
        "premise_nums": [
            "0/41 (0.00%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "b8473ae8-11c9-4578-aab8-ee96e6287715",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "label": "Entailment",
        "statement_text": "Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial  there is no mimimum life expectancy define for the secondary trial ",
        "statement_nums": [
            "3 months to"
        ],
        "premise_text": "Exclusion Criteria: Life expectancy of less than 12 weeks Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease) HER2-positive metastatic or locally advanced breast cancer For MBC participants: Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease  amenable for treatment with docetaxel History of disease progression within 3 months prior to study entry For LABC participants: Newly diagnosed locally advanced breast cancer  Stage IIA-IIIC (American Joint Committee on Cancer [AJCC] staging system) Exclusion Criteria: Significant cardiac disease Inadequate bone marrow  liver or renal function For MBC participants: ",
        "premise_nums": [
            "3 months prior",
            "12 weeks Inclusion",
            "2 will be",
            "2-positive metastatic"
        ]
    },
    {
        "id": "b8473ae8-11c9-4578-aab8-ee96e6287715",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "label": "Entailment",
        "statement_text": "Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial  there is no mimimum life expectancy define for the secondary trial ",
        "statement_nums": [
            "3 months to"
        ],
        "premise_text": "Participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastasesBrain metastases that are untreated  symptomatic or require therapy to control symptoms; or any radiation  surgery  or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment  For LABC participants: Clinically or radiologically detectable metastasis (M1 disease) Participants for whom surgery as primary intent procedure is the best option to treat their disease Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease ",
        "premise_nums": [
            "2 months of"
        ]
    },
    {
        "id": "4243dc45-5a64-486d-ae2a-11448db00dcf",
        "primaryId": "NCT00246090",
        "secondaryId": "NCT00266799",
        "label": "Entailment",
        "statement_text": "Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial ",
        "statement_nums": [
            "2 of the",
            "15% less",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 88/291 (30.24%) Adverse Events 2: Total: 46/102 (45.10%) ",
        "premise_nums": [
            "88/291 (30.24%)",
            "46/102 (45.10%)"
        ]
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Contradiction",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the Investigator PFS is defined as the time from randomization until the earliest date of disease progression (PD) or death due to any cause  if sooner  The date of documented PD is defined as the date of radiological PD as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression  Per Response Evaluation Criteria in Solid Tumors (RECIST 1.0), PD is defined as a 20% increase in the sum of the longest diameter (LD) of target lesions  taking as a reference the smallest sum LD recorded since the treatment started  or the appearance of 1 or more new lesions  ",
        "premise_nums": [
            "1 or more",
            "20% increase"
        ]
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Contradiction",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Time frame: From the date of randomization until the date of the first documented progression or date of death from any cause  whichever came first  assessed for up to 46 monthsResults 1: Arm/Group Title: Placebo + Letrozole 2.5 mg Arm/Group Description: Participants received 6 tablets of placebo  identical in appearance to lapatinib tablets  orally daily (approximately at the same time each day)  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received 1 tablet of letrozole 2.5 milligrams (mg) orally daily  preferably with the daily dose of lapatinib  Overall Number of Participants Analyzed: 108 Measure Type: Count of Participants Unit of Measure: Participants 89 82.4% Results 2: ",
        "premise_nums": [
            "1 tablet of",
            "89 82.4% Results 2",
            "6 tablets of",
            "1 hour (or",
            "46 monthsResults 1:",
            "108 Measure Type:",
            "Letrozole 2.5 mg Arm",
            "5 milligrams (mg)"
        ]
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Contradiction",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Title: Lapatinib 1500 mg + Letrozole 2.5 mgArm/Group Description: Participants received 6 tablets of Lapatinib orally daily (250 mg lapatinib/tablet for a total of 1500 mg of lapatinib/day; approximately at the same time each day)  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received 1 tablet of letrozole 2.5 mg orally daily  preferably with the daily dose of lapatinib  Overall Number of Participants Analyzed: 111 Measure Type: Count of Participants Unit of Measure: Participants 88 79.3% Outcome Measurement: Time to Disease Progression (Initial Treatment) ",
        "premise_nums": [
            "88 79.3% Outcome Measurement",
            "1 tablet of",
            "1500 mg of",
            "6 tablets of",
            "1 hour (or",
            "Letrozole 2.5 mgArm/Group",
            "111 Measure Type:",
            "letrozole 2.5 mg orally"
        ]
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "label": "Contradiction",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days Treatment continues until progression of disease at which time crossover treatment begins  Overall Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) ",
        "premise_nums": [
            "1000 milligrams per",
            "75 mg/m2,",
            "1 every 21",
            "73 to 10.79)",
            "1 and 8",
            "95% Confidence",
            "21 days plus"
        ]
    },
    {
        "id": "f616e3d8-6c1a-4b99-ac79-ea87895e37b7",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial ",
        "statement_nums": [
            "2 of the",
            "1 is the"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Cranial Microcurrent Electrical Stimulation [CES]) Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes  The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz  and to automatically turn off at the end of 1 hour  Patients use their CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks INTERVENTION 2: Arm II (Sham CES) ",
        "premise_nums": [
            "1 hour of",
            "100 Microcurrent Stimulator)",
            "1-18. energy-based",
            "50% duty",
            "18 weeks INTERVENTION"
        ]
    },
    {
        "id": "f616e3d8-6c1a-4b99-ac79-ea87895e37b7",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial ",
        "statement_nums": [
            "2 of the",
            "1 is the"
        ],
        "premise_text": "Patients receive a CES unit as in arm I  but the ear-lobe electrodes do not pass electrical current  Patients use their CES unit once daily in weeks 1-18.sham intervention: Given once a day for 18 weeks INTERVENTION 1: Treatment Gel + Oral Placebo 4-hydroxytamoxifen gel 2mg/breast applied daily  Oral placebo taken daily  oral placebo: Oral placebo taken daily for 4-10 weeks  afimoxifene: 2mg/breast applied daily in the form of a gel for 4-10 weeks  INTERVENTION 2: Placebo Gel + Oral Treatment Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  ",
        "premise_nums": [
            "4-hydroxytamoxifen gel",
            "2mg/breast applied",
            "1-18.sham intervention:",
            "4-10 weeks",
            "18 weeks INTERVENTION"
        ]
    },
    {
        "id": "f616e3d8-6c1a-4b99-ac79-ea87895e37b7",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "label": "Entailment",
        "statement_text": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial ",
        "statement_nums": [
            "2 of the",
            "1 is the"
        ],
        "premise_text": "tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  ",
        "premise_nums": [
            "10 weeks placebo",
            "4-10 weeks"
        ]
    },
    {
        "id": "d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710",
        "primaryId": "NCT01073865",
        "statement_text": "Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial ",
        "statement_nums": [
            "2 years prior"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation  and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of randomisation  ",
        "premise_nums": [
            "10 pg/mL and",
            "1 year of",
            "30 mIU/mL within",
            "4 weeks of",
            "20 years and"
        ]
    },
    {
        "id": "1ac9c526-91e6-4e0d-8570-0a78e3ec78db",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 17/94 (18.09%) Anaemia 2/94 (2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Ileus 1/94 (1.06%) Nausea 1/94 (1.06%) Vomiting 1/94 (1.06%) Asthenia 1/94 (1.06%) Disease progression 0/94 (0.00%) Oedema peripheral 1/94 (1.06%) ",
        "premise_nums": [
            "1/94 (1.06%)",
            "17/94 (18.09%)",
            "0/94 (0.00%)",
            "2/94 (2.13%)"
        ]
    },
    {
        "id": "1ac9c526-91e6-4e0d-8570-0a78e3ec78db",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2:Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/39 (0.00%) Ischaemic cardiomyopathy 0/39 (0.00%) Myocardial infarction 1/39 (2.56%) Haemorrhoids 1/39 (2.56%) Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Vomiting 1/39 (2.56%) Asthenia 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%) ",
        "premise_nums": [
            "2/39 (5.13%)",
            "1/39 (2.56%)",
            "0/39 (0.00%)",
            "9/39 (23.08%)",
            "2:Total: 9/39"
        ]
    },
    {
        "id": "ce88c763-0062-48dc-b5e1-f81af32f2628",
        "primaryId": "NCT00593827",
        "secondaryId": "NCT00478257",
        "label": "Entailment",
        "statement_text": "Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "2 negative BC"
        ],
        "premise_text": "Inclusion Criteria: Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) 50 Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - ",
        "premise_nums": [
            "(HER2) negative",
            "18 pregnancy metastatic",
            "50 Has Human"
        ]
    },
    {
        "id": "e6901a45-4c97-4618-bfcb-6f6dd046ef0c",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group ",
        "statement_nums": [
            "3 months difference"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Time to Progression (TTP) - Expert Evaluation Committee Assessment Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer  whichever comes first  Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started  For participants with bone metastasis only  at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition)  Time frame: Up to 2008 days of the treatment Results 1: Arm/Group Title: Exemestane ",
        "premise_nums": [
            "2008 days of",
            "25% increase",
            "version 1.0 as an",
            "20% increase"
        ]
    },
    {
        "id": "e6901a45-4c97-4618-bfcb-6f6dd046ef0c",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group ",
        "statement_nums": [
            "3 months difference"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) ",
        "premise_nums": [
            "25 mg and",
            "95% Confidence",
            "8 to 16.5)"
        ]
    },
    {
        "id": "e94ea1b1-1816-4bac-b1ca-f6d66b95702a",
        "primaryId": "NCT00004888",
        "statement_text": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study ",
        "statement_nums": [
            "8 of the",
            "3 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event This table summarizes the cardiotoxicity events of different grades  Grade 1 is a decline of left ventricular ejection fraction(LVEF) greater than or equal 10% but smaller than 20% of baseline value  Grade 2 is LVEF below LLN (50%) or decline of LVEF greater than or equal 20% of baseline value  Grade 3 is congestive heart failure responsive to treatment  Please note that only a subset of patients reported cardiotoxic events so the totals will not add up to the total number of participants  Time frame: Baseline  after cycle 4 (~84 days)  after cycle 8 (~168 days)  and 30 or more days after last cycle of induction therapy ",
        "premise_nums": [
            "10% but",
            "30 or more",
            "2 is LVEF",
            "1 is a",
            "3 is congestive",
            "(50%) or",
            "20% of"
        ]
    },
    {
        "id": "e94ea1b1-1816-4bac-b1ca-f6d66b95702a",
        "primaryId": "NCT00004888",
        "statement_text": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study ",
        "statement_nums": [
            "8 of the",
            "3 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Results 1:Arm/Group Title: Arm I: Doxorubicin and Taxotere Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour after PLD completion  every 3 weeks for a total of 8 cycles  Dexamthasone 8 mg orally twice a day was administered the day before  the day of  and the day following docetaxel  The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD  Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 ",
        "premise_nums": [
            "200 mg PO",
            "60 mg/m^2",
            "30 mg/m^2",
            "3 weeks for",
            "1:Arm/Group Title:",
            "1 and continued",
            "1 of Cycle",
            "1 After Cycle",
            "16 Measure Type:",
            "240 mg/m^2.",
            "2 IV followed",
            "8 mg orally"
        ]
    },
    {
        "id": "e94ea1b1-1816-4bac-b1ca-f6d66b95702a",
        "primaryId": "NCT00004888",
        "statement_text": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study ",
        "statement_nums": [
            "8 of the",
            "3 or above"
        ],
        "label": "Contradiction",
        "premise_text": "Grade 1 After Cycle 8 (approx  168 days): 4Grade 1 After 30 days or more after last cycle: 1 Grade 2 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168 days): 4 Grade 2 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84 days): 1 Grade 3 After Cycle 8 (approx 168 days): 0 Grade 3 After 30 days or more after last cycle: 0 ",
        "premise_nums": [
            "4 Grade 2",
            "30 days or",
            "1 Grade 2",
            "1 After 30",
            "1 After Cycle",
            "3 Grade 2",
            "1 Grade 3",
            "0 Grade 3"
        ]
    },
    {
        "id": "639ccada-370d-4709-bdd7-1b29bbcc8769",
        "primaryId": "NCT01597193",
        "statement_text": "ECOG greater than 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial ",
        "statement_nums": [
            "1 and a",
            "12 weeks are"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1; Estimated life expectancy of at least 3 months ",
        "premise_nums": [
            "0 or 1;"
        ]
    },
    {
        "id": "ea505463-c509-416e-ad88-11576764b734",
        "primaryId": "NCT01771666",
        "secondaryId": "NCT01256567",
        "label": "Entailment",
        "statement_text": "Japanese participants with an ECOG smaller than =1 are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "1 are eligible"
        ],
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2. Inclusion Criteria: The participant is Japanese The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ",
        "premise_nums": [
            "0,1,2. Inclusion",
            "0 or 1"
        ]
    },
    {
        "id": "b64ae9c9-956a-421e-a41f-1886408fec2a",
        "primaryId": "NCT00003782",
        "statement_text": "One of the cohorts in the primary trial had more than 5% of patients experiencing side effects ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 66/1748 (3.78%) Adverse Events 2: Total: 43/1748 (2.46%) ",
        "premise_nums": [
            "43/1748 (2.46%)",
            "66/1748 (3.78%)"
        ]
    },
    {
        "id": "3366c10a-3d41-48ae-bfa8-26b9e655761e",
        "primaryId": "NCT00005908",
        "statement_text": "There were 8 cases of pharyngitis in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "8 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 29/30 (96.67%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Dehydration 1/30 (3.33%) Nausea 1/30 (3.33%) Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%) Vomiting 1/30 (3.33%) Adverse Events 2: ",
        "premise_nums": [
            "5/30 (16.67%)",
            "3/30 (10.00%)",
            "29/30 (96.67%)",
            "1/30 (3.33%)",
            "2/30 (6.67%)"
        ]
    },
    {
        "id": "be29030a-98e8-40ad-9138-90076fdb50d3",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202 (0.00%) CONSTIPATION 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: ",
        "premise_nums": [
            "2/202 (0.99%)",
            "61/202 (30.20%)",
            "5/202 (2.48%)",
            "1/202 (0.50%)",
            "0/202 (0.00%)"
        ]
    },
    {
        "id": "be29030a-98e8-40ad-9138-90076fdb50d3",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Total: 42/201 (20.90%)FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%) CATARACT 1/201 (0.50%) OPTIC NEUROPATHY 1/201 (0.50%) ABDOMINAL PAIN 1/201 (0.50%) CONSTIPATION 1/201 (0.50%) DIARRHOEA 3/201 (1.49%) ",
        "premise_nums": [
            "0/201 (0.00%)",
            "42/201 (20.90%)FEBRILE",
            "3/201 (1.49%)",
            "1/201 (0.50%)"
        ]
    },
    {
        "id": "a31298d5-20ae-4a3d-a57b-e97288fff6c0",
        "primaryId": "NCT01097460",
        "statement_text": "Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years ",
        "statement_nums": [
            "1 Treatment-emergent adverse"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Incidence of Treatment-emergent AE's [Not Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin Arm/Group Description: MM-111 will be combined with Herceptin MM-111 and Herceptin: For Phase 1: Dose escalation cohorts  MM-111 and Herceptin are administered weekly or bi-weekly via IV Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants 16 ",
        "premise_nums": [
            "111 and Herceptin:",
            "16 Measure Type:",
            "2 years Results",
            "111 will be"
        ]
    },
    {
        "id": "54e93334-0f21-4ea2-b0f2-34473385da53",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected less than 1% of patients ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 2/2788 (0.07%) Nervous system disorders - Other  specify 0/2788 (0.00%) Respiratory  thoracic and mediastinal disorders - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2800 (0.00%) ",
        "premise_nums": [
            "0/2788 (0.00%)",
            "1/2788 (0.04%)",
            "2/2788 (0.07%)",
            "5/2800 (0.18%)",
            "8/2800 (0.29%)",
            "5/2788 (0.18%)",
            "0/2800 (0.00%)",
            "9/2788 (0.32%)"
        ]
    },
    {
        "id": "54e93334-0f21-4ea2-b0f2-34473385da53",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected less than 1% of patients ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Nervous system disorders - Other  specify 1/2800 (0.04%)Respiratory  thoracic and mediastinal disorders - Other  specify 1/2800 (0.04%) Thromboembolic event 2/2800 (0.07%) ",
        "premise_nums": [
            "2/2800 (0.07%)",
            "1/2800 (0.04%)Respiratory"
        ]
    },
    {
        "id": "4bd9f061-6420-443d-8f84-b703733644ac",
        "primaryId": "NCT01202591",
        "statement_text": "100% of patients in the primary trial suffered life threatening adverse events ",
        "statement_nums": [
            "100% of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious) [Not Specified] Time frame: 3 years  10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: AZD4547 40mg Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 ",
        "premise_nums": [
            "28 days safety",
            "5 Results 2:",
            "5 Measure Type:",
            "AZD4547 BD",
            "80 mg AZD4547",
            "10 months (Adverse",
            "25 mg exemestane",
            "40 mg AZD4547"
        ]
    },
    {
        "id": "e6d3354b-b36a-42b9-b406-61a9af594686",
        "primaryId": "NCT00046891",
        "statement_text": "cohort 1 of the primary trial recieves 120 mg of Ginkgo Biloba twice daily ",
        "statement_nums": [
            "120 mg of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Ginkgo Biloba Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID) ",
        "premise_nums": [
            "120 mg per",
            "60 mg BID)"
        ]
    },
    {
        "id": "065a6cfe-3991-4dd5-8a55-22b9b31d1fc3",
        "primaryId": "NCT00317603",
        "statement_text": "Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer  ECOGsmaller than 2 and a life expectancy exceeding 6 months ",
        "statement_nums": [
            "3 or above",
            "2 and a"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Histologically confirmed Stage IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy of greater than or equal to 6 months 18 years of age or older ",
        "premise_nums": [
            "6 months 18",
            "0 or 1"
        ]
    },
    {
        "id": "497188e0-9d88-406f-b163-c154516cb12c",
        "primaryId": "NCT01560416",
        "statement_text": "There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial ",
        "statement_nums": [
            "2 than in",
            "10% more",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/15 (13.33%) Adverse Events 2: Total: 11/35 (31.43%) ",
        "premise_nums": [
            "11/35 (31.43%)",
            "2/15 (13.33%)"
        ]
    },
    {
        "id": "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Entailment",
        "statement_text": "Patients with BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "3 may be",
            "8,000/mm3 may",
            "5,000/mm3 to"
        ],
        "premise_text": "Inclusion Criteria: Biopsy-diagnosed breast cancer with metastasis in multiple organs Performance Status (World Health Organization :WHO) 0-2 Functions below are maintained in major organs: Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater than 9.5 g/dL Total bilirubin: greater than 1.5 mg/dL AST(GOT): within twice a normal upper value in an institution ",
        "premise_nums": [
            "2,000/mm3 or",
            "2 Functions below",
            "than 9.5 g/dL",
            "4,000/mm3 to",
            "12,000/mm3 Neutrophil",
            "3 Neutrophil count:",
            "100,000/mm3 or",
            "3 or more",
            "than 1.5 mg/dL",
            "0-2 Functions"
        ]
    },
    {
        "id": "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Entailment",
        "statement_text": "Patients with BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "3 may be",
            "8,000/mm3 may",
            "5,000/mm3 to"
        ],
        "premise_text": "AST(GPT): within twice a normal upper value in an institutionBUN: smaller than 25 mg/dL Creatinine: within a normal upper value in the institution 24 hours creatinine clearance: greater than 50 mL/min (using the Cockcroft-Gault formula) Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 Inclusion Criteria: Histologically- or cytologically-proven diagnosis of breast adenocarcinoma that is not amenable to surgery  radiation  or combined modality therapy with curative intent ",
        "premise_nums": [
            "72 x Serum",
            "25 mg/dL Creatinine",
            "x 0.85 Inclusion Criteria",
            "(140-Age)/(72 x",
            "24 hours creatinine",
            "85 Inclusion Criteria:",
            "50 mL/min"
        ]
    },
    {
        "id": "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "label": "Entailment",
        "statement_text": "Patients with BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "20 mg/dL",
            "90,000/mm3, Leukocyte",
            "3 may be",
            "8,000/mm3 may",
            "5,000/mm3 to"
        ],
        "premise_text": "Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/ Sunfural (tegafur)  UFT/UFT-E (tegafur/uracil)  TS-1 (tegafur/gimeracil/oteracil) or Mifurol (carmofur) in metastatic disease setting",
        "premise_nums": [
            "(5-FU) and",
            "5-FU derivatives"
        ]
    },
    {
        "id": "90dd042b-c16c-4ea7-b360-625bd5e64590",
        "primaryId": "NCT00388726",
        "statement_text": "A 75 year old female patient  with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial ",
        "statement_nums": [
            "1 and an",
            "75 year old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Age greater than or equal 18 years  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of greater than or equal 3 months  ",
        "premise_nums": [
            "0 to 2."
        ]
    },
    {
        "id": "20cc98f8-a71a-466d-a39c-735899791613",
        "primaryId": "NCT00915603",
        "secondaryId": "NCT02511730",
        "label": "Entailment",
        "statement_text": "INR equal to or above 1.5 is mandatory for participation in the primary trial  it is not necessary for the secondary trial ",
        "statement_nums": [
            "above 1.5 is mandatory"
        ],
        "premise_text": "Inclusion Criteria: International normalized ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  ",
        "premise_nums": [
            "5 or prothrombin"
        ]
    },
    {
        "id": "fa1c6f63-ae37-4c18-918b-7b9ba445fd81",
        "primaryId": "NCT00391092",
        "statement_text": "In total there were 32 cases of Febrile neutropenia in the primary trial ",
        "statement_nums": [
            "32 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Febrile neutropenia * 14/206 (6.80%) Adverse Events 2: Febrile neutropenia * 18/215 (8.37%) ",
        "premise_nums": [
            "14/206 (6.80%)",
            "18/215 (8.37%)"
        ]
    },
    {
        "id": "7e9c3980-9f12-40c7-920e-76594db26fd1",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "label": "Entailment",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid  in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "3 Fatty Acid"
        ],
        "premise_text": "INTERVENTION 1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty Acid) Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 1: Cohort A ",
        "premise_nums": [
            "3 fatty acid",
            "3 Fatty Acid:",
            "3 Fatty Acid)"
        ]
    },
    {
        "id": "7e9c3980-9f12-40c7-920e-76594db26fd1",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "label": "Entailment",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid  in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "3 Fatty Acid"
        ],
        "premise_text": "750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settingsINTERVENTION 2: Cohort B 750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings  ",
        "premise_nums": [
            "2 prior trastuzumab",
            "0-1, and",
            "2 and/or more"
        ]
    },
    {
        "id": "c83e003d-d12d-4f72-ab1f-c39f3a13326b",
        "primaryId": "NCT00499083",
        "secondaryId": "NCT03045653",
        "label": "Entailment",
        "statement_text": "In order to be eligible for both the secondary trial and the primary trial  patients must be female  over the age of 18, ECOG smaller than 2 and have Histologically confirmed HER2 negative breast cancer ",
        "statement_nums": [
            "2 negative breast",
            "2 and have"
        ],
        "premise_text": "HER2/neu-negative tumor by IHC Female ECOG performance status 0-1 Inclusion Criteria: ",
        "premise_nums": [
            "0-1 Inclusion",
            "1 Inclusion Criteria:",
            "2/neu-negative tumor"
        ]
    },
    {
        "id": "103fbaa8-1852-402a-9368-36bbf6c747b2",
        "primaryId": "NCT00022516",
        "statement_text": "At most 3 patients in the primary trial suffered from Neutropenia ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 1/473 (0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) ",
        "premise_nums": [
            "0/0 Leukopenia",
            "1/473 (0.21%)",
            "0/0 Neurologic-other",
            "0/0 Radiation",
            "2/473 (0.42%)",
            "0 CNS hemorrhage",
            "0/0 Adverse",
            "0/0 Neutropenia",
            "0 Elevated SGPT",
            "0 Adverse Events",
            "11/473 (2.33%)",
            "0/0 Arthralgia",
            "0/0 Ocular-other",
            "0 Radiation dermatitis",
            "0/0 CNS",
            "0/0 Elevated",
            "5/473 (1.06%)"
        ]
    },
    {
        "id": "103fbaa8-1852-402a-9368-36bbf6c747b2",
        "primaryId": "NCT00022516",
        "statement_text": "At most 3 patients in the primary trial suffered from Neutropenia ",
        "statement_nums": [
            "3 patients in"
        ],
        "label": "Contradiction",
        "premise_text": "Neurologic-other 1/473 (0.21%)Radiation dermatitis 1/473 (0.21%) ",
        "premise_nums": [
            "1/473 (0.21%)Radiation"
        ]
    },
    {
        "id": "731dc36f-983d-4d4c-97ac-6e3eeee23a40",
        "primaryId": "NCT00581256",
        "statement_text": "Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial ",
        "statement_nums": [
            "3 are excluded"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: All patients must have left-sided breast cancer  Performance status should be 0-2 by ECOG criteria  Exclusion Criteria: Performance status greater than 2 by ECOG criteria ",
        "premise_nums": [
            "0-2 by",
            "2 by ECOG"
        ]
    },
    {
        "id": "cc0d6fe8-69c4-49d3-b321-00e47c155db6",
        "primaryId": "NCT03098550",
        "statement_text": "There results from cohort 3 of the primary trial were inconclusive ",
        "statement_nums": [
            "3 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Number of Participants With Adverse Events (AEs) Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab Time frame: From first dose to 30 days post last dose (up to 34 months) Results 1: Arm/Group Title: Nivolumab + Daratumumab (TNBC) ",
        "premise_nums": [
            "30 days post"
        ]
    },
    {
        "id": "cc0d6fe8-69c4-49d3-b321-00e47c155db6",
        "primaryId": "NCT03098550",
        "statement_text": "There results from cohort 3 of the primary trial were inconclusive ",
        "statement_nums": [
            "3 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of Measure: Participants 41 100.0% Results 2: Arm/Group Title: Nivolumab + Daratumumab (NSCLC) ",
        "premise_nums": [
            "1 to 8),",
            "41 100.0% Results 2",
            "16 mg/kg Q",
            "41 Measure Type:",
            "3 to 24)",
            "240 mg Q2W",
            "9-24)Overall Number"
        ]
    },
    {
        "id": "cc0d6fe8-69c4-49d3-b321-00e47c155db6",
        "primaryId": "NCT03098550",
        "statement_text": "There results from cohort 3 of the primary trial were inconclusive ",
        "statement_nums": [
            "3 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of Measure: Participants 21 100.0% ",
        "premise_nums": [
            "1 to 8),",
            "16 mg/kg Q",
            "3 to 24)",
            "240 mg Q2W",
            "21 Measure Type:",
            "9-24)Overall Number"
        ]
    },
    {
        "id": "0fbb4fb4-620b-4ee9-aaa8-956992026cef",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Infection-ulcer 20/11 (0.00%) Hemoglobin 20/11 (0.00%) Hypoglycemia 20/11 (0.00%) Pain-rib cage due to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11 (9.09%) Pain-breast 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: ",
        "premise_nums": [
            "22/11 (18.18%)",
            "20/11 (0.00%)",
            "5/11 (45.45%)",
            "21/11 (9.09%)"
        ]
    },
    {
        "id": "0fbb4fb4-620b-4ee9-aaa8-956992026cef",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "Total: 0/6 (0.00%)",
        "premise_nums": [
            "0/6 (0.00%)"
        ]
    },
    {
        "id": "9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7",
        "primaryId": "NCT00829166",
        "statement_text": "Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial ",
        "statement_nums": [
            "3 or 4"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Peripheral neuropathy of Grade greater than /= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)  Version 3.0 ",
        "premise_nums": [
            "3 per National"
        ]
    },
    {
        "id": "9872cf9f-6f43-44d3-97ce-e205e0e5fc6c",
        "primaryId": "NCT00464646",
        "statement_text": "Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast  IHC results were 1+. She is eligible for the primary trial ",
        "statement_nums": [
            "57 year old",
            "1+. She"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Patients must be female  The patient must be greater than or equal to 18 years old  The patient's ECOG performance status must be 0 or 1. The tumor must be invasive adenocarcinoma of the breast on histologic examination  The breast cancer must be determined to be HER2-positive prior to study entry  Assays performed using FISH require gene amplification  Assays using IHC require a strongly positive (3+) staining score  By pathologic evaluation  ipsilateral nodes must be pN2 or pN3. ",
        "premise_nums": [
            "2-positive prior",
            "2 or pN3.",
            "(3+) staining",
            "18 years old",
            "0 or 1."
        ]
    },
    {
        "id": "efc15257-5e19-4b7e-8b51-da94840784d8",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 1 patient with a deficiency of platelets in the blood  whereas a total of 6 patients with a platelet deficiency where found in the secondary trial ",
        "statement_nums": [
            "6 patients with",
            "1 patient with"
        ],
        "premise_text": "Adverse Events 1: Total: 18/52 (34.62%) Anaemia 2/52 (3.85%) Febrile Neutropenia 1/52 (1.92%) Haemolytic Uraemic Syndrome 1/52 (1.92%) Leukopenia 1/52 (1.92%) Neutropenia 1/52 (1.92%) Thrombocytopenia 1/52 (1.92%) Cardiac Failure Congestive 1/52 (1.92%) Cardio-Respiratory Arrest 1/52 (1.92%) Abdominal Pain 1/52 (1.92%) Constipation 1/52 (1.92%) ",
        "premise_nums": [
            "18/52 (34.62%)",
            "1/52 (1.92%)",
            "2/52 (3.85%)"
        ]
    },
    {
        "id": "efc15257-5e19-4b7e-8b51-da94840784d8",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 1 patient with a deficiency of platelets in the blood  whereas a total of 6 patients with a platelet deficiency where found in the secondary trial ",
        "statement_nums": [
            "6 patients with",
            "1 patient with"
        ],
        "premise_text": "Diarrhoea 1/52 (1.92%)Adverse Events 1: Total: 14/54 (25.93%) anaemia 2/54 (3.70%) Febrile neutropenia 7/54 (12.96%) Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%) Cardiac failure congestive 1/54 (1.85%) Pericardial effusion 1/54 (1.85%) Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) ",
        "premise_nums": [
            "7/54 (12.96%)",
            "1/52 (1.92%)Adverse",
            "3/54 (5.56%)",
            "2/54 (3.70%)",
            "14/54 (25.93%)",
            "1/54 (1.85%)",
            "6/54 (11.11%)"
        ]
    },
    {
        "id": "efc15257-5e19-4b7e-8b51-da94840784d8",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 1 patient with a deficiency of platelets in the blood  whereas a total of 6 patients with a platelet deficiency where found in the secondary trial ",
        "statement_nums": [
            "6 patients with",
            "1 patient with"
        ],
        "premise_text": "Catheter site erythema 1/54 (1.85%)Chest discomfort 1/54 (1.85%) Adverse Events 2: Total: 5/20 (25.00%) anaemia 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 0/20 (0.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Pericardial effusion 0/20 (0.00%) Nausea 0/20 (0.00%) ",
        "premise_nums": [
            "5/20 (25.00%)",
            "0/20 (0.00%)",
            "1/54 (1.85%)Chest",
            "2/20 (10.00%)"
        ]
    },
    {
        "id": "efc15257-5e19-4b7e-8b51-da94840784d8",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "label": "Entailment",
        "statement_text": "the primary trial recorded 1 patient with a deficiency of platelets in the blood  whereas a total of 6 patients with a platelet deficiency where found in the secondary trial ",
        "statement_nums": [
            "6 patients with",
            "1 patient with"
        ],
        "premise_text": "Vomiting 0/20 (0.00%)Catheter site erythema 0/20 (0.00%) Chest discomfort 0/20 (0.00%) ",
        "premise_nums": [
            "0/20 (0.00%)Catheter"
        ]
    },
    {
        "id": "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Contradiction",
        "statement_text": "19.57% of patients in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "19.57% of"
        ],
        "premise_text": "Adverse Events 1: Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia with urinary tract infection 0/22 (0.00%) dyspnoea 1/22 (4.55%) hypoxia 0/22 (0.00%) thromboembolism 0/22 (0.00%) Adverse Events 2: Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) ",
        "premise_nums": [
            "4/17 (23.53%)",
            "3/22 (13.64%)",
            "0/22 (0.00%)",
            "1/17 (5.88%)",
            "1/22 (4.55%)"
        ]
    },
    {
        "id": "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Contradiction",
        "statement_text": "19.57% of patients in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "19.57% of"
        ],
        "premise_text": "febrile neutropenia with respiratory infection 0/17 (0.00%)urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%) hypoxia 1/17 (5.88%) thromboembolism 1/17 (5.88%) Adverse Events 1: Total: 9/46 (19.57%) Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) ",
        "premise_nums": [
            "0/17 (0.00%)urosepsis",
            "9/46 (19.57%)",
            "1/46 (2.17%)",
            "1/17 (5.88%)"
        ]
    },
    {
        "id": "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "label": "Contradiction",
        "statement_text": "19.57% of patients in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "19.57% of"
        ],
        "premise_text": "Upper gastrointestinal hemorrhage 1/46 (2.17%)Chest pain 1/46 (2.17%) Fatigue 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%) Anorexia 1/46 (2.17%) Dehydration 1/46 (2.17%) Serum potassium increased 1/46 (2.17%) ",
        "premise_nums": [
            "1/46 (2.17%)Chest",
            "2/46 (4.35%)"
        ]
    },
    {
        "id": "7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9",
        "primaryId": "NCT02129556",
        "statement_text": "Cohort 1 of the primary trial had a much higher number of deaths than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Death 2/6 (33.33%) Adverse Events 2: Death 9/52 (17.31%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "9/52 (17.31%)"
        ]
    },
    {
        "id": "180d7b66-9ee9-40fb-b4c7-a6060e6f67b7",
        "primaryId": "NCT02129556",
        "statement_text": "Cohort 1 of the primary trial had a much higher mortality rate than cohort 2.",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Death 2/6 (33.33%) Adverse Events 2: Death 9/52 (17.31%) ",
        "premise_nums": [
            "2/6 (33.33%)",
            "9/52 (17.31%)"
        ]
    },
    {
        "id": "02407f87-235d-4240-98fe-498b352cce75",
        "primaryId": "NCT00167414",
        "statement_text": "Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial ",
        "statement_nums": [
            "(HER2) overexpressive"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Age: no limit Karnofsky performance status (KPS) 70 No more than 5 metastatic sites involving one or more different organs (liver  lung or bone)  The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol  Previously treated lesions are not eligible unless the prescribed dose can be safely delivered  Concurrent therapy is allowed and recommended  The chemotherapy protocol type and schedule are at the discretion of the medical oncologist  Informed consent must be obtained  Pregnancy test must be negative for women of child bearing potential Exclusion Criteria: Inability of patient to be followed longitudinally as specified by protocol  Technical inability to achieve required dose based on safe dose constraints required for radiosurgery  Women who are pregnant or nursing  Failure to meet requirements in Inclusion Criteria Contraindications to radiation  ",
        "premise_nums": [
            "70 No more",
            "5 metastatic sites"
        ]
    },
    {
        "id": "304977b6-9742-4c3b-84fd-e5ef1737a143",
        "primaryId": "NCT01597193",
        "statement_text": "ECOG smaller than 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial ",
        "statement_nums": [
            "2 and a",
            "12 weeks are"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1; Estimated life expectancy of at least 3 months ",
        "premise_nums": [
            "0 or 1;"
        ]
    },
    {
        "id": "bc617e84-a0c1-400b-9ad5-88b56d1805e8",
        "primaryId": "NCT01671319",
        "statement_text": "1/42 patients in cohort 1 of the primary trial fainted ",
        "statement_nums": [
            "42 patients in",
            "1 of the",
            "1/42 patients"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 4/42 (9.52%) Perforation  GI 1/42 (2.38%) Febrile neutropenia 1/42 (2.38%) Syncope 1/42 (2.38%) Rash/desquamation 1/42 (2.38%) ",
        "premise_nums": [
            "1/42 (2.38%)",
            "4/42 (9.52%)"
        ]
    },
    {
        "id": "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe",
        "primaryId": "NCT00354640",
        "statement_text": "Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Anastrozole and Simvastatin adjuvant therapy : laboratory analysis pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD for 14 days ",
        "premise_nums": [
            "40 milligram tablet",
            "1 milligram tablet",
            "14 days anastrozole"
        ]
    },
    {
        "id": "b059e44b-9830-4c45-858e-ebd007fbaf69",
        "primaryId": "NCT00148668",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 5/41 (12.20%) Neutropenia 4/41 (9.76%) Febrile Neutropenia 0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT (ALT) 0/40 (0.00%) ",
        "premise_nums": [
            "0/41 (0.00%)",
            "4/41 (9.76%)",
            "5/41 (12.20%)",
            "4/40 (10.00%)",
            "1/41 (2.44%)",
            "1/40 (2.50%)",
            "5/40 (12.50%)",
            "0/40 (0.00%)"
        ]
    },
    {
        "id": "fec065ca-fbde-476d-ab0d-7e7054e29858",
        "primaryId": "NCT00436917",
        "statement_text": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine  or with a prior surgery at the lumbosacral spine are excluded from the primary trial  as these would interfere with the necessary CT and MRI scans for the study ",
        "statement_nums": [
            "20 degrees at"
        ],
        "label": "Contradiction",
        "premise_text": "No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following: History of surgery at the lumbosacral spine  with or without implantable devices Scoliosis with a Cobb angle greater than 15 degrees at the lumbar spine ",
        "premise_nums": [
            "15 degrees at"
        ]
    },
    {
        "id": "576e519a-1ef3-43e5-a13c-6058ad71f388",
        "primaryId": "NCT00297596",
        "secondaryId": "NCT00580333",
        "label": "Contradiction",
        "statement_text": "Patients have received prior radiation treatment  to treat the current breast cancer  in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "2 weeks before"
        ],
        "premise_text": "Inclusion Criteria: Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab  All prior chemotherapy  trastuzumab and radiation therapy should be completed greater than 2 weeks before enrollment  Exclusion Criteria: Any prior cytotoxic chemotherapy or radiation for the current breast cancer ",
        "premise_nums": [
            "2 weeks before"
        ]
    },
    {
        "id": "699d0cb5-1ebb-441d-aa7e-041a48923b00",
        "primaryId": "NCT03374995",
        "statement_text": "the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks ",
        "statement_nums": [
            "3-6 weeks"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Group I (Topical Keratin) Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks)  Quality-of-Life Assessment: Ancillary studies Topical Keratin: Given topically INTERVENTION 2: Group II (Standard of Care) Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks)  Best Practice: Receive standard of care Quality-of-Life Assessment: Ancillary studies ",
        "premise_nums": [
            "3-6 weeks"
        ]
    },
    {
        "id": "6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b",
        "primaryId": "NCT01127373",
        "statement_text": "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial ",
        "statement_nums": [
            "0 and TxN1M0"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Pathologic confirmation of metastatic disease in at least one regional lymph node  Regional lymph nodes are defined as the ipsilateral axillary lymph nodes  ipsilateral supraclavicular lymph nodes  and ipsilateral internal mammary lymph nodes  Thus  any T stage is allowed as long as the N stage is 1 and M stage is 0. ",
        "premise_nums": [
            "1 and M"
        ]
    },
    {
        "id": "6e882de6-e55f-40a4-95a1-bdb176e68a18",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 30/98 (30.61%) NEUTROPENIA 1/98 (1.02%) ATRIAL FIBRILLATION 1/98 (1.02%) CARDIAC FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) ABDOMINAL PAIN 0/98 (0.00%) COLITIS 0/98 (0.00%) DIARRHOEA 2/98 (2.04%) FEMORAL HERNIA 0/98 (0.00%) HAEMATEMESIS 0/98 (0.00%) ILEUS 0/98 (0.00%) ",
        "premise_nums": [
            "1/98 (1.02%)",
            "2/98 (2.04%)",
            "30/98 (30.61%)",
            "0/98 (0.00%)"
        ]
    },
    {
        "id": "6e882de6-e55f-40a4-95a1-bdb176e68a18",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "NAUSEA 0/98 (0.00%)",
        "premise_nums": [
            "0/98 (0.00%)"
        ]
    },
    {
        "id": "670443b0-89bf-4af4-a9ab-4cdff26d09a8",
        "primaryId": "NCT00005957",
        "statement_text": "T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial ",
        "statement_nums": [
            "0 adenocarcinoma of"
        ],
        "label": "Contradiction",
        "premise_text": "DISEASE CHARACTERISTICS: Histologically proven invasive carcinoma of the breast No evidence of T4, N2-3, or M1 disease prior to surgery Node positive or high-risk node negative ",
        "premise_nums": [
            "2-3, or",
            "1 disease prior"
        ]
    },
    {
        "id": "2649c857-f98d-4529-9a4a-4f8b17813cb8",
        "primaryId": "NCT00337103",
        "statement_text": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "1 patients was",
            "2 of the",
            "44 days longer"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: From date of randomization until date of death from any cause  assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 yearsResults 1: Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2 Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days  Overall Number of Participants Analyzed: 554 Median (95% Confidence Interval) Unit of Measure: days 484 (462 to 536) Results 2: Arm/Group Title: Capecitabine 2.5 g/m^2/Day ",
        "premise_nums": [
            "2-5 minutes",
            "462 to 536)",
            "Mesylate 1.4 mg/m",
            "mesylate 1.4 mg/m",
            "1 and 8",
            "95% Confidence",
            "12 Mar 2012,",
            "2 intravenous (IV)",
            "Capecitabine 2.5 g/m",
            "5 minutes on",
            "6 yearsResults 1:"
        ]
    },
    {
        "id": "2649c857-f98d-4529-9a4a-4f8b17813cb8",
        "primaryId": "NCT00337103",
        "statement_text": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "1 patients was",
            "2 of the",
            "44 days longer"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Capecitabine : Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days Overall Number of Participants Analyzed: 548 Median (95% Confidence Interval) Unit of Measure: days 440 (400 to 487) ",
        "premise_nums": [
            "21 days Overall",
            "1 to 14",
            "95% Confidence",
            "400 to 487)",
            "Capecitabine 2.5 g/m",
            "2/day administered"
        ]
    },
    {
        "id": "0a6e8720-ea47-4520-bd02-e0eb8fcd880f",
        "primaryId": "NCT00399802",
        "statement_text": "The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "5 mg group",
            "4 mg group"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 u-NTx is a biochemical index of bone resorption  Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx  Time frame: Baseline and Week 4 Results 1: Arm/Group Title: Single IV Infusion of ZA 4 mg Arm/Group Description: Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks  Overall Number of Participants Analyzed: 14 ",
        "premise_nums": [
            "4 mg at",
            "4 mg Arm",
            "4 u-NTx is",
            "4 for measurement",
            "4 Results 1:"
        ]
    },
    {
        "id": "0a6e8720-ea47-4520-bd02-e0eb8fcd880f",
        "primaryId": "NCT00399802",
        "statement_text": "The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "5 mg group",
            "4 mg group"
        ],
        "label": "Entailment",
        "premise_text": "Mean (95% Confidence Interval)Unit of Measure: Percentage change -73 (-80 to -62) Results 2: Arm/Group Title: Once-daily Odanacatib 5 mg Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment  Overall Number of Participants Analyzed: 27 Mean (95% Confidence Interval) Unit of Measure: Percentage change -77 (-82 to -71) ",
        "premise_nums": [
            "5 mg Arm",
            "95% Confidence",
            "5 mg tablet",
            "4 weeks and"
        ]
    },
    {
        "id": "e21171de-ad49-4fc5-9c5d-aa362ca61c8a",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded 41.",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) ",
        "premise_nums": [
            "49/680 (7.21%)",
            "11/680 (1.62%)",
            "83/680 (12.21%)",
            "0/680 (0.00%)",
            "1/680 (0.15%)"
        ]
    },
    {
        "id": "e21171de-ad49-4fc5-9c5d-aa362ca61c8a",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded 41.",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 2:Total: 86/688 (12.50%) Hemoglobin 15/688 (2.18%) Transfusion: Platelets 1/688 (0.15%) Transfusion: pRBCs 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%) Ischemia/infarction 0/688 (0.00%) Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) ",
        "premise_nums": [
            "1/688 (0.15%)",
            "0/688 (0.00%)",
            "41/688 (5.96%)",
            "86/688 (12.50%)",
            "2:Total: 86/688",
            "15/688 (2.18%)"
        ]
    },
    {
        "id": "e21171de-ad49-4fc5-9c5d-aa362ca61c8a",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded 41.",
        "statement_nums": [
            "680 patients experiecing",
            "2/680 patients"
        ],
        "label": "Contradiction",
        "premise_text": "Colitis 0/688 (0.00%)",
        "premise_nums": [
            "0/688 (0.00%)"
        ]
    },
    {
        "id": "5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32",
        "primaryId": "NCT02518191",
        "statement_text": "Cohort 2 of the primary trial is the control group  as the Eligible patients with breast cancer treated with GnRHa every 28 days ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy  INTERVENTION 2: None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated without GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  ",
        "premise_nums": [
            "2 weeks before",
            "leuprorelin 3.75mg subcutaneous",
            "1-2 weeks",
            "4-8 weeks",
            "8 weeks after"
        ]
    },
    {
        "id": "e41917b8-d921-4797-b845-0121a75104a4",
        "primaryId": "NCT00129376",
        "statement_text": "More than 2% of patients in the primary trial experienced a clinically significant inflammation of the back of the throat ",
        "statement_nums": [
            "2% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Acute Pharyngitis * 1/63 (1.59%) ",
        "premise_nums": [
            "1/63 (1.59%)"
        ]
    },
    {
        "id": "3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7",
        "primaryId": "NCT02491892",
        "secondaryId": "NCT00887575",
        "label": "Contradiction",
        "statement_text": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial  this is due to the significant difference in cohort size ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: DIARRHEA 1/41 (2.44%) DYSPEPSIA 1/41 (2.44%) ",
        "premise_nums": [
            "0/41 (0.00%)",
            "1/41 (2.44%)"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis  whichever occurred earlier  Tumor responses were assessed every 6 weeks using  Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir ",
        "premise_nums": [
            "30% decrease",
            "6 weeks using",
            "20% increase"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A  34 months for Arm B and 35 months for Arm CResults 1: Arm/Group Title: Arm A: Nab-Paclitaxel + Gemcitabine ",
        "premise_nums": [
            "16 December 2016;",
            "31 months for",
            "35 months for",
            "34 months for"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatmentOverall Number of Participants Analyzed: 61 Median (95% Confidence Interval) Unit of Measure: months 5.5 (4.1 to 7.0) ",
        "premise_nums": [
            "1 to 7.0)",
            "1000 mg/m^2",
            "1 and 8",
            "95% Confidence",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "83% less"
        ],
        "label": "Contradiction",
        "premise_text": "Results 2:Arm/Group Title: Arm B: Nab-Paclitaxel + Carboplatin Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment  Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) ",
        "premise_nums": [
            "2:Arm/Group Title:",
            "1 and 8",
            "95% Confidence",
            "125 mg/m^2",
            "21-day treatment",
            "2 on Days"
        ]
    },
    {
        "id": "662f4992-0155-4a82-926f-b1821539aab7",
        "primaryId": "NCT00723125",
        "secondaryId": "NCT00617942",
        "label": "Contradiction",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery  compared to 60% in cohort 1 of the secondary trial ",
        "statement_nums": [
            "57% of",
            "60% in",
            "1 of the"
        ],
        "premise_text": "Outcome Measurement: Pathological Complete Response Rates at Surgery [Not Specified] Time frame: at surgery approximately 5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 ",
        "premise_nums": [
            "5 months after"
        ]
    },
    {
        "id": "662f4992-0155-4a82-926f-b1821539aab7",
        "primaryId": "NCT00723125",
        "secondaryId": "NCT00617942",
        "label": "Contradiction",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery  compared to 60% in cohort 1 of the secondary trial ",
        "statement_nums": [
            "57% of",
            "60% in",
            "1 of the"
        ],
        "premise_text": "Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks",
        "premise_nums": [
            "100 mg/m2 IV",
            "60 minutes cycles",
            "2 IV over",
            "10 Avastin 10",
            "30 minutes weekly",
            "14 Abraxane 100",
            "30-90 minutes",
            "12 weeks with",
            "6 over 30",
            "30-60 minutes",
            "10 mg/kg IV",
            "60 minutes q2weeks",
            "90 minutes weeks",
            "60 mg/m2*",
            "15 mg/kg IV",
            "600 mg/m2 IV",
            "4 cycles Definitive",
            "1,4,7, and",
            "90 minutes day",
            "2 IV q2weeks"
        ]
    },
    {
        "id": "662f4992-0155-4a82-926f-b1821539aab7",
        "primaryId": "NCT00723125",
        "secondaryId": "NCT00617942",
        "label": "Contradiction",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery  compared to 60% in cohort 1 of the secondary trial ",
        "statement_nums": [
            "57% of",
            "60% in",
            "1 of the"
        ],
        "premise_text": "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 28 Measure Type: Number Unit of Measure: participants 16 Outcome Measurement: Number of Patients With Complete Pathologic Response Rate  Observed Following Treatment With q3week Carboplatin  Weekly Abraxane and Weekly Trastuzumab in Resectable and Unresectable LABC; ",
        "premise_nums": [
            "30 minutes weekly",
            "100 mg/m2 IV",
            "1 and Cohort",
            "28 Measure Type:",
            "2 IV over",
            "16 Outcome Measurement:",
            "30-90 minutes",
            "1,4,7, and",
            "12 weeks with",
            "90 minutes weeks",
            "6 over 30",
            "15 mg/kg IV"
        ]
    },
    {
        "id": "662f4992-0155-4a82-926f-b1821539aab7",
        "primaryId": "NCT00723125",
        "secondaryId": "NCT00617942",
        "label": "Contradiction",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery  compared to 60% in cohort 1 of the secondary trial ",
        "statement_nums": [
            "57% of",
            "60% in",
            "1 of the"
        ],
        "premise_text": "These numbers represent patients with a RCB score of zero (0). RCB stands for residual cancer burden Time frame: 1 year Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 37 Measure Type: Number Unit of Measure: participants 12 ",
        "premise_nums": [
            "1 Arm/Group Description",
            "37 Measure Type:",
            "1 year Results"
        ]
    },
    {
        "id": "43421f19-878e-46f7-b456-8031835af649",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with Body surface area ",
        "statement_nums": [
            "1000 mg PO"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib ",
        "premise_nums": [
            "LBH589 With",
            "10 additional patients",
            "589 and will",
            "589 with Capecitabine",
            "14 of every",
            "589 With Capecitabine",
            "589 will be",
            "589 and Lapatinib",
            "LBH589 with",
            "LBH589 and",
            "LBH589 will",
            "2 orally BID",
            "21 days in",
            "14 days out",
            "825 mg/m2 to",
            "2 to 1250",
            "1250 mg/m2 orally"
        ]
    },
    {
        "id": "43421f19-878e-46f7-b456-8031835af649",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with Body surface area ",
        "statement_nums": [
            "1000 mg PO"
        ],
        "label": "Entailment",
        "premise_text": "LBH589 and LapatinibLBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  ",
        "premise_nums": [
            "1000 mg PO",
            "589 will be",
            "21 days in",
            "2 to 1250",
            "10 additional patients",
            "14 of every",
            "825 mg/m2 to",
            "589 and will",
            "589 and LapatinibLBH589:",
            "LBH589 will",
            "1250 mg/m2 orally",
            "LBH589 and",
            "2 orally BID"
        ]
    },
    {
        "id": "13fa44e7-38be-48fb-a0eb-6b212549f526",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: CNS Objective Response Rate (ORR) The central nervous system (CNS) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on treatment: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  ",
        "premise_nums": [
            "30% decrease",
            "RECIST 1.1 criteria in"
        ]
    },
    {
        "id": "13fa44e7-38be-48fb-a0eb-6b212549f526",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Disease assessments occurred every 6 cycles  Patients with stable or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles  Response was evaluated up to 25 months Results 1: Arm/Group Title: Cohort 1 - Cabozantinib  Trastuzumab for HER2+ Arm/Group Description: HER2-positive Cabozantinib- orally administered daily per treatment cycle Trastuzumab- IV administered once per cycle MRI- Baseline  Cycle 2 Day 1, and every 2 cycles Magnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, ",
        "premise_nums": [
            "6 cycles could",
            "2 Day 1,",
            "2 cycles Magnetic",
            "2-positive Cabozantinib-",
            "25 months Results"
        ]
    },
    {
        "id": "13fa44e7-38be-48fb-a0eb-6b212549f526",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Entailment",
        "premise_text": "Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops Trastuzumab: For HER2-Positive participants only  Administered by IV on day 1 of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort 2 - Cabozantinib for ER+ and/or PR+ Arm/Group Description: Hormone receptor-positive (ER+ and/or PR+) Cabozantinib- orally administered daily per treatment cycle ",
        "premise_nums": [
            "60 mg tablet",
            "1 of each",
            "2-Positive participants",
            "2 to 24)",
            "21 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "13fa44e7-38be-48fb-a0eb-6b212549f526",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "2-positive group"
        ],
        "label": "Entailment",
        "premise_text": "MRI- Baseline  Cycle 2 Day 1, and every 2 cyclesMagnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage of participants 14 (.4 to 58) ",
        "premise_nums": [
            "2 Day 1,",
            "4 to 58)",
            "60 mg tablet",
            "2 cyclesMagnetic Resonance",
            "7 Measure Type:",
            "21 day cycle"
        ]
    },
    {
        "id": "2823adfc-b3a4-4626-9690-0c292aa8da04",
        "primaryId": "NCT01422408",
        "statement_text": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks ",
        "statement_nums": [
            "fluocinonide 0.05% face cream"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Supportive Care (Fluocinonide Cream) This is a single-arm  single-stage  open-label phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms  All subjects will receive topical fluocinonide 0.05% cream to apply twice daily for two weeks and then once daily for two weeks to the vagina  The duration of treatment will be 4 weeks  ",
        "premise_nums": [
            "fluocinonide 0.05% cream to"
        ]
    },
    {
        "id": "50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9",
        "primaryId": "NCT00193050",
        "secondaryId": "NCT00232479",
        "label": "Contradiction",
        "statement_text": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "6 months to",
            "18 and have"
        ],
        "premise_text": "Inclusion Criteria: Female Patients greater than 18 years of age Exclusion Criteria: Life expectancy of smaller than than 6 months Inclusion Criteria: HER-2 overexpressing breast cancer Clinical stage 2-3B Normal ejection fraction Exclusion Criteria: Metastatic disease Low ejection fraction ",
        "premise_nums": [
            "18 years of",
            "6 months Inclusion",
            "2-3B Normal",
            "2 overexpressing breast"
        ]
    },
    {
        "id": "f3cebdf7-be0c-45ad-85bd-bde827524e20",
        "primaryId": "NCT00693719",
        "statement_text": "the primary trial recorded less than 5 different Adverse Events  ",
        "statement_nums": [
            "5 different Adverse"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 4/31 (12.90%) Bleeding 1/31 (3.23%) Pain 2/31 (6.45%) Dehydration 1/31 (3.23%) Dyspnea 1/31 (3.23%) ",
        "premise_nums": [
            "4/31 (12.90%)",
            "2/31 (6.45%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "53c62057-d6ea-4639-adaf-98cb1544a394",
        "primaryId": "NCT00425672",
        "statement_text": "Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle  up to a total of 6 times  but will stop earlier if they suffer disease progression or unacceptable toxicity occurs ",
        "statement_nums": [
            "21 day treatment",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity  ONTAK: Given IV flow cytometry: Correlative studies immunohistochemistry staining method: Correlative studies enzyme-linked immunosorbent assay: Correlative studies laboratory biomarker analysis: Correlative studies protein expression analysis: Correlative studies ",
        "premise_nums": [
            "6 courses in",
            "1-5. Treatment",
            "21 days for",
            "1 hour on"
        ]
    },
    {
        "id": "62b5fe62-470d-46e3-82a6-d57cd6cab452",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Entailment",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Nausea 2/83 (2.41%) Vomiting 2/83 (2.41%) Diarrhea 1/83 (1.20%) Gastrointestinal Haemorrhage 1/83 (1.20%) Asthenia 1/83 (1.20%) Hyperbilirubinaemia 1/83 (1.20%) Anal abscess 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) ",
        "premise_nums": [
            "2/83 (2.41%)",
            "13/83 (15.66%)",
            "3/83 (3.61%)",
            "1/83 (1.20%)"
        ]
    },
    {
        "id": "62b5fe62-470d-46e3-82a6-d57cd6cab452",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Entailment",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Adverse Events 1:Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) ",
        "premise_nums": [
            "1:Total: 7/26",
            "0/26 (0.00%)",
            "1/26 (3.85%)",
            "7/26 (26.92%)"
        ]
    },
    {
        "id": "62b5fe62-470d-46e3-82a6-d57cd6cab452",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "label": "Entailment",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "Thrombosis in device 0/26 (0.00%)",
        "premise_nums": [
            "0/26 (0.00%)"
        ]
    },
    {
        "id": "8de31b0f-7127-4c8b-b5e0-060e7a83fae5",
        "primaryId": "NCT01299038",
        "statement_text": "Joe has a known history of Hepatitis  However as he is over the age of 18 is still eligible for the primary trial ",
        "statement_nums": [
            "18 is still"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria: Metastatic adenocarcinoma of the breast (Stage IV) Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1 or 2 Normal organ and marrow function as defined in the protocol Exclusion Criteria: Participants may not be receiving any other study agents Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks Asian decent (including Filipino  Chinese  Japanese  Korean  Vietnamese or Asian-Indian origin) ",
        "premise_nums": [
            "3 weeks Asian",
            "6 weeks (with",
            "2 therapy )",
            "5 weeks Any",
            "1 or 2",
            "18 years ECOG"
        ]
    },
    {
        "id": "207a1d82-a61b-4b5f-bebf-0706def6729d",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Entailment",
        "statement_text": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial ",
        "statement_nums": [
            "1 more case"
        ],
        "premise_text": "Adverse Events 1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 0/42 (0.00%) Influenza like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/42 (2.38%)",
            "0/42 (0.00%)",
            "7/42 (16.67%)"
        ]
    },
    {
        "id": "207a1d82-a61b-4b5f-bebf-0706def6729d",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Entailment",
        "statement_text": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial ",
        "statement_nums": [
            "1 more case"
        ],
        "premise_text": "Total: 7/42 (16.67%)Febrile neutropenia 0/42 (0.00%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: ",
        "premise_nums": [
            "2/42 (4.76%)",
            "0/42 (0.00%)",
            "1/42 (2.38%)",
            "7/42 (16.67%)Febrile"
        ]
    },
    {
        "id": "207a1d82-a61b-4b5f-bebf-0706def6729d",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Entailment",
        "statement_text": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial ",
        "statement_nums": [
            "1 more case"
        ],
        "premise_text": "Total: 21/209 (10.05%)Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Acute myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: ",
        "premise_nums": [
            "1/209 (0.48%)",
            "21/209 (10.05%)Anaemia",
            "0/209 (0.00%)"
        ]
    },
    {
        "id": "207a1d82-a61b-4b5f-bebf-0706def6729d",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "label": "Entailment",
        "statement_text": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial ",
        "statement_nums": [
            "1 more case"
        ],
        "premise_text": "Total: 29/216 (13.43%)Anaemia 2/216 (0.93%) Febrile neutropenia 2/216 (0.93%) Thrombocytopenia 2/216 (0.93%) Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%) Oral pain 2/216 (0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) ",
        "premise_nums": [
            "2/216 (0.93%)",
            "1/216 (0.46%)",
            "0/216 (0.00%)",
            "29/216 (13.43%)Anaemia"
        ]
    },
    {
        "id": "968aeaf1-44b9-4454-8c99-e3c207037485",
        "primaryId": "NCT01491737",
        "statement_text": "There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial ",
        "statement_nums": [
            "4 cases of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Febrile neutropenia 4/127 (3.15%) Cardiac failure 0/127 (0.00%) ",
        "premise_nums": [
            "0/127 (0.00%)",
            "4/127 (3.15%)"
        ]
    },
    {
        "id": "2b79f9cc-4262-4353-ad28-91cda07a9b9a",
        "primaryId": "NCT02988986",
        "statement_text": "Patients must have AST  ALP and ALT smaller than 1.5 ULN to participate in the primary trial ",
        "statement_nums": [
            "than 1.5 ULN to"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Hepatic status: Serum total bilirubin 1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome  a higher serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5 x ULN; ",
        "premise_nums": [
            "5 x ULN;",
            "than 1.5 x ULN",
            "1 x upper",
            "phosphatase 1.5 x ULN",
            "aminotransferase 1.5 x ULN",
            "5 x ULN]"
        ]
    },
    {
        "id": "f62e6c20-862b-4ce3-9121-0d93ff050839",
        "primaryId": "NCT01373671",
        "secondaryId": "NCT00686127",
        "label": "Contradiction",
        "statement_text": "Lidoderm products are used in a intervention arm 1 of the secondary trial  and an FFDM product is used in arm 1 of the primary trial",
        "statement_nums": [
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  ",
        "premise_nums": [
            "1 patch was",
            "12 hours each"
        ]
    },
    {
        "id": "84aa97cf-efce-484e-825e-5af509e5988f",
        "primaryId": "NCT01441596",
        "statement_text": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy  up to 160% of the starting dose ",
        "statement_nums": [
            "160% of",
            "1 of the"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Afatinib Mono Afatinib monotherapy administered orally: starting dose 40 mg per day  continuous treatment in a 3-weekly course  If well tolerated  the dose may be escalated to 50 mg  ",
        "premise_nums": [
            "40 mg per",
            "3-weekly course"
        ]
    },
    {
        "id": "f29768ba-5d79-4528-839f-933ab13faaa1",
        "primaryId": "NCT01943916",
        "secondaryId": "NCT01653964",
        "label": "Contradiction",
        "statement_text": "All subjects in the primary trial and the secondary trial will be adminstered 4 mCi Tc-99m sestamibi and undergo Molecular breast imaging ",
        "statement_nums": [
            "4 mCi Tc"
        ],
        "premise_text": "INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  ",
        "premise_nums": [
            "4 mCi Tc",
            "8 mCi Tc"
        ]
    },
    {
        "id": "4d51608c-b0d8-4019-9b9a-34cf1c3d5087",
        "primaryId": "NCT00558103",
        "statement_text": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg ",
        "statement_nums": [
            "1500 mg PO"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD)  INTERVENTION 2: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  ",
        "premise_nums": [
            "800 mg (2",
            "1500 milligrams (mg)",
            "6 x 250",
            "1500 mg (6",
            "800 mg Participants",
            "250 mg tablets)",
            "400 mg tablets)"
        ]
    },
    {
        "id": "fa28753a-aa3b-4642-9fd4-a2414fd8a472",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  post T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Entailment",
        "premise_text": "Time frame: Cycle 1 Day 1, pre-dose (Baseline); Cycle 1 Day 1, 15 and 60 minutes post-dose; Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60 minutes post-dose Results 1: Arm/Group Title: T-DM1 Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg  Overall Number of Participants Analyzed: 51 Mean (Standard Deviation) ",
        "premise_nums": [
            "1 Day 8;",
            "3 Day 1,",
            "51 Mean (Standard",
            "3 week cycle",
            "1 of every",
            "of 3.6 mg/kg",
            "15 and 60",
            "15 minutes pre",
            "1 Day 1,"
        ]
    },
    {
        "id": "fa28753a-aa3b-4642-9fd4-a2414fd8a472",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  post T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3)Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 1, Day 8 [N=43]: -4.0 (13.4) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 3, Day 1, 15 minutes post-dose [N=37]: 4.7 (9.6) ",
        "premise_nums": [
            "15 minutes post",
            "60 minutes post",
            "15 minutes pre"
        ]
    },
    {
        "id": "fa28753a-aa3b-4642-9fd4-a2414fd8a472",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  post T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "1 of the",
            "1 intravenous (IV)"
        ],
        "label": "Entailment",
        "premise_text": "Cycle 3, Day 1, 60 minutes post-dose [N=37]: 4.7 (10.9)",
        "premise_nums": [
            "60 minutes post"
        ]
    },
    {
        "id": "ff797dd4-0b4d-42fc-808d-27c439563ce2",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial none of the patients had Complete Response  7 had partial response and 15 had progressive disease ",
        "statement_nums": [
            "48 of the",
            "7 had partial",
            "15 had progressive"
        ],
        "label": "Entailment",
        "premise_text": "The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.Time frame: At 48 weeks Results 1: Arm/Group Title: Everolimus and Exemestane ",
        "premise_nums": [
            "4 weeks apart",
            "48 weeks Results"
        ]
    },
    {
        "id": "ff797dd4-0b4d-42fc-808d-27c439563ce2",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial none of the patients had Complete Response  7 had partial response and 15 had progressive disease ",
        "statement_nums": [
            "48 of the",
            "7 had partial",
            "15 had progressive"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o  and exemestane 25mg daily p.o Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: participants Patients with measurable disease at baseline: 39 Patients with non-measurable disease at baseline: 10 Best at WK 48 - Complete Response (CR): 0 Best at WK 48 - Partial Response (PR): 7 Best at WK 48 - Stable Disease (SD): 18 Best at WK 48 - Progressive Disease (PD): 15 Unknown: 1 Missing: 8 ",
        "premise_nums": [
            "39 Patients with",
            "18 Best at",
            "49 Measure Type:",
            "7 Best at",
            "10 Best at"
        ]
    },
    {
        "id": "ae583ea3-36a5-472c-acda-825cd7d513b6",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31 (6.45%) Ascites 0/31 (0.00%) Ileus 1/31 (3.23%) Small Intestinal Obstruction 1/31 (3.23%) Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) ",
        "premise_nums": [
            "15/31 (48.39%)",
            "2/31 (6.45%)",
            "0/31 (0.00%)",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "ae583ea3-36a5-472c-acda-825cd7d513b6",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Entailment",
        "premise_text": "Hypokalaemia 0/31 (0.00%)Adverse Events 2: Total: 4/31 (12.90%) Intracardiac Thrombus 0/31 (0.00%) Diarrhoea 0/31 (0.00%) Nausea 0/31 (0.00%) Vomiting 0/31 (0.00%) Ascites 1/31 (3.23%) Ileus 0/31 (0.00%) Small Intestinal Obstruction 0/31 (0.00%) Multi-Organ Failure 1/31 (3.23%) Sepsis 0/31 (0.00%) Weight Decreased 0/31 (0.00%) ",
        "premise_nums": [
            "1/31 (3.23%)",
            "0/31 (0.00%)Adverse",
            "4/31 (12.90%)"
        ]
    },
    {
        "id": "ae583ea3-36a5-472c-acda-825cd7d513b6",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "statement_nums": [
            "1 or 2"
        ],
        "label": "Entailment",
        "premise_text": "Dehydration 0/31 (0.00%)Hypokalaemia 1/31 (3.23%) ",
        "premise_nums": [
            "0/31 (0.00%)Hypokalaemia",
            "1/31 (3.23%)"
        ]
    },
    {
        "id": "0ef77b5d-684a-4a87-bf61-8d4bc9975b7f",
        "primaryId": "NCT01446159",
        "statement_text": "the primary trial only had a total of 6 patients in across both its cohorts ",
        "statement_nums": [
            "6 patients in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 2/3 (66.67%) Adverse Events 2: Total: 0/3 (0.00%) ",
        "premise_nums": [
            "0/3 (0.00%)",
            "2/3 (66.67%)"
        ]
    },
    {
        "id": "e43c01e9-20a2-4435-a32b-224d5f460d7c",
        "primaryId": "NCT01997333",
        "statement_text": "The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months ",
        "statement_nums": [
            "1 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Progression Free Survival (PFS) PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions  or progression in a non-target lesion  or the appearance of new lesions  The primary analysis of PFS was based on PFS events determined retrospectively by the central independent review committee  blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria  Time frame: Evaluated every 6 - 9 weeks following treatment initiation Results 1: Arm/Group Title: Capecitabine ",
        "premise_nums": [
            "9 weeks following",
            "20% increase"
        ]
    },
    {
        "id": "e43c01e9-20a2-4435-a32b-224d5f460d7c",
        "primaryId": "NCT01997333",
        "statement_text": "The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months ",
        "statement_nums": [
            "1 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Capecitabine administered on Days 1 through 14 of each 21 day cycle until disease progression  discontinuation due to toxicity  withdrawal of consent  or end of study Overall Number of Participants Analyzed: 109 Median (95% Confidence Interval) Unit of Measure: months 2.8 (1.6 to 3.2) ",
        "premise_nums": [
            "6 to 3.2)",
            "1 through 14",
            "95% Confidence",
            "21 day cycle"
        ]
    },
    {
        "id": "0ee36ceb-5790-440e-b6ad-10a0b7a23f43",
        "primaryId": "NCT01925170",
        "secondaryId": "NCT00324259",
        "label": "Entailment",
        "statement_text": "Participant in cohort 1 of the primary trial undergo a Mammography  whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol  and no Mammography ",
        "statement_nums": [
            "6 mg Estradiol",
            "1 of the"
        ],
        "premise_text": "INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 1: Arm 1 (6 mg Estradiol) 6 mg of estradiol daily (2 mg tid)  ",
        "premise_nums": [
            "2 mg tid)",
            "6 mg Estradiol)",
            "6 mg of"
        ]
    },
    {
        "id": "2535da13-e0f7-44df-aa02-89765d8d51cb",
        "primaryId": "NCT02419807",
        "secondaryId": "NCT00777101",
        "label": "Contradiction",
        "statement_text": "Patients with HER2 + breast cancer stage 1-4 are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "1-4 are",
            "4 are eligible"
        ],
        "premise_text": "Inclusion Criteria: Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer Inclusion Criteria: Stage IIIB  IIIC  or IV erbB2 (HER2) positive breast cancer ",
        "premise_nums": [
            "1 or 2",
            "(HER2) positive"
        ]
    },
    {
        "id": "0057172f-d019-401b-a516-993a7b46a67b",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2.",
        "statement_nums": [
            "1 in the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  INTERVENTION 2: ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "2 Cohort 1:",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "28-day cycle",
            "100mg/Trastuzumab",
            "80mg/m2 Cohort"
        ]
    },
    {
        "id": "0057172f-d019-401b-a516-993a7b46a67b",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2.",
        "statement_nums": [
            "1 in the"
        ],
        "label": "Entailment",
        "premise_text": "Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2Cohort 2: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 140mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  ",
        "premise_nums": [
            "1 of a",
            "2mg/kg/Paclitaxel",
            "80mg/m2Cohort",
            "3 weeks followed",
            "2 weekly x",
            "4-week cycles",
            "2 mg/kg IV",
            "80 mg/m2 weekly",
            "4 mg/kg in",
            "140mg/Trastuzumab",
            "28-day cycle"
        ]
    },
    {
        "id": "bb23e8b8-c7d6-4e58-80a2-0555db5645e9",
        "primaryId": "NCT03096847",
        "secondaryId": "NCT01840163",
        "label": "Entailment",
        "statement_text": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial  but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english ",
        "statement_nums": [
            "1 to 2"
        ],
        "premise_text": "Exclusion Criteria Patient who received any CDK4/6 inhibitor or any mTOR inhibitor  Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male ",
        "premise_nums": [
            "CDK4/6 inhibitor",
            "6 inhibitor or",
            "2 invasive breast",
            "1-2 invasive"
        ]
    },
    {
        "id": "c4588d2c-b0d4-428d-a958-29787b9d4ec5",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive Bevacizumab  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) ",
        "premise_nums": [
            "3 weeks plus",
            "15mg/kg every"
        ]
    },
    {
        "id": "c4588d2c-b0d4-428d-a958-29787b9d4ec5",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive Bevacizumab  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent Letrozole Bevacizumab Fulvestrant ",
        "premise_nums": [
            "15mg/kg i",
            "1 every 3"
        ]
    },
    {
        "id": "50a524ae-2135-45f7-ae9b-515fd4e2e404",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "label": "Contradiction",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and 100% of patients in the secondary trial did not experience an adverse event ",
        "statement_nums": [
            "100% of"
        ],
        "premise_text": "Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%) Stomatitis 1/52 (1.92%) ",
        "premise_nums": [
            "5/52 (9.62%)",
            "2/52 (3.85%)",
            "1/52 (1.92%)",
            "31/52 (59.62%)"
        ]
    },
    {
        "id": "50a524ae-2135-45f7-ae9b-515fd4e2e404",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "label": "Contradiction",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and 100% of patients in the secondary trial did not experience an adverse event ",
        "statement_nums": [
            "100% of"
        ],
        "premise_text": "Haematemesis 1/52 (1.92%)Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) ",
        "premise_nums": [
            "9/33 (27.27%)",
            "23/23 (100.00%)",
            "0/33 (0.00%)",
            "1/52 (1.92%)Adverse",
            "57/57 (100.00%)",
            "15/33 (45.45%)",
            "2/11 (18.18%)",
            "13/33 (39.39%)"
        ]
    },
    {
        "id": "50a524ae-2135-45f7-ae9b-515fd4e2e404",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "label": "Contradiction",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and 100% of patients in the secondary trial did not experience an adverse event ",
        "statement_nums": [
            "100% of"
        ],
        "premise_text": "Herpetic eruption 3/11 (27.27%)Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) ",
        "premise_nums": [
            "23/23 (100.00%)",
            "9/11 (81.82%)",
            "3/11 (27.27%)Dry"
        ]
    },
    {
        "id": "b2062e01-0ea6-4ee8-94a1-b59dc40901d3",
        "primaryId": "NCT01688609",
        "statement_text": "Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer  with Primary tumor greater than 2 cm in diameter to participate in the primary trial ",
        "statement_nums": [
            "2 cm in"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: Patients must have histologically or cytologically confirmed primary invasive breast cancer Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) + when IHC 2+ ",
        "premise_nums": [
            "2 is confirmed",
            "2 cm in",
            "(T2) as"
        ]
    },
    {
        "id": "4dbce51b-1cfc-4d5f-82bb-ce9319ace3af",
        "primaryId": "NCT00826267",
        "statement_text": "Cohort 1 and 2 of the primary trial receive different quantities of different drugs ",
        "statement_nums": [
            "1 and 2"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  ",
        "premise_nums": [
            "50 mg orally",
            "50 mg Patients",
            "21 of each",
            "2 treatment courses",
            "1500 mg Patients",
            "1 to Day",
            "1500 mg orally"
        ]
    },
    {
        "id": "43a9cc96-4020-459c-8fa4-4bbde7173f7a",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11 patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients passed away from Unexpected adverse events ",
        "statement_nums": [
            "11 patients had"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions) Percentage of patients with AEs  Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient  Results 1: Arm/Group Title: Single Arm Arm/Group Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81 Measure Type: Number Unit of Measure: Percentage of participants Adverse Events(AE): 81.5 (71.3 to 89.3) ADR; based on current South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to 20.1) Serious ADR: 0 (0 to 4.4) ",
        "premise_nums": [
            "7 to 49.7)",
            "6 months for",
            "81 Measure Type:",
            "2 to 20.1)",
            "3 to 89.3)",
            "0 to 4.4)"
        ]
    },
    {
        "id": "43a9cc96-4020-459c-8fa4-4bbde7173f7a",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11 patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients passed away from Unexpected adverse events ",
        "statement_nums": [
            "11 patients had"
        ],
        "label": "Contradiction",
        "premise_text": "Unexpected AE: 71.6 (60.5 to 81.1)Unexpected ADR: 24.7 (15.8 to 35.5) ",
        "premise_nums": [
            "8 to 35.5)",
            "5 to 81.1)Unexpected"
        ]
    },
    {
        "id": "ff319fa6-89b6-4f1a-871d-456edb91b69b",
        "primaryId": "NCT03045653",
        "statement_text": "Sharone had a hip replacement 3 weeks prior  she is not elgible for the primary trial ",
        "statement_nums": [
            "3 weeks prior"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases  including uncontrolled hypertension  active bleeding diatheses  or active infection including hepatitis B  hepatitis C and HIV With the exception of alopecia  any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia  altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures  including inability to take regular oral medication ",
        "premise_nums": [
            "1 before study",
            "30 days Inability",
            "4 weeks before"
        ]
    },
    {
        "id": "a321acf0-2296-4588-bf96-85b22bf1420f",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts ",
        "statement_nums": [
            "14 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 0/76 (0.00%) ",
        "premise_nums": [
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "10/76 (13.16%)",
            "14/76 (18.42%)"
        ]
    },
    {
        "id": "a321acf0-2296-4588-bf96-85b22bf1420f",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts ",
        "statement_nums": [
            "14 cases of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2:Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) Optic ischaemic neuropathy 1/76 (1.32%) Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 1/76 (1.32%) ",
        "premise_nums": [
            "12/76 (15.79%)",
            "1/76 (1.32%)",
            "2:Total: 12/76",
            "0/76 (0.00%)",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "b841dfd8-4676-4d3c-a57d-6ba1055b8597",
        "primaryId": "NCT02027376",
        "statement_text": "A patient was treated with Pertuzumab for 6 months  and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects  hence this patient is eligible for the primary trial ",
        "statement_nums": [
            "2 months prior"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Patients who have received biologic therapy (e.g  antibodies) 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy  ",
        "premise_nums": [
            "4 weeks prior"
        ]
    },
    {
        "id": "48d40c7e-3514-43c3-a31a-7b391727f012",
        "primaryId": "NCT01209195",
        "statement_text": "Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2, Paclitaxel doses are the same for both cohorts ",
        "statement_nums": [
            "121 are utilised",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Part 1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV ",
        "premise_nums": [
            "2 MM-121",
            "80mg/m2 weekly",
            "2 weekly IV",
            "40 mg/kg loading",
            "20 mg/kg weekly",
            "12 mg/kg weekly",
            "1 MM-121",
            "20 mg/kg loading"
        ]
    },
    {
        "id": "0a6418c8-63a6-4900-bfc9-1659acbe1ad7",
        "primaryId": "NCT02581839",
        "statement_text": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 3 months ",
        "statement_nums": [
            "8 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) The study team will assess the percent of participants without CNS progression at 3 months  The study team will generate a Kaplan- Meier curve of CNS PFS and estimate the PFS and 95% confidence interval (CI) of the PFS  Response and progression by MR were evaluated using WHO/modified McDonald's criteria  Time frame: At 12 weeks Results 1: Arm/Group Title: Eribulin Mesylate ",
        "premise_nums": [
            "95% confidence",
            "12 weeks Results"
        ]
    },
    {
        "id": "0a6418c8-63a6-4900-bfc9-1659acbe1ad7",
        "primaryId": "NCT02581839",
        "statement_text": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 3 months ",
        "statement_nums": [
            "8 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylateEribulin Mesylate: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  MRI: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate ",
        "premise_nums": [
            "is 1.4 mg/m2",
            "at 1.4 mg/m2",
            "2 to 5",
            "2 administered intravenously",
            "12 weeks after",
            "1 and 8",
            "12 and every",
            "21-day cycle"
        ]
    },
    {
        "id": "0a6418c8-63a6-4900-bfc9-1659acbe1ad7",
        "primaryId": "NCT02581839",
        "statement_text": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 3 months ",
        "statement_nums": [
            "8 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Pre-Medication: Zofran: Zofran at 8mg orally  Given at the discretion of the treating physicianPre-Medication: Decadron: decadron at 8mg orally  Given at the discretion of the treating physician Overall Number of Participants Analyzed: 9 Measure Type: Number Unit of Measure: percentage of participants 88.9 (51 to 99.7) ",
        "premise_nums": [
            "51 to 99.7)",
            "9 Measure Type:"
        ]
    },
    {
        "id": "3129e58d-0c16-42a5-90b4-f26e048dfe58",
        "primaryId": "NCT01644890",
        "statement_text": "Throughout the primary trial  one patient in cohort 1 developed issues with their vision ",
        "statement_nums": [
            "1 developed issues"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 34/214 (15.89%) Leukocytosis 0/214 (0.00%) Atrial fibrillation 0/214 (0.00%) Cardiac failure congestive 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%) Diarrhoea 2/214 (0.93%) Enterocolitis 0/214 (0.00%) Ileus 1/214 (0.47%) Nausea 3/214 (1.40%) Adverse Events 2: Total: 27/213 (12.68%) ",
        "premise_nums": [
            "27/213 (12.68%)",
            "2/214 (0.93%)",
            "1/214 (0.47%)",
            "34/214 (15.89%)",
            "3/214 (1.40%)",
            "0/214 (0.00%)"
        ]
    },
    {
        "id": "3129e58d-0c16-42a5-90b4-f26e048dfe58",
        "primaryId": "NCT01644890",
        "statement_text": "Throughout the primary trial  one patient in cohort 1 developed issues with their vision ",
        "statement_nums": [
            "1 developed issues"
        ],
        "label": "Contradiction",
        "premise_text": "Leukocytosis 1/213 (0.47%)Atrial fibrillation 1/213 (0.47%) Cardiac failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%) Diarrhoea 1/213 (0.47%) Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%) ",
        "premise_nums": [
            "0/213 (0.00%)",
            "1/213 (0.47%)Atrial"
        ]
    },
    {
        "id": "7be7cecb-d265-4098-9969-a40555702573",
        "primaryId": "NCT00679211",
        "statement_text": "1 patient in the primary trial was diangosed with Influenza ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Influenza like illness 1/110 (0.91%) ",
        "premise_nums": [
            "1/110 (0.91%)"
        ]
    },
    {
        "id": "a378f448-eef0-465a-abc0-8b4dd1156bb5",
        "primaryId": "NCT00372424",
        "secondaryId": "NCT00041067",
        "label": "Entailment",
        "statement_text": "Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "2 positive breast"
        ],
        "premise_text": "Inclusion Criteria: Breast cancer with evidence of unresectable  locally recurrent  or metastatic disease  Tumors over-expressing Her-2 Candidate for treatment with docetaxel/trastuzumab HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting ",
        "premise_nums": [
            "2-positive by",
            "2 Candidate for"
        ]
    },
    {
        "id": "f30182a1-b82a-497c-885c-9bd2e805db62",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 237 ml of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "237 ml of"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Arm I: Alkaline Water Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  alkaline water: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  INTERVENTION 2: Arm II: Distilled Water Patients undergo external beam radiation therapy as in arm I  Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy ",
        "premise_nums": [
            "30 minutes immediately",
            "5 days a",
            "8 ounces of"
        ]
    },
    {
        "id": "f30182a1-b82a-497c-885c-9bd2e805db62",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 237 ml of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "237 ml of"
        ],
        "label": "Entailment",
        "premise_text": "distilled water: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  ",
        "premise_nums": [
            "30 minutes immediately",
            "5 days a",
            "8 ounces of"
        ]
    },
    {
        "id": "ae87e5a3-fdd8-4003-ae80-4b370cade158",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients had Recurrence-free Survival smaller than 3 years ",
        "statement_nums": [
            "2% of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Recurrence-free Survival Recurrence-free survival curves will be plotted for subjects treated with stage I and II disease  Time frame: Time from the start of treatment to recurrence  second malignancy  or death as a first event  assessed up to 3 years Results 1: Arm/Group Title: Treatment (Chemotherapy With or Without Maintenance Therapy) Arm/Group Description: SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  ",
        "premise_nums": [
            "3 hours on",
            "6 courses in",
            "1 hour and",
            "14 days for",
            "3 years Results"
        ]
    },
    {
        "id": "ae87e5a3-fdd8-4003-ae80-4b370cade158",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients had Recurrence-free Survival smaller than 3 years ",
        "statement_nums": [
            "2% of"
        ],
        "label": "Entailment",
        "premise_text": "MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity cyclophosphamide  paclitaxel  trastuzumab: Given IV Overall Number of Participants Analyzed: 100 Measure Type: Number Unit of Measure: percentage of subjects 98 (92.2 to 99.5) ",
        "premise_nums": [
            "21 days for",
            "2 to 99.5)",
            "14 days for",
            "30 minutes on",
            "5 courses and",
            "100 Measure Type:",
            "2 neu positive",
            "14 courses in"
        ]
    },
    {
        "id": "28d8f88a-e8cb-40c0-a12b-ef555f83ff59",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "label": "Contradiction",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "50% to"
        ],
        "premise_text": "LVEF smaller than 50% and 40% documented in echocardiogram done within the last 30 days Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease ",
        "premise_nums": [
            "40% documented",
            "2-negative adenocarcinoma",
            "0 or 1",
            "3 weeks from",
            "50% and",
            "2-positive status",
            "30 days Inclusion"
        ]
    },
    {
        "id": "28d8f88a-e8cb-40c0-a12b-ef555f83ff59",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "label": "Contradiction",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "50% to"
        ],
        "premise_text": "Prior hormonal therapy smaller than 2 weeks prior to randomizationPrior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death ",
        "premise_nums": [
            "12 weeks Inadequate",
            "5 years prior",
            "28 days of",
            "12 months prior",
            "2 weeks prior"
        ]
    },
    {
        "id": "274d9d2b-9227-4496-a525-d5477b0003ce",
        "primaryId": "NCT00796978",
        "secondaryId": "NCT01276041",
        "label": "Contradiction",
        "statement_text": "More patients in cohort 1 of the secondary trial suffered from oedema in their limbs  compared to patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 8/56 (14.29%) Platelets * 1/56 (1.79%) Heart failure * 1/56 (1.79%) Left ventricular systolic dysfunction * 1/56 (1.79%) Dehydration * 1/56 (1.79%) Diarrhea * 1/56 (1.79%) Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%) Sodium  serum-low (hyponatremia) * 1/56 (1.79%) Fracture * 2/56 (3.57%) Adverse Events 1: ",
        "premise_nums": [
            "1 or 2",
            "1/56 (1.79%)",
            "8/56 (14.29%)",
            "2/56 (3.57%)"
        ]
    },
    {
        "id": "274d9d2b-9227-4496-a525-d5477b0003ce",
        "primaryId": "NCT00796978",
        "secondaryId": "NCT01276041",
        "label": "Contradiction",
        "statement_text": "More patients in cohort 1 of the secondary trial suffered from oedema in their limbs  compared to patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Total: 18/70 (25.71%)Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) ",
        "premise_nums": [
            "5/70 (7.14%)",
            "18/70 (25.71%)Cardiac",
            "1/70 (1.43%)",
            "2/70 (2.86%)",
            "3/70 (4.29%)"
        ]
    },
    {
        "id": "d39078d9-9bc3-4b91-a012-e95f14813c9a",
        "primaryId": "NCT01252277",
        "statement_text": "Fiona's step sister  who is 34 years old was diagnosed with a ductal carcinoma  therefore fiona may be eligible for the primary trial ",
        "statement_nums": [
            "34 years old"
        ],
        "label": "Contradiction",
        "premise_text": "Inclusion Criteria A first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer  ",
        "premise_nums": [
            "60 or multiple"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "DISEASE CHARACTERISTICS: Histologically confirmed stage IV breast cancer Metastasis to the ipsilateral supraclavicular lymph nodes allowed HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting No effusions or ascites as only sites of disease No primary or metastatic brain or central nervous system tumor Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: ",
        "premise_nums": [
            "18 and over",
            "3 Platelet count",
            "100,000/mm^3 Hepatic:",
            "2-positive by",
            "0-2 Life",
            "2 Life expectancy:",
            "1,500/mm^3 Platelet"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Bilirubin normalaspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN Renal: Not specified Cardiovascular: left ventricular ejection fraction normal by multigated radionuclide angiography or echocardiogram (patients who have received prior anthracycline therapy) No clinical evidence or history of cardiomyopathy Other: No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80 ",
        "premise_nums": [
            "than 2.5 times ULN",
            "2 or greater",
            "than 1.5 times upper"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer  carcinoma in situ of the cervix  or other adequately treated stage I or II cancer currently in complete remissionNo known sensitivity to E  coli-derived proteins Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 months since prior chemotherapy Prior anthracycline as adjuvant therapy allowed No prior cumulative dose of doxorubicin more than 360 mg/m^2 No prior cumulative dose of epirubicin more than 720 mg/m^2 No more than 1 prior adjuvant or neoadjuvant chemotherapy regimen for primary disease No prior docetaxel ",
        "premise_nums": [
            "2 No more",
            "720 mg/m^2",
            "5 years except",
            "2 No prior",
            "360 mg/m^2",
            "1 prior adjuvant",
            "6 months since"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "No prior vinorelbinePrior paclitaxel allowed Endocrine therapy: Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed No concurrent hormonal therapy Radiotherapy: At least 3 weeks since prior radiotherapy Surgery: At least 2 weeks since prior surgery and recovered Inclusion Criteria: Male and Female patients must be at least 18 years of age Pathologically confirmed diagnosis of breast cancer Metastatic or advanced stage breast cancer Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy) Patients with HER2+ disease must have received prior treatment with Trastuzumab Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy ",
        "premise_nums": [
            "2 weeks since",
            "18 years of",
            "3 weeks since"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) 3 weeksMeasurable disease by RECIST 1.1 Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090 Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of at least 3 months Adequate hematologic function as defined by: Absolute neutrophil count 1,500 cells/μL Platelets 100,000/μL Hemoglobin 9.0g/dL Adequate hepatic function as defined by: Serum bilirubin 1.5 X upper limit of normal (ULN); ",
        "premise_nums": [
            "bilirubin 1.5 X upper",
            "RECIST 1.1 Central nervous",
            "0 or 1",
            "Hemoglobin 9.0g/dL",
            "100,000/μL Hemoglobin",
            "1,500 cells/",
            "3 weeksMeasurable disease",
            "9090 Eastern Cooperative",
            "4 weeks prior",
            "3 months Adequate"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Adequate renal function as defined by a serum creatinine 1.5 x ULNAST  ALT  and alkaline phosphatase 3 × ULN except for: Patients with hepatic metastases: ALT and AST 5 × ULN Patients with hepatic and/or bone metastases: alkaline phosphatase 5 × ULN Patients with Gilbert's disease: serum bilirubin smaller than 5 mg/dL Willingness and ability to comply with scheduled visits  treatment plans  laboratory tests  and other study procedures Female subjects of childbearing potential and males must agree to use adequate contraception (e.g.  hormonal or barrier method of birth control; abstinence) for the duration of study treatment ",
        "premise_nums": [
            "creatinine 1.5 x ULNAST",
            "5 mg/dL Willingness"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Female subjects of childbearing age must have a negative serum pregnancy test at study entry Exclusion Criteria: Surgery  radiotherapy  or lesion ablative procedure to the only area of measurable disease Major surgery within 4 weeks prior to first dose of STA-9090 Poor peripheral venous access for study drug administration  Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material  History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g.  Polyethylene glycol [PEG] 300 and Polysorbate 80) Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than 50% at baseline ",
        "premise_nums": [
            "9090 Poor peripheral",
            "4 weeks prior",
            "470 msec Ventricular",
            "50% at",
            "300 and Polysorbate",
            "3 or 4)"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "Treatment with chronic immunosuppressants (e.g.  cyclosporine following transplantation)Women who are pregnant or lactating Uncontrolled intercurrent illness including  but not limited to  human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  ventricular arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements Other medications  or severe acute/chronic medical or psychiatric condition  or laboratory abnormality that may increase the risk associated with study participation or study drug administration  or may interfere with the interpretation of study results in the judgment of the investigator Seizure disorder or requirement for seizure medication Prior treatment with an HSP90 inhibitor ",
        "premise_nums": [
            "HSP90 inhibitor"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "label": "Entailment",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "2 positive tumors"
        ],
        "premise_text": "persistent adverse events of prior therapies that are greater than 1 grade 1 in severityhistory of or current coronary artery disease  myocardial infarction  angina pectoris  angioplasty or coronary bypass surgery history of or current uncontrolled dysrhythmias  or requirement for antiarrhythmic medications  or Grade 2 or greater left bundle branch block New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea  orthopnea  or edema that requires current treatment with angiotensin converting enzyme inhibitors  angiotensin II receptor blockers  beta blockers or diuretics ",
        "premise_nums": [
            "2 or greater",
            "1 grade 1"
        ]
    },
    {
        "id": "6d9113b4-9d18-4a1b-bc78-cc3ac1150876",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "label": "Entailment",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients receive 1 of 2 possible drugs ",
        "statement_nums": [
            "1 of 2",
            "3 different drugs"
        ],
        "premise_text": "INTERVENTION 1: Pertuzumab + Trastuzumab + Taxane Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end  unacceptable toxicity  withdrawal of consent  disease progression  or death  whichever occurred first  Taxane chemotherapy was docetaxel  paclitaxel  or nab-paclitaxel  per the investigator's choice  INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg ",
        "premise_nums": [
            "50 mg orally",
            "50 mg Patients",
            "21 of each",
            "3 weeks per",
            "2 treatment courses",
            "1 to Day"
        ]
    },
    {
        "id": "6d9113b4-9d18-4a1b-bc78-cc3ac1150876",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "label": "Entailment",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients receive 1 of 2 possible drugs ",
        "statement_nums": [
            "1 of 2",
            "3 different drugs"
        ],
        "premise_text": "Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial ",
        "premise_nums": [
            "21 of each",
            "1500 mg orally",
            "2 treatment courses",
            "1 to Day"
        ]
    },
    {
        "id": "99599b71-85d7-4c15-8d23-4294732f87cf",
        "primaryId": "NCT00558103",
        "statement_text": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD ",
        "statement_nums": [
            "1500 mg PO"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD)  INTERVENTION 2: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  ",
        "premise_nums": [
            "800 mg (2",
            "1500 milligrams (mg)",
            "6 x 250",
            "1500 mg (6",
            "800 mg Participants",
            "250 mg tablets)",
            "400 mg tablets)"
        ]
    },
    {
        "id": "adbc193f-ffd6-49ce-9acd-7b1675adf0c0",
        "primaryId": "NCT00768222",
        "statement_text": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan  she cannot take part in the primary trial ",
        "statement_nums": [
            "19 years old"
        ],
        "label": "Entailment",
        "premise_text": "Inclusion Criteria: 18 years of age or older with written informed consent Exclusion Criteria: Has inflammatory cancers or skin ulceration Has known allergy or intolerance to triclosan ",
        "premise_nums": [
            "18 years of"
        ]
    },
    {
        "id": "39d685a4-b179-4687-a273-2a44e675f2c6",
        "primaryId": "NCT00900627",
        "statement_text": "The two groups in the primary trial receive the same drug treatment  but group 2 gets double the dose ",
        "statement_nums": [
            "2 gets double"
        ],
        "label": "Contradiction",
        "premise_text": "INTERVENTION 1: AZD8931 160 mg bd Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2: AZD8931 120 mg bd Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle ",
        "premise_nums": [
            "160 mg bd",
            "90mg/m2 on",
            "28 day cycle",
            "8 and 15",
            "2 on days",
            "120 mg bd"
        ]
    },
    {
        "id": "f541ce25-c43e-496b-98e6-8470fe23f840",
        "primaryId": "NCT00559845",
        "secondaryId": "NCT00426556",
        "label": "Contradiction",
        "statement_text": "In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%) Adverse Events 1: Total: 3/6 (50.00%) Adverse Events 2: ",
        "premise_nums": [
            "8/54 (14.81%)",
            "3/6 (50.00%)",
            "1/54 (1.85%)"
        ]
    },
    {
        "id": "f541ce25-c43e-496b-98e6-8470fe23f840",
        "primaryId": "NCT00559845",
        "secondaryId": "NCT00426556",
        "label": "Contradiction",
        "statement_text": "In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Total: 6/17 (35.29%)",
        "premise_nums": [
            "6/17 (35.29%)"
        ]
    },
    {
        "id": "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b",
        "primaryId": "NCT01224678",
        "statement_text": "Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1.",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women  The percent change in breast density will be reported here  Time frame: 12 months Results 1: Arm/Group Title: Placebo Arm/Group Description: Patients receive oral placebo once daily for 12 months  Overall Number of Participants Analyzed: 46 Mean (Standard Deviation) Unit of Measure: percent change -3.4 (7.1) Results 2: Arm/Group Title: Vitamin D Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months  Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) ",
        "premise_nums": [
            "46 Mean (Standard",
            "40 Mean (Standard",
            "12 months Results"
        ]
    },
    {
        "id": "e90f7748-f4b4-4822-8768-586c3f2f9980",
        "primaryId": "NCT00499083",
        "secondaryId": "NCT03045653",
        "label": "Contradiction",
        "statement_text": "In order to be eligible for both the secondary trial and the primary trial  patients must be female  over the age of 18, ECOG smaller than 2 and have Histologically confirmed HER2 + breast cancer ",
        "statement_nums": [
            "2 and have"
        ],
        "premise_text": "HER2/neu-negative tumor by IHC Female ECOG performance status 0-1 Inclusion Criteria: ",
        "premise_nums": [
            "0-1 Inclusion",
            "1 Inclusion Criteria:",
            "2/neu-negative tumor"
        ]
    },
    {
        "id": "6babfc60-5043-4f2b-9605-3e44744265e9",
        "primaryId": "NCT00398567",
        "statement_text": "80% of patients in the primary trial did not suffer any adverse events ",
        "statement_nums": [
            "80% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 1/4 (25.00%) ",
        "premise_nums": [
            "1/4 (25.00%)"
        ]
    },
    {
        "id": "5ca02204-6120-4b02-bf3b-fba94d6fac4f",
        "primaryId": "NCT00274469",
        "statement_text": "No more than 1% of either cohorts of the primary trial felt nauseous ",
        "statement_nums": [
            "1% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: NAUSEA 1/101 (0.99%) Adverse Events 2: NAUSEA 0/103 (0.00%) ",
        "premise_nums": [
            "0/103 (0.00%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "52e8d676-1744-4fdb-bab4-a553874329bd",
        "primaryId": "NCT00829166",
        "statement_text": "Female patients with Peripheral neuropathy greater than 0 are excluded from the primary trial ",
        "statement_nums": [
            "0 are excluded"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Peripheral neuropathy of Grade greater than /= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)  Version 3.0 ",
        "premise_nums": [
            "3 per National"
        ]
    },
    {
        "id": "96f41881-6ba5-4688-8471-9462fc727919",
        "primaryId": "NCT00089661",
        "statement_text": "On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density  whereas those in cohort 2 lost mineral density ",
        "statement_nums": [
            "2 lost mineral",
            "1 participants in"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  Time frame: 12 months Results 1: Arm/Group Title: Denosumab 60 mg Q6M Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results 2: Arm/Group Title: Placebo Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 122 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline -.7 (-1.3 to -.1) ",
        "premise_nums": [
            "12 Bone Mineral",
            "12 months Results",
            "123 Least Squares",
            "95% Confidence",
            "122 Least Squares",
            "60 mg Q6M",
            "3 to 5.4)"
        ]
    },
    {
        "id": "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "10% higher",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Best Overall Response (BOR) Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST)  Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized  20 June 2007, until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and Cetuximab ",
        "premise_nums": [
            "6 weeks until",
            "31 July 2009",
            "20 June 2007,"
        ]
    },
    {
        "id": "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "10% higher",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly  Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity Overall Number of Participants Analyzed: 115 Measure Type: Number Unit of Measure: percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatin ",
        "premise_nums": [
            "3 weeks with",
            "1 until every",
            "2 IV infusion",
            "400 mg/m^2",
            "250 mg/m^2",
            "6 cycles of",
            "6 cycles and",
            "1 to 28.5)",
            "75 milligram per",
            "2 followed by",
            "115 Measure Type:"
        ]
    },
    {
        "id": "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "10% higher",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD  unacceptable toxicity or withdrawal of consent Overall Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 10.3 (3.9 to 21.2) ",
        "premise_nums": [
            "3 weeks with",
            "1 until every",
            "6 cycles until",
            "2 IV infusion",
            "58 Measure Type:",
            "9 to 21.2)",
            "75 mg/m^2"
        ]
    },
    {
        "id": "4a6dc84a-3afd-4060-b8c5-981895f31099",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%) Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) ",
        "premise_nums": [
            "1/1634 (0.06%)",
            "3/1634 (0.18%)",
            "331/1634 (20.26%)",
            "0/1634 (0.00%)",
            "18/1634 (1.10%)"
        ]
    },
    {
        "id": "4a6dc84a-3afd-4060-b8c5-981895f31099",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Cardiomyopathy 1/1634 (0.06%)Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%) Lymphedema 2/1635 (0.12%) Pancytopenia 1/1635 (0.06%) Thrombocytopenia 1/1635 (0.06%) Arrhythmia 3/1635 (0.18%) ",
        "premise_nums": [
            "5/1635 (0.31%)",
            "520/1635 (31.80%)",
            "0/1635 (0.00%)",
            "2/1635 (0.12%)",
            "1/1635 (0.06%)",
            "56/1635 (3.43%)",
            "1/1634 (0.06%)Adverse",
            "3/1635 (0.18%)"
        ]
    },
    {
        "id": "4a6dc84a-3afd-4060-b8c5-981895f31099",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Arrhythmia Ventricular 1/1635 (0.06%)Cardiomyopathy 0/1635 (0.00%) ",
        "premise_nums": [
            "0/1635 (0.00%)",
            "1/1635 (0.06%)Cardiomyopathy"
        ]
    },
    {
        "id": "11e84dc4-6573-4ad7-b2d9-cfc66b626e1c",
        "primaryId": "NCT02574455",
        "statement_text": "More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event ",
        "statement_nums": [
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 69/258 (26.74%) ",
        "premise_nums": [
            "69/258 (26.74%)"
        ]
    },
    {
        "id": "f1f2e066-a016-422f-8627-d0e477933352",
        "primaryId": "NCT00193063",
        "statement_text": "In the primary trial patient cohort  3 different types of infections are observed ",
        "statement_nums": [
            "3 different types"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 14/41 (34.15%) Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41 (2.44%) Infection - pneumonia 2/41 (4.88%) Infection - port site 2/41 (4.88%) Infection - urinary tract 1/41 (2.44%) Disease progression 3/41 (7.32%) Confusion 1/41 (2.44%) ",
        "premise_nums": [
            "2/41 (4.88%)",
            "14/41 (34.15%)",
            "1/41 (2.44%)",
            "3/41 (7.32%)"
        ]
    },
    {
        "id": "a604244f-789f-4c12-8c5a-96c86d1b976e",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group  with a -75.9 % change from baseline ",
        "statement_nums": [
            "75.9 % change",
            "4 observed in",
            "175 mg group"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 Result at Week 4 minus result at baseline as a percentage of the result at baseline  based on log transformed data  Back transformation of the least squares (LS) mean  Time frame: Baseline to Week 4 Results 1: Arm/Group Title: AZD0530 175 mg Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants Analyzed: 46 Geometric Mean (95% Confidence Interval) ",
        "premise_nums": [
            "175 mg Arm",
            "95% Confidence",
            "175 mg once",
            "4 Results 1:",
            "46 Geometric Mean",
            "4 minus result",
            "4 Result at"
        ]
    },
    {
        "id": "a604244f-789f-4c12-8c5a-96c86d1b976e",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group  with a -75.9 % change from baseline ",
        "statement_nums": [
            "75.9 % change",
            "4 observed in",
            "175 mg group"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Percentage change in betaCTX -71.1 (-75.9 to -65.4)Results 2: Arm/Group Title: Zoledronic Acid 4 mg Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of Measure: Percentage change in betaCTX -68.4 (-73.0 to -63.2) ",
        "premise_nums": [
            "65 Geometric Mean",
            "4 mg Arm",
            "4-week treatment",
            "95% Confidence",
            "4 mg on",
            "1 of the"
        ]
    },
    {
        "id": "2b543cc7-e295-4dc6-ad04-a2e43e9b3d97",
        "primaryId": "NCT01565083",
        "statement_text": "Two different types of tachycardia occurred to patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 2: Supraventricular tachycardia * 1/107 (0.93%) Tachycardia * 1/107 (0.93%) ",
        "premise_nums": [
            "1/107 (0.93%)"
        ]
    },
    {
        "id": "987b1da5-0276-417d-a659-8e298529ccac",
        "primaryId": "NCT01684215",
        "statement_text": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991.",
        "statement_nums": [
            "100 mg vs",
            "125 mg of"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1 ",
        "premise_nums": [
            "1 Phase 1"
        ]
    },
    {
        "id": "b838a265-99e4-42f0-bd72-b4f72d7eb16e",
        "primaryId": "NCT02027376",
        "statement_text": "A patient was treated with Pertuzumab for 6 months  and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects  hence this patient is eligible for the primary trial ",
        "statement_nums": [
            "1 month prior"
        ],
        "label": "Contradiction",
        "premise_text": "Exclusion Criteria: Patients who have received biologic therapy (e.g  antibodies) 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy  ",
        "premise_nums": [
            "4 weeks prior"
        ]
    },
    {
        "id": "ba533122-db9d-49e1-a2d1-936c8fdfdd00",
        "primaryId": "NCT01298193",
        "statement_text": "More than 15 patients in cohort 1 of the primary trial experienced adverse events ",
        "statement_nums": [
            "15 patients in",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 31/185 (16.76%) ",
        "premise_nums": [
            "31/185 (16.76%)"
        ]
    },
    {
        "id": "f20cd859-7159-457a-a1cb-56bdb01d521b",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 7 cases of Gastritis in the primary trial across both cohorts ",
        "statement_nums": [
            "7 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 0/76 (0.00%) Adverse Events 2: ",
        "premise_nums": [
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "10/76 (13.16%)",
            "14/76 (18.42%)"
        ]
    },
    {
        "id": "f20cd859-7159-457a-a1cb-56bdb01d521b",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 7 cases of Gastritis in the primary trial across both cohorts ",
        "statement_nums": [
            "7 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Total: 12/76 (15.79%)Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) Optic ischaemic neuropathy 1/76 (1.32%) Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 1/76 (1.32%) ",
        "premise_nums": [
            "1/76 (1.32%)",
            "0/76 (0.00%)",
            "12/76 (15.79%)Neutropenia",
            "2/76 (2.63%)"
        ]
    },
    {
        "id": "d33df923-6c12-4135-b339-5cefdd240985",
        "primaryId": "NCT00003782",
        "statement_text": "Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects ",
        "statement_nums": [
            "5% of"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 66/1748 (3.78%) Adverse Events 2: Total: 43/1748 (2.46%) ",
        "premise_nums": [
            "43/1748 (2.46%)",
            "66/1748 (3.78%)"
        ]
    },
    {
        "id": "3f89537a-479e-4314-b9de-4caf845850fc",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group  with a -73.0 % change from baseline ",
        "statement_nums": [
            "73.0 % change",
            "4 observed in",
            "4 mg group"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 Result at Week 4 minus result at baseline as a percentage of the result at baseline  based on log transformed data  Back transformation of the least squares (LS) mean  Time frame: Baseline to Week 4 Results 1: Arm/Group Title: AZD0530 175 mg Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants Analyzed: 46 Geometric Mean (95% Confidence Interval) ",
        "premise_nums": [
            "175 mg Arm",
            "95% Confidence",
            "175 mg once",
            "4 Results 1:",
            "46 Geometric Mean",
            "4 minus result",
            "4 Result at"
        ]
    },
    {
        "id": "3f89537a-479e-4314-b9de-4caf845850fc",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group  with a -73.0 % change from baseline ",
        "statement_nums": [
            "73.0 % change",
            "4 observed in",
            "4 mg group"
        ],
        "label": "Contradiction",
        "premise_text": "Unit of Measure: Percentage change in betaCTX -71.1 (-75.9 to -65.4)Results 2: Arm/Group Title: Zoledronic Acid 4 mg Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of Measure: Percentage change in betaCTX -68.4 (-73.0 to -63.2) ",
        "premise_nums": [
            "65 Geometric Mean",
            "4 mg Arm",
            "4-week treatment",
            "95% Confidence",
            "4 mg on",
            "1 of the"
        ]
    },
    {
        "id": "8ba451be-606a-4a57-a85e-82b5e5b286fc",
        "primaryId": "NCT03366428",
        "statement_text": "3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms ",
        "statement_nums": [
            "3/49 the",
            "2-expressing Metastatic",
            "49 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported  Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title: DS-8201a Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49 Measure Type: Count of Participants ",
        "premise_nums": [
            "1 of each",
            "3 Day 15",
            "2-expressing Metastatic",
            "received 6.4 mg/kg",
            "7 days before",
            "3 weeks on",
            "49 Measure Type:",
            "21-day cycle"
        ]
    },
    {
        "id": "8ba451be-606a-4a57-a85e-82b5e5b286fc",
        "primaryId": "NCT03366428",
        "statement_text": "3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms ",
        "statement_nums": [
            "3/49 the",
            "2-expressing Metastatic",
            "49 the primary"
        ],
        "label": "Entailment",
        "premise_text": "Unit of Measure: Participants Maximum change from baseline in QTcF: greater than 30 ms: 3 6.1%Maximum change from baseline in QTcF: greater than 60 ms: 0 0.0% ",
        "premise_nums": [
            "3 6.1%Maximum change"
        ]
    },
    {
        "id": "ab17f223-3f70-4b63-bfc5-1fca5d6ec05d",
        "primaryId": "NCT00121992",
        "statement_text": "In order to be eligible for the primary trial  patients must not have prior radiation  anthracycline or systemic anticancer therapy   and must have T1-3, N0 and M0 breast cancer ",
        "statement_nums": [
            "1-3, N0",
            "0 and M0"
        ],
        "label": "Entailment",
        "premise_text": "Exclusion Criteria: Prior systemic anticancer therapy for breast cancer (immunotherapy  hormonotherapy  chemotherapy)  Prior anthracycline therapy or taxoids (paclitaxel  docetaxel) for any malignancy  Prior radiation therapy for breast cancer  Any T4 or N1-3 or M1 breast cancer  ",
        "premise_nums": [
            "N1-3 or",
            "3 or M1"
        ]
    },
    {
        "id": "619d88fd-cef5-4f1a-83dc-3cc710c1c93d",
        "primaryId": "NCT00203502",
        "statement_text": "Less than 30% of patients in the primary trial experienced at least 1 adverse event ",
        "statement_nums": [
            "1 adverse event",
            "30% of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Total: 39/39 (100.00%) ",
        "premise_nums": [
            "39/39 (100.00%)"
        ]
    },
    {
        "id": "42d6a15e-fa43-4ebc-b627-70f4dd0233f8",
        "primaryId": "NCT00322374",
        "statement_text": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin ",
        "statement_nums": [
            "2 of the"
        ],
        "label": "Entailment",
        "premise_text": "INTERVENTION 1: Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  ",
        "premise_nums": [
            "30 mg/m^2",
            "2 Ixabepilone as",
            "25 mg/m^2",
            "75 mg^m2 Participants",
            "30 mg^m2",
            "2 Participants received",
            "25 mg^m2",
            "2 epirubicin every",
            "3-hour IV",
            "5-minute IV",
            "75 mg/m^2"
        ]
    },
    {
        "id": "dfe1236f-ac29-4c1c-a287-6f46abb7703d",
        "primaryId": "NCT00810797",
        "secondaryId": "NCT00828074",
        "label": "Contradiction",
        "statement_text": "Skin infections were more common in patients in cohort 2 of the secondary trial  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "2 of the",
            "1 of the"
        ],
        "premise_text": "Adverse Events 1: Skin infection * 1/36 (2.78%) Adverse Events 2: Skin infection * 0/5 (0.00%) ",
        "premise_nums": [
            "0/5 (0.00%)",
            "1/36 (2.78%)"
        ]
    },
    {
        "id": "6ce5a9d7-5793-43b0-92ed-980cca3be02b",
        "primaryId": "NCT01961544",
        "statement_text": "the primary trial reported a combined total of 3 cases of Pericardial effusion  Asthenia and Gastritis in cohort 1.",
        "statement_nums": [
            "3 cases of"
        ],
        "label": "Contradiction",
        "premise_text": "Adverse Events 1: Pericardial effusion * 2/101 (1.98%) Gastritis * 1/101 (0.99%) Asthenia * 1/101 (0.99%) ",
        "premise_nums": [
            "2/101 (1.98%)",
            "1/101 (0.99%)"
        ]
    },
    {
        "id": "b2a4f905-c6b5-4977-95de-5aa6424a5bb6",
        "primaryId": "NCT00217399",
        "statement_text": "To be included in the primary trial  patients must have at least 1 unidimensionally measurable lesion  there are no size boundaries for eligibility ",
        "statement_nums": [
            "1 unidimensionally measurable"
        ],
        "label": "Contradiction",
        "premise_text": "Measurable disease  defined as greater than or equal 1 unidimensionally measurable lesion  including greater than or equal 1 of the following: Lesion greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or MRI (10 mm sections) Lesion greater than or equal 10 mm on physical exam ",
        "premise_nums": [
            "1 unidimensionally measurable",
            "10 mm on",
            "10 mm sections)",
            "20 mm on",
            "5 mm sections)",
            "1 of the"
        ]
    },
    {
        "id": "a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4",
        "primaryId": "NCT00591851",
        "statement_text": "There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial ",
        "statement_nums": [
            "4 different Gastrointestinal",
            "1 of the"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Abdominal Pain 2/70 (2.86%) Diarrhea 21/70 (1.43%) Lower gastrointestinal hemorrhage 21/70 (1.43%) Nausea 21/70 (1.43%) ",
        "premise_nums": [
            "2/70 (2.86%)",
            "21/70 (1.43%)"
        ]
    },
    {
        "id": "a283b69c-0f36-4773-a711-9e6088a8ee63",
        "primaryId": "NCT01712009",
        "secondaryId": "NCT00343382",
        "label": "Entailment",
        "statement_text": "Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine ",
        "statement_nums": [
            "2 patients in"
        ],
        "premise_text": "INTERVENTION 2: Naproxen 500 mg BID Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles  beginning on the day of pegfilgrastim administration  INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  ",
        "premise_nums": [
            "500 mg orally",
            "500 mg BID",
            "5 days in",
            "2 Times Per",
            "2 times per"
        ]
    },
    {
        "id": "83251670-803e-4fec-a5cf-50f052932752",
        "primaryId": "NCT00708214",
        "statement_text": "All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "50 mg With",
            "16 Weeks of"
        ],
        "label": "Contradiction",
        "premise_text": "Outcome Measurement: Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New bone lesion(s) on bone scan or on magnetic resonance imaging; Progression or occurrence of new lesion(s) according to the Response Evaluation Criteria In Solid Tumours version 1.0 (RECIST); an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline  at 2 consecutive examinations; occurrence of disease-related skeletal events  If a patient did not fulfil any criteria and was withdrawn because of clinical deterioration amounting to PD according to the Investigator  they were considered as having PD  Time frame: 16 weeks Results 1: Arm/Group Title: Afatinib 50 mg With Letrozole ",
        "premise_nums": [
            "CA 15.3 of more",
            "16 Weeks of",
            "50 mg With",
            "2 consecutive examinations;",
            "1 of the",
            "16 weeks Results"
        ]
    },
    {
        "id": "83251670-803e-4fec-a5cf-50f052932752",
        "primaryId": "NCT00708214",
        "statement_text": "All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "50 mg With",
            "16 Weeks of"
        ],
        "label": "Contradiction",
        "premise_text": "Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 40 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression  Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 0.00 (0.00 to 24.71) ",
        "premise_nums": [
            "50 mg therapy",
            "40 mg With",
            "13 Measure Type:",
            "67 to 70.96)",
            "letrozole 2.5 mg over",
            "00 to 24.71)",
            "40 mg therapy",
            "7 Measure Type:",
            "28-day treatment"
        ]
    },
    {
        "id": "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had an abrupt loss of heart function ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Adverse Events 1: Total: 146/573 (25.48%) Anaemia 4/573 (0.70%) Disseminated intravascular coagulation 0/573 (0.00%) Neutropenia 1/573 (0.17%) Thrombocytopenia 0/573 (0.00%) Acute coronary syndrome 1/573 (0.17%) Angina pectoris 1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) ",
        "premise_nums": [
            "0/573 (0.00%)",
            "1/573 (0.17%)",
            "146/573 (25.48%)",
            "2/573 (0.35%)",
            "101/570 (17.72%)",
            "4/573 (0.70%)"
        ]
    },
    {
        "id": "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had an abrupt loss of heart function ",
        "statement_nums": [
            "1 patient in"
        ],
        "label": "Entailment",
        "premise_text": "Anaemia 3/570 (0.53%)Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%) Thrombocytopenia 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial fibrillation 0/570 (0.00%) Atrial flutter 1/570 (0.18%) Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%) ",
        "premise_nums": [
            "1/570 (0.18%)",
            "3/570 (0.53%)Disseminated",
            "0/570 (0.00%)"
        ]
    },
    {
        "id": "a577e819-c928-4217-8743-f4809e852919",
        "primaryId": "NCT00834678",
        "statement_text": "Patients must have a white blood cell count above 1,500/mm¬¨‚â• to participate in the primary trial ",
        "statement_nums": [
            "1,500/mm¬¨‚â• to"
        ],
        "label": "Entailment",
        "premise_text": "WBC greater than 1,500/mm³ ",
        "premise_nums": [
            "1,500/mm³"
        ]
    }
]